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ABSTRACT 
OBJECTIVE 
The principal objective of this study was to measure various aspects of immunity in 
children with invasive infections due to Haemophilus influenzae type b and Staphylococcus 
aureus. These serious infections are a significant cause of childhood morbidity and 
mortality in all populations and affect healthy as well as compromised children. Evidence 
suggests that imbalances or deficiencies in certain aspects of immunity such as IgG 
subclasses, the capacity to make specific subclass antibodies, antibody affinities, 
complement isotypes, immunoglobulin allotypes or mannose binding protein may place 
certain children at risk for developing invasive disease. 
Investigation of these factors in a group of children with infection necessitated that normal 
ranges be established for children of comparable ages from the same population. A 
secondary objective of this study has therefore been to establish normal percentiles for the 
IgG subclasses in age, race and sex matched healthy controls. 
METHODS 
Patients admitted to the Red Cross War Memorial Children's Hospital with septic 
meningitis due to Haemophilus influenzae type b and osteomyelitis/septic arthritis due to 
Haemophilus influenzae type b or Staphylococcus aureus formed the study population. 
Section A of this thesis describes the methods for establishing, validating and standardizing 
ELISAs for measuring the IgG subclasses (lgGl, IgG2, IgG3 and IgG4) and subclass 
antibodies specific to Haemophilus influenzae polyribosylribitol phosphate, Staphylococcus 
aureus teichoic acid and tetanus toxoid. The relative affinity of antibodies in these ELISAs 
was determined by the incorporation of diethylamine (DEA). 
XXV 
In order to determine the immunoglobulin allotypes ELISAs were developed to measure 
the Glm(t), G2m(n) and Km(3) allotypes. The frequency of these allotypic markers in the 
different ethnic groups was established. The relationship between immunoglobulin 
allotypes and IgG subclass values were investigated in both patient and control groups. 
RESULTS 
ELISA assays to measure IgG subclasses; IgG, IgG 1 and IgG4 tetanus toxoid antibodies; 
IgG, IgG 1 and IgG2 H. influenzae type b polyribosylribitol phosphate capsular 
polysaccharide antibodies; IgG, IgGl and IgG2 S.aureus teichoic acid antibodies and 
Glm(t), G2m(n) and Km(3) allotypes were successfully established. Where possible the 
assays were standardized with reference sera and specimens were exchanged with 
international laboratories. 
Age, race and sex related percentile charts and tables of normal ranges for IgG and IgG 
subclasses of Black and Coloured children were established. The IgG and IgG 1 values 
were higher than those previously reported for children in developed countries. Black 
children with H. influenzae meningitis had significantly lower IgG 1, IgG2 and IgG3 levels 
compared to the controls and although similar trends were seen for IgG and IgG4 levels 
they were not statistically significant. Coloured children with H. influenzae meningitis and 
Coloured and Black children with H.influenzae osteomyelitis/septic arthritis also showed a 
similar tendency of lower IgG and IgG subclass levels than the controls but these trends 
were also not significantly different. 
All patients responded to tetanus toxoid antigen suggesting normal immunocompetence to 
protein antigens. 
H. influenzae type b capsular polysaccharide antibodies were low in children with 
H.influenzae type b meningitis and osteomyelitis/septic arthritis and did not increase during 
the illness. 
XXVI 
IgG and IgG 1 teichoic acid antibodies were raised in patients with S. aureus 
osteomyelitis/septic arthritis although no further rise in these antibodies was seen when 
measured several weeks after the illness. 
The antibody affinity ELISAs showed that IgG 1 tetanus toxoid antibody had a greater 
affinity than IgG4 tetanus toxoid antibody, the IgG 1 and IgG2 H. injluenzae capsular 
polysaccharide antibodies were of similar affinity and the IgG 1 teichoic acid antibody was 
of higher affinity than the IgG2 antibody. 
The Glm(f) and G2m(n) positive allotypes were uncommon in Black but common in the 
Coloured populations whereas Km(3) was common in both groups. There was a 
significantly decreased frequency of the G2m(n) positive allotype in Coloured patients with 
H. injluenzae type b meningitis and H. injluenzae type b osteomyelitis/septic arthritis which 
was not found in patients with S.aureus osteomyelitis/septic arthritis. In both Coloured 
and Black children with H. injluenzae meningitis there was a significantly decreased 
frequency of the Km(3) allotype. 
No differences in C4 isotypes and mannose binding protein levels were evident in the 
patient and control groups. 
CONCLUSION 
This study has developed simple, specific and reproducible ELISAs to measure IgG 
subclasses and subclass antibodies specific to tetanus toxoid, H.injluenzae polyribosylribitol 
phosphate and S.aureus teichoic acid. Age, sex and race related normal ranges for IgG 
subclasses in the local Black and Coloured populations have been established. Black 
children with H. injluenzae type b meningitis had significantly lower IgG 1, IgG2 and IgG3 
levels compared to the controls. There was a clear association between a decrease of the 
XXVll 
G2m(n) allotype and the Km(3) allotype and susceptibility to invasive infections caused by 
H. injluenzae. 
SECTION A - Chapter 1: Enzvme-linked immunosorbenr assay 
CHAPTER 1 
ENZYME-LINKED IMMUNOSORBENT ASSAY 
(A review of methodology) 
1 
Enzyme-linked immunosorbent assay (ELISA), first introduced in 1971, has gained wide 
acceptance and application for the detectioin of antigens and antibodies. This is largely 
due to the sensitivity, specificity and reproducibility of these assays (Engvall and Perlmann 
1971, Van Weemen and Schuurs 1971). They also require relatively limited equipment, 
can accommodate large numbers of samples and are reasonably economical. 
The ELISA technique has been comprehensively and extensively reviewed in the literature 
(Kurstak 1985; Voller and Bidwell 1986; Kemeny and Chantler 1988; Kemeny 1992; 
Porstmann and Kiessig 1992). This chapter reviews the important technical aspects that 
must be taken into consideration in order to establish the ELISA assays used in this thesis 
and is divided into the following sections: 
1.1 ELISA SYSTEMS 
1.2 CHOICE OF SOLID PHASE 
1.3 SOLID PHASE IMMOBILIZATION 
1.4 INTERFERENCE 
1.5 WASHING 
1.6 SAMPLES, BUFFERS AND INCUBATION TIMES 
1.7 SAMPLE DILUTION AND DISPENSING 
SECTION A - Chapter 1: Enzyme-linked immunosorbent assay 2 
1.8 ANTIBODY REAGENTS 
1.9 ENZYME DETECTOR SYSTEMS 
1.10 SUBSTRATES 
1.11 PLATE FORMAT 
1.12 DATA ACQUISITION 
1.13 DATA INTERPRETATION AND QUALITY CONTROL 
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1.1 
1.1.1 
1.1.1.1 
1.1.1.2 
ELISA SYSTEMS 
There are many different ways of configuring ELISAs and the choice 
depends on the nature of the sample, availability of reagents and the 
precision and sensitivity required. Two fundamentally different solid phase 
ELISAs can be distinguished, the non-competitive and competitive assays. 
Non-Competitive ELISA 
Antigen coated plate 
These are probably the simplest type of assays, which are also known as 
indirect ELISAs and are commonly used for the detection of antibodies to an 
antigen which is immobilized on the solid phase. The antigen will capture 
specific antibodies from the test serum before the addition of a class or 
subclass specific monoclonal antibody which can then be detected by 
addition of an enzyme labelled antibody specific for the bound monoclonal 
antibody. The signal generated from the enzyme label is proportional to the 
amount of analyte bound to the solid phase. This assay design is used in the 
development of the IgG subclass specific ELIS As in this study. 
Antibody coated plate 
In these immunoassays the immunoglobulin class of interest is isolated from 
other immunoglobulin classes (antibody capture). This design was used in 
the IgG subclass ELISAs where the microtitre plate is coated with 
monoclonal antibody specific for the respective IgG subclass. The bound 
anti-IgG subclass monoclonal antibody is used to absorb its respective 
subclass in the sample. A labelled antibody is used to detect the quantity of 
captured antibody. 
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1.1.2 Competitive ELISA 
1.2 
Competitive assays use antigen coated plates where a fixed level of enzyme 
labelled antibody competes with variable amounts of unlabelled antibody in 
the test sample. Competitive assays were not used in the assays established 
for this thesis. 
CHOICE OF SOLID PHASE 
Although plastic is the most generally used solid phase in enzyme 
immunoassays it has a lower capacity for binding proteins (10%) than 
nitrocellulose (100%). Plastic microtitre plates have low background 
binding and are therefore more suitable for the measurement of IgG 
antibodies (Grant et al 1981). Different plastics have distinct uptake 
characteristics, polystyrene causing lower background signals than polyvinyl 
chloride (PVC) as it takes up less protein. It can therefore be used where a 
low coating level is acceptable and where non-specific uptake from the 
sample (e.g. serum) is to be minimized (Voller and Bidwell 1986). 
Attachment of antibody to the polymer surface appears to occur by a process 
of adsorption (Ansari et al 1985) and is dependent upon the nature of both 
protein and polymer. The nature of interaction of the antigens or antibodies 
with the plastic is not known but both hydrophobic binding and the charge 
of the antibody or antigen play an important role. Binding of antibody to 
polystyrene increases with antibody concentration, and the time of 
incubation before reaching a maximum value. The stable binding of antigen 
or antibody to the solid phase is of central importance since if this is not 
successful the rest of the assay will fail. 
The following requirements of solid phases are common to all assays: 
1. a high binding capacity for antigen or antibody which does not 
interfere with immunological activity after binding 
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n. binding stability on storage 
111. bound material should not become detached m the course of the 
assay. 
The most common layout for solid phase ELISAs are microtitre plates with 
12 x 8 wells (round or flat bottomed). With these plates an 'edge' effect 
(differences in binding of the sample to the outer wells) has been described. 
Much of this edge effect may be due to the poor conduction of heat by 
polystyrene. This can be reduced by carrying out the incubation steps in an 
incubator or increasing the incubation times. Non-usage of the outer wells 
would result in a loss of about 40 % of the plate. Although a theoretical 
possibility, the 'edge' effect has not been a problem in the ELISA' s 
described in this thesis. 
SOLID PHASE IMMOBILIZATION (COATING OF ANTIGEN OR 
ANTIBODY) 
1.3.1 Direct 
The easiest and most popular method to coat the microtitre plate is directly 
by passive adsorption to the surface of the plastic (Cantarero et al 1980). 
Observations over the past 30 years have shown that adsorption of proteins 
on hydrophobic synthetic surfaces result in protein alteration. There are no 
reports contradicting this. Butler et al (1992) have shown that polyclonal 
capture antibodies retain only 5-10% of their binding sites whereas the most 
stable monoclonal antibodies have ::;; 3 % of functional binding sites after 
adsorption. 
1.3.2 Indirect 
Bacterial polysaccharides carry a net negative charge due to many acid 
groups and absorb poorly to plastic. This problem has been overcome by 
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covalently binding the polysaccharide to poly-L-lysine using cyanogen 
chloride as the coupling agent (Gray 1979). The poly-L-lysine protein binds 
more efficiently to the plastic thus immobilizing the coupled polysaccharide. 
1.3.3 Concentration 
Coating conditions must be optimized for each ELISA system. The optimal 
coating concentration depends on the antigen or antibody used but it is 
usually between 1 and 10 µglml protein (McLaren et al 1981, Kemeny 
1992). Ideally all the binding sites on the solid phase should be occupied by 
the antigen molecules during coating. Overcoating with antigen is a 
disadvantage as a monolayer of antigen is not maintained and antigen 
molecules may later become detached. This will affect the assay especially 
if the antigen has already bound the analyte as these complexes are unlikely 
to re-attach to the solid phase. 
1.3.4 Buffer and pH 
Buffers generally have little or no effect on the immobilization of proteins 
(Kurstak 1985). Carbonate (0.05 M, pH 9.6), Tris-saline (0.01 M), Tris-
HCL, pH 8.5, with 0.1 M NaCl) and phosphate buffered saline (PBS) (0.01 
M phosphate buffer pH 7.2, with 0.1 M/NaCl) are widely used. Aqueous 
diluents of neutral or alkaline pH (especially carbonate or phosphate buffers) 
have been successfully used for most proteins. 
1.3.5 Time 
The coating incubation period is usually 4 °C overnight but can be 
shortened, if incubated at room temperature or 37°C. 
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1.4.1. 
INTERFERENCE 
Blocking of unreacted sites 
A common problem in ELISAs is non-specific, or specific undesirable 
binding of different test serum or other proteins to the solid phase. To 
prevent non-specific adsorption it is common practice to block unreacted 
sites after the primary coating step with an irrelevant protein e.g. 1-5 % 
bovine serum albumin (BSA), casein or gelatin diluted in PBS, or a non-
ionic detergent (Tween 20, Triton xlOO). The blocking protein is usually 
added in excess (0.1-5.0 gm/100 ml) of the well's protein binding capacity 
(typically 1 µg/well). The choice of blockers is not universally suitable for 
all assays. As human serum albumin is invariably contaminated with a 
small percentage ( < 1 % ) of immunoglobulins it is unsuitable as a blocking 
agent for IgG and IgG subclass assays. 
Blocking agents can reduce sensitivity by interfering with antigenic 
determinants of the coated proteins but provided this is not excessive is 
outweighed by the benefits of reduced background binding. If BSA or other 
common ingested proteins are used to block the plates, they may capture 
naturally occurring antibodies for these proteins that are present in the test 
sample. If the blocking protein is included in the assay diluent this effect 
can largely be prevented. 
Despite the widespread usage of blocking agents there are reports of this 
being an unnecessary or even harmful step (Mohammad and Esen 1989; 
Gosling 1990). 
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1.4.2 Heterophile antibodies 
Heterophilic antibodies are endogenous antibodies found in patients' serum 
that can bind to immunoglobulins from other species, including the species 
used to raise the antibody reagents for the ELISAs. 
The use of F(ab')2 fragments of the antibody reagent has been advocated as 
a means of decreasing heterophilic antibody interference (Schroff et al 1985; 
Clark and Price 1987) but may not always be effective (Boscato and Stuart 
1988). Interference with heterophilic antibodies can be decreased by adding 
excess non-immune immunoglobulin, generally obtained from the same 
species as the reagent antibody. 
1.4.3 Other 
Other interfering substances include complement, rheumatoid factors, 
lysozyme and enzymes that are potential contaminants of antigen 
preparations (Gosling 1990). 
ELISA assays always involve some non-specific adsorption which is one of 
the major factors limiting the accurate measurement of very small amounts 
of antigen or antibody. 
1.4.4 Serum background 
The OD measurements obtained in assays included values for both the 
specific antibody/antigen reaction plus non-specific background values. 
These non-specific values can be determined by including blank wells with 
serum dilutions but minus antigen, and wells with antigen but minus serum. 
Many serum specimens display 'background' i.e. significant OD readings in 
the 'minus antigen' control well. 
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'Background' values may be due to reactivity of antibodies, other than the 
test antibody with antigenic determinants in the reagents or to non-reactive 
serum components that are detected by second antibodies or conjugate 
antibodies. The background values from wells with no serum but with 
antigen may be due to impurities in the antigen solution which react with 
second or conjugate antibody. It can also be due to adherence of unreacted 
conjugate to the well surface because of inadequate blocking of all the well 
surfaces. This is usually overcome by using at least double the volume of 
blocking solution to fill the wells. It is common practice to subtract the OD 
background readings of the minus antigen wells from each serum dilution. 
In all the assays described in this thesis the total of the 'minus antigen' and 
the 'minus serum' background values were subtracted from each serum 
dilution. 
WASHING 
Efficient washing is important if reliable results and good replicate values 
are required. The aim of washing is to minimize non-specific binding by 
removing reagents which are either unbound or weakly absorbed to the solid 
phase. Wash steps are necessary after each incubation step to remove 
weakly immobilized immunoreactants, to decrease non-specific reactivity 
and to prevent carry over of unbound immunoreactants. 
Phosphate buffered saline (0.01 M PBS, pH 7.2) with 0.05% of polysorbate 
-20 e.g. Tween 20 (PBST) is most commonly used as a washing solution. 
Tap water may be substituted for the PBS, provided it has a neutral pH and 
a low chlorine content. In this thesis either PBST or Tris buffered saline 
(TBS) with 0.01 % Tween 20 (TBST) was used as the washing fluid 
depending on the buffers used in the various assays developed. The 
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concentration of Tween 20 is not critical and a range from 0.005% to 0.5% 
was found to be equally effective in this study. 
It has been suggested that the solid phase should be washed by rinsing wells 
at least three times for 3-5 minutes each (McLaren et al 1981). It is 
important that there is no carry over from one washing step to the next and 
that the carrier surface is thoroughly washed. Plates can either be washed 
by hand or using automated machines. 
In the assays described in this study hand washing was preferred as it is 
gentler and less time consuming. For each wash the plate's contents are 
emptied by inverting them over a sink with a flicking action of the wrist. 
The plate is then held at a 45 ° angle and the washing buffer poured from a 
beaker across the plate in a right to left and left to right fashion working 
down the plate. This ensures that all wells are flooded. After the final rinse 
the contents of the plate are shaken out and the inverted plate firmly blotted 
several times onto a pad of paper towelling. 
After coating and blocking, plates are washed once with PBS. After the 
addition of either serum, monoclonal antibody or conjugate, incubation 
plates are washed five times with PBST. 
SAMPLES, BUFFERS AND INCUBATION TIMES 
Serum and plasma samples can both be used in ELISA. In these studies 
blood was collected under sterile conditions. Serum was stored at -70°C in 
small aliquots to avoid repeated freezing and thawing of samples. It is 
important that samples are measured in the concentration range in which the 
standard curve has steep dose-response curve characteristics. To decrease 
non-specific binding of irrelevant proteins in the test sample a detergent 
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(e.g. Tween 20) can be added to the diluent in addition to blocking agents 
such as BSA or gelatin. It is well known that detergents prevent attachment 
of proteins to plastic surfaces (Gripenberg and Kuruki, 1986). Buffers used 
for dilution generally contain 0.05 % Tween and/or inert proteins (BSA, 
gelatin) to prevent non-specific binding to the solid phase. The most 
common buffers are PBST (PBS, pH 7.4, with 0.05% Tween-20) or Tris-T 
(0.02 M Tris-HCL, pH 7.4, with 0,15 M NaCl, 0.005 M KCL and 0.05% 
Tween-20). Tris-Tis particularly useful when the enzyme system is alkaline 
phosphatase. Optimal incubation conditions for the binding of test samples 
should be established for each particular system. For example incubation at 
37°C may be excellent for one system but will give poor results with 
another owing to the nature of the antibody/antigen interaction. Generally 
incubation for 1-2 hours is sufficient but shorter incubations in some assays 
are possible. 
The assumption that non-specific binding is constant over the complete range 
of dilutions is not valid (Kurstak 1985). Negative control sera should 
therefore be tested at the same dilutions as the test and positive sera. 
Pooled serum makes a practical reference standard as when stored at ::;; 
-20°C it retains its antibody activity because of the stable natural 
environment of proteins in serum and the minimum proteolytic activity for 
antibodies in serum (Butler 1988). Various pooled serum samples were used 
for the standard curves and reference standards in all the assays described in 
this thesis. 
Despite reports of background binding increasing with serum storage time at 
-20°C (Shillitoe 1982) this was not found in the assays described in this 
thesis using sera stored at -70°C. 
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1.8 
SAMPLE DILUTION AND DISPENSING 
The step with the greatest potential for creating assay imprecision and 
inaccuracy is the physical preparation of sample dilutions. Inadequate 
mixing of highly diluted samples is a major source of error in ELISAs. It is 
recommended that the same pipetting device should be used for the 
preparation of dilutions of the reference standard and the test specimens. In 
these assays dilutions were made using Gilson pipettes to dispense volumes 
of less than 1 ml. Graduated glass pipettes where used to dispense larger 
volumes manually. All dilutions were prepared in 10 x 75 mm disposable 
glass test tubes or 20 ml glass scintillation vials. Samples were vortexed 
before transfer to the appropriate wells of microtitre plates using Gilson 
pipettes. Providing that the weakest dilution was transferred first, the same 
pipette tip was used sequentially to transfer the stronger dilutions of the 
same sample. An initial dilution of standard curve serum was made, from 
which the other 8 standard curve dilutions were independently made. 
Multi-channel-pipettes (Eppendorf) were used to add blocking solutions, 
antibody dilutions, substrate and reaction stopping solutions. 
Solutions must be pipetted into each well in a timed sequence. This is 
particularly important for the conjugate, substrate and reaction stopping 
solutions where incubation times must be accurate and the end results are 
read immediately after stopping the reaction. 
ANTIBODY REAGENTS 
Both monoclonal and polyclonal antibodies can be used in ELISAs. 
Monoclonal antibodies are highly specific as capture reagents. However as 
they represent a single antibody lineage within a polyclonal immune 
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response it is sometimes necessary to use a mixture of antibodies with 
different epitope specificities. Although antibodies lose activity on 
adsorption to a solid phase, most antibodies retain their ability to bind 
antigen. The binding ability of some monoclonal antibodies may be 
improved by chemically coupling to BSA (Papadea et al 1985) or by 
treatment of the antibody with either low pH, high temperature or urea 
(Conradie et al 1983). 
A disadvantage of coating wells with whole serum or ascitic fluid reagents 
rather than an immunoglobulin fraction is the increased potential of non-
specific reactions due to the many other proteins present in serum or ascitic 
fluid. Even with affinity purified reagents unwanted cross-reactions must be 
controlled. In several assays developed in this study affinity purified 
conjugate antibodies gave poorer signals and higher non-specific binding 
than non-affinity purified antibodies. 
The storage and handling of antibody reagents is important. Whole serum 
and ascitic fluid should be stored in aliquots at -20°C to minimise repeated 
freezing and thawing. 
The antibody reagents used m this study were all purchased from 
commercial suppliers. 
1.8.1 Antibody reagents for IgG subclass ELISAs 
Polyclonal anti-IgG subclass antibodies have restricted application as 
reagents for IgG subclass assays. Polyclonal antisera that are monospecific 
for IgG subclasses are difficult to prepare and are only available from 
limited sources. Repeated immunization and bleeding, may over time affect 
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the affinity and specificity of the polyclonal antisera making it difficult to 
produce large quantities of standardized reproducible antibody. 
Murine monoclonal antibodies specific for IgG subclasses were first reported 
in the mid 1980's. The International Union of Immunological Societies 
(IUIS) in collaboration with the World Health Organisation (WHO) 
evaluated monoclonal antibodies with putative specificity for the human IgG 
subclasses that had been produced by several laboratories (Jefferis et al 
1985). Each clone evaluated was given an HP designation. The monoclonal 
subclass specific antibodies used in this study were selected from the panel 
of antibodies reviewed in the IUIS/WHO report because they displayed good 
specificity and were commercially available. These monoclonal antibodies 
all have a clone number and an IUIS/WHO study number and are referred to 
using the HP designation of the IUIS/WHO. Details of the anti-human IgG 
monoclonal antibodies used in this study are listed in Appendix A. Quality 
control information on the subclass specific monoclonal antibodies is not 
supplied by commercial firms necessitating assessment of new vials of 
antibody in the assay system prior to depletion of old stocks. 
ENZYME DETECTOR SYSTEMS 
In immunoassays, a detector is any molecule that has specificity for the 
sample which it is used to detect (Kemeny 1992). The final step of the 
ELISA is an enzyme catalysed reaction. These enzymes are conjugated to a 
detection antibody that binds either to the test antigen or antibody or is 
coupled to streptavidin which then binds to biotiny lated antibody. The 
kinetics of the enzyme reaction can be affected by a number of factors e.g. 
concentration of enzyme, temperature, the solvent of the enzyme substrate 
and the pH of the solution. The working dilution of the conjugate is 
determined to give both high detection values and low background readings. 
SECTION A - Chapter 1: Enzyme-linked immunosorbent assay 15 
To obtain reproducible results in ELISAs, it is important to control as many 
factors as possible, particularly if the end point is based on time as 
commonly occurs in many ELISAs. This is controlled by critically stopping 
the enzyme substrate reaction. Many different enzymes have been used in 
ELISAs, of which horseradish peroxidase (HRPO), alkaline phosphatase and 
8-D-galactosidase are the most commonly used. 
Horseradish peroxidase is used in about 50 % of described ELISA methods 
and alkaline phosphatase in about 25 % (Gosling 1990; Porstmann and 
Keissig 1992). Horseradish peroxidase has a high turnover rate, is pure, 
relatively cheap and readily available. In the ELISAs developed in this 
study horseradish peroxidase was used in preference to alkaline phosphatase 
because of cost and availability. 
The quality of the detector antibody used for enzyme conjugation and the 
efficacy of conjugation is directly related to assay performance. Cross-
reactivity with components in the assay must be removed by pre-adsorption 
of the unlabelled antibody or neutralizated by the addition of the appropriate 
material in the conjugate diluent. Anti-species immunoglobulin cross-
reactivity may be effectively decreased by addition of 1-2 % of serum from 
the reacting species. 
There are a number of approaches designed to reduce the loss of antibody 
and enzyme activity on conjugation, the most widely used being the avidin-
biotin complex. A vidin has an extremely high affinity for biotin with an 
association constant of 10-l5M. Biotin is linked to antibody and used as a 
primary label with enzyme conjugated streptavidin or avidin as the final 
assay reagent. As the affinity of avidin for biotin is high, the enzyme 
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labelled conjugate binds efficiently to the biotinylated antibody. 
Streptavidin is often preferred because it has a lower isoelectric point (5.5-
6.5) and is not glycosylated, which helps to decrease non-specific binding 
(Hart and Taaffe 1987). The streptavidin-biotin interaction has been used to 
amplify the signal in some of the IgG subclass specific ELISAs where a 
biotin-labelled antibody reacts with an immobilized antigen and is then 
revealed by the addition of streptavidin conjugated horseradish peroxidase. 
1.10 SUBSTRATE 
Although horseradish peroxidase is one of the most frequently used markers 
in ELISAs its reaction kinetics are highly complex and have not been fully 
elucidated (Porstmann et al 1981). Horseradish peroxidase catalyses the 
reduction of H202 with the concurrent oxidation of a chromagen producing 
an optically measurable colour change in the ELISA. A large number of 
chromogens are commercially available, several of which may be used with 
the horseradish peroxidase conjugates. The most commonly used are ortho-
phenylenediamine (OPD), 2, 2-azino-di(3-ethy lbenzthiazline-6-sulphate) 
(ABTS), 5-aminosalicylic acid (5-AS) and 3,3', 5,5' tetra-methylbenzidine 
hydrochloride (TMB). OPD is light sensitive. It produces a strong yellow 
colour and when the enzyme reaction is stopped by sulphuric acid the colour 
conveniently changes to orange-brown. The recommended peroxide 
concentrations for these chromogenic solutions varies from 0.003 % for 5-
AS to 0.02 % for OPD. It is advisable to store hydrogen peroxide in 
aliquots at 4 °C. Peroxidase is sensitive to micro-organisms, sodium azide 
and methanol. This must be borne in mind as many of the antibodies have 
azide added as a bacteriocidal agent. 
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It has been clearly shown that the sensitivity of the ELISA can be strongly 
affected by the choice of chromogen (Porstmann et al 1981). OPD has been 
reported to be the substrate that gives the most sensitive and reliable 
measurements (Porstmann et al 1981; Avrameas 1983). It was found in this 
thesis that OPD was more sensitive than ABTS giving a signal 8 times and 
thus it was used for all the ELISAs. With this substrate the optical density 
was measured with an ELISA photometer at a wavelength of 492 nm using a 
reference wavelength of 620 nm. 
1.11 PLATE FORMAT 
A 
B 
C 
D 
E 
F 
G 
H 
The plate format used for all assays in this study except the Km(3) ELISA is 
shown in Figure 1.1. Every assay plate included 9 dilutions of the standard 
for the construction of calibration curves, background reaction wells (minus 
serum, minus antigen and minus monoclonal antibody wells where 
applicable) and dilutions of controls for monitoring reproducibility. 
1 2 3 4 5 6 7 8 9 10 11 12 
C IA L I B tR A rr I IO N B C C 
s T IA N D A tR D S B C C 
B C C 
M I N U s IA N tt I 1G E IN vi E I L S 
-
-
u lN K IN o 1W N S AM p 1 E S 
M I N u s AN T I G E N W E L 1 s 
B = Mmus serum and mmus monoclonal antibody blanks C = Controls 
Figure: 1.1: Elisa Template 
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Rows A, B, C, E, F and G were coated with antigen whereas rows D and H 
were not (minus antigen wells). Nine dilutions of the standard serum were 
added to columns 1-9 rows A-D. The two dilutions of the positive controls 
were in columns 11 and 12 - rows A-D. Unknown serum samples were 
placed in columns 1-12 rows E-H with blanks in column 10 rows A-D. In 
the IgG ELISA these blanks were minus serum blanks. The blanks of 
column 10 in the subclass specific assays were as follows: 
Row A: Minus serum, plus monoclonal antibody 
RowB: Plus serum, minus monoclonal antibody 
Row C & D: Minus serum, minus monoclonal antibody 
This format allows samples to be run in triplicate on a plate and for the 
appropriate background corrections to be made. Antigen blanks and the 
highest value of the minus serum or minus monoclonal antibody blanks were 
added together and subtracted from the mean of the triplicate of each of the 
standard and sample dilutions. Initially these blanks were carried out in 
triplicate but if they were consistently low ( ~ 4% of signal), they were only 
included as a single blank in routine runs to allow for more unknown 
samples to be included. 
1.12 DATA ACQUISITION 
In this study two ELISA readers were used: i. SLT 210 photometer (SLT -
Lab Instruments, Austria); ii. Anthos Reader 2001 (Labtec). Each of these 
is linked to a personal computer. The data can be stored and analysed at a 
suitable time. 
There is no standardized method for the analysis of ELISA data. Various 
relationships between OD and log (serum dilution) have been assessed which 
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include: OD as a linear function of log (serum dilution), log (OD) as a 
linear function of log (serum dilution); OD as a quadratic or quartic 
polynomial function of log (serum dilution); and 4-parameter log - logistic 
function. A variety of estimation procedures have also been applied 
including visually drawn straight lines, weighted and simple least squares 
and weighted and unweighted non-linear least squares (Karpinski et al 
1987). In evaluating analysis of ELISA data Karpinski et al (1987) found 
that OD as a linear function of log serum dilution is inappropriate. It 
involves subjective judgement of the range and adequacy of the straight line 
relationship. The weighted non-linear least squares analysis of 4 parameter 
logit was also shown to be inappropriate because it requires the specification 
of an arbitrary variance function. 
The most appropriate procedure for determining the concentration of 
antigens or antibodies by the ELISA method is to represent OD as a 4-
parameter logistic function with estimation carried out on the log scale. This 
approach was shown to provide excellent fits of data over a wide range of 
serum dilutions and is recommended in a variety of systems for the 
determination of the concentration of antigens or antibodies (Karpinski 
1987). 
The standard curve is assumed to be sigmoidal and 1s described by the 
following equation: OD = C + D - C 
1 +e-2(a + Bx) 
where a, B, C and D are the coefficients which determine the curve. C and 
D are the lower and upper asymptotes respectively while a and B are 
indicators of the location and steepness of the curve. The error function is 
the sum of the squares of the differences between each measured value and 
the corresponding calculated value, using the current coefficients. The 
initial values for the coefficients are based on an assumption of linearity. 
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The programme then uses formulas for first and second partial derivatives of 
the above function with respect to the four coefficients to repeatedly 
improve the initial guess. At each step a vector in four dimensions is 
generated in the direction of the steepest descent of the error function, and 
the second derivative is used to approximate the step required to obtain the 
extrapolated position of the minimum. Using this method a software 
programme was written by P W Becker (Custom Software Solutions, South 
Africa). This programme was used to analyse all the routine assays in this 
study. The user may specify a wide range of formats to be used for 
interpreting the data. Each format specifies: 
1. The area to display on the graph and the distance between the ticks of 
the x and y axes 
11. The neat standard concentration 
111. The units (grams or units) and magnitude (e.g. 6 for micrograms) for 
the standard and the magnitude of the units to be used on the 
printouts 
1v. The standard dilutions 
v. The sample dilution used 
The system is programmed to calculate a mean of the triplicate 
dilutions and to subtract the appropriate background controls. The 
programme fits a sigmoidal curve to the 9 standard OD readings. 
Once the best fit is achieved, the resultant sum of the errors squared 
is reduced to < 0.02. The values of the samples are read off the 
curve and the final concentration calculated correcting for initial 
dilutions of the specimen. Figure 1.2(a) and Figure 1.2(b) below is 
an example of a computer printout from this programme. 
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A B C Blank Mean SD CV X value Cale x gx!O -3/ml % Err 
1.489 1.459 1.460 0.039 1.410 0.014 0.9 1.301 1.329 0.944 -1.087 
1.310 1.272 1.263 0.025 1.236 0.020 1.6 1.602 1.575 0.480 1.954 
1.028 0.992 0.972 0.019 0.958 0.023 2.3 1.875 1.851 0.254 2.886 
0.811 0.782 0.785 0.015 0.757 0.013 1.6 2.000 2.023 0.170 -3.936 
0.631 0.636 0.608 0.016 0.588 0.012 2.0 2.176 2.176 0.120 0.023 
0.348 0.361 0.354 0.016 0.319 0.005 1.5 2.477 2.473 0.061 1.000 
0.215 0.232 0.224 0.019 0.184 0.007 3.1 2.699 2.695 0.036 0.988 
0.122 0.109 0.118 0.014 0.082 0.005 4.7 3.000 2.990 0.018 2.792 
0.091 0.085 0.096 0.017 0.050 0.003 3.0 3.176 3.155 0.013 6.580 
The standard curve data: (from left to right) 
ii. 
iii. 
iv. 
v. 
vi. 
vii. 
viii. 
A, B, C are the triplicates of each dilution 
'Blank' denotes uncoated well of each dilution 
'Mean' indicates the mean OD of the triplicates with each individual uncoated blank subtracted 
SD and CV are the standard deviation and coefficients of variation of the triplicates 
'x value' is the log of the inverse of the sample dilution 
'Cale J.f~S the calculated log value of the dilution 
g x 10 /ml is the calculated value of each sample 
'% Err' is the % error between the known and calculated value of each sample. 
Figure l.2(a): Computer printout of the standard curve data for the measurement of 
IgG 1 antibodies to Haemophilus influenme b PRP using the plate format described in 
Chapter 1.11 
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Figure 1.2(b): Standard curve of IgGl antibody to Haemophilus influenzae type b (Hib) 
polyribosylribitol phosphate (PRP). Graph of OD on y axis vs log serum dilution on x 
axis with ( +) representing data points before background blanks are subtracted. The 
sigmoidal curve is fitted to the 9 standard points (•) after the background blanks have 
been subtracted. cx, 6, C and D are the coefficients used to determine the curve (see 
Chapter 1.12 for details). 
The format for the sample data is the same as for the standard except for the 
addition of a column indicating the absolute value of the sample extrapolated 
from the standard curve before correction for dilution. 
1.13 DATA INTERPRETATION AND QUALITY CONTROL 
Assay precision is of great importance and is usually expressed as a 
coefficient of variation (CV). This is performed by testing at least 3 
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dilutions of the appropriate reference to cover the upper, middle and lower 
parts of the standard curve in triplicate in several assays performed on 
different occasions. The CV is obtained by using the following equation: 
CV = standard deviation x 100 
mean 
Various CVs can be measured: 
1. Intra-assay (within assay) variation, determined by testing one 
sample many times in one assay which tends to give an over-
estimation of precision; and 
ii. Inter-assay (between assay) variation based on testing one sample in 
a sequential number of different assays on different days (McLaren et 
al 1981). 
111. Inter-dilutional (between dilution) variation achieved by testing one 
sample of different dilutions in one assay. 
The aim is to achieve an intra-assay CV < 10% and inter-assay CV < 15% 
(Porstmann and Kiessig 1992). Inter-dilutional CV's of ::;; 20% were taken 
as evidence of assay parallelism. For quantitative measurements of antibody 
a greater degree of precision is needed, particularly if a change in antibody 
level is being investigated. Precision performance of an assay can be 
monitored by plotting the means and standard deviations of positive and 
negative reference sera for each test on standard quality control charts (Batty 
1981). Technical performance can be checked by placing reference samples 
or samples of known antibody activity amongst samples for routine testing in 
each run. This ensures precision of the test from run to run within the 
laboratory and enables the mean and standard deviations (SD) of these 
internal standards to be plotted. 
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To ensure uniformity of a test it is necessary: 
1. to accurately calibrate local standards with international standards; or 
n. to exchange coded samples with other laboratories if no international 
standard exists. 
Theoretically there should be a linear relationship between optical density 
and analyte concentrations. As this is the exception rather than the rule, it is 
undesirable to express results as absolute optical density units. Where 
reference preparations are available, the results can be extrapolated from a 
standard curve run on each plate and given a value. Where reference 
preparations are not available a pool of serum or antigen extract with a high 
concentration of analyte can be used as an internal reference preparation and 
given arbitrary unitage. Results can only be recorded from a reference 
curve if the reference material and sample have parallel dilution curves. 
Parallelism is shown when the same final concentration of the sample is 
estimated following correction for the serum dilution. When non-
parallelism is seen in samples with low analyte concentration, quantitation 
must be interpreted with caution. 
Parallelism is also useful for identifying any changes in assay performance 
secondary to reagent variability and stability. 
Dose-response curves for antigen or antibody usually have a sigmoidal form 
on which a level has to be set to discriminate between positive and negative 
results. Establishing a lower limit or cut-off of the assay always presents 
problems in ELISA due to the large variation in absolute absorbance values 
obtained on different occasions. The cut off has been derived in different 
ways by different groups and expressed as a multiple of mean background, 
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as an absorbance value above mean background, or relative to a known 
reactive sample (Kemeny and Chantler 1988). In the assays developed in 
this thesis the cut-off values were determined as twice the mean of the 
background readings (wells with diluent alone). The end point is not the 
least amount of antibody or antigen present but the smallest quantity that can 
reliably be detected by the methods used. End points that are too close to 
the background are unreliable because small differences in concentration 
give equally small changes in colour. End points have been defined as 0.20 
OD units above background (Kemeny 1992). The end points of assays 
developed in this thesis were determined from serial dilution of the standards 
until the results were no longer reproducible. The OD of the greatest 
dilution giving accurate quantitation of the standard was taken as the end 
point of the assay. The analyte in samples with an OD greater than this end 
point OD could be accurately quantitated. 
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CHAYfER 2 
IgG SUBCLASS IMMUNOASSA YS 
The accurate measurement and interpretation of IgG subclass values have become 
increasingly relevant to clinical medicine in the diagnosis of humoral immunodeficiencies. 
Sensitive and reproducible methods are required to measure IgG subclasses. This chapter 
discusses the need for and the various methods of IgG subclass measurement and describes 
the development of optimal assay conditions and the selection of the methods employed. 
The assay methodology is detailed and results of experiments relating to the precision and 
standardization of the assays are described. Finally aspects of the assays and future 
application of the assays are highlighted. 
2.1 INTRODUCTION 
2.2 DETERMINATION OF OYfIMAL ASSAY CONDITIONS 
2.3 METHODS 
2.4 ASSAY STANDARDIZATION 
2.5 SUMMARY 
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2.1 INTRODUCTION 
The clinical significance of IgG subclass deficiencies has been studied for 
the past 15 years. Sensitive assays are required to measure IgG subclass 
levels particularly in children as levels are relatively low. Various methods 
have been used to quantitate these proteins. 
IgG subclasses were originally defined by serological methods but their 
measurement was hampered because of the difficulty in producing antibodies 
specific for each of the IgG subclasses (Natvig and Kunkel 1973). Even 
when a specific antibody is produced its use may be restricted to the assay 
method used for developing the antibody (Jefferis et al 1985). 
Initially assays for IgG subclass proteins used polyclonal precipitating 
antisera. The need for antibody specificity, reproducibility and availability 
was resolved with the advent of monoclonal antisera. 
Immunodiffusion was one of the first methods applied to the quantitative 
measurement of each subclass protein in serum (Yount et al 1968, Shakib et 
al 1975, van der Giessen et al 1975, Mancini et al 1965). Radial 
immunodiffusion (RID) is based upon the precipitation of immune 
complexes as serum is allowed to diffuse into an agar matrix containing anti-
IgG antibodies. Wells are cut in thin agarose gel which contain subclass 
specific antiserum. Serum is pipetted into the wells. As the IgG subclass 
protein diffuses radially, it binds and precipitates with antibody, forming a 
white precipitin ring where the antigen-antibody complexes reach 
equivalence. The concentration of immunoglobulin is proportional to the 
ring of precipitation. A small error in such a measurement may result in a 
large error in the determination of the immunoglobulin concentration. 
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Leibl et al (1992) have recently shown that RID with polyclonal antibodies 
is suitable for reliable quantification of IgG subclasses. When comparing 
RID using either polyclonal reagents or monoclonal reagents, the results for 
IgG 1 and IgG2 subclasses were comparable, but were discrepant for IgG3 
and IgG4 subclasses (Leibl et al 1992). RID is simple, but its major 
disadvantages are the need for relatively large volumes of expensive 
antiserum and limited sensitivity. 
To improve sensitivity, rocket immunoelectrophoresis was attempted. Here 
IgG subclass proteins are forced by electrophoresis, into a gel containing 
subclass-specific antiserum (Oxelius 1978). At equivalence a precipitin is 
formed in the shape of a rocket, the height of which is proportional to the 
concentration of IgG subclass protein in the human serum. As with RID, 
rocket immunoelectrophoresis requires large volumes of antiserum and 
requires preci pi ta ting an ti body. 
Nephelometric (Beck and Kaiser 1981) and turbidimetric (Maynard et al 
1986) assays have been reported for the quantification of IgG subclasses but 
are probably not sensitive enough for the detection of IgG3 and IgG4 when 
using the HP series of monoclonal antibodies. In these assays IgG subclass 
protein in serum and subclass-specific antibody react in solution and the 
extent of immune-complex formation is measured by the degree of light 
scattering or absorption of light. 
Haemagglutination and haemagglutination inhibition assays have been used 
in the semi-quantitative measurement of IgG proteins and subclass typing of 
IgG myelomas (Jefferis et al 1985). Particle-counting immunoassay 
(PACIA) is a quantitative agglutination method involving agglutination 
inhibition of latex particles coated with purified monoclonal IgG subclass 
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proteins by subclass-specific antisera (Magnusson et al 1984). IgG subclass 
proteins in human serum compete with solid phase IgG that inhibits 
agglutination in a concentration dependent manner. The disadvantages of 
PACIA are possible interference by rheumatoid factor and Clq, limited 
sensitivity and that it requires high affinity precipitating antisera. Particle 
concentration fluorescence immunoassay (PCFIA) has been adapted to 
measure IgG subclasses (Mayus et al 1986). This method uses fluorescence-
labelled antigen in competition with unlabelled antigen for antibody that has 
been coated on latex particles. Following incubation, unbound antigen is 
removed by filtration and latex particles bearing captured antigens (both 
fluorescent and unlabelled) are concentrated to a small area before their 
fluorescence is measured. The method is sensitive and precise but requires 
special instrumentation. 
The technique most suited for detection and quantification of IgG subclass 
proteins and antibodies is ELISA. No internationally standardized method 
exists, resulting in inter-laboratory variations which may be attributed to 
reagents, working conditions or genetic and environmental variables in 
population samples. Several ELISA formats have been used to quantify IgG 
subclasses in human serum (Hamilton 1987). One format employs an IgG 
capture antibody to extract all 4 subclasses of IgG from serum and a 
conjugated anti-IgG subclass monoclonal antibody to detect only one 
subclass. A disadvantage of this method is that an excess of capture 
antibody is needed to extract IgG of all 4 subclasses from serum. This is 
difficult to achieve in a microtitre plate that has limited protein binding 
capacity. In addition, in the presence of a predominance of IgGl and IgG2 
there is poor binding of IgG3 and IgG4. 
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The most widely used ELISA format for total IgG subclass measurement has 
employed IgG subclass-specific monoclonal antibody to capture a single IgG 
subclass and an enzyme-conjugated IgG specific antibody to detect bound 
IgG. Variations between the reported assays include the source of capture 
and detection monoclonal antibodies, the purity of the coating monoclonal 
antibody (ascitic fluid vs purified), incubation times, types of microtitre 
plates, working dilutions of the serum and the conjugated anti-human IgG 
detection antibody. These factors make the results of different clinical 
studies difficult to compare. 
In this study the four IgG subclasses were initially measured by RID using 
commercially available monoclonal IgG subclass antisera (Kumararatne et al 
1990). Briefly test sera were added at several dilutions to wells cut in 
agarose gel (1.4% in 0.1 M barbitone buffer pH 8.6) which contained 6% 
PEG 3000 and the appropriate monoclonal antiserum. A standard curve was 
established using a standard reference serum from the World Health 
Organization (WHO) (67/97). The gels were incubated for 3 days at 4°C. 
A standard curve was plotted on semi-log paper plotting the diameter of the 
precipitin ring against serum dilution. The unknown values were read off 
the standard and the actual concentration calculated. 
Measuring the subclasses in this way proved to be very expensive as it 
required large volumes of commercially available monoclonal antibodies. 
The method worked well and was easy to perform but it was not accurate 
enough for the quantitative results needed in this project. Therefore an 
ELISA method for the measurement of the subclasses was established. The 
advantages of the ELISA in terms of simplicity, safety and sensitivity are 
well documented. 
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2.2 
Initially immunoassays using polyclonal capture antibodies were assessed. 
A chicken anti-human polyclonal antibody (gift from Dr Bellstred, 
University of Stellenbosch) and a commercial goat anti-human IgG Hand L 
chain (Cappel, Catalogue No 55087) were used as capture coating antibodies 
for the subclass specific assays. However, background blanks ranged 
between 30% and 50% of the signal and the maximal signal achieved for all 
4 subclasses was low. There was very little signal drop off with decreasing 
serum concentration (1: 100 - 1 :5 000) suggesting high non-specific binding. 
These assays were not developed further and efforts were concentrated on 
developing IgG subclass ELISAs using monoclonal IgG subclass specific 
antibodies as capture antibodies. 
The most important technical aspects of the assay include selection of ideal 
capture and detection antibody combinations; the concentration of 
monoclonal anti-human IgG subclass reagent insolubilized on the solid 
phase; the methods used for binding monoclonal antibody to the solid phase 
(adsorption vs covalent binding); the assay buffers; and the test and 
reference serum dilutions used in the assay. Although the general protocol 
for performing the different IgG subclass assays is similar, each assay was 
independently standardized and quality-controlled. These assays and their 
development will be described in this chapter. 
DETERMINATION OF OPTIMAL ASSAY CONDITIONS 
In each ELISA a number of assay conditions were analysed to determine 
optimal functioning and assay conditions. The time and temperature of 
incubation, the buffers used for the washing, the incubation steps and the 
type and concentration of reagents were chosen so that background (non-
specific) absorbance was reduced by preventing non-specific interactions but 
at the same time favouring the immunological and enzymatic reactions. 
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2.2.1 
2.2.1.1 
Coating Monoclonal Antibody 
Selection 
Although the development of these assays was aided by the availability of 
well characterized monoclonal antibodies, various unbiotinylated and 
biotinylated monoclonal antibodies specific for the individual subclasses 
IgG 1, IgG2, IgG3, IgG4 were evaluated to select the most suitable. Details 
of these antibodies are listed in Appendix A. 
2.2.2 Backgrounds 
Table 2.1 shows the effect of the various monoclonal antibodies on non-
specific binding. The background readings were obtained from: 
minus monoclonal antibody i.e. minus coating monoclonal antibody 
but including serum and conjugated antibody 
minus serum i.e. wells coated with monoclonal antibody and 
conjugated antibody but minus serum 
minus monoclonal antibody and serum blanks i.e. wells without 
monoclonal antibody or serum but with conjugated antibody 
For all the assays the minus monoclonal antibody and serum blank values 
were all very low (Table 2.1) and were therefore not subtracted from the 
signal. 
Minus monoclonal antibody blanks and minus serum blanks were both 
subtracted from each serum dilution before the standard curves were 
constructed. 
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2.2.2.1 IgGJ subclass ELISA 
The minus serum blanks were high (56.7%) when coating with the 
unbiotinylated monoclonal antibody HP6012 (Table 2.1). This was not 
decreased by changing the serum diluent from 0.25 % BSA in PBST to 2 % 
albumin in PBS, 0.5% casein in PBS or 0.25% gelatin in PBST (the minus 
serum blanks being 32.8%, 55.3% and 51 % respectively). Unbiotinylated 
monoclonal antibodies HP6070 and HP6069 gave reasonable sigmoid curves 
(Figure 2.1) with acceptable background blanks. 
2s m 
2 
-
HP6069B 1.5 
-+- HP6070 
--*- HP6069 
0.5 
0 
3 3.5 4 4.5 5 5.5 6 
I og serum di I uti ons 
Figure 2.1: Standard curves for IgG 1 using in-house AB serum standard, coating with 
biotinylated monoclonal antibody HP6069B (•) and unbiotinylated monoclonal 
antibodies HP6070 ( +) and HP6069 (*) diluted 1: 1000 
Coating the plate with streptavidin and then using the biotinylated anti-IgG 1 
antibody HP6069 (HP6069B) gave a steep standard curve and low minus 
monoclonal and minus serum blanks (Table 2.1). This system was selected 
for further assays. 
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The minus monoclonal wells in these assays were coated with streptavidin 
but had no biotinylated monoclonal antibody. In preliminary experiments 
blank values of wells without streptavidin and with serum but without 
monoclonal antibody were also included. Readings from these wells were 
negligible (OD all less than 0.026). 
Initial experiments were done to determine the optimum coating 
concentrations of the streptavidin and biotinylated antibody. Streptavidin 
was tested from 0.025 µg/ml - 10.0 µg/ml diluted in PBS. There was no 
difference in the shape of the standard curve using streptavidin 0.5 - 2.0 
µg/ml but at concentrations above and below this the signal was lower and 
the curve was flatter. A coating concentration of 0.5 µg/ml was found to be 
optimal and selected for further experiments (Figure 2.2). 
<y.., ug/rri 1.5 
-- 10.0 
-t- 5.0 
+ 20 
*" 1.0 
+ 0.5 
-A- 0.25 
-a- 0.05 0.5 
0+----.------..------,--__:;=-----~ 
3 35 4 45 5 
I og serum d I uti ons 
5.5 
Figure 2.2: Standard curves for IgGl using in-house AB serwn standard, coating with 
decreasing streptavidin (SA) concentrations: 10.0 µg/ml (•); 5.0 µg/ml ( + ); 2.0 µg/ml 
(*); 1.0 µg/ml (x); 0.5 µg/ml ( <> ); 0.25 µg/ml (a); 0.05 µg/ml (D) 
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The performance of the biotinylated anti-IgG 1 monoclonal antibody was 
assessed at dilutions of 1 :500 to 1: 10 000. Results show that a coating 
dilution of 1: 1 000 was suitable (Figure 2.3). 
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Figure 2.3: Standard curves for IgGl, IgG2, IgG3 and IgG4 using the monoclonal 
antibodies: biotinylated HP6069 for IgGl, HP6008:HP6014 for IgG2, HP6010 for 
IgG3 and HP6013 for IgG4 at dilutions of 1 :250 (•); 1 :500 ( + ); 1:1000 (*); 1 :2000 (•); 
1:5000 (x) 
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2.2.2.2 IgG2 Subclass ELISA 
Unlike the IgGl ELISA the minus serum blanks in these assays were low 
whether a biotinylated or unbiotinylated monoclonal antibody was used 
(Table 2.1). However, the minus monoclonal blanks were high in the IgG2 
assays when the biotinylated monoclonal antibody was used. Thus the assay 
format of coating the plates with unbiotinylated anti-IgG2 antibody was 
selected for IgG2 subclass measurement. As the minus monoclonal antibody 
background blanks were unacceptably high (fluctuating between 15% - 25% 
of maximum signal) these assays were developed further. A combination of 
two unbiotinylated monoclonal antibodies, HP6008 and HP6014 was used to 
coat the plates. The optimum combination of the mixture was found to be a 
2: 1 ratio of HP6008:HP6014 (Figure 2.4) and a 1 :500 dilution of both 
antibodies (Figure 2.3). This caused a shift to the right of the curve which 
enabled the most concentrated serum dilution to be decreased from 1: 1 000 
to 1 :3 000 which accounted for the reduction in readings of the minus 
monoclonal antibody blanks. The minus serum blanks increased marginally 
using the monoclonal antibody combination (Table 2.1) but the sum of the 
minus monoclonal antibody and minus serum blanks as a percentage of the 
most concentrated standard was significantly lower with the 
HP6008:HP6014 mixture when compared to HP6008 alone. 
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Figure 2.4: Standard curves for IgG2 using in-house AB serum standard, coating with 
monoclonal antibodies HP6008 and HP6014, diluted 1:500, in combinations 1:1 (•); 2:1 
( + ); 3:1 (*); 1:0 (D) 
IgG3 Subclass ELISA 
Both biotinylated or unbiotinylated anti-IgG3 monoclonal antibodies gave 
low minus serum blank readings. The readings of the minus monoclonal 
antibody blanks were significantly lower (Table 2.1) and the standard curve 
steeper when using the unbiotinylated antibody to coat the plates. Hence the 
unbiotinylated anti-human IgG3 antibody (HP6010) was used to coat the 
plates in the IgG3 subclass assays. Results show that a coating dilution of 
1 :500 was optimal (Figure 2.3). 
IgG4 Subclass ELISA 
Unbiotinylated antibody HP6013 was selected in preference to the 
biotinylated antibody for the capture antibody as it gave lower minus 
monoclonal antibody and minus serum blanks (Table 2.1). Results show 
that a coating dilution of 1:500 was optimal (Figure 2.3). 
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2.2.2.5 
The unbiotinylated monoclonal antibody HP6011 was evaluated but gave a 
much lower positive signal when compared to HP6013 even when used at a 
greater concentration (Figure 2.5). The signal could be improved using it in 
combination with HP6013 but was not better than HP6013 alone (Figure 
2.5). The unbiotinylated monoclonal antibody HP6013 was selected for use 
in the IgG4 subclass assays in this study. 
25 OJ 
2 
HP6013. 6011 
1:0 1.5 
--+- 01 
-Er 1:1 
-*- 1:2 
-+- 21 
0.5 
oL-~-------.--:==::!::::==:i~L-, 
3 3.5 4 4.5 5 5.5 
I og serum di I uti ons 
Figure 2.5: Standard curves for IgG4 using in-house AB serum standard coating with 
monoclonal antibodies HP6013 and HP6011, concentration 1:500, in combinations 1:0 
(•); 0:1 (*), 1:1 (D); 1:2 (x); 2:1 (<>) 
Conclusion and discussion 
Standard curves for the four IgG subclasses could be produced in a system 
which used monoclonal antibodies to coat the plates to trap specific serum 
IgG isotypes, and polyclonal anti-IgG antibodies as detection conjugates. 
The selection of the most appropriate monoclonal antibodies is dependent in 
part on the system they are to be used in. In an extensive study of 59 
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monoclonal antibodies of supposed specificity for human IgG subclasses, 
tested by different methods the results were discouraging with IgG 1 and 
particularly IgG2, demonstrating assay restriction (Jefferis et al 1985). It 
has also been shown that the murine monoclonal antibodies recognize only a 
limited number of unique epitopes of the IgG subclasses (Jefferis 1986). A 
critical starting factor in the IgG subclass ELISAs is the stable binding of 
functional monoclonal antibodies to a solid-phase support. Most antibodies 
retain their ability to bind antigen when coated to plastic, despite losing a 
portion of their activity (Kemeny 1992). However, some monoclonal 
antibodies lose their reactivity when absorbed directly onto plastic material. 
Hussain et al (1986) were unable to obtain calibration curves with HP6012, 
HP6022, HP6021 and HP6006 bound to a polystyrene surface and 
meaningful calibration curves could not be obtained with HP6012 attached 
directly to the plates. Papadea et al (1985) were able to bind these same 
monoclonal antibodies to polystyrene wells that had been precoated with 
BSA and then cross-linked with glutaraldehyde before addition of the four 
monoclonal antibodies. Kemeny (1992) found that the binding capacity of 
HP6012 was enhanced when linked to the plate with anti-mouse antibodies 
than when bound to the plate directly. 
In this study it was also found that anti-IgGl monoclonal antibody HP6012 
functioned poorly when adsorbed directly to the plates. Covalently coupling 
the biotinylated monoclonal antibody (HP6069) to streptavidin coated plates 
enhanced the assay sensitivity. Butler et al (1992) have shown that 
immobilization of capture antibodies via a streptavidin bridge resulted in 
preservation of antibody sites when compared to direct absorption. 
HP6014 is known to preferentially bind lambda (A) over kappa (k)-bearing 
IgG2 protein when used in limiting concentrations (Hamilton 1987, 
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Madassery et al 1988, Aucouturier et al 1992a). HP6008 is also said to 
have a slightly higher detection efficacy for IgG2 A than for IgG2 k and a 
low sensitivity (Madassery et al 1988). Although HP6008 has a lower 
affinity for IgG2 than does HP6014 it is a better reagent for IgG 
measurement. HP6008 is widely used in IgG2 ELISAs. It was found in 
this study that a combination of HP6008 and HP6014 in a ratio of 2: 1 
increased the sensitivity of the IgG2 assay. 
HP60IO and HP6047 have both been used in previous reports of IgG3 
subclass ELISAs (Table 2.2). In this study HP60IO was selected as the anti-
IgG3 antibody in preference to the biotinylated HP6047 as it has lower 
minus monoclonal antibody blanks. 
Although HP6011 has been used in previous reports of IgG4 subclass assays 
(Aucouturier et al 1985) it gave poor results in the experiments reported 
here. HP6013 was selected as the best anti-IgG4 antibody. 
The selected monoclonal antibodies used in this study were unpurified and 
still in ascitic fluid. Chemical purity of the monoclonal antibody has been 
found by Hamilton et al (1988) to be the most important variable influencing 
the binding of anti-human IgG monoclonal antibody to the plate. They 
found the use of unpurified monoclonal antibodies in ascitic fluid as primary 
capture antibodies, produced large variation and low binding capacities 
when compared to the direct coating of chromatographically purified 
antibody. There are not many references directly comparing the use of 
purified and unpurified ascitic fluid as coating antibodies. However, ascitic 
fluid has been used successfully to establish IgG subclass ELISAs (Table 
2.2). 
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2.2.3 
2.2.3.1 
2.2.3.2 
2.2.3.3 
Coating Buffer 
IgG 1 subclass ELISA 
The streptavidin used to coat the plates was diluted in PBS buffer pH 7.2. It 
made no difference to the sum of the background blanks (minus monoclonal 
antibody and minus serum blanks) expressed as a percentage of the 
maximum standard signal whether the monoclonal antibody was diluted in 
PBS, glycine/Tris pH 7.0-7.5 or 0.25% BSA in PBST. The biotinylated 
monoclonal antibody was diluted in 0.25 % BSA in PBST as this diluent 
resulted in the highest positive signal with acceptable background blanks 
(Table 2.3). 
IgG2 subclass ELISA 
Coating of monoclonal antibody in a glycine/Tris buffer pH 7.0-7.5 gave a 
standard curve with a higher signal and steeper slope than that obtained 
using a carbonate coating buffer pH 9.6 (Figure 2.6). As it had no 
detrimental effect on the background blanks when they were expressed as a 
percentage of the maximum signal the glycine/Tris buffer was selected for 
use in this assay (Table 2.3). 
IgG3 subclass ELISA 
The glycine/Tris coating buffer pH 7. 0-7. 5 gave a greater signal and 
produced a standard curve with a steeper slope than that obtained with 
carbonate coating buffer pH 9.6 (Figure 2.6). The coating buffer did not 
affect the minus monoclonal antibody or minus serum blanks and the 
glycine/Tris was used as the coating buffer in the IgG3 ELISA {Table 2.3). 
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2.2.3.4 
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Figure 2.6: Standard curves for IgG2, IgG3 and lgG4 using in-house AB serum 
standard, coating with monoclonal antibodies in glycine/Tris buffer pH 7.0-7.5 (•), and 
carbonate huff er pH 9.6 ( +) 
IgG4 subclass ELISA 
The glycine/Tris coating buffer pH 7.0-7.5 gave a higher signal than the 
carbonate buffer in the IgG4 ELISA as it had in the IgG2 and IgG3 ELISAs, 
although the differences were not as marked and the shapes of the curves 
were similar (Figure 2.6). Coating in the glycine/Tris buffer pH 7.0-7.5 
resulted in lower minus monoclonal antibody blanks without increasing the 
minus serum blanks (Table 2.3) and was therefore also found most suitable 
for the IgG4 assay. 
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TABLE 2.3: EFFECT OF COATING BUFFERS ON THE lgG SUBCLASS 
ASSAYS 
SUBCLASS COATING OD MAX• OPTICAL DENSITY (OD) OF 
ASSAY BUFFER SIGNAL BACKGROUND BLANKS 
(% of Maximum Signal) 
Minus Moab Minus Serum 
IgGl PBS 1.526 0.301 0.179 
HP6069 (19. 7) (11. 7) 
biotinylated 0.25% BSA in PBST 2.000 0.331 0.204 
(16.5) (10.2) 
gly/Tris pH 7.0-7.5 1.116 0.298 0.082 
(25.6) (7.0) 
IgG2 gly/Tris pH 7.0-7.5 1.887 0.090 0.241 
HP6008: (4.8) (12.8) 
HP6014 Carbonate pH 9.6 1.080 0.040 0.117 
(3.8) (10.8) 
IgG3 gly/Tris pH 7.0-7.5 1.580 0.46 0.125 
HP6010 (2.9) (7.9) 
Carbonate pH 9. 6 0.790 0.026 0.066 
(3.3) (8.4) 
IgG4 gly/Tris pH 7.0-7.5 1.891 0.074 0.135 
HP6013 (3.9) (3.9) 
Carbonate pH 9. 6 1.450 0.299 0.101 
(20.6) (7.0) 
• OD max signal = highest optical density reading of AB standard 
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2.2.3.5 Conclusion and discussion 
The binding of individual monoclonal antibodies depends largely on the 
nature of the solid phase support and on the coating buffer. 
Antibody-antigen reactions normally take place between pH 6.0 and 9.0. 
The pH of the coating buffer can influence the amount of mouse 
immunoglobulin that binds to the plate (Kemeny 1992). 
In these assays, some monoclonal antibodies (HP6008:HP6014 and HP6010) 
gave a much higher signal when they were coated on polystyrene plates in a 
glycine/Tris buffer pH 7.0-7.5 than when they were diluted in the usual 
carbonate buffer pH 9.6. Hussain et al (1986) found that monoclonal 
antibodies HP6003 and HP6024 gave higher signals when coated in a pH 
7.5 buffer. Hamilton et al (1988) found no difference in antibody binding 
capacity or sensitivity when the coating monoclonal antibody was diluted in 
carbonate buffer or PBS and selected PBS because it was more physiological 
than the carbonate buffer. In the IgG2, IgG3 and IgG4 subclass assays 
developed in this study the glycine/Tris buffer pH 7.0-7.5 was selected as it 
gave better antibody binding than the more commonly used carbonate buffer 
pH9.6. 
Black et al (1988) found that coating monoclonal antibody with relatively 
high dilutions of ascitic fluid in distilled water maintained antigen binding 
capability when dried on plastic surfaces. 
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2.2.4 
2.2.4.1 
Plates 
Ninety six well flat bottomed polystyrene Nunc certificated (Denmark, 
Catalogue No 39454) and flat bottomed polyvinyl chloride Falcon 
(Catalogue No 3912) plates were compared for these immunoassays. 
IgGI subclass ELISA 
In the IgG 1 assays (Figure 2. 7) no significant differences in the shapes of 
the standard curve or background values were found when using Nunc or 
Falcon plates. 
lgG1 I~ 
25 CX) 25 Cl) 
2 2 
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1.5 1.5 
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05 05 
0 0 
3 3.5 4 4.5 5 55 3 3.5 4 4.5 5 55 6 
log serum dlutions log serun dlutions 
lgG3 lgG4 
25 CX) 25 Cl) 
2 2 
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1.5 15 
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Figure 2.7: Standard curves for IgGl, IgG2, IgG3 and IgG4 using in-house AB serum 
standard on Nunc (flat bottomed polystyrene certificated) plates (•) or Falcon (flat 
bottomed polyvinyl chloride) plates ( + ). 
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2.2.4.2 
2.2.4.3 
2.2.4.4 
2.2.4.5 
IgG2 subclass ELISA 
The signal of the IgG2 standard curve on the Falcon plates was lower (65 % ) 
than on the Nunc plates (Figure 2.7). There was no significant difference in 
minus monoclonal antibody or minus serum blank backgrounds between the 
two plates. 
IgGJ subclass ELISA 
The shape of the IgG3 standard curve was flatter and the signal lower (± 
31 % ) on the Falcon plates (Figure 2. 7). There was no significant difference 
in the background values on the two plates. 
IgG4 subclass ELISA 
In the IgG4 assays the signal and shape of the curve were similar between 
the two plates (Figure 2. 7). However, the minus serum blanks were 
significantly higher on the Falcon plates compared to the Nunc plates. 
Conclusion and discussion 
In previously described IgG subclass ELISAs various plates have been used: 
Nunc Immunolon I (Hamilton et al 1988, Leibl et al 1992), Dynatech 
(Aucouturier et al 1985, Hussain et al 1986, Hamilton et al 1988, Meissner 
et al 1990), Limbro (Hamilton et al 1988) and Falcon (Hamilton et al 1988). 
Hamilton et al (1988), compared Dynatech, Falcon and Limbro plates and 
found that these plates all bound purified antibody maximally at the same 
concentration and produced equivalent final assay performance when 
compared directly. Other authors have not commented as to why particular 
plates were selected or whether other plates were assessed. The expensive 
high binding plates advocated for ELISA have been found to give high 
backgrounds due to non-specific binding (Aucouturier et al 1984). 
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The results from this study indicate that the type of plate used may affect the 
ELISA sensitivity, this effect varying from one subclass assay to another. 
The Falcon plates were more difficult to work with and gave greater 
variation in triplicate samples than did the Nunc plates. Nunc plates were 
selected for use in all four subclass assays as they were easier to load 
without splashing, cheaper (1/5 of the cost) and overall gave steeper 
standard curves and lower background blanks than the Falcon plates. 
No significant differences were observed when Nunc certificated and non-
certificated flat bottomed plates were compared. 
2.2.5 Blocking Agents 
2.2.5.1 
Various blocking agents used to prevent non-specific binding to the 
microtitre plates were assessed in these assays: 
Bovine serum albumin (BSA), albumin fraction V - Boehringer 
Mannheim, Catalogue No 735086 
Fetal calf serum (FCS) - Flow, Catalogue No 29-101-49 
Gelatin - Biorad, Catalogue No 170-6537 
Casein - Unilab Saarchem, Catalogue No 152813 
Casein - Hammarsten, Catalogue No 44020 
IgGJ subclass ELISA 
The background readings of the minus monoclonal antibody and mmus 
serum blanks ranged between 5-10% of the maximum signal and were 
unaffected by altering the blocker. There was also no difference to either of 
the blanks when the plates were blocked pre- or post- the monoclonal 
antibody incubation step or when they were not blocked at all (Figure 2.8). 
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Figure 2.8: Standard curves for IgGl using in-house AB serum standard with(•) and 
without ( +) blocking with 1 % casein 
IgG2 subclass ELISA 
There was no difference in minus monoclonal antibody blanks when 0.5%, 
1 % , 2 % or 5 % BSA in PBS was used as a blocking agent but the minus 
monoclonal antibody backgrounds increased when 0.2 % BSA was used. 
The effect of various blockers on the background readings in the IgG2 
subclass assays when the plates were coated with 1 :500 dilution of HP6008 
or HP6014 or a 2: 1 mixture of HP6008:HP6014 monoclonal antibodies is 
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2.2.5.3 
2.2.5.4 
shown m Table 2.4. Differences were most noticeable with the minus 
monoclonal antibody blanks. Although the addition of detergents to 
blocking agents has been used to decrease non-specific binding to the solid 
phase the minus monoclonal antibody blanks increased significantly when 
0.5% Tween 20 was added to 2% BSA as the blocking agent (Table 2.4). 
1 % casein consistently gave the lowest background readings. The Unilab 
casein was just as effective as the higher grade Hammarsten casein and was 
less expensive. 
IgG3 subclass ELISA 
The various blockers assessed made little difference to the minus monoclonal 
antibody or minus serum blanks which were consistently less than 3 % and 
7% respectively of the signal of the maximum standard dilution. 
IgG4 subclass ELISA 
There was no significant difference in readings or blanks with the various 
blockers. 
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TABLE 2.4: EFFECT OF BLOCKING AGENT ON THE 
BACKGROUND BLANKS IN THE lgG2 ELISA 
lgG2 HP6008 
BLOCKING AGENT OD Maximum * OPTICAL DENSITY (OD) OF 
Signal BACKGROUND BLANKS 
(% of Maximum Signal) 
Minus Moab Minus Serum 
2% BSA 1.308 0.356 0.086 
(27.2) (6.6) 
5% BSA 1.213 0.284 0.032 
(23.4) (2.6) 
2% BSA 1.294 0.421 0.036 
+ 10% FCS (32.5) (2.8) 
2% BSA 1.449 1.303 0.087 
+ 0.5 % Tween-20 (89.9) (6.0) 
10% FCS 1.121 0.246 0.039 
(21. 9) (3.5) 
1 % Gelatin 1.215 0.369 0.089 
(30.4) (7.3) 
1 % Casein 1.025 0.151 0.033 
Unilab (14. 7) (3.2) 
1 % Casein 0.705 0.078 0.022 
Hammers ten (11.1) (3.1) 
* OD max1mwn signal = highest OD reading of AB standard 
SECTION A: Chapter 2: IgG Subclass lmmunoassays 55 
Table 2.4 continued 
IgG2 HP6014 
BLOCKING AGENT OD Maximum * OPTICAL DENSITY (OD) OF 
Signal BACKGROUND BLANKS 
(% of Maximum Signal) 
Minus Moab Minus Serum 
2% BSA 2.245 0.367 
(16.4) 
5% BSA 2.180 0.363 
(16.7) 
2% BSA 2.009 0.242 
+ 10% FCS (12.1) 
2% BSA ND ND 
+ 0.5 % Tween-20 
10% FCS 1.959 0.155 
(7.9) 
1 % Gelatin 2.070 0.133 
(6.4) 
1 % Casein 2.139 0.062 
Unilab (2.9) 
1 % Casein 1.829 0.051 
Hammers ten (2.8) 
* OD maximwn signal = highest OD reading of AB standard 
ND= not done 
0.268 
(11.94) 
0.251 
(11.5) 
0.113 
(5.6) 
ND 
0.113 
(5.8) 
0.232 
(11.2) 
0.092 
(4.3) 
0.057 
(3.1) 
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Table 2.4 continued 
BLOCKING AGENT 
2% BSA 
5% BSA 
2% BSA 
+ 10% FCS 
2% BSA 
+ 0.5 % Tween-20 
10% FCS 
1 % Gelatin 
1 % Casein 
Unilab 
1 % Casein 
Hammers ten 
lgG2 HP6008:HP6014 
2:1 
OD Maximum * 
Signal 
2.094 
1.928 
1.770 
1.914 
1.833 
1.962 
1.911 
1.700 
56 
OPTICAL DENSITY (OD) OF 
BACKGROUND BLANKS 
(% of Maximum Signal) 
Minus Moab Minus Serum 
0.210 0.224 
(10.0) (10.7) 
0.145 0.230 
(7.5) (11.9) 
0.210 0.75 
(11.9) (4.2) 
0.970 0.108 
(50. 7) (5.7) 
0.153 0.078 
(12.0) (4.3) 
0.176 0.120 
(9.0) (6.1) 
0.050 0.059 
(2.6) (3.1) 
0.072 0.041 
(4.2) (2.4) 
* OD maximum signal = highest OD reading of AB standard 
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2.2.5.5 Conclusion and discussion 
It is common practise to block unreacted sites with an irrelevant protein after 
the primary coating step. In the IgG 1 assays the plates were blocked after 
the streptavidin coating and before the addition of the monoclonal antibody. 
Human serum albumin is not suitable as a blocking protein in IgG subclass 
assays because it contains a small percentage ( ~ 1 % ) of immunoglobulins 
that produce high background values. BSA is the most common blocker 
used in IgG subclass ELISAs (Table 2.1) and although both BSA and 1 % 
casein were found to be equally suitable in the IgG 1, IgG3 and IgG4 
subclass assays developed in this study, 1 % casein gave lower minus 
monoclonal antibody blanks in the IgG2 assays. 1 % casein was therefore 
selected as the blocker for all the subclass assays. The minus monoclonal 
antibody blanks were significantly reduced in the IgG2 subclass assay when 
the incubation time of the blocking step was increased from 1 hour at 37°C 
to overnight at 37°C but in the IgG 1, IgG3 and IgG4 subclass ELISAs the 
one hour incubation at 37°C was adequate. In order to coordinate the 
addition of the sera to all 4 subclass assays, the coating times were adjusted. 
For the IgG 1 assay, after the streptavidin coating overnight at 4 °C, the 
plates were blocked for 1 hour at 37°C and then the monoclonal antibody 
was left on for 2 hours at room temperature. 
For the IgG2 assay, the monoclonal antibody was left on for 2 hours at 
room temperature and then the plates were blocked overnight at 37°C. For 
the IgG3 and IgG4 assays, the monoclonal antibodies were left on overnight 
at 4 °C and the plates were then blocked for 1 hour at 37°C. 
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2.2.6 
2.2.6.1 
2.2.6.2 
2.2.6.3 
Serum Diluents 
IgG 1, IgG3 and IgG4 subclass ELISAs 
1 % casein was compared to 0.25 % BSA in PBST as a serum diluent. No 
difference in serum blanks was observed in the IgG 1, IgG3 and lgG4 assays. 
IgG2 subclass ELISA 
When 1 % casein was used as a serum diluent in the IgG2 assay, lower 
blanks (2-7% of the signal) were observed than when 0.25% BSA in PBST 
was the diluent (10-20% ). 
Conclusion and discussion 
A 1 % casein solution was selected for use in all four of the subclass assays 
as the blocking solution and serum diluent, as there was a significant 
decrease in the minus monoclonal antibody blanks of the IgG2 subclass 
assays and it did not adversely affect the other IgG subclass assays. 
2.2. 7 Serum Standards 
A large pool of serum, blood group AB (Rh +ve) was obtained from the 
Western Province Blood Transfusion Service and used as the in-house 
laboratory standard. This pool was calibrated against the WHO 
immunoglobulin reference preparation 67 /97 obtained from the Department 
of Health and Human Services, Atlanta, USA. WHO 67 /97 is produced 
from pooled serum from normal adult donors with no history of malaria or 
hepatitis (Rowe et al 1970). WHO 67/97 was calibrated (Rowe et al 1972) 
as a secondary standard against the WHO primary standard for human IgG, 
IgA and IgM (WHO 67/86). WHO 67/97 reference preparation is widely 
recognized as a reference for the determination of IgG subclasses. A 
collaborative study (Klein et al 1985) re-examined the calibration of the IgG 
subclass concentrations in the WHO 67 /97 reference serum using purified 
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human myeloma IgG proteins in immunodiffusion with polyclonal sheep 
anti-human IgG subclass antisera. They proposed WHO 67 /97 be used as a 
calibrator for IgG subclasses with the designated values of 5.0 g/1 for IgGl, 
2.6 g/1 for IgG2, 0.4 g/1 for IgG3 and 0.5 g/1 for IgG4. The concentrations 
of the 4 subclasses in the WHO 67 /97 reference standard received from 
Geneva or Atlanta vary slightly (Table 2.5). The in-house standard was 
calibrated with the WHO subclass values received from Geneva. The 
subclass concentrations of the AB in-house standard were calculated by 
using 5 dilutions with absorbance readings on the linear section of the curve 
and taking the mean concentration of them. This was repeated over 12 
consecutive runs and the results are shown in Table 2.5. At intervals the in-
house standard has been recalibrated but there has been no drift in the 
concentration of the subclasses. 
TABLE 2.5: lgG SUBCLASS VALUES OF THE REFERENCE 
SERUM POOLS (g/1) 
SAMPLES 
WHO 67/97, Geneva 
WHO 67/97, Atlanta 
In-House AB Standarda 
IgGl 
5.10 
5.00 
9.85 
IgG2 
2.50 
2.60 
3.31 
IgG3 
0.55 
0.40 
0.73 
a = AB standard was calibrated from the WHO 67 /97 Geneva reference 
IgG4 
0.35 
0.50 
0.40 
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2.2.7.1 IgG I subclass ELISA 
Pooled human AB serum (the in-house standard) and the WHO reference 
standard serum 67 /97 (international standard) were compared. The standard 
curves were parallel (Figure 2.9). The pooled AB serum was used as the 
calibrator for the standard curve. The WHO standard was included in two 
dilutions as a positive control in each assay. Various dilutions of the control 
and samples were compared for their ability to give reproducible results. 
Calculated antibody concentrations were similar for dilutions read off any 
part of the linear section of the curve. Dilutions of 1: 15 000 and 1 :20 000 
were selected for the control samples. The unknown samples were diluted 
to read off the linear portion of the standard curve. This dilution was 
1 :50 000 in the majority of samples. 
lgG1 lgG2 
25 CX) 25 CX) 
-Afl 15 
1.5 ~ -Afl -+- 1Af10 I -+- 1Af10 I 05 Q5 
0 0 
3 3.5 4 4.5 
log serum dlulia,s 
5.5 3 35 4 45 5 
log serun dlutiCJ1S 
55 
lgG3 lgG4 
25 CX) 25 CX) 
-Afl 
15 1 5 
-Afl 
-+- 1Af10 I -+- 1Af10 I 
05 Q5 
0 0 
3 3.5 4 4.5 
log serum dlutims 
55 3 35 4 4.5 
log serun dlutiCJ1S 
5 55 
Figure 2.9: Standard curves for IgGl, IgG2, IgG3 and IgG4 using in-house AB serum 
standard (•) and WHO serum standard ( + ). 
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2.2.7.2 
2.2.7.3 
2.2. 7.4 
2.2.7.5 
IgG2 subclass ELISA 
Titration curves of the in-house standard and the international reference 
standard were parallel (Figure 2.9). Control samples were diluted to 
1:30 000 and 1:50 000. The unknown samples were diluted to 1:30 000 
(except serum from very young children which was diluted to 1:20 000). 
IgG3 subclass ELISA 
Titration curves of the in-house standard and international reference standard 
were parallel (Figure 2.9) and the control samples were diluted to 1:20 000 
and 1 :30 000. The unknown samples were diluted to 1 :30 000. 
IgG4 subclass ELISA 
Titration curves of the standards were parallel (Figure 2.9) and control 
samples were diluted 1: 10 000 and 1 :20 000. The unknown samples were 
diluted to 1 :5 000 except samples from very young children which were 
diluted to 1: 1 000. 
Conclusion and discussion 
The World Health Organization International Reference Standard for Human 
Serum Immunoglobulins: IgA, IgG and IgM (WHO 67/97) was used to 
establish the quantitative basis for the IgG subclass standardization of these 
assays. Non-standardized materials used to calibrate assays have ranged 
from purified myeloma proteins to pooled human sera. A large pool of 
serum, blood group AB (Rh +ve) was used as the in-house standard in these 
assays and was calibrated from WHO 67/97. WHO 67/97 is an official 
standard for IgA, IgG and IgM but not for the subclasses. Morell et al 
(1972a), van der Giessen et al (1975) and Klein et al (1985) independently 
established the mass concentration of the IgG subclasses in this preparation 
and these 'standard' values have been used by a number of groups studying 
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2.2.8 
2.2.8.1 
IgG subclasses (Chapter 9, Table 9.6). Use of this reference allows 
interlaboratory comparison of subclass assays. 
Serum Incubation times 
IgGJ, IgG2, IgG3 and IgG4 subclass ELISAs 
The shapes of the standard curves when the serum was incubated for 2.5 
hours at room temperature or overnight at 4 °C were parallel but the signal 
was higher and the curve was shifted to the right with the overnight 
incubation (Figure 2.10). There was no difference in the minus monoclonal 
antibody or minus serum blanks between the two incubation periods. 
lgG1 I~ 
2/l) /l) 
2 
1.5 
- 251Ts - 251Ts 1 
-+- o/n ~ -+- o/n Q5 0 0 
3 35 4 4.5 5 55 6 3 35 4 45 5 55 
l<XJ Sffi1Tl d I uti ms l<XJ serun dlutims 
lgG3 1(,4 
25 Cl) 2 OD 
2 
1. 
- 251Ts 1.S 
- 251Ts 
-+- o/n 
-+- o/n 1 
Q Q5 
0 0 
3 35 4 4.5 5 55 3 35 4 4.5 5 55 6 
l<XJ SffiJfTl dlutioos I og SffiITl di uti ms 
Figure 2.10: Standard curves for IgGl, IgG2, lgG3 and IgG4 using in-house AB 
serum standard, incubating the serum for 2.5 hours at room temperature (•) and 
overnight (o/n) at 4 °C ( + ). 
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2.2.8.2 Conclusion and discussion 
The overnight incubation period at 4 °C was chosen as it gave a higher signal 
and was more convenient. 
2.2.9 Evaluation of the Enzyme Detection System 
2.2.9.1 
The following conjugated antibodies were evaluated: 
Non-affinity purified goat anti-human gamma chain specific HRPO 
(Cappel, Catalogue No 3301-0121) 
Affinity purified goat anti-human gamma chain specific HRPO 
absorbed with mouse serum proteins (Zymed, Catalogue No 62-
8420) 
Sheep anti-human IgG (H and L) specific HRPO (Binding Site, 
Catalogue No PP003). 
IgG 1 subclass ELISA 
The Zymed goat anti-human conjugate diluted at 1:1 500 in 0.25% 
BSA/PBST was selected for use in these assays as it gave the lowest minus 
monoclonal antibody and minus serum blank readings of the conjugates 
assessed (Table 2.6). The Cappel and Binding Site anti-human conjugates 
gave high background readings (Table 2.6). 
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TABLE 2.6: EFFECT OF VARIOUS CONJUGATES ON THE 
BACKGROUND READINGS IN THE lgGl, lgG2, IgG3 and IgG4 
SUBCLASS ASSAYS 
SUBCLASS ANTI-HUMAN CONJUGATESa BACKGROUND BLANKS % * 
ASSAY 
Minus Moab 
IgGl Zymed 6.8 
Zymed + 1 % MSb 8.6 
Binding Site 34.2 
Binding Site + 1 % ssc 30.3 
Cappel 24.2 
IgG2 Zymed 14.7 
Zymed + 1 % MSb 14.3 
Zymed + 1 % GSd 14.3 
Binding Site 15.5 
Binding Site + 1 % ssc 16.7 
Cappel 16.1 
Cappel + 1 % Msb 3.3 
IgG3 Zymed 7.3 
Cappel 2.5 
IgG4 Zymed 12.8 
Zymed + 1 % GSb 10.6 
Zymed + 1 % MSb 12.2 
Cappel 2.1 
Cappel + 1 % MSb 2.8 
a See text for details of conjugates 
b 1 % MS = addition of 1 % mouse serum to the conjugate 
c 1 % SS = addition of 1 % sheep serum to the conjugate 
d 1 % GS = addition of 1 % goat serum to the conjugate 
Minus Serum 
2.0 
2.0 
33.0 
31.8 
51.8 
46.9 
14.3 
46.7 
12.9 
13.1 
45.4 
23.8 
5.3 
5.3 
16.5 
15.6 
17.4 
9.1 
4.8 
* = OD of Background blanks expressed as a % of the highest OD reading of AB 
standard 
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2.2.9.2 
2.2.9.3 
2.2.9.4 
IgG2 subclass ELISA 
The addition of 1 % mouse serum to the Zymed goat anti-human HRPO 
conjugate significantly decreased the minus serum blanks (46.9% to 14.3%) 
(Table 2.6). The addition of 1 % goat serum to the Zymed goat anti-human 
conjugate did not decrease the high minus serum blank. The addition of 
sheep serum to the Binding Site sheep anti-mouse conjugate made no 
difference to minus monoclonal antibody or minus serum blanks. The 
addition of 1 % mouse serum to the Cappel goat anti-human conjugate 
significantly decreased the high minus serum blanks and decreased the minus 
monoclonal antibody blanks (Table 2.6). The Zymed goat anti-human 
HRPO conjugate diluted 1:1 500 in 0.25% BSA/PBST with 1 % mouse 
serum was selected for use in these assays. 
IgG3 subclass ELISA 
There was no difference in the minus serum blanks when using either the 
Zymed or Cappel goat anti-human conjugates (Table 2.6). The minus 
monoclonal antibody blanks were slightly lower using the Cappel conjugate 
than with the Zymed conjugate (Table 2.6). The Cappel conjugate could be 
used at half the concentration of the Zymed conjugate so was more 
economical. The Cappel goat anti-human HRPO conjugate diluted 1 :24 000 
in 0.25 % BSA/PBST was selected for use in this assay. 
IgG4 subclass ELISA 
The Cappel conjugate gave a steeper standard curve and lower minus 
monoclonal antibody and minus serum blanks than the Zymed conjugate 
(Table 2.6). The addition of 1 % goat serum or 1 % mouse serum to the 
Zymed conjugate made no difference to these background blanks. The 
addition of 1 % mouse serum to the Cappel conjugate lowered the minus 
serum blanks. 
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2.2.9.5 Conclusion and discussion 
Selection of the optimal enzyme conjugated anti-human IgG detection 
antibody is complicated by the fact that some of the HP series murine 
monoclonal anti-human IgG subclass antibodies react with sheep or goat 
immunoglobulin (Jefferis et al 1985). In this study various polyclonal 
HRPO conjugated anti-human IgG antibodies were assessed with and 
without the addition of animal sera to decrease non-specific binding. 
Results obtained in the various assays showed that the Zymed conjugate was 
suitable for IgG 1 and IgG2 assays and that the Cappel conjugate was best for 
the IgG3 and IgG4 assays. The addition of 1 % mouse serum to the 
conjugates in the IgG2 and IgG4 assays significantly reduced background 
values. As a result of these experiments the following conjugates and 
diluents were used in the assays: 
IgG 1 and IgG2 
IgG3 
IgG4 
Zymed goat anti-human HRPO diluted 1:1 500 in 0.25% 
BSA/PBST (with 1 % mouse serum for IgG2) 
Cappel goat anti-human HRPO conjugate diluted 
1:24 000 in 0.25% BSA/PBST 
Cappel goat anti-human HRPO conjugate diluted 
1:12 000 in 0.25% BSA/PBST with 1 % mouse serum. 
0.25% BSA in PBST was selected as the diluent for the conjugates in all 4 
subclasses as it had been used successfully when determining optimal assay 
conditions. When the conjugates were diluted in 1 % casein there was a 
significant increase in the minus serum blanks. 
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2.3 METHODS 
Optimum reaction conditions and reagents had been determined in 
preliminary experiments. All reagents and samples were added to the wells 
in 100 µl volumes except the 2N H2S04 where 50 µl volumes were used. 
After serum incubation and conjugate incubation respectively plates were 
washed five times with PBST. A summary of the reagents used in all of the 
IgG 1, IgG2, IgG3 and IgG4 subclass assays is given in Table 2. 7. All 
incubations were in a moist chamber. 
2.3.1 lgGl Subclass ELISA 
Microtitre wells were coated with streptavidin (0.5 µg/ml) (Zymed, 
Catalogue No 43-4301) diluted in PBS. Plates were incubated overnight at 
4 °C. The contents were discarded and non-specific binding sites were 
blocked with 250 µI/well of 1 % casein for 1 hour at 37°C. Plates were then 
washed once with PBS and the biotinylated mouse monoclonal antibody 
(HP6069) diluted 1: 1 000 in 0.25 % BSA in PBST was added to the wells 
and incubated for 2 hours at room temperature. Plates were washed once 
with PBST and sera diluted in 1 % casein were added to triplicate wells. 
Standard curves were generated using the in-house standard of human AB 
serum in 9 serial dilutions ranging from 1:3000-1:300000 (1:3000, 
1 :4 000, 1 :7 500, 1: 10 000, 1 :20 000, 1 :30 000. 1 :50 000, 1: 100 000, 
1 :300 000). Positive controls (International WHO reference standard) were 
added in two dilutions of 1: 15 000 and 1 :20 000. Test samples were diluted 
so as to be read on the linear part of the curve, usually 1 :50 000. The 
samples were incubated overnight at 4 °C. Minus serum blanks i.e. wells 
containing only diluent were included on every plate. 
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The plates were then washed five times with PBST. Affinity purified goat 
anti-human IgG gamma chain specific horseradish peroxidase conjugate 
(Zymed) diluted 1: 1 500 in 0. 25 % BSA in PBST was added to the wells and 
incubated for 90 minutes at room temperature. After washing 5 times with 
PBST, OPD diluted in 0.1 M citrate buffer with 0.1 % hydrogen peroxide 
was added and incubated in the dark for 15 minutes at room temperature. 
The colour reaction was stopped by the addition of 50 µl 2N H2S04 and the 
OD was read on an ELISA photometer at a wavelength of 492 nm. 
2.3.2 lgG2 Subclass ELISA 
Microtitre wells were coated with a 2: 1 mixture of monoclonal antibodies 
HP6008 and HP6014 diluted 1:500 in a glycine/Tris buffer pH 7.0-7.5. 
This was left for 2 hours at room temperature. The contents of the plates 
were discarded and the plates were blocked with 1 % casein overnight at 
37°C. The plates were washed once with PBS and dried. Standard AB 
serum in 9 dilutions ranging from 1:3 000-1:400 000 (1:3 000, 1:5 000, 
1:10000, 1:20000, 1:40000, 1:50000, 1:100000, 1:200000, 1:400000) 
and positive controls (WHO reference standard) were added in two dilutions 
(1 :20 000 and 1 :30 000). Test samples were diluted to read on the linear 
part of the curve, usually 1 :30 000 for adults and 1: 10 000 and 1 :20 000 for 
children. The samples were incubated overnight at 4 °C. Further steps were 
as for the IgG 1 ELISA. 
2.3.3 lgG3 Subclass ELISA 
This was similar to the method described above for the IgG2 subclass 
ELISA except for the following dilution and antibody differences: 
blocking step was at 37°C for 1 hour 
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the monoclonal antibody used to coat the plates was an anti-human 
IgG3 antibody HP6010 diluted 1:500 in glycine/Tris buffer pH 7.0-
7. 5 and it was left on overnight at 4 ° C 
the standard curve dilutions of the pooled standard AB serum ranged 
from 1 :2 500-1 :300 000 (1 :2 500, 1 :5 000, 1: 10 000, 1 :20 000, 
1:30 000, 1:40 000, 1:75 000, 1:100 000, 1:300 000). 
Positive WHO controls were diluted to 1 :20 000 and 1 :30 000 and 
test samples were diluted to 1 :30 000. 
The Cappel affinity purified goat anti-human IgG gamma chain 
specific horseradish peroxidase was diluted 1 :24 000 in 0.25 % BSA 
in PBST. 
2.3.4 IgG4 Subclass ELISA 
This was similar to the IgG3 subclass ELISAs with the following dilution 
and antibody differences: 
The mouse anti-human IgG4 monoclonal antibody HP6013 diluted 
1: 500 in glycine/Tris buffer pH 7. 0-7. 5 was used to coat the 
microtitre plates and it was left on overnight at 4 °C 
The standard curve dilutions of the pooled human AB serum ranged 
from 1 :2 500-1 :200 000 (1 :2 500, 1 :4 000, 1 :7 500, 1: 10 000, 
1 :20 000, 1 :30 000, 1 :50 000, 1: 100 000, 1 :200 000) 
Positive WHO controls were diluted 1: 10 000 and 1 :20 000 and test 
samples were diluted to 1 :5 000 for adults and 1: 1 000 for children 
Cappel goat anti-human peroxidase conjugated antibody was diluted 
1: 12 000 in O. 25 % BSA in PBST with 1 % mouse serum. 
2.3.5 Design of Plate 
Every assay plate included 9 dilutions of the standard pooled human AB 
serum for the calibration curves, dilutions of the WHO International 
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Standard for monitoring reproducibility and blanks (wells minus monoclonal 
antibody, wells minus serum and wells minus both monoclonal antibody and 
serum). All reactions were performed in triplicate. For the routine analysis 
of unknown samples the design of the plate is the same for each subclass 
ELISA and is shown in Chapter 1, Figure 1.1. In these assays the blanks in 
column 10, rows A-D and are as follows: 
Column 10: Row A-C: Minus serum, plus monoclonal antibody 
Column 10: Row D: Minus serum, minus monoclonal antibody 
2.3.6 Calculation of Results 
The minus monoclonal antibody blank and the mmus serum blank were 
subtracted from the mean of the triplicate of the standard/sample dilutions. 
Standard curves relating absorbance to the concentration of the 4 subclasses 
in the AB serum standard were constructed using the curve fitting four 
parameter logistic programme (Chapter 1.12). 
2.4 ASSAY STANDARDIZATION 
2.4.1 Standard Curves 
An in-house standard of pooled AB serum quantitated against an 
International WHO standard 67 /97 was used to construct standard curves for 
IgG 1, IgG2, IgG3 and lgG4 subclasses relating absorbance to subclass 
concentration (Figure 2.9). Each standard curve was constructed from nine 
different triplicate dilutions of standard serum on each plate and included in 
every ELISA plate. The titration curves of the in-house standard and WHO 
International Standard were parallel for all four subclasses (Figure 2.9). 
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2.4.2 
2.4.2.1 
2.4.2.2 
The concentrations of immunoglobulin used to construct a standard curve for 
IgGl = 0.033-3.283 µg/ml; IgG2 = 0.008-1.100 µg/ml; IgG3 = 0.0024-
0.292 µg/ml and IgG4 = 0.0020-0.160 µglml. 
Precision and Sensitivity 
Coefficients of variation 
To determine assay precision, the coefficient of variation (CV) of assay 
results of a single sample was determined using one assay plate (intra-plate) 
or multiple plates in the same run (intra-assay) or 3 samples on different 
runs (inter-assay). 
The inter-assay variation was assessed with 3 samples assayed in triplicate in 
16 different runs. The sera selected were the standard WHO control and 2 
random samples one of which had low total IgG. The CV ranged from 3.6 
to 18.0% with a mean of 8.75% (Table 2.8). 
The intra-assay variation was obained for the WHO standard serum. These 
samples were assayed 14 times in one run and the coefficient of variation 
ranged from 6.0 to 8.1 % with an average of 6.93% (Table 2.8). 
Running means 
If the values of the controls inserted in each run fell outside the 2 SD range, 
the run was repeated. Running means of these controls were calculated to 
detect trends. Mean values were calculated and added onto cumulative data. 
The running means calculated in this way were plotted and the variation 
from the value of the control observed. 
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2.4.2.3 Correlation with total lgG 
The prerequisite of a reliable IgG subclass determination is its correlation to 
the total IgG value. Using the data of the controls, a linear regression 
analysis was used to estimate the relationship between the sum of the 
subclasses and total measured IgG. The four subclasses and total IgG were 
quantitated in 937 samples. In each case the values for the IgG subclasses 
were summed to obtain the calculated total concentration which was then 
compared with results from an accepted standardized method of total IgG 
measurement by nephelometry. A scatter plot of calculated versus measured 
IgG values showed a highly significant correlation (r = 0.90) between 
measured total IgG and the sum of the IgG subclasses when applying 
Pearson's correlation coefficient estimation (Figure 2.11). 
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Figure 2.11: Regression analysis of IgG measured by nephelometry on the sum of the 
four lgG subclasses measured by ELISA 
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2.4.2.4 
Standard deviations about the regression line between the 'gold standard' 
method (as y) and the new technique (as x) provides information about the 
range of true values which are consistent with a particular reading obtained 
by the new technique. When this is done on these data (Figure 2.11) it can 
be seen that most readings fall within the ± 2 SD range about the regression 
line. It is also noted that for a unit increase in 'x' there is not a unit 
increase in 'y'. At low IgG levels, the IgG measured by nephelometry is 
greater than the IgG obtained from the sum of the four subclasses whereas at 
high levels the opposite is true. The intercept does not go through the origin 
and is calculated as 1.57. 
When IgG was calculated as the sum of the IgG subclasses, 45. 7 % of the 
samples had higher value than when IgG was measured by nephelometry. 
Although the slope of the regression line between measured and calculated 
total IgG concentrations of the different sera was 0.90 (Figure 2.11) there 
was a slight positive bias. This may indicate that the calculated value 
includes the errors of four assays or simply that the total IgG and IgG 
subclasses are measured with different assay methods. 
In these experiments this positive bias may have been eliminated if an 
ELISA was used to measure total IgG and if the monoclonal antibodies used 
for the IgG subclasses and total IgG assays were of the same murine isotype 
to ensure comparable reaction with the secondary antibody. 
Differences between the sum of the IgG subclasses and the total IgG 
It has been argued that correlation coefficients should not be used to 
compare two methods of measurements as this measures the strength of the 
relationship between them and not the agreement between them. It would be 
expected that the data would be highly correlated (Bland and Altman 1986). 
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To assess agreement between methods, differences between the pairs of data 
can be plotted against the means of the pairs (Figure 2.12) (Bland and 
Altman 1986). If the mean of the differences is zero then there is perfect 
agreement between the methods. In Figure 2.12 the central horizontal line 
corresponds to the mean difference and the two outer horizontal lines 
correspond to plus or minus two standard deviations. If the differences have 
a Normal distribution, 95 % of the differences will be between these limits. 
The measurements themselves do not have to follow a Normal distribution 
and in the case of the IgG subclasses, do not. The histogram of the 
differences of these data has a Normal distribution. The mean difference 
between the IgG measured by nephelometry and the sum of the subclasses is 
0.375 (IgG nephelometry > subclasses summed). The differences are 
distributed fairly symmetrically about the mean difference. 
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Figure 2.12: The difference between the IgG measured by nephelometry and the total 
IgG calculated by the sum of the four subclasses (ELISA) is plotted against the mean of 
the measured and calculated IgG. The central horizontal line corresponds to the mean 
difference and the two outer horizontal lines correspond to the mean difference + and -
2 SD (standard deviations) 
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2.4.3 
2.4.3.1 
2.4.3.2 
The correlation between pair differences and pair means provides a 
comparison of the variances of the IgG measured by both methods. This 
correlation (r = 0.03; p = 0.60) indicated no significant difference between 
the variances of the two methods used to determine IgG levels. 
Quality Control 
Inter-laboratory Correlations 
The results of 15 specimens measured in this laboratory using IgG subclass 
ELISAs described here correlated (r: IgGl = 0.90; IgG2 = 0.93; IgG3 = 
0.63 and IgG4 = 0. 75) with the results obtained on the same 15 specimens 
measured by Dr Rabson in the Department of Pathology, Boston, using an 
ELISA method (Black et al 1988). 
Quality assurance scheme 
This laboratory participates in an international quality control programme 
run by the Binding Site, Birmingham, United Kingdom. A sample is sent 
from Binding Site 5-6 times a year. Results of the sample measured in this 
laboratory are forwarded to Binding Site within a given time and once the 
results of all the participants have been analysed they are returned to the 
participating laboratories. Results of 7 runs participated in since May 1992 
are given in Table 2.9 and it can be shown that the IgG subclass results from 
these assays are accurate. 
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TABLE 2.9: COMPARISON OF RESULTS OF IgG SUBCLASSES 
MEASURED IN THIS LABORATORY AND THE QA* SCHEME 
Binding Site 
Sample No 
6/Q106 
7/Q107 
8/Ql08 
9/Q109 
10/Ql 10 
11/Qlll 
12/Ql 12 
Assay 
Laboratory 
QA Scheme 
Laboratory 
QA Scheme 
Laboratory 
QA Scheme 
Laboratory 
QA Scheme 
Laboratory 
QA Scheme 
Laboratory 
QA Scheme 
Laboratory 
QA Scheme 
QA = quality assurance 
2.5 SUMMARY 
IgGl 
g/1 
4.63 
4.68 
8.74 
8.26 
Not done 
Not sent 
7.17 
5.63 
5.99 
5.24 
27.52 
20.45 
5.98 
5.12 
IgG2 
g/1 
2.47 
2.74 
1.20 
1.66 
2.19 
2.18 
2.50 
3.0 
1.77 
2.78 
0.84 
1.05 
3.35 
3.63 
IgG3 IgG4 
g/1 g/1 
0.41 0.29 
0.45 0.30 
1.20 0.35 
1.60 0.40 
0.39 0.33 
0.37 0.33 
0.49 0.44 
0.56 0.43 
0.41 0.29 
0.49 0.31 
0.13 0.05 
0.15 0.05 
0.45 0.22 
0.49 0.22 
The importance of IgG subclass determinations in clinical practice is 
generally accepted, but the choice of methods for their determination 
remains controversial. Although numerous kits are commercially available, 
they are very expensive and studies have shown them not to be fully reliable 
(Meissner et al 1990; Aucouturier et al 1992b). RID kits using monoclonal 
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antibodies lack accuracy and show poor interlaboratory and interbatch 
reproducibility (Aucouturier et al 1992b). In addition these IgG2 ELISA 
kits all use the monoclonal antibody HP6014 which has a preference for 
binding A rather than k IgG2. The RID kits using polyclonal antibodies are 
not specific particularly for IgG2. The methods developed in this study 
using a capture non-competitive ELISA system have proved to be 
quantitative, sensitive and allow reproducible measurement of IgG 
subclasses. In this study a panel of antibodies that have been well 
characterized were selected from the IUIS/WHO Report (Jefferis et al 
1985). These commercially available monoclonal antibodies provide 
consistency and specificity not possible with polyclonal reagents and offer 
easy availability and standardization for comparison with other laboratories. 
The ELISA routinely includes in-house and international controls and has 
been standardized against the WHO International Serum for IgG, IgA and 
IgM (WHO 67/97). Such standardization with a universally available 
reference provides the basis for uniform calibration and permits inter-
laboratory comparsions. 
The ELISAs for IgG 1, IgG2, IgG3 and IgG4 are similar assays in terms of 
methodology but different in terms of specific details (reagents, 
performance, serum dilutions). 
In the IgG 1 assay a great improvement in the attachment of the IgG 1 
antibody to the plastic plates was obtained when the plates were coated with 
streptavidin followed by biotinylated monoclonal antibody. 
In the IgG2 subclass assays, prolonged serum incubation overnight resulted 
in an improved signal. Improved binding of the monoclonal antibodies was 
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observed when a glycine/Tris buffer pH 7.0-7.5 was used instead of the 
more conventional carbonate buffer pH 9.6. 
The IgG2 monoclonal antibody HP6014 is a high affinity antibody 
commonly used in IgG2 measurement despite the fact that it binds IgG2 ),., in 
preference to IgG2 k (Aucouturier et al 1992a). HP6014 may give false 
results and will over- or under-estimate the IgG2 depending on the kk ratio 
in the serum. The IgG2 antibody HP6008 did not perform well in IgG2 
ELISA. However, a combination of HP6008:HP6014 in a 2: 1 mixture 
performed well and overcame the problems of inaccurate measurement using 
HP6014 alone. 
Ten microlitres of serum is sufficient to measure all four subclass levels. 
This microsample volume is especially desirable in testing children's sera. 
Furthermore, these ELISAs are suitable for the accurate quantitation of IgG 
subclasses in children's sera where low levels are to be expected. The 
sensitivity of these assays varies from 0.010 g/1 to 30 g/1 depending on the 
assay system used. Working ranges (ng/ml) for IgG subclass detection are: 
IgGl = 32.8 - 3283 using HP6069; IgG2 = 8.2 - 1110 using a 2:1 mixture 
of HP6008 and HP6014; IgG3 = 2.4 - 292 using HP6010 and IgG4 = 2.0 -
160 using HP6013. Inter- and intra-assay precision was within acceptable 
limits for clinical immunoassays and quality control studies with other 
laboratories (Binding Site and Boston) showed good correlations. 
There was good agreement between the sum of the four IgG subclasses 
measured by ELIS As and total IgG measured by nephelometry. 
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CHAPTER 3 
TETANUS TOXOID IMMUNOASSAYS 
The measurement of tetanus toxoid (TT) has long been used to evaluate specific humoral 
immune responses. This chapter describes in detail the methodology involved in 
establishing the optimal conditions and reagents for IgG, IgG 1 and IgG4 tetanus toxoid 
ELISAs. With the use of a chaotropic agent it was possible to measure the antibody 
affinity of IgG 1 and IgG4. These assays were applied to assess specific antibody responses 
to tetanus toxoid in controls and patients. This chapter is subdivided into the following 
sections: 
3.1 INTRODUCTION 
3.2 DETERMINATION OF OPTIMAL ASSAY CONDITIONS 
3.3 METHODS 
3.4 ASSAY STANDARDIZATION 
3.5 ANTIBODY AFFINITY 
3.6 SUMMARY 
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3.1 INTRODUCTION 
Immunisation with tetanus toxoid has been used for many years to evaluate 
the ability to mount a specific humoral immune response (Knutsen et al 
1981; Litwin 1981; WHO Scientific Group 1983). 
In 1890 Von Behring and Kitasto originally demonstrated tetanus toxoid 
antibodies using toxin neutralisation tests in mice and guinea pigs (Farzad et 
al 1986). This test measures the ability of anti-tetanus antibodies to protect 
mice from a standard innoculum of tetanus toxin. Subsequently numerous 
methods have been developed for the quantitation of anti-tetanus antibodies 
including passive agglutination (Barr et al 1975; Wang et al 1982), reversed 
rocket immunoelectrophoresis (Hoyeraal et al 1975), latex agglutination (De 
Saint Martin et al 1975), radioimmunoassay (Repetti and Gill 1980) and 
ELISA (Hagenaars et al 1984; Virella et al 1985). 
The sensitivity, accuracy and reproducibility of these assays for tetanus 
antibodies vary widely. For example, the latex agglutination assay was 
proposed as a screening test but only detects sera with high antibody titres 
(Booth and Nuttall 1978). Quantitative immuno-electrophoretic assays are 
relatively simple and reproducible, but not very sensitive (Hoyeraal et al 
1975). Haemaggl utination methods are simple to perform, sensitive but 
imprecise (Virella et al 1985). 
Radioimmunoassays and ELISAs are sensitive, reproducible and easy to 
perform. In addition ELISAs are safe, rapid and relatively inexpensive. 
ELISAs are also capable of detecting tetanus antibodies of all the specific 
immunoglobulin classes and subclasses (French and Harrison 1985; 
Dengrove et al 1986; Rubin et al 1986). The ELISA detects IgG antibodies, 
which contain all the toxin-neutralizing activity and titres are often higher 
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than neutralization assays particularly in sera taken from people shortly after 
immunization (Hagenaars et al 1984). 
The affinity of an antibody for its corresponding antigen has been shown to 
be an important determinant of the biological efficacy of that antibody and 
may play a major role in immune processes in man. Excessive production 
of low affinity antibody has been considered to be an expression of relative 
immunodeficiency (Soothill and Steward 1971). High affinity antibodies 
have been shown to be biologically more effective than low affinity 
antibodies (Steward 1981). If this is true a predominantly low affinity 
antibody response may be an important factor in increased susceptibility to 
infection. Analysis of the affinity of the subclass type of IgG antibody 
produced after immunization with tetanus toxoid has shown that high levels 
of IgG4 antibodies are associated with an overall low affinity response to 
tetanus toxoid whereas high levels of IgG 1 antibodies are associated with 
high affinity responses (Devey et al 1985; 1987; 1988). 
The use of chaotropic agents in ELISA methods has been shown to have an 
effect on the dose response curve, producing a marked shift to the left by 
antibodies produced early in the immune response (generally accepted as 
being of low affinity) but having less effect on high affinity antibodies 
(Inouye et al 1984; Pullen et al 1986). 
The purpose of establishing an assay to quantitate IgG and IgG subclass 
antibodies to tetanus toxoid was to evaluate the capacity to generate antibody 
responses to protein antigens in children of different ages and to differentiate 
between high and low affinity antibody production. 
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3.2 DETERMINATION OF OPTIMAL REAGENTS AND CONDITIONS 
The assay procedures described later (Chapter 3.3) resulted from a process 
of trial and error. Various technical factors and test conditions affecting the 
performance of the assays were assessed initially. 
3.2.1 Plates 
3.2.1.1 
Various 96 well polystyrene and polyvinyl chloride plates were compared 
for these immunoassays. These included: Nunc round bottomed plates 
(Weil, Denmark, Catalogue No 1-63320), Nunc flat bottomed plates (Weil, 
Denmark, Catalogue No 4-42404), Falcon microtest flexible plastic (PVC) 
round bottomed (Catalogue No 3911) and flat bottomed (Catalogue No 
3912) plates. 
IgG tetanus toxoid ELISA 
In the IgG assay (Figure 3.1) no significant differences were found between 
Nunc and Falcon flat bottomed plates or Falcon round bottomed plates. At 
the higher coating concentrations of tetanus toxoid (1.0 Lf/ml and 4.0 
Lf/ml) Nunc round bottomed plates gave similar shaped standard curves to 
the other 3 plates. However, at the more dilute concentrations the shapes of 
the standard curves were flatter (Figure 3.1 and 3.4). Nunc flat bottomed 
plates were selected with a coating concentration of 0.4 Lf/ml of tetanus 
toxoid. 
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Figure 3.1: Standard curves of IgG tetanus toxoid ELISA comparing Nunc flat and 
round bottomed and Falcon flat and round bottomed plates, using coating 
concentrations of tetanus toxoid ranging from 4 to 0.04 Lf/ml: 4 Lf/ml (•), 2 Lf/ml ( + ), 1 Lf/ml (*), 0.4 Lf/ml (•), 0.2 Lf/ml (x), 0.1 Lf/ml ( +) and 0.04 Lf/ml ( •) 
IgGJ tetanus toxoid ELISA 
The trends were identical to those seen in the IgG tetanus toxoid ELISA 
(Figure 3.1). Again flat bottomed Nunc plates were selected with a coating 
concentration of 0.4 Lf/ml of tetanus toxoid (Figure 3.2 and 3.4). 
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Figure 3.2: Standard curves of IgGl tetanus toxoid ELISA comparing Nunc flat and 
round bottomed and Falcon flat and round bottomed plate-; using coating 
concentrations of tetanus toxoid ranging from 4.0 to 0.04 Lf/ml: 4 Lf/ml(•), 2Lf/ml 
( + ), 1 Lf/ml (*), 0.4 Lf/ml (•), 0.2 Lf/ml (x), 0.1 Lf/ml ( +) and 0.04 Lf/ml ( • ). 
IgG4 tetanus toxoid ELISA 
The only difference in these assays was that the shapes of the standard 
curves coated with dilute (0.4 Lf/ml - 0.04 Lf/ml)) tetanus toxoid weremuch 
flatter on all plates (Figure 3.3). As with the IgG tetanus toxoid and IgG 1 
tetanus toxoid ELISA the Nunc flat bottomed plates were selected with a 
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3.2.1.4 
coating concentration of 0.4 Lf/ml of tetanus toxoid. Nunc round bottomed 
plates were unsuitable. 
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Figure 3.3: Standard curves of IgG4 tetanus toxoid ELISA comparing Nunc flat and 
round bottomed and Falcon flat and round bottomed plates using coating 
concentrations of tetanus toxoid, ranging from 4.0 to 0.04 Lf/ml: 4 Lf/ml, (•) 2 Lf/ml 
( + ), 1 Lf/ml (*), 0.4 Lf/ml (•), 0.2 Lf/ml (x), 0.1 Lf/ml ( +) and 0.04 Lf/ml ( • ). 
Conclusion and discussion 
In previously reported ELISAs measuring IgG and IgG subclass specific 
antibodies various plates have been used viz, Dynatech (Dengrove et al 
1986; Farzad et al 1986; Rubin et al 1986), Limbro (Sedgwick et al 1983), 
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Flow (Hagenaars et al 1984; Devey et al 1987; 1988), Nunc (French and 
Harrison 1985), and Nunc flat bottomed (Lau 1987; Simonsen et al 1987). 
The authors do not specify if other plates were assessed in these assays and 
why those particular plates were selected. Data from this study indicates 
that the type of plate used may affect the sensitivity and results of the assay. 
The Nunc flat bottomed plates were chosen for use in further assays as these 
plates produced steeper standard curves at optimum antigen coating 
concentrations (0.4 Lf/ml tetanus toxoid) than the Nunc round bottomed 
plates (Figure 3.4). The flat bottomed Nunc plates were selected for use 
over the Falcon plates as they were easier to load without splashing, readily 
available and much cheaper (1/5 of the cost). It was also more convenient 
to use the same plates in all the tetanus toxoid ELISAs. 
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Figure 3.4: Comparison of standard curves of IgG, lgGl and IgG4 tetanus toxoid 
ELISAs using various microtitre plates. The plates used were Nunc flat (NF) ( +) or 
Nunc round (NR) (D) bottomed polystyrene plates and Falcon flat (FF) (+)or Falcon 
round (FR) (x) bottomed PVC plates. The plates were coated with 0.40 Lf/ml tetanus 
toxoid antigen 
SECTION A: Chapter 3: Tetanus Toxoid Jmmunoassays 89 
3.2.2 Antigen Coating 
3.2.2.1 
The coating antigen used in these assays was purified tetanus formol-toxoid 
(20 Lf/ml) preserved with 0.01 % thiomersal produced by the South African 
Institute of Medical Research (SAIMR). All dilutions of coating antigen 
were made in carbonate buffer pH 9.6 
IgG tetanus toxoid ELISA 
Maximal coating was obtained between 4.0 and 0.4 Lf/ml of tetanus formol-
toxoid (Figure 3.1). The concentration of 0.4 Lf/ml was selected for the 
assays. No difference was found between coating the plates overnight at 
4 °C or for 11/i hours at 37°C. The standard curve of a plate stored at 4 °C 
for a week in an air tight container shifted to the left when compared to a 
freshly coated plate (Figure 3.5). Thus all plates were coated just prior to 
use. 
2 OJ 
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0.5 
0+---~----,----.-__:_____::_~===::::::±:.......-----. 
3 3.5 4 4.5 5 
I og serum di I uti ons 
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Figure 3.5: Comparison of standard curves of IgG tetanus toxoid ELISA using plates 
coated with antigen just prior to use (•) and plates coated and stored for 1 week prior 
to use(+) 
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3.2.2.2 
3.2.2.3 
3.2.2.4 
IgG I tetanus toxoid ELISA 
As in the IgG tetanus toxoid ELISA a coating concentration of 0.4 Lf/ml 
tetanus toxoid was selected for these assays (Figure 3.2). 
IgG4 tetanus toxoid ELISA 
A coating concentration of 0.4 Lf/ml was selected for these assays (Figure 
3.3). 
Conclusion and discussion 
The antigen most commonly used in reported ELISAs has been either 
tetanus toxoid vaccine at coating concentrations between 5.0 - 0.2 Lf/ml 
(Sedgwick et al 1983; Hagenaars et al 1984; French and Harrison 1985; 
Rubin et al 1986; Lau 1987) or affinity purified tetanus toxoid at a 
concentration of 5-10 µg/ml (Farzad et al 1986; Devey et al 1988). 
Hagenaars et al (1984) found that by decreasing the tetanus toxoid coating 
concentration in the ELISA from 5.0 to 0.2 Lf/ml a better correlation was 
obtained between ELISA results and bioassay titres. 
In this study the standard curves of IgG, IgG 1 and IgG4 showed little 
change in the shape of the curves when the plates were coated with 
concentrations of tetanus toxoid ranging from 4.0-0.4 Lf/ml (Figures 3.1, 
3.2 and 3.3). 
Decreases in toxoid concentration below this resulted in flattening of the 
standard curve and unacceptably low assay absorbances. Tetanus formol-
toxoid vaccine at a coating concentration of 0.4 Lf/ml was selected for the 
IgG, IgGl and IgG4 assays described here. 
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Coating times for tetanus toxoid range from 1 hour at 37°C to overnight at 
4 °C, the latter being the most commonly employed (Sedgwick et al 1983; 
Hagenaars et al 1984; French and Harrison 1985; Dengrove et al 1986; 
Farzad et al 1986; Lau 1987; Devey et al 1988). Voller and Bidwell's 
(1986) general guide to antigen coating of overnight incubation at 4 °C was 
followed. The results showed that this period was satisfactory as well as 
being convenient. Although there are reports that sensitized plates can be 
stored for time intervals ranging from 2 weeks (Lau 1987; Devey et al 1988) 
to 1 year (Farzad et al 1986) without loss of sensitivity, experiments 
performed here were unable to reproduce this (Figure 3.5). 
3.2.3 Blocking Agents 
3.2.3.1 
Various blocking agents were compared in these assays to prevent non-
specific binding to the microtitre plates: 
Gelatin - (Biorad (EIA grade), Catalogue No 170-6537) in PBS 
Casein - (Centrolab, SAARCHEM Catalogue No 152813) in TBS 
BSA - Albumin Fraction V, (Boerhinger Mannheim, Catalogue No 
735086) in PBS 
IgG tetanus toxoid ELISA 
Casein 1 % was selected as the blocking agent and serum diluent as it gave 
the lowest uncoated well blanks without altering the capability for detecting 
antibody (Table 3 .1). 1 % gelatin and 2 % BSA both gave high minus 
antigen blank readings (Table 3.1). 
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3.2.3.2 
3.2.3.3 
3.2.3.4 
IgG I tetanus toxoid ELISA 
1 % Casein was selected as the blocking agent and serum diluent for the 
same reasons (Table 3.1). 
IgG4 tetanus toxoid ELISA 
Very high minus antigen well blanks (91. 2 % ) were found when BSA was 
used and 1 % casein gave the best results (Table 3.1). 
Conclusion and discussion 
In previous reports gelatin (1 %) (Rubin et al 1986; Devey et al 1988) and 
BSA (0.1 % to 2%) (French and Harrison 1985; Farzad et al 1986; 
Simonsen et al 1987) were used as blocking agents for IgG and IgG subclass 
specific tetanus toxoid assays. In other reports the blocking step has been 
omitted and the sera have then been diluted in 5 % BSA (Hagenaars et al 
1984), 5% FCS (Lau 1987), 1 % casein (Devey et al 1987) or simply in PBS 
buffer with 0.05% Tween 20. Comparison of the effectiveness of blocking 
agents in the ELISAs in these reports is not possible as the values of blank 
readings with the various blockers were not documented. 
In the present assays 1 % casein in TBS was selected as the blocking agent. 
It was more effective as a blocker when compared to 1 % gelatin although 
the latter was considered acceptable. 2 % BSA was unacceptable as a 
blocker as in all the assays the minus antigen well blanks were high ( ~ 
29% of the maximum signal). Casein is also the cheapest agent. 
3.2.4 Choice of Serum Standards and Controls 
Normal pooled human immunoglobulin and hyperimmune human anti-
tetanus immunoglobulin (125 IU/ml) both supplied by Natal Blood 
Transfusion Service (NBTS) were evaluated as standards. 
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3.2.4.1 IgG tetanus toxoid ELISA 
In the IgG tetanus toxoid ELISA hyperimmune anti-tetanus immunoglobulin 
shifted the curve to the right compared to the normal immunoglobulin 
(Figure 3.6). Hyperimmune anti-tetanus immunoglobulin was selected as 
the calibrator for the standard curve as it could be used in greater dilutions 
which resulted in lower uncoated well blank readings. The normal pooled 
human immunoglobulin was used as the positive control in each assay. 
Pooled batches of the standard and positive control were aliquotted and 
stored at -70°C until use. When new batches of normal human 
immunoglobulin were required they were recalibrated against the standard. 
Calculated antibody concentrations were similar for dilutions read off the 
linear part of the curve and control serum dilutions of 1: 1 000 and 1: 1 500 
were selected. Unknown samples pre- and post-tetanus toxoid immunization 
were initially tested at dilutions of 1 :200 and 1: 1 000 respectively. Titration 
curves of the positive control serum and test samples were parallel to the 
standard curve (Figure 3. 6). 
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Figure 3.6: IgG, IgGl and IgG4 tetanus toxoid ELISAs demonstrating parallelism of 
the standard ( •) (hyperimmune human anti-tetanus immunoglobulin), the control ( +) 
(Nlg-pooled normal human immunoglobulin), and individual serum samples post 
tetanus toxoid immuni7..ation: A(*), B (D), C (x), D ( + ), E (a) 
IgG 1 tetanus toxoid ELISA 
Results were similar to IgG tetanus toxoid ELISA and the positive control 
samples were diluted to 1: 1 000 and 1: 1 500. Unknown samples pre- and 
post-tetanus toxoid immunization were diluted 1: 100 and 1: 1 000 
respectively. The titration curves of the sera samples were parallel to the 
standard curve (Figure 3.6). 
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3.2.4.3 
3.2.4.4 
IgG4 tetanus toxoid ELISA 
Results were identical to the IgG tetanus toxoid ELISA except that the 
control samples were diluted to 1:300 and 1:400 and the unknown samples 
pre- and post-tetanus toxoid immunization to 1/15 and 1: 1 000 respectively. 
Only titration curves of sera samples with high concentrations of IgG4 
tetanus toxoid were parallel to the standard curve (Figure 3. 6). 
Conclusion and discussion 
For accurate quantitation it is important that the titration of test samples 
parallel that of the standard. In the IgG, IgG 1 and IgG4 tetanus toxoid 
ELISAs titration of sera with high titre antibodies paralleled the standard 
curves allowing accurate analysis of results (Figure 3.6). Due to the non 
parallelism observed with low levels of IgG4, the results must be interpreted 
with caution. The immunochemical basis for non-parallelism may be 
secondary to: 
reagent instability and variability or 
high non-specific binding of the specimen 
combination of isotype competition and epitope heterogeneity when 
multivalent antigens are used 
competitive inhibition between isotypes for the same antigen (Butler 
1988) 
3.2.5 Serum Incubation Periods 
The role of incubation time in the assay was studied by incubating the serum 
for 1 hour at 37°C or overnight at 4 °C. There was no difference in the 
shape of the curve or intensity of the signal. For convenience a serum 
incubation period of 1 hour at 37°C was selected for all 3 assays. 
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3.2.6 Monoclonal Antibody - Selection 
Details of the various unbiotinylated and biotinylated monoclonal antibodies 
specific for the individual subclasses IgG 1, IgG2, IgG3 and IgG4 evaluated 
for these assays can be found in Appendix A. The monoclonal antibodies 
were all diluted in 1 % casein in TBS. 
3.2. 7 Monoclonal Antibody - Backgrounds 
Table 3.2 shows the effect of the various monoclonal antibodies on non-
specific background binding. Background readings were obtained from the 
following blanks: 
Minus antigen blanks i.e. minus tetanus toxoid antigen but including 
serum and monoclonal antibody 
Minus monoclonal antibody blanks i.e. antigen coated wells with 
serum but minus monoclonal antibody 
Minus serum blanks i.e. antigen coated wells with monoclonal 
antibody but minus serum 
Background blanks i.e. antigen coated wells with no serum or 
monoclonal antibody. 
For all the assays the background values obtained from wells with antigen 
and monoclonal antibody but minus serum were very similar to those with 
antigen but minus serum and monoclonal antibody. These background 
blanks gave OD readings in the range of 0.002 - 0.040 and accounted for 
less than 2.5 % of the total signal (Table 3.2). 
Minus antigen blanks and the highest value of the serum blanks or 
monoclonal antibody blanks were added together and subtracted from each 
serum dilution before standard curves were constructed. 
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A major reason for raised background measurements was the monoclonal 
antibody blank. This was due to non-specific binding of the conjugate 
antibody to the antigen coated wells containing test serum. Each serum 
dilution had its own monoclonal antibody blank in the development of the 
assays. For the unbiotinylated antibodies the monoclonal antibody blanks 
accounted for 21.45% to 91.60% of the signal (Table 3.2). The non-
specific binding reflected by these monoclonal antibody blanks could not be 
decreased significantly by using different horseradish peroxidase conjugated 
mouse anti-human antibodies or by the addition of animal sera such as 
mouse, goat or fetal calf serum. By using biotinylated IgG 1, IgG2, IgG3 
and IgG4 monoclonal antibodies and streptavidin conjugated horseradish 
peroxidase as the detecting agent, the monoclonal antibody blanks could be 
significantly reduced and accounted for less than 0.2 % of the maximum 
signal (Table 3.2). 
When only the mmus antigen well blanks and mmus serum blanks were 
subtracted from the signal, sigmoidal curves were obtained for IgG 1, IgG2, 
IgG3 and IgG4 tetanus toxoid subclass specific assays using both 
unbiotinylated and biotinylated monoclonal antibodies (Figures 3. 7 and 3.8). 
However, when monoclonal antibody blanks were also subtracted from the 
signal, sigmoidal curves were lost in the IgG2 and IgG3 assays when 
unbiotiny lated antibodies were employed (Figures 3. 7 and 3. 8). This 
illustrates how a failure to include subtraction of monoclonal antibody 
blanks can lead to erroneous standard curves. 
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Figure 3.7: Standard curves for IgGl, IgG2, IgG3 and IgG4 tetanus toxoid ELISAs 
using unbiotinylated monoclonal antibodies (see text for details) without (•) and with 
( +) the minus monoclonal antibody (Moab) background OD subtracted 
SECTION A: Chapter 3: Tetanus Toxoid lmmunoassays 101 
3.2.7.1 
(Jlfi~tj(Jlk 
- ftj(Jlk 
-+- - tj(Jlk 
(Jlfi~tj(Jlk 
-ttj(Jlk 
-+- - tj(Jlk 
lgG1 
1.5 
Q5 
0+--.---,-.......,.-,....-...,......-,----,.--, 
I ~ 2 ~ 3 ~ 4 ~ 5 
log serum dlutioos 
lgG3 
/TI 
1.5 
1 
Q5 
0 
I 1.5 2 25 
log serum dlutioos 
3 
1.5 
<Jrtj~tj(Jlk 
- rn<n< 1 
-+- - tj<n( 
2 OJ 
1.5 
<Jrtj~tj(Jlk 
- ftj<n( 
-+- - tj<n( 
Q5 
0 
I 1.5 
I~ 
1.5 2 25 3 
log sa-um dlutioos 
lgG4 
2 25 
log sa-um dlutioos 
3 3.5 
Figure 3.8: Standard curves for IgGI, IgG2, IgG3 and IgG4 tetanus toxoid ELISAs 
using biotinylated monoclonal antibodies (see text for details) without (•) and with ( +) 
the minus antigen background OD subtracted 
IgG 1 tetanus toxoid ELISA 
In the IgG 1 tetanus toxoid ELISAs both unbiotinylated and biotinylated 
monoclonal antibody gave low antigen blanks, accounting for 6.3% and 
0.43 % respectively of the signal of the most concentrated standard dilution. 
The monoclonal blanks of the biotinylated antibody were much lower than 
those of the unbiotinylated antibody being 0.1 % and 21.45% respectively, 
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of the most concentrated standard dilution (Table 3.2). Therefore, the 
biotinylated anti-IgG 1 monoclonal antibody HP6069 was selected for the 
IgG 1 subclass specific tetanus toxoid assay. 
Checkerboard titrations of monoclonal antibody, serum and conjugate 
concentrations were done to optimize the IgG 1 tetanus toxoid antibody 
assays. The performance of the biotinylated anti-IgG 1 monoclonal antibody 
was tested at 1: 1 000, 1 :2 000 and 1 :4 000 dilutions and the results show 
that a 1:2 000 dilution was the optimum (Figure 3.9). 
lgG1 lgG4 
25 m 
1.5 
HP6069 I 5 
-IICO'J 
-+- 12 CO'J 
ff'6025 
- 1:1 CO') I 
-+- L4CO'J -+- 1:2 CO'J 
05 05 
25 3 35 
log senrn dlutions 
4.5 25 3 35 4 4.5 
ICXJ sm.rn di utions 
Figure 3.9: Effect of monoclonal antibody (Moab) dilutions on the standard curves of 
the IgGl and IgG4 tetanus toxoid ELISAs. The biotinylated anti-IgGl Moab HP6069 
was tested at 1:1000 (•), 1:2000 (+) and 1:4000 (x) dilutions and the biotinylated 
anti-IgG4 Moab HP6025 at 1:1 000 (•) and 1:2 000 (+ ). 
IgG4 tetanus toxoid ELISA 
Antigen blanks were low usmg either the unbiotinylated or biotinylated 
antibodies but monoclonal antibody blanks were high (41 % of the maximum 
SECTION A: Chapter 3: Tetanus Toxoid lmmunoassays 103 
3.2.7.3 
signal) using the unbiotinylated antibody and low (0.2 % of the maximum 
signal) using the biotinylated antibody (Table 3.2). The biotinylated anti-
IgG4 antibody HP6025 was selected for these assays at a concentration of 
1:1 000 (Figure 3.9). 
IgG2 tetanus toxoid ELISA 
In the IgG2 assays, the unbiotinylated monoclonal antibody HP6008, gave 
monoclonal blanks of 91.6% of the signal whereas using the biotinylated 
IgG2 antibody the antigen blanks were almost 50% of the signal. These 
blanks could not be lowered even with the addition of various animal sera to 
diluents, or by using other blockers. Because of this problem and because 
there appeared to be only a relatively small amount of IgG2 tetanus toxoid 
antibody present in the hyperimmune anti-tetanus immunoglobulin 
preparation (Figure 3 .10), IgG2 subclass specific tetanus toxoid assays were 
not developed. 
-- lgG 
--+- I gGl 
+ lgG2 
-e- lgG3 
-*- I gG4 
2 OJ 
1.5 
0.5 
O,;------,-----.-----.----~-----, 
0 2 3 4 5 
I og serum di I uti ons 
Figure 3.10: Standard curves of IgG (•); IgGl (+ ); IgG2 (*); lgG3 (D) and lgG4 (x) 
subclass specific tetanus toxoid ELISAs using hyperimmune human anti-tetanus 
immunoglobulin as the standard 
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3.2.7.4 
3.2.7.5 
IgG3 tetanus toxoid ELISA 
In the IgG3 assays the unbiotinylated HP6010 antibody blanks were 77.32% 
of the signal. Using the biotinylated IgG3 monoclonal antibody all the 
blanks were acceptable ( < 10%) (Table 3.2) but this antibody had to be 
used at a high concentration (1 :250). For these reasons and the fact that the 
IgG3 response to tetanus toxoid was thought not to be as important, this 
assay was not standardised. 
Conclusion and discussion 
Standard curves of total IgG and IgG subclass specific tetanus toxoid 
antibodies were established using hyperimmune human anti-tetanus 
immunoglobulin as the standard (Figure 3.10). For reasons mentioned 
above IgG2 and IgG3 tetanus toxoid ELISAs were not standardized for 
routine use. 
Devey et al (1987; 1988) and Rubin et al (1986) have used the monoclonal 
antibody HP6012 (NL16) and French and Harrison (1985) used the 
monoclonal antibody HP6007 (JL5 l 2) to establish IgG 1 subclass specific 
tetanus toxoid assays (Table 3.3). There are no reports of the use of the 
unbiotinylated or biotinylated anti-IgG 1 monoclonal antibody HP6069 used 
in the experiments described here. The biotinylated antibody HP6069 was 
selected in preference to HP6012 because it gave lower non-specific 
binding. 
The three groups that have reported IgG4 tetanus toxoid assays have all used 
a different anti-IgG4 monoclonal antibody (Table 3.3) (French and Harrison 
1985; Rubin et al 1986; Devey et al 1988). Again there are no reports of 
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the use of the biotinylated IgG4 monoclonal antibody HP6025 which was 
selected for the assay described above. 
Although previous reports of IgG2 tetanus toxoid assays use the monoclonal 
antibody HP6008 (French and Harrison 1985; Rubin et al 1986; Devey et al 
1987) (Table 3.3) it was found to be unsuitable in the assay system 
described above because of the high background monoclonal antibody blank 
readings obtained. 
There are reports of the anti-IgG3 monoclonal antibody HP6010 (French 
and Harrison 1985; Devey et al 1987) and SK33 (Rubin et al 1986) being 
used to establish IgG3 subclass specific tetanus toxoid assays (Table 3.3). 
There are no reports of the use of the biotinylated antibody HP6047 which 
was found to be better suited to the assay system described above than the 
antibody HP6010. This assay was not developed further. 
It is not possible to make a direct comparison of the assays developed in our 
laboratory with those previously reported because of the different 
combinations of reagents, in particular the monoclonal and conjugated 
antibodies used. 
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3.2.8 
3.2.8.1 
3.2.8.2 
Evaluation of Enzyme Detector Systems 
IgG tetanus toxoid ELISA 
The detection antibody was a goat anti-human IgG gamma chain specific 
antibody coupled to horseradish peroxidase (HRPO). The following 
conjugated antibodies were evaluated: 
Non affinity purified goat anti-human gamma chain specific HRPO 
(Cappel, Catalogue No 3301-0121) 
Affinity purified goat anti-human gamma chain specific HRPO 
(Cappel, Catalogue No 3601-0121). 
Affinity purified goat anti-human gamma chain specific HRPO 
absorbed with mouse serum proteins (Zymed, Catalogue No 62-
8420) 
F(ab')2 fragment affinity purified goat anti-human gamma chain 
specific HRPO (Sigma, Catalogue No 62-8420) 
The Cappel affinity purified goat anti-human gamma chain specific 
horseradish peroxidase conjugate gave a very low signal whereas the Cappel 
non-affinity purified goat anti-human gamma chain specific horseradish 
peroxidase conjugate could be used at a dilution of 1:30 000. The Zymed 
and Sigma goat anti-human conjugates at dilutions of 1 :5 000 and 1: 1 000 
respectively gave lower signals than the non-affinity purified Cappel 
conjugate (Figure 3.11) which was selected for reasons of precision and 
economy. It was diluted from a 1:100 stock to 1:30 000 in 1 % casein in 
TBS. 
IgGJ tetanus toxoid ELISA 
In the subclass specific assays where biotinylated monoclonal antibodies 
were selected streptavidin conjugated horseradish peroxidase was used. The 
effect of various concentrations (1: 10 000, 1: 15 000, 1 :20 000, 1 :30 000, 
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1: 35 000) of Streptavidin horseradish peroxidase on the detection of IgG 1 
tetanus toxoid antibodies using a biotinylated monoclonal antibody (at a 
concentration of 1 :2000) can be seen in Figure 3.11. The dilution of 
streptavidin horseradish peroxidase of 1: 30 000 was selected. The conjugate 
was diluted in 1 % casein TBS from a stock solution of 1: 1 000. 
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Figure 3.11: Effect of various goat anti-human IgG conjugates on the standard curve 
of the IgG tetanus toxoid ELISA: Cappel (•), Zymed ( +) and Sigma (*) and of various 
dilutions of streptavidin peroxidase (SA): 1:10 000 (•), 1:15 000 ( + ), 1:20 000 (*), 
1:30 000 ( + ), 1:35 000 (•)on the IgGl and IgG4 tetanus toxoid ELISAs. 
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3.2.8.3 
3.2.8.4 
3.3 
IgG4 tetanus roxoid ELISA 
The results obtained in the IgG4 tetanus toxoid ELISA were very similar to 
the IgG 1 assay above and a 1 :20 000 dilution of streptavidin horseradish 
peroxidase was selected for routine use (Figure 3.11). 
Conclusion and discussion 
Most reports have used alkaline phosphatase or peroxidase conjugated 
antibodies as detection antibodies. There is little uniformity in purity or 
source of these antibodies. However Lau (1987) incorporated the use of the 
biotin streptavidin system to measure IgG tetanus toxoid antibodies. This 
system has proven very useful in the IgG 1 tetanus toxoid and IgG4 tetanus 
toxoid assays described in this study. 
METHODS 
Optimum reaction conditions had been determined in preliminary 
experiments. All reagents and samples were added to the wells in 100 µl 
volumes except for the 2N H2S04 of which 50 µl volumes were used. 
3.3.1 lgG tetanus toxoid ELISA 
Flat bottomed Nunc microtitre plates (Catalogue No 4-4204) were coated 
with tetanus formol-toxoid SAIMR (20 Lf/ml) diluted to 0.4 Lf/ml in 
carbonate buffer pH 9.6. This coating concentration of 0.04 Lf per well 
was shown to be optimal in preliminary assays. Plates were incubated 
overnight in a moist chamber at 4 °C. Non-specific protein binding sites 
were then blocked with 1 % casein diluted in TBS for 30 minutes at 37°C in 
a moist chamber. Plates were washed once with PBS and dilutions of sera 
diluted in 1 % casein in TBS were added to quadruplicate wells. 
Hyperimmune human anti-tetanus immunoglobulin from NBTS (125 JU/ml) 
in 9 dilutions ranging from 1:250-1:100 000 (1:250, 1:500, 1:1 000, 
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1:2 500, 1:5 000, 1:10 000, 1:25 000, 1:50 000, 1:100 000) was used as the 
standard. Positive control sera (normal human immunoglobulin) (NBTS) 
dilutions of 1: 1 000 and 1: 1 500 were selected. Dilutions of pre- and post-
tetanus toxoid immunization sera of 1 :200 and 1: 1 000 respectively were 
suitable to quantitate antibody both pre- and post-tetanus toxoid 
immunization samples in the majority of specimens. If the OD of the 
sample did not read off the linear section of the standard curve the samples 
were reassayed at appropriate dilutions. The samples were incubated for 1 
hour at 37°C. 
Buffer and diluent were included in each assay as negative controls. 
Agammaglobulinaemic sera had no detectable reaction in the assay. 
The plates were washed with PBST five times. F(ab')2 fragment goat anti-
human IgG Fe gamma chain specific horseradish peroxidase conjugated 
antibody (Cappel Catalogue No 3301-0121) diluted 1:30 000 in 1 % casein 
was added to the wells and incubated for 30 minutes at 37°C. The plates 
were again washed five times with PBST. OPD substrate buffer was added 
and incubated in the dark at room temperature for 15 minutes. The reaction 
was stopped with 50 µ1 of 2N H2S04. The OD was read at 492nm in an 
SLT ELISA reader. 
3.3.2 lgG 1 tetanus toxoid ELISA 
The coating, washing, blocking and substrate steps were identical to those 
described for the IgG tetanus toxoid ELISA. The following changes were 
made: 
The standard curve dilutions of human hyperimmune anti-tetanus 
immunoglobulin ranged from 1:1 000-1:75 000 (1:1 000, 1:2 500, 
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1:5 000, 1:7 500, 1:10 000, 1:15 000, 1:25 000, 1:40 000, 
1:75 000) 
Positive control dilutions of 1: 1 000 and 1: 1 500 were selected 
Initially, patient sera pre- and post-tetanus toxoid immunization were 
added at two dilutions of 1: 100 and 1: 1 000 respectively 
The sera samples were diluted in 1 % casein and incubated for 1 hour 
at 37°C 
Monoclonal biotinylated mouse anti-human IgG subclass specific 
antibody to IgG 1 (HP6069) diluted 1 :2 000 in 1 % casein was then 
added to the wells and incubated overnight at 4 °C 
After washing streptavidin conjugated horseradish peroxidase 
(Zymed Catalogue No 43-4323) diluted 1 :30 000 in 1 % casein was 
added and incubated at 37°C in a moist chamber for 1 hour. 
3.3.3 lgG4 tetanus toxoid ELISA 
This was similar to the method mentioned above for the IgG 1 tetanus toxoid 
ELISA except for the following dilution and antibody differences. 
The standard curve dilutions of the human anti-tetanus 
immunoglobulin ranged from 1 :25 - 1 :2 500 (1 :25, 1 :50, 1: 100, 
1 :250, 1 :500, 1 :750, 1: 1 000, 1: 1 500, 1 :2 500) 
Positive control dilutions of 1 :300 and I :400 were selected. 
Initially patient sera pre- and post-tetanus toxoid immunization were 
added at dilutions of 1/15 and I: 1 000 respectively 
The biotinylated mouse anti-human IgG subclass specific antibody to 
IgG4 (HP6025) was diluted in 1 % casein to I: 1 000 
Streptavidin conjugated horseradish peroxidase was diluted in 1 % 
casein to 1 :20 000 
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3.3.4 Design of Plate 
All reactions were performed m triplicate. Every assay plate included 9 
dilutions of the standard anti-tetanus toxoid immunoglobulin for the 
calibration curves, background reaction wells (wells minus serum, minus 
antigen, and minus monoclonal antibody (where applicable)) and dilutions 
of the sample of pooled normal immunoglobulin for monitoring 
reproducibility. For the routine analysis of unknown samples the design of 
the plate is similar for the IgG, IgGl and IgG4 tetanus toxoid ELISAs and 
is shown in Chapter 1, Figure 1.1. 
The blanks are in column 10 rows A-D. In the IgG tetanus toxoid ELISA 
these blanks are minus-serum blanks. The blanks in column 10 in the 
subclass specific assays are minus monoclonal antibody blanks i.e. each well 
contains the most concentrated standard dilution minus the relevant 
monoclonal antibody. 
Rows A-C and E-G were coated with tetanus toxoid antigen whilst row D 
and H were the minus antigen blanks and were only coated with the 
carbonate coating buffer. 
Initially serum blanks were monitored in the subclass assays but since they 
were consistently low (Table 3.2) only the minus monoclonal antibody blank 
was retained. This allowed more unknown samples to be included on each 
plate. 
The mmus serum, mmus antigen and mmus monoclonal antibody blanks 
were subtracted from the mean of the triplicates of the standard and sample 
dilutions. 
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3.3.5 Calculation of Results 
The commercial human anti-tetanus immunoglobulin contains 250 JU/vial 
and the volume of each vial ranged between 1.5 - 2.5 ml. Six vials of this 
standard were pooled giving 16.25 mis containing 1 500 IU which is 
equivalent to 93.2 IU/ml. A value of 93.2 units/ml for IgG was assigned to 
the standard to allow IgG tetanus toxoid antibodies to be quantitated. 
A value of 100 units/ml for IgG 1 and 10 units/ml for IgG4 was arbitrarily 
assigned to this standard to allow the subclass specific tetanus toxoid 
antibodies to be quantitated. The proportion of the value of the IgG 1 and 
IgG4 tetanus toxoid antibody units of 10: 1 roughly equates the proportion of 
IgG 1 subclass to IgG4 subclass in serum. This was done to enable the value 
of the arbitrary units to be realistic. Levels of antibody for each subclass 
were calculated relative to these references. 
Standard curves relating absorbance to the concentration of IgG, IgG 1 and 
IgG4 specific tetanus toxoid antibodies in the standard serum dilutions were 
constructed. 
Standard dose curves were constructed from average absorbance values and 
concentrations that had been entered into a curve fitting four parameter 
logistic programme based on the mathematical model described elsewhere 
(Chapter 1.12). The concentration of each analyte in each sample was 
obtained by interpolating the average absorbance values from the standard 
curve and multiplying the result by the dilution factor. 
These standard curves were used to calculate the antibody concentrations in 
samples tested by using at least 2 absorbance readings on the straight line 
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portion of the curve and taking the mean concentration of them. Samples 
which fell out of this range were repeated at appropriate dilutions. 
3.3.6 Diethylamine-ELISA for lgGl and lgG4 tetanus toxoid 
These assays are based on those of Devey et al 1988, using diethylamine 
(DEA) as the chaotropic agent. The details of these ELISAs are identical to 
those described earlier except for the addition of DEA to the serum diluent. 
Serial dilutions of sera were made in 1 % casein in the presence and absence 
of various concentrations of DEA (5-50 mM). 
OD was plotted against serum dilution and the leftward shift in dose-
response curve in the presence of DEA was measured at 50% of the 
maximum OD. Results were expressed as the log10 of this shift. 
3.4 ASSAY ST AND ARD ISA TION 
3.4.1 Standard Curves 
Commercial human hyperimmune anti-tetanus toxoid immunoglobulin was 
used to construct standard curves for IgG, IgG 1 and IgG4 tetanus toxoid 
ELIS As relating absorbance to IgG, IgG 1 or IgG4 subclass concentrations 
(Figure 3.10). Each plate contained a standard curve constructed from 
triplicate samples of nine different dilutions of standard serum. 
3.4.2 Precision and Sensitivity 
The inter-assay variation was assessed with 3 samples assayed in triplicate in 
12 different runs. The sera selected had high, intermediate and low IgG, 
IgG 1 and IgG4 specific tetanus toxoid antibodies. For each assay the mean 
of each sample's results over 12 runs was calculated and the SDs and CV s 
were then derived. The CVs ranged from 4.5% to 12.7% with an average 
of 9.27% (Table 3.4). 
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The intra-assay variation was also obtained for high, intermediate and low 
titred serum. These samples were assayed 14 times in one run and the CV 
ranged from 4.3% to 12.4% with an average of 6.56% (Table 3.4). 
The lowest detection limit for each assay was 0.003 U/ml for IgG and 0.005 
U/ml for IgG 1 and IgG4. These levels were determined from serial 
dilutions of the normal immunoglobulin control until the results were no 
longer reproducible. These detection limits correlated with the most dilute 
standard of the standard curve in all 3 assays. Samples with ODs below the 
OD of the most dilute standard were considered negative. 
Assays in which the results of the control were more than two standard 
deviations from the known mean value of the normal immunoglobulin 
control were repeated. 
3.4.3 Specificity 
The specificity of the IgG, IgG 1 and IgG4 tetanus toxoid ELISA assays 
were assessed by a competitive inhibition ELISA using either tetanus toxoid 
or a non-specific antigen diphtheria toxoid (SAIMR, Catalogue No P6190). 
These ELISAs were carried out as described in Chapter 3.3 except that the 
competitive antigens (tetanus and diphtheria toxoids) were mixed with the 
serum in dilutions ranging from 1/2-1:50 000 (10 Lf/ml - 0.0004 Lf/ml for 
tetanus toxoid and 25 Lf/ml - 0.001 Lf/ml for diphtheria toxoid). Two 
dilutions of the serum, both reading on the linear section of the sigmoid 
curves for the assays were selected. In the IgG tetanus toxoid ELISA these 
dilutions were 1 :5 000 and 1: 10 000, in the IgG 1 tetanus toxoid ELISA 
1 :5 000 and 1 :7 500 and in the IgG4 ELISA 1 :500 and 1 :750. The mixtures 
of the serum and competitive antigens were either added immediately to the 
tetanus toxoid coated wells or after pre-incubation of the serum and soluble 
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antigen for 30 minutes at room temperature. Wells containing serum 
without soluble tetanus toxoid were incubated as positive controls. Binding 
of the tetanus toxoid antibody to wells coated with tetanus toxoid could be 
inhibited by incubation with tetanus toxoid antigen but not with the non-
specific antigen diphtheria toxoid. The percentage inhibition for each 
concentration of inhibitor was calculated (Table 3.5 and 3.6). In the 
ELISAs where the inhibiting antigens were mixed with the serum and added 
immediately to the plates, the dilution of tetanus toxoid required to cause a 
50% inhibition of the signal assay ranged between 1 :25 and 1 :50 (0.8-0.4 
Lf/ml) in the IgG and IgGl assay, and between 1/10 and 1:25 (2.0-0.8 
Lf/ml) for the IgG4 assay (Table 3.5). 
TABLE 3.5: COMPETITIVE INHIBITION ELISA FOR 
SPECIFICITY IN TETANUS TOXOID ASSAY (NO PRE-
INCUBATION) 
Dilutions of % Inhibition 
Tetanus Toxoid 
(20 Lf/ml) IgG IgGl IgG4 
1/2 87 97 99 
1/5 85 94 97 
1:10 81 89 83 
1:25 71 72 24 
1:50 38 40 13 
1:100 38 49 0 
1:500 25 16 0.8 
1:1 000 10 0.3 0 
1:10000 12 8 
1:50 000 8 4 
* Diphtheria toxoid caused no inhibition in these assays 
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TABLE 3.6: COMPETITIVE INHIBITION ELISA FOR 
SPECIFICITY IN TETANUS TOXOID ASSAY (PRE-INCUBATION) 
Dilutions of % Inhibition 
Tetanus Toxoid 
(20 Lf/ml) IgG IgGl IgG4 
1/2 96 95 100 
1/5 79 96 100 
1/10 94 94 100 
1:25 88 91 100 
1:50 11 23 25 
1:100 4 8 9 
1:500 0 3 0 
1:1 000 0 3 8 
1:10 000 0 4 9 
1:50 000 2 7 9 
* Diphtheria toxoid caused no inhibition in these assays 
However, if the antigen was preincubated with the serum before addition to 
the plate, the dilutions of tetanus toxoid required to cause 50% inhibition of 
the signal were between 1: 25 and 1 : 50 (0. 8-0 .4 Lf /ml) for the IgG tetanus 
toxoid, IgGl tetanus toxoid and IgG4 tetanus toxoid assays (Table 3.6). 
These results show that these assays are specific for the measurement of 
tetanus toxoid antibodies. 
However, in the assays where the antigen was preincubated with the serum 
the concentration of tetanus toxoid required for 50% inhibition was the same 
for the IgG 1 tetanus toxoid and IgG4 tetanus toxoid antibodies. 
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3.5 ANTIBODY AFFINITY 
3.5.1 Optimal Dilution of DEA 
The incorporation of 5-50 rnM DEA in the serum diluent resulted in a 
progressive parallel shift to the left of the dose response curve for both IgG 1 
and IgG4 antibodies to tetanus toxoid (Figure 3.12). 
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1.5 OD 2 CD 
DEA [l(A 
~ Ont1 ~ Ont1 1.5 
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Figure 3.12: Effect of increasing concentrations of DEA (0-50 mM) on the standard 
curves of IgGl and IgG4 tetanus toxoid antibodies. DEA concentrations: no DEA(•), 
5 mM (+), 10 mM (*), 15 mM (•), 20 mM (x), 25 mM (+), 35 mM (.~) and 50 mM 
(o). The shift was measured at 50% of the maximum OD which is represented by the 
solid line drawn at 0.6 OD and 0.9 OD for the IgGl and lgG4 tetanus toxoid ELISAs 
respectively 
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This shift of the antibody titration curves was greater in the IgG4 tetanus 
toxoid assays than in the IgG 1 tetanus toxoid assays. 
Absorbance readings in the absence of DEA represented total binding of 
specific antibody. With various molar concentrations of DEA the shift in 
the log of the serum dilution from the initial OD reading to 50% of the 
initial OD reading was calculated and used to determine relative affinities of 
anti-tetanus toxoid antibodies in sera. 
Using the standard serum (hyperimmune anti-tetanus immunoglobulin), the 
shift for IgG4 tetanus toxoid antibody was greater than that for IgG 1 tetanus 
toxoid antibody. This indicates that the IgG4 tetanus toxoid antibody is of 
lower affinity than the IgG 1 tetanus toxoid antibody. With DEA 
concentrations of 15 to 35 mM the % difference of the IgG 1 shift minus 
IgG4 shift was fairly constant at 60% (Table 3. 7). The concentration of 
DEA selected for subsequent experiments with this antigen system was 25 
mM. 
SECTION A: Chapter 3: Tetanus Toxoid Immunoas.rnys 121 
TABLE 3.7: INCREASING CONCENTRATIONS OF DEA 
SHOWING THE LEFT SHIFT OF THE DOSE-RESPONSE CURVE 
OF IgGl AND lgG4 TETANUS TOXOID ELISAs IN STANDARD 
HYPERIMMUNE ANTI-TETANUS IMMUNOGLOBULIN 
DEA Log 10 dilution Log10 shift at % difference 
Concentra- at 50% max OD 50% max OD in shift 
tion (mM) 
OD=0.6 OD=0.9 OD=0.6 OD=0.9 lgGl-lgG4xlOO 
lgGl lgG4 lgGl IgG4 lgGl 
0 3.94 2.62 
5 3.91 2.53 0.04 0.09 - 125 
10 3.87 2.46 0.07 0.16 - 129 
15 3.74 2.30 0.20 0.32 - 60 
20 3.64 2.23 0.30 0.40 - 32 
25 3.64 2.14 0.30 0.48 - 60 
35 3.42 1.77 0.52 0.85 - 64 
50 2.99 1.41 0.95 1.21 - 27 
3.5.2 Effect of DEA on Solid-phase Antigen 
In order to exclude the possibility that DEA altered the dose-response curves 
by a direct effect on the solid-phase antigen, tetanus toxoid coated plates 
were incubated with 25 mM DEA in the 1 % casein blocker for 1 hour at 
37°C and washed before the addition of sera with or without DEA in the 
normal DEA-ELISA. Results showed that pre-incubation with DEA had no 
effect on the subsequent dose-response curve (Figure 3.13). With DEA in 
the serum the curve was displaced to the left and in the case of IgG4 was 
flattened confirming the lower affinity binding capacity of the IgG4 tetanus 
toxoid antibodies. 
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Figure 3.13: Effect of 25 mM DEA in the blocking solution (B) or serum diluent (S) on 
the DEA-ELISA in the IgGl and IgG4 tetanus toxoid assays. No DEA in either the 
blocker or the serum diluent (•), DEA in the blocker ( + ), DEA in the serum diluent 
(*), DEA in blocker and serum diluent (D) 
SUMMARY 
Tetanus toxoid is a potent immunogen and has been used to measure normal 
antibody responses. This response can be used as an indicator of the 
patient's ability to respond to an antigenic stimulus. 
This chapter describes the establishment of IgG, IgG 1 and IgG4 tetanus 
toxoid antibody ELISAs which are reproducible, sensitive and simple to 
perform. A number of variables were tested in order to establish suitable 
assays. 
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An important aspect of the subclass specific assays is the inclusion of 
sufficient background blanks to detect the degree of non-specific binding. 
Each tier of the ELISA must have its own blank. Using unbiotinylated 
monoclonal antibodies to detect subclass specific tetanus toxoid antibodies 
demonstrates how the exclusion of monoclonal antibody blanks can lead to 
inaccurate standard curves (Figure 3. 7). These problems were overcome 
with the use of biotinylated monoclonal antibodies. There are no previous 
reports of IgG subclass specific tetanus toxoid ELISAs using biotinylated 
antibodies although it has been reported for use in IgG tetanus toxoid 
ELISAs (Lau 1987). 
The competitive inhibition ELISAs confirmed the assays are specific for 
IgG, IgG 1 and IgG4 tetanus toxoid antibodies. 
It was found that no single dilution of serum can measure all serum levels in 
various individuals due to the highly variable tetanus toxoid response. 
The DEA-ELISA is a simple and convenient method of assessing functional 
affinities of antibodies to complex antigens. Results of the DEA-ELISA 
suggest that the IgG4 antibody responses to tetanus toxoid were of lower 
affinity than the IgG I responses, in agreement with earlier studies. 
These assays were used to quantitate IgG, IgGl and IgG4 subclass 
antibodies to tetanus toxoid in the patient groups (Chapter 10.5). 
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CHAPTER 4 
HAEMOPHILUS INFLUENZAE TYPE b IgG SUBCLASS IMMUNOASSAY 
This chapter describes the development of ELIS As to measure IgG, IgG 1 and IgG2 
subclass specific antibodies to the capsular polysaccharide, polyribose phosphate (PRP), of 
H.influenzae type b (Hib). The introduction outlines the general background and principles 
of these assays and includes a brief review of previously published assays. Various 
experiments involved in establishing optimal reagents and conditions for the IgG, IgG 1 and 
IgG2 Hib PRP ELISAs are described. The assay methodology and experiments 
determining assay precision and standardization are detailed. These assays will be used to 
measure the immune response in children with invasive Hib infections. This chapter is 
sub-divided into the following sections: 
4.1 INTRODUCTION 
4.2 DETERMINATION OF OPTIMAL ASSAY CONDITIONS 
4.3 METHODS 
4.4 ASSAY STANDARDIZATION 
4.5 SUMMARY 
SECTION A: Chapter 4: Hib PRP IMMUNOASSAYS 125 
4.1 INTRODUCTION 
Haemophilus influenzae type b (Hib) is the leading cause of bacterial 
meningitis in children younger than 2 years of age in both industrialized and 
developing countries (Fraser 1982; Munson et al 1989). Antibodies against 
the Hib capsular polysaccharide, a polymer of repeating 3-13-D-ribose-(l-1)-
D-ribitol-5-phosphate units (polyribose phosphate (PRP)) are protective in 
both animals and humans (Halsay et al 1983; Schreiber et al 1986). 
Antibody to the Hib capsular antigen PRP has been measured by a variety of 
methods to study immunity to disease (Schneerson et al 1971; Anderson et 
al 1972) and to evaluate the immunogenicity of polysaccharide vaccines 
(Ward et al 1988). 
Measurement of antibody responses to PRP after clinical infection requires a 
very sensitive assay because the post-infection antibody response of young 
infants is low and may be delayed by a few months (Insel and Anderson 
1986a; Claesson et al 1988). Infants with a poor response are subject to a 
further Hib infection (Insel and Anderson 1986a). 
Direct measurement of serum bactericidal activity against Hib can be used to 
detect complement-fixing anti-PRP antibodies but the assay also detects 
antibodies directed at other surface antigens of Hib and is not suitable for 
routine use. Passive haemagglutination with PRP sensitized erythrocytes is 
rapid and inexpensive and does not require the use of radioactive reagents 
but it is too insensitive for the detection of antibody in human infants. RIA 
(radioimmunoassay) and ELISA are sensitive, reproducible and simple to 
perform. Most anti-PRP antibody assays use RIA adapted from the method 
originally described by Farr (1958). Antibody binding is measured by 
adding dilutions of sera to radiolabelled antigen and then separating and 
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counting the antibody bound antigen. Because of the difficulty, instability 
and expense of preparing pure radio-labelled antigen, RIA is not practical or 
economical for assay measurement on a small scale. The slope of RIA 
curves (bound antigen versus serum dilution), for some children's sera does 
not parallel the slope of the US Food and Drug Administration (FDA) 
standard (Lot 1983) slope (Anderson et al 1987; Hetherington and 
Rutkowski 1990). An advantage of the ELISA method over RIA is that it 
allows measurement of the isotype and subclass of the anti-Hib PRP 
antibodies through the use of selective secondary antibody reagents. 
Although ELISA is widely used for measuring antibodies to protein antigens 
the measurement of antibody to purified cell surface carbohydrates by 
ELISA is hindered by the failure of polysaccharides to efficiently and 
reproducibly adhere to a solid phase. PRP is negatively charged and binds 
poorly to polystyrene microtitre plates. Techniques to enhance binding of 
Hib PRP to polystyrene microtitre plates include the use of high 
concentrations (30-100 µglml) of PRP and extended coating times (Callahan 
et al 1979; Dahlberg and Branefors 1980; Barra et al 1988). Alternative 
procedures to adsorb polysaccharides have included pre-coating of plates 
with poly-L-lysine (PLL) (Leinonen and Frasch 1982) or covalent binding to 
poly-L-lysine (Gray 1979; Kaplan et al 1983), biotin (Schneerson et al 1980; 
Sutton et al 1985), tyramine (Anthony et al 1982) or albumin (Phipps et al 
1990). Some of these methods have high background values and 
questionable specificity. 
This chapter describes the development of ELISA techniques to measure 
IgG, IgG 1 and IgG2 subclass specific Hib PRP antibody concentrations. 
The PRP was produced in the laboratory and linked to poly-L-lysine to 
allow reproducible binding to the microtitre plates. 
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4.2 
The purpose of establishing these assays was to determine: 
The IgG, IgG 1 and IgG2 specific Hib PRP antibody levels in acute 
and convalescent sera of children with Hib meningitis and Hib 
osteomyelitis/septic arthritis. 
The IgG, IgG 1 and IgG2 specific Hib PRP antibody concentrations 
in healthy infants before and after immunization with Hib vaccine. 
DETERMINATION OF OPTIMAL REAGENTS AND CONDITIONS 
Various contributing technical factors and test conditions affecting assay 
performance needed assessment before finalised assay procedures were 
established (4.3) 
4.2.1 Plates 
4.2.1.1 
The following ninety six well plastic plates were tested: Nunc Maxisorb 
flat-bottomed (Weil Organisation, Catalogue No 442404), Nunc Maxisorb C 
(certificated) flat bottomed (Catalogue No 439454), Nunc Polysorb flat 
bottomed (Catalogue No 475094), Nunc Polysorb C (certificated) flat 
bottomed (Catalogue No 449824) and Falcon PVC flat bottomed (Catalogue 
No 3912). 
Tora[ IgG Hib PRP ELISA 
Although the shape of the standard curve was similar for all plates tested 
(Figure 4.1), OD readings varied by as much as 0.70 (32%) for a 1:100 
dilution of serum. Maxisorb, Maxisorb C and Falcon plates resulted in 
higher OD readings than Polysorb plates. No major differences were found 
in negative control wells which were acceptably low in all plates (Table 
4.1). 
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Figure 4.1: lgG, IgGI and IgG2 Hib PRP ELISA standard curves comparing 
microtitre plates: Maxisorb (•); Maxisorb certificated ( + ); Polysorb (*); Polysorb 
certificated (D); and Falcon (x). 
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4.2.1.2 
4.2.1.3 
4.2.1.4 
IgG 1 Hib PRP ELISA 
The Maxisorb and Falcon plates gave steeper standard curves than the 
Polysorb plates (Figure 4.1). 
The OD readings were lower using the Polysorb plates, particularly 
Polysorb C. No significant differences in any of the background blanks 
were found but the minus monoclonal blanks were relatively high (± 18% 
of the maximum signal) (Table 4.2). 
IgG2 Hib PRP ELISA 
The Maxisorb and Maxisorb C plates gave steeper standard curves than the 
Polysorb or Falcon plates (Figure 4.1). The background blanks were 
similar to those of the IgG 1 Hib assays with high minus monoclonal blanks 
(±20%) (Table 4.3). 
Conclusion and discussion 
These results show that very different OD readings and curve shapes were 
obtained with different plates. The Nunc Maxisorb C (certificated) plates 
were selected for use as they were found to be suitable in all 3 assay systems 
giving steep sigmoid shaped curves. There was no significant difference 
between the Maxisorb and Maxisorb C plates, the only manufacturing 
difference is the stringency of the quality control checks. 
In previously reported ELISAs measuring IgG and IgG subclass specific Hib 
antibodies various plates have been used viz: Dynatech (Sutton et al 1985; 
Barra et al 1988), Immunolon (Barra et al 1988; Herrmann et al 1992), 
Costar (Shackelford et al 1987) and Nunc polysorb (Phipps et al 1990) 
(Table 4.4). In these assays Hib PRP had been conjugated to a variety of 
different proteins and it is not stated if other plates were assessed. 
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4.2.2. Comparison of PRP Antigens 
No preparation of PRP is commercially available. Purified H.influenzae 
PRP was prepared in the laboratory from an organism isolated from a 
patient with invasive Hib meningitis. The method of extraction and 
purification of PRP was adapted fron Insel and Anderson (1986a) and is 
described in detail in Appendix B. Various batches of PRP were prepared 
for use in these assays and each batch was verified against gifts of antigen 
obtained from the following sources: 
Purified Hib PRP (gift from Pasteur Merieux, May Baker, SA) 
Hib oligosaccharide-human serum albumin (Hbo-HA) (Praxis 
Biologics, Inc.) 
Hib capsular antigen (PRP, sodium salt form) gift from Dr P 
Anderson, University of Rochester via Lederle Laboratories. 
The usual coating concentration of antigen is between 1-10 µg/1. The 
recommended coating concentration for the Hbo-HA was 1 µg/ml. 
ELISAs were established using these antigen preparations and and the 
prepared PRP antigen with the US Standard human anti-haemophilus 
injluenzae antibody serum (Lot 1983) as a standard antibody. The Hbo-HA 
was coated directly onto the plate at concentrations of 1 µg/ml and 5 µg/ml. 
The other antigen preparations were linked to poly-L-lysine using the 
method described in Appendix C prior to coating of the plates. The coating 
concentration of the various preparations was as follows: PRP - Merieux - 5 
µg/ml; PRP - Lederle 5 µglmI; in-house PRP 5 µglml and 10 µglml. Curve 
shape (i.e. parallelism), OD readings and concentrations were considered in 
the evaluation. 
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The 'in-house' antigen preparation at a coating concentration of either 5 or 
10 µg/ml gave very similar shaped curves to the 'recognized' antigen 
preparations (Figure 4.2). 
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Figure 4.2: Standard curves of IgG Hib PRP ELISA assaying the reference serum with 
different antigen preparations: A=Merieux 5 µg/ml (•); B=Hbo-HA 5 µg/ml (+); 
C=Hbo-HA 1 µg/ml (*); D=Lederle 5 µg/ml (D); E=in-house PRP 10 µg/ml (x); 
F=in-house PRP 5 µg/ml ( 0 ). 
Batches of PRP antigen were selected for use when they demonstrated 
curves that were parallel to the commercial antigen when assayed using the 
US reference standard (Lot 1983) and a post-vaccination serum pool (In-
house antibody standard (Section 4.2.5)). 
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4.2.3 
4.2.3.1 
Antigen Coating 
IgG, IgGJ and JgG2 Hib PRP ELISAs 
Concentrations of in-house PRP antigen ranging from 1 µg/ml to 50 µg/ml 
was assessed using both the in-house antibody standard and US reference 
antibody standard. There was little difference in the shapes of the standard 
curves using antigen concentrations between 5 µg/ml and 50 µg/ml. When 
plates were coated with 1 µg/ml PRP the standard curve shifted to the left 
and flattened (Figure 4.3). A coating concentration of 5 µg/ml was 
selected for IgG, IgG 1 and IgG2 Hib PRP ELIS As. 
Various PRP antigen diluents were also tested to facilitate optimal binding to 
the plate. Phosphate buffered saline (PBS), PBS with 0.5 % human serum 
albumin (HSA), glycine/Tris buffer (pH 7.3) and carbonate buffer (pH 9.6) 
were used. Carbonate buffer was selected as this diluent resulted in the 
lowest minus antigen blanks, highest ODs and steepest standard curve. 
Incubation of coating antigens for 2 hours as opposed to overnight coating 
was also tested, but no significant differences were noted. 
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Figure 4.3: IgG, lgGl and IgG2 Hib PRP ELISA standard curves of in-house serum 
standard assayed using a range of PRP concentrations: 50 µg/ml (•); 20 µg/ml (+); 10 
µg/ml (*); 5 µg/ml (D); 1 µg/ml (x). 
Conclusion and discussion 
The assays performed using plates coated with either the in-house PRP 
antigen or 'recognised antigens' (Figure 4.2) gave parallel standard curves 
using the US (Lot 1983) standard serum. The control result read off these 
curves yielded the same values irrespective of which antigen was used. 
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A coating concentration of 5 µg/ml in-house PRP antigen was suitable for 
the IgG, IgG 1 and IgG2 Hib PRP ELISAs. 
In preliminary experiments when unlinked PRP antigen was coated directly 
onto the plates in the total IgG assay system, ODs of approximately a third 
of linked PRP were obtained (results not shown). This confirmed the 
efficacy of the poly-L-lysine-linking in facilitating antigen binding to the 
plate. Coating PRP coupled to poly-L-lysine has been used in several 
reported studies (Granoff et al 1986a; Moss et al 1987; Herrmann et al 
1992). 
The poly-L-lysine linked to PRP did not interfere in the assay system. In 
the IgG, IgG 1 and IgG2 Hib PRP assays wells coated with 5-50 µg/ml of 
poly-L-lysine alone gave signals of less than 5%, 3.5% and 12% 
respectively of the signal achieved with Hib PRP linked to poly-L-lysine. 
Phipps et al (1990) reported that if Hib PRP conjugated to human serum 
albumin was diluted in PBS made up with sterile distilled non-pyrogenic 
water, the minus antigen well blanks were reduced. In these experiments no 
difference was noted in the signal of the minus antigen wells irrespective of 
whether distilled water or sterile non-pyrogenic distilled water was used in 
the antigen-coating carbonate buffer. 
4.2.4 Blocking Agents and Diluents 
No major differences were seen when 1 % casein was compared to 2 % BSA 
as a blocking agent. 1 % casein as a diluent for monoclonal antibody, serum 
and conjugate reduced the minus antigen readings by half. For the reasons 
of cost consideration and availability, 1 % casein was selected for blocking 
and diluent solutions. 
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4.2.5 
4.2.5.1 
Serum Standards and Controls 
IgG, IgGJ and IgG2 Hib PRP ELISAs 
The US Standard human anti-haemophilus influenzae type b capsular 
polysaccharide serum (Lot 1983) from the Office of Biologics, FDA, 
Bethesda, Maryland was used as a reference antibody standard. The 
reference values of anti-Rib antibodies were: IgG = 60.9 µg/ml, IgGl = 
27.0 µg/ml and IgG2 = 13.4 µglml. Initial assays were established using 
this standard, but due to its limited availability an in-house antibody 
standard was prepared. This was done by vaccinating healthy volunteers 
and testing the antibody response 2, 4 and 6 weeks post vaccination. Five 
adult volunteers were immunized with RIB-IMMUNE (H.influenzae type b 
polysaccharide vaccine) (Lederle). Ten adult volunteers were immunized 
with RibTITER (H. influenzae tybe b polysaccharide covalently linked to 
non-toxic diphtheria toxin variant CRM 197) (Praxis Biologics, Rochester, 
NY). Five adult volunteers were immunized with Pedvax Rib TM 
(H. influenzae type b conjugate vaccine linked to meningococcal protein 
conjugate) (Merck, Sharp and Dohme). Although these vaccines were not 
licenced in South Africa at the time of immunization, permission for their 
use in adult volunteers was obtained from the Medical Control Council. All 
sera were initially stored individually in aliquots at -70°C. After 
individual testing for anti-Rib PRP antibodies, the sera from high titre 
vaccine responders were pooled to form an in-house standard. This variety 
of vaccines and number of post immunization bleeds ensured a range of 
antibody levels with differing isotype and subclass composition. When the 
in-house standard was tested against the US Standard (Lot 1983) parallel 
standard curves were obtained between the two. The in-house standard 
curve was shifted to the left indicative of lower values (Figure 4.4). The 
US standard serum (Lot 1983) was used to calculate anti-Rib PRP antibody 
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values for the in-house standard: IgG = 35.2 µg/ml, IgGl = 18.01 µg/ml, 
IgG2 = 5 .59 µglml. Subclass specific antibody levels of various test sera 
were calculated using both these reference antibody preparations. Similar 
results were obtained when the US standard and the in-house standard 
antibody were used to construct standard curves. The in-house pooled sera 
was used as the standard in routine assays and the US Standard (Lot 1983) 
served as a quality control serum. Dilutions of the US Standard as a control 
were 1: 150 and 1 :200 for all assays. 
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Figure 4.4: Comparison of lgG, lgGI and IgG2 Hib PRP ELISA standard curves of 
in-house standard serum ( + ); with the US standard serum (Lot 1983) (•); 
demonstrating parallelism. 
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There was a substantial discrepancy m the reference serum (Lot 1983) 
between the total IgG anti-Rib antibodies and the sum of IgG 1 and IgG2 
antibody concentrations. A similar discrepancy was carried over into the in-
house standard. In general immunological assays reflect the affinity as well 
as the concentration of antibody. The serum IgG antibodies to Hib PRP 
include several subclasses all with a potential for variation in affinity. Two 
markers of a qualitative IgG subclass assay are the ability of the test and 
reference sera to dilute in parallel and on agreement between the sum of 
IgGl-4 and the total IgG. The total IgG value of 60.9 µg/1 in the reference 
standard (Madore et al 1990) may be an overestimate as Herrmann et al 
(1992) using a different assay and calibration system estimated the value of 
this reference standard to be 21. 9 µgl ml. In their assay the sum of IgG 1-4 
anti-Rib (21.5 µg/ml) was only 1.8% less than that of the total IgG (21.9 
µg/ml). Reasons for these differences were assumed to be due to inherent 
technical variables (in particular the monoclonal antibodies) in these 
analyses. 
4.2.6 Incubation Period 
4.2.7 
4.2.7.1 
Antigen coating times of 2 hours at room temperature vs overnight at 4 °C 
and serum incubation times of 1 hour at 37°C vs overnight at 4 °c were 
compared. No significant difference was found between the two incubation 
conditions. 
Monoclonal Antibody Selection 
IgG Hib PRP ELISA 
The use of biotinylated monoclonal antibody (HP6017) resulted in very low 
OD readings and was unsuitable. ELISA formats without using a 
monoclonal antibody and using an anti-human conjugate or incorporating 
unbiotinylated monoclonal antibody (HP6064) both produced good steep 
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standard curves (Figure 4.5) with all blanks and control readings acceptable 
(Table 4.5). Unbiotinylated HP6064 was selected for use in these assays. 
A dilution range of 1 :500 to 1 :3 000 was tested and a 1 :2 500 dilution was 
found to be satisfactory. 
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Figure 4.5: IgG, IgGl and IgG2 Hib PRP ELISA standard curves assayed with 
various Moabs: lgG: HP6064 (•), No Moab ( +) (without monoclonal antibody and 
using an anti-human IgG conjugate); IgG 1: biotinylated HP6069 B (•), HP6070 ( + ), 
HP6007 (*), HP6012 (D); IgG2 = HP6008 (•), HP6008:6014@ 2:1 ( + ), HP6002 (*) 
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4.2.7.2 
TABLE 4.5: BACKGROUND BLANKS IN THE IgG Hib PRP ASSAY 
Moab Maximum OPTICAL DENSITY OF BACKGROUND BLANKS 
Optical ( % of the maximum signal) 
Density 
of Standard Minus Minus Minus 
antigen serum Moab 
HP 6064 1.959 0.125 0.010 0.006 
(6.4) (0.5) (0.3) 
No Moab * 1.901 0.150 0.017 -
(7.9) (0.9) 
HP6017 0.332 0.025 0.008 0.005 
(7.5) (2.4) (1.5) 
* Without the use of a monoclonal antibody and using an anti-human IgG 
conjugate 
IgG I Hib PRP ELISA 
Virtually no difference in standard curve shape or background blanks was 
seen between the assays when either biotinylated (HP6069) or unbiotinylated 
(HP6070) monoclonal antibodies were used in the system (Figure 4.5). The 
HP6070 was chosen for use. The other monoclonal antibodies HP6012, 
HP6007, and unbiotinylated HP6069 resulted in much lower ODs when 
tested in the system at the same dilutions (Table 4.6). 
SECTION A: Chapter 4: Hib PRP IMMUNOASSAYS 144 
TABLE 4.6: BACKGROUND BLANKS IN THE lgGl Hib PRP 
ASSAY 
Moab Maximum OPTICAL DENSITY OF BACKGROUND BLANKS 
Optical ( % of the maximun signal) 
Density 
of Standard Minus Minus Minus 
antigen serum Moab 
HP6069 1.827 0.031 0.011 0.015 
Biotiny- (1. 7) (0.6) (0.8) 
lated 
HP6070 1.861 0.026 0.015 0.022 
(1.4) (0.8) (1.2) 
HP6069 1.557 0.122 0.043 0.039 
Unbio- (7.8) (2.8) (2.5) 
tiny lated 
HP6012 0.211 0.046 0.060 0.224 
(21.8) (28.4) (106.0) 
HP6007 0.771 0.087 0.111 0.259 
(11.3) (14.4) (33.6) 
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4.2.7.3 IgG2 Hib PRP ELISA 
Although the curve shapes were very similar for both monoclonal 
antibodies tested (HP6008 and Biotinylated HP6002) (Figure 4.5) all the 
blanks were significantly lower using the biotinylated HP6002 (Table 4. 7). 
A combination of unbiotinylated monoclonal antibodies HP6008:HP6014 in 
a ratio of 2: 1 also reduced the minus antigen and minus monoclonal 
antibody blanks. The biotinylated antibody HP6002 could be used at a 
dilution of 1: 1000 (1 :250 - 1: 3000 tested) when compared to a dilution of 
1 :500 for the HP6008:HP6014 combination and was selected for use in 
these assays. 
TABLE 4. 7: BACKGROUND BLANKS IN THE lgG2 Hib PRP 
ASSAY 
Moab Maximum OPTICAL DENSITY OF BACKGROUND 
Optical BLANKS 
Density ( % of the maximun signal) 
of Standard 
Minus Minus Minus 
Serum antigen serum 
Moab 
HP6002 
Biotiny- 1.621 0.053 0.003 0.005 
lated (3.3%) (0.2%) (0.3%) 
HP6008 1.394 0.141 0.034 0.297 
(10.1 %) (2.4%) (21.5%) 
HP6008: 1.504 0.031 0.023 0.208 
HP6014 (2.1 % ) (1.5 % ) (13.8%) 
2: 1 
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4.2. 7.4 
4.2.8 
4.2.8.1 
Conclusion and discussion 
The majority of published total IgG anti-Rib PRP assays have not utilised 
monoclonal antibodies (Table 4.4). Herrmann et al (1992) used the 
biotinylated HP6017 but it was found to give very low OD readings in this 
sytem. Unbiotinylated HP6064 gave a steep curve and strong signal. 
In the reports of anti-IgGl specific Hib PRP ELISAs (Booy et al 1992; 
Barra et al 1988; Borradari et al 1990) used the IgG 1 specific monoclonal 
antibody HP6012 and Herrmann et al (1992) used the biotinylated Moab 
HP6069. These two monoclonal antibodies as well as the monoclonal 
antibodies HP6070 and unbiotinylated HP6069 were compared in this study. 
HP6070 and HP6069 were found to give the best results in this system. 
There are only a few reported methods of anti-IgG2 specific ELISAs using 
commercially available monoclonal antibodies (Barra et al 1988; Borradori 
et al 1990; Ruths et al 1991; Herrmann et al 1992; Booy et al 1992) (Table 
4.4). The most commonly used monoclonal antibodies were HP6014 and 
HP6008 either alone or together in various ratios. The findings in this study 
showed that in this system the biotinylated monoclonal antibody HP6002 
gave the best results and was again similar to the report of Herrmann et al 
(1992). 
Evaluation of Conjugated Antibody/Enzyme/Substrates 
IgG Hib PRP ELISA 
The detection antibodies assessed were 
Peroxidase conjugated F(ab')2 fragment goat anti-mouse IgG (Fe 
fragment, gamma chain specific), Cappel (Catalogue No 3311-0121). 
Goat anti-mouse IgG (Fe specific) peroxidase conjugate, Sigma 
Immunochemicals (Catalogue No A-2554) 
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4.2.8.2 
4.2.8.3 
Sheep anti-mouse IgG, A, M (heavy and light chains) peroxidase 
conjugate, Binding Site (Catalogue No PP270). 
Very similar results were obtained with all 3 horseradish peroxidase 
conjugates. The Sigma conjugate was difficult to import and the Cappel 
conjugate was unsuitable for the IgG 1 assay due to the high monoclonal 
antibody blanks (15-20% of the maximum signal). A dilution of 1 :5 000 
was concentrated enough to attain the required OD readings. The Binding 
Site conjugate, was selected as the backgrounds blanks were low (1-2 % of 
the maximum signal). 
IgGJ Hib PRP ELISA 
The same peroxidase conjugates were tested in the IgG 1 assay system with 
dilutions selected as follows: Cappel 1: 750; Sigma 1: 1 000 and Binding 
Site 1: 1 000. Binding Site sheep anti-mouse HRP conjugate was selected 
for the same reasons as in the IgG Hib PRP assay. 
IgG2 Hib PRP ELISA 
As a biotinylated monoclonal antibody was used in this assay, streptavidin 
conjugated horseradish peroxidase was used in the detection system. Two 
streptavidin peroxidase conjugates were assessed viz. Zymed, (Catalogue 
No 43-4323) and Calbiochem (Catalogue No 189733). Both these 
conjugates were tested at dilutions ranging from 1 :5 000 to 1 :40 000. The 
Zymed streptavidin peroxidase conjugate (1: 17 500) was selected although 
both conjugates were equally suitable in the assay at similar dilutions. 
4.3. METHODS 
The exact methods based on the experiments described above are 
summarised in this section. 
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4.3.1 IgG Hib PRP ELISA 
All reagents and samples were added to the wells in 100 µl volumes except 
for the blocker at 250 µl and 2N H2S04 at 50 µl. Flat bottomed Nunc 
Maxisorb microtitre plates were coated with Hib PRP at a concentration of 5 
µg/ml in carbonate buffer (pH 9.6). Uncoated wells (minus Hib PRP) 
contained only carbonate buffer. Plates were incubated in a moist chamber 
for 2 hours at room temperature and blocked with 1 % casein for 1 hour at 
37°C. After washing, sera which had been previously diluted in 1 % casein, 
were added to quadruplicate wells. Pooled post vaccination sera was used to 
obtain a standard curve by diluting from 1:30 to 1:3 500 (1:30, 1:50, 1:100, 
1:200, 1:300, 1:500; 1:1 000, 1:2 500, 1:3 500) which was equivalent to 
1173 - 10 ng/ml range. Two dilutions of the US standard (1983) served as a 
control (1: 150, 1 :200). Adult sera were assayed at 1: 100 and 1 :500 
dilutions. Samples with absorbance readings which did not fall on the linear 
portion of the curve were repeated at appropriate dilutions. The sera of 
infants containing low levels of antibody had to be assayed at a 1/2 dilution 
which usually read off the lower slopes of the curve. Once added, serum 
dilutions were incubated overnight at 4 °C. Wells containing only diluent 
(minus serum) were included as negative controls. Five washes with PBST 
followed before the addition of mouse anti-human IgG antibody (HP6064) at 
a dilution of 1 :2 500 in 1 % casein. The plates were incubated for 1 hour at 
37°C and then washed 5 times in PBST. Sheep anti-mouse IgG, A, M 
conjugated to horseradish peroxidase (Binding Site, Catalogue No PP270) 
was added at a dilution of 1 :5 000 and incubated at room temperature for 1 
hour. The plates were washed five times with PBST before the addition of 
OPD. After 15 minutes the reaction was stopped with 2N H2S04 and the 
plates were read at 492 nm. 
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4.3.2 IgGl Hib PRP ELISA 
This method was identical to the IgG assay described above except for the 
following: 
Standard curve dilutions ranged from 1 :20 - 1: 1 000 which was 
equivalent to 900 - 18 ng/ml 
Mouse anti-human IgG 1 monoclonal antibody (HP6070) was added 
at 1 :500 dilution. 
Sheep anti-mouse IgG, A, M peroxidase conjugate was diluted to 
1: 1 500 
4.3.3 IgG2 Hib PRP ELISA 
All the steps were similar to that of previous assays except for: 
Standard curve dilutions ranged from 1 :20 - 1: 1 000 which is 
equivalent to 279.5 - 5.6 ng/ml 
Mouse anti-human IgG2 biotinylated monoclonal antibody (HP6002) 
was added at a dilution of 1: 1 000. 
Streptavidin conjugated horseradish peroxidase (Zymed, Catalogue 
No 43-4323) diluted 1: 17 500 in 1 %casein was then added. 
4.3.4 Calculation of results 
Standard dose curves were constructed from OD readings and concentrations 
that had been entered into a curve fitting four parameter logistic programme 
based on the mathematical model described elsewhere (Chapter 1.12). 
These standard curves were used to calculate the Hib PRP antibody 
concentrations. 
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4.4 ASSAY STANDARDIZATION 
4.4.1 Standard Curves 
The in-house pooled serum standard, quantitated against a US Reference 
serum (1983) (4.2.5) was used to construct standard curves for IgG, IgGl 
and IgG2 specific Hib antibodies relating absorbance to antibody 
concentration (Figure 4.4). Each standard curve was constructed from nine 
different triplicate dilutions of standard serum on each plate. The titration 
curves of the in-house standard and US Reference serum were parallel in all 
three assays (Figure 4.4). The immunoglobulin concentrations of the 
standard curves range from: 1173 to 10 ng/ ml for IgG, from 900 to 18 
ng/ml for IgGl and 279.5 to 5.6 ng/ml for IgG2. Individual post 
vaccination sera gave titration curves that demonstrated linearity and 
parallelism with the in-house standard curve (Figure 4.6). 
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Figure 4.6: Curves of individual post-vaccination responders serum, A ( + ), B (*), C 
(D), D (x) and E (<>)for IgG, IgGl and IgG2 Hib PRP and compared to the in-house 
serum standard curve(•) for linearity and parallelism. 
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4.4.2 Precision and Sensitivity 
To determine assay precision intra-plate, intra-assay, inter-assay and inter-
dilutional CVs were calculated (Table 4.8). 
TABLE 4.8: EVALUATION OF Hib PRP ELISA ASSSAY 
PRECISION 
IgG IgGl IgG2 
Intra-plate CV (%) 2.1 2.3 1.7 
Intra-assay CV (%) 4.3 2.7 2.1 
Inter-assay CV (%) 9.9 8.8 18.0 
Inter-dilutional CV(%) 7.2 6.7 11.4 
CV = coefficient of variation 
The lowest level of sensitivity in these assays was 0.011 µg/ml for IgG, 
0.012 µg/ml for IgGl and 0.006 µg/ml for IgG2. The background minus 
antigen blanks were always less than 7% of the standard OD reading at the 
lowest dilution. 
Assay results in which the control value was more than 2 SD from the 
known mean value of the control were repeated. 
4.4.3 Inter-laboratory Comparison 
It has been assumed that antibody levels measured in different laboratories 
by different methods are similar because all assays used a US (FDA) serum 
standard for quantitation of antibody binding. There is evidence that 
quantitation of antibody in various laboratories using different assay methods 
differs significantly (Ward et al 1988; Edwards et al 1987; Greenberg et al 
1987). 
SECTION A: Chapter 4: Hib PRP !MMUNOASSA YS 153 
Hib PRP was measured in 5 adult samples pre- and two weeks post-
HibTITER immunization and 5 samples from children with Hib meningitis 
using the ELISAs described here and also and by Dr P Shackelford, 
Department of Pediatrics, Washington School of Medicine, St Louis, 
Missouri using their ELISA and RIA (FARR) methods. Although the 
results are largely in agreement some variability is present (Table 4.9). 
TABLE 4.9: INTER-LABORATORY COMPARISON OF HIB PRP 
ANTIBODY MEASUREMENT (µg/ml) 
1ST SPECIMEN 2ND SPECIMEN 
Specimen ELISA* RIA* RXH** ELISA* 
ELISA 
RIA* RXH** 
ELISA 
A 2.9 4.0 1.94 972 475 572.7 
B 0.7 3.4 0.22 38 30 11.0 
C s0.3 3.3 0.037 73 125 61.4 
D 5.6 26.0 18.10 41 45 39.6 
E 4.0 8.6 5.02 313 350 386.9 
F s0.3 0.10 0.000 
G s0.3 0.08 0.063 
H s0.3 0.08 0.061 
I s0.3 0.42 0.044 
J s0.3 0.12 0.043 
1st specimen = Initial specimen taken prior to HibTITER immunization or at the time 
of dignosis of Hib meningitis 
2nd specimen = Specimen taken 2 weeks post-immunization with HibTITER 
* = Hib PRP antibody measured by Dr Shackelford, St Louis, 
Missouri by ELISA + radioimmunoassay (RIA) methods 
** = IgG Hib PRP measured by the ELISA developed in this study 
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4.4.4 Specificity 
The specificity of the IgG, IgGl and IgG2 Hib ELISA assays were assessed 
by a competitive inhibition ELISA using soluble antigen inhibition with 
either Hib PRP, or non-specific carbohydrate antigen S. aureus teichoic acid 
(Appendix D) and pneumococcal polysaccharide (Pneumovax). 
These ELISAs were carried out as described in section 4.3.1, 4.3.2 and 
4.3.3 except that the competitive antigens were pre-incubated with standard 
serum for 2 hours at room temperature before the addition of the mixture to 
the PRP coated wells. 
Unlinked PRP was mixed with serum in concentrations ranging from 50 to 
0.01 µglml. S.aureus teichoic acid was added to the serum in dilutions 
ranging from 50 to 0.01 µg/ml, and pneumococcal polysaccharide 
(Pneumovax Merck, Sharpe and Dohme) from 10 µg/ml to 0.01 µglml. A 
dilution of the standard serum falling on the linear section of the sigmoid 
curves for these assays was selected viz 1: 150. Binding of the Hib PRP 
antibody to wells coated with Hib PRP could be inhibited by incubation with 
unlinked Hib PRP antigen but not with the non-specific carbohydrate 
antigens S.aureus teichoic acid or pneumococcal polysaccharide (Table 
4.10). These results show that these assays are specific for the measurement 
of Hib PRP antibodies. 
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TABLE 4.10: COMPETITIVE INHIBITION ELISAs FOR 
SPECIFICITY IN Hib PRP ASSAYS 
PRP µg/ml IgG 
50 100 
20 96 
10 81 
5 79 
1 63 
0.75 65 
0.5 46 
0.25 33 
0.1 23 
0.05 18 
0.025 3 
0.01 0 
% INHIBITION 
IgGl 
99 
97 
84 
82 
69 
78 
64 
50 
33 
25 
10 
3 
IgG2 
95 
97 
94 
92 
84 
86 
76 
63 
45 
31 
7 
12 
* S.aureus teichoic acid or pneumococcal polysaccharide (Pneumovax) (50-0.01 
µg/mL) caused no inhibition in these assays 
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4.4.5 
4.4.5.1 
Antibody Affinity 
DEA-ELISA.for lgGI and lgG2 Hib PRP 
These assays were based on the method described by Devey et al (1988), 
using DEA as the chaotropic agent. The details of the ELISAs are identical 
to those described earlier (4.3) except for the addition of DEA to the serum 
diluent. 
Serial dilutions of sera were made in 1 % casein in the presence or absence 
of various concentrations of DEA (5-50 mM). OD was plotted against 
serum dilution and the left shift in the dose response curve with DEA 
measured at 50% of the maximum OD of the curve without DEA. The 
absorbance readings in the absence of DEA represented total binding of 
specific antibody. The shift in the log of the serum dilution from the initial 
OD reading to 50% of the initial OD reading was calculated with the various 
molar concentrations of DEA. Results were expressed as the log10 of the 
shift. 
The addition of increasing concentrations of DEA from 5-50 mM in the 
serum diluent resulted in an increasing parallel shift to the left of the dose 
response curve for both IgG 1 and IgG2 Hib PRP antibodies (Figure 4. 7). 
Calculation of these antibody shifts at 50% of the maximum OD showed that 
when using the in-house standard serum, the shifts were similar for IgG 1 
and IgG2 Hib PRP ELISAs (Table 4.11). These results suggest that the 
IgG 1 and IgG2 Hib PRP antibody responses are of similar affinity. 
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Figure 4. 7: Effect of increasing concentrations of DEA (0-50 mM) on the standard 
curves of IgGl and IgG2 Hib PRP antibodies. DEA concentrations: 0 mM (•), 5 mM 
( + ), 10 mM (*), 15 mM (D), 20 mM (x), 25 mM ( 0 ), 35 mM (..1) and 50 mM (o). The 
shift was measured at 50% of the maximum OD with no DEA which is represented by 
the solid line drawn at 0.9 and 0.8 OD for the IgGl and IgG2 Hib PRP ELISAs 
respectively 
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TABLE 4.11: EFFECT OF INCREASING CONCENTRATIONS OF 
DEA ON THE LEFT SHIFT OF THE DOSE-RESPONSE CURVE OF 
IgG 1 AND IgG2 HIB PRP ANTIBODIES 
DEA Log10 dilution Log10 shift at % shift 
Concentra- at 50% max OD 50% max OD Log 1o-shiftx100 
tion (mM) Log10 dilution 
OD=0.9 OD=0.8 OD=0.9 OD=0.8 IgGl IgG2 
IgGl IgG2 IgGl IgG2 
0 2.176 2.038 - - - -
5 2.141 1.997 0.035 0.041 1.6 2.0 
10 2.130 1.982 0.046 0.056 2.2 2.8 
15 2.078 1.974 0.098 0.064 4.7 3.2 
20 1.888 1.845 0.288 0.193 15.2 10.5 
25 1.324 1.240 0.852 0.798 64.3 64.3 
35 1.065 0.548 1.111 1.490 104 272 
4.5 SUMMARY 
Few of the studies reporting measurement of human IgG antibodies to Hib 
PRP have used the same reagents or methods and thus it is difficult to 
compare reported IgG antibody levels and subclass patterns from these 
studies. Most studies have used Farr type radioimmunoassays to measure 
total anti-PRP antibodies and ELISA to measure IgG subclass specific 
antibodies to PRP. 
ELIS As are described for the quantitation of total IgG, IgG 1 and IgG2 anti-
Hib PRP antibodies that employ commercially available HP series 
monoclonal antibodies. The coating of polysaccharide directly to 
polystyrene plates was problematical. In these ELISAs Hib PRP was 
prepared and covalently linked to poly-L-lysine to facilitate binding of the 
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Hib PRP to microtitre plates whilst still retaining its specific antigenicity. 
Precision, specificity, sensitivity and parallelism in the assays have been 
evaluated. 
These assays were standardized using US Reference standard (Lot 1983) and 
inter-laboratory analysis total Hib PRP antibody levels gave comparable 
results. 
The antibody concentration sufficient for protection is not definitely known 
but is estimated to be between 0.06 and 1.0 µg/ml of total Hib PRP 
antibody as measured by Farr-type antigen-binding assays (Robbins et al 
1973; Kayhty et al 1983a). The assays developed in this study are sensitive 
enough to accurately detect these low antibody levels. 
These ELISAs provided a simple and reproducible method which were 
applied to evaluate Hib antibody responses in children after natural 
infections with Hib meningitis and Hib osteomyelitis/septic arthritis. 
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This chapter discusses the previous methods used to measure S. aureus teichoic acid (TA) 
antibodies and the rationale for setting up the assays. The development of ELISAs to 
measure IgG, IgG 1 and IgG2 subclass specific S. aureus TA antibodies and experiments 
involved in establishing optimal reagents and conditions for these assays are described. 
The ELISA methods used to measure IgG, IgG 1 and IgG2 S. aureus subclass specific 
antibodies are detailed and results of experiments relating to the precision and 
standardization of the assays are discussed. Finally the merits of the assays and their 
application are mentioned. This chapter is divided into a number of sections as follows: 
5.1 INTRODUCTION 
5.2 DETERMINATION OF OPTIMAL ASSAY CONDITIONS 
5.3 METHODS 
5.4 ASSAY STANDARDIZATION 
5.5 SUMMARY 
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5.1 INTRODUCTION 
S.aureus is a gram positive coccus which occurs in pairs, short chains or 
clusters. There are several immunodominant antigens of S.aureus reported 
e.g. teichoic acid, peptidoglycan (PG), protein A and leukocidin (Cohen 
1986). The principle component of the cell wall is peptidoglycan. This 
substance consists of chains of alternating links of N-acetyl glycosamine and 
N-actyl muramic acid moieties connected by 8 1, 4 glycosidic bonds. A 
second important component of the cell wall is ribitol teichoic acid. A third 
major cell wall component is protein A which interacts non-specifically with 
IgG. 
Teichoic acids are maJor cell wall components comprising 40% of the 
staphylococcal cell wall. Teichoic acids of S. aureus consist of polymers of 
ribitol connected by phosphate diester linkage, with side chains of D-alanine 
and varying proportions of N-acetylglucosamine in either a or B glycosidic 
linkage. Teichoic acids are in themselves poor immunogens, but when 
bound to the peptidoglycan they incite specific antibody formation. Most 
human pathogenic staphylococci contain both the a and 8 forms of ribitol 
teichoic acid (Nagel et al 1977). Most strains of S.epidermidis contain only 
glycerol teichoic acid which is immunologically distinct from the ribitol 
teichoic acid of S.aureus. Some strains of S.epidermidis contain ribitol 
teichoic acid as minor antigen determinants. Most people produce teichoic 
acid antibodies following staphylococcal infections (Crowder and White 
1972; Tuazon and Sheagren 1976; Wheat et al 1978; Tenenbaum and Archer 
1980). 
Demonstration of teichoic acid antibodies in serum has been reported to be 
of diagnostic value in patients with endocarditis and osteomyelitis 
(Tenenbaum and Archer 1980). Since Crowder and White (1972) reported a 
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strong correlation between the presence of serum antibodies to 
staphylococcal teichoic acid and the diagnosis of staphylococcal 
endocarditis, methods to measure such antibodies have been of interest. The 
gel diffusion method was found to be specific but relatively insensitive, 
whereas counter-immunoelectrophoresis was more sensitive but less specific 
(Nagel et al 1975). RIA has been found to be more sensitive than counter-
immunoelectrophoresis for detecting teichoic acid antibodies (Wheat et al 
1978). ELISA has been reported to be a sensitive, specific and rapid 
method of quantifying antibody to S. aureus teichoic acid in adults with 
staphylococcal disease (Verbrugh et al 1981; Granstrom et al 1983; Yamada 
et al 1983). 
Osteomyelitis/septic arthritis (OM/SA) are senous infections most 
commonly caused by S.aureus and sometimes by S.pyogenes or 
H.injluenzae. Immune defences involve opsonization by complement and/or 
antibodies and killing by phagocytic cells (Adlam and Easmon 1983). 
Serum IgA, IgG and IgM levels have been measured in patients with 
osteomyelitis but there are few reports on the measurement of IgG 
subclasses in these patients. Osteomyelitis has been reported in an IgG2 
(Gottsegen 1987) and an IgG4 deficient patient (Heiner et al 1988). 
IgG subclass deficiencies may occur even in the presence of normal total 
serum IgG levels and may be an important indicator of impaired antibody 
production to certain types of antigens. 
The purpose of establishing these assays was to assess whether children who 
have S.aureus osteomyelitis/septic arthritis develop a specific antibody 
response to the infecting organism. IgG, IgGl and IgG2 S.aureus subclass 
specific ELISAs were developed in order to do this. 
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5.2 DETERMINATION OF OPTIMAL ASSAY CONDITIONS 
Factors affecting the performance of the assays were assessed to determine 
the optimal conditions for the ELISAs and are described in the following 
section. 
5.2.1 Plates 
Experience from establishing previous ELISAs had shown that Nunc 96 well 
flat bottomed microtitre plates were suitable for this type of ELISA. They 
are readily available, cheap and easy to load without splashing, giving good 
reproducibility. Since the background blanks were in acceptable ranges, 
other sources and types of plates were not assessed. 
5.2.2 Coating Antigen 
Cell wall teichoic acid of the Lafferty strain of S. aureus was used as a 
standard antigen. It has previously been found that antibody titres obtained 
with Lafferty strain antigen were the same as titres obtained with antigen 
from individual blood stream isolates. 
Most studies have used preparations of crude extracts of the Lafferty strain 
of S.aureus (Crowder and White 1972; Thisyakorn et al 1984; Wheat et al 
1984; Leung et al 1988). Antigen preparations from the Lafferty strain have 
been as sensitive and specific as preparations of infecting S. aureus isolated 
from a patient (Sheargren et al 1981). However other studies have used 
Wood 46 (Julander et al 1983; Granstrom et al 1983; Thisyakorn et al 1984; 
Monteil et al 1990) or Copenhagen (Larinkari et al 1977; Thisyakorn et al 
1984) strains of S.aureus. Several methods have been used to partially 
purify antigen such as ultrasonic disruption (Crowder and White 1972; 
Wheat et al 1984), disruption with Lysostaphin or other enzymes (Ryden et 
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al 1990), acid extraction, ethanol precipitation (Tenenbaum and Archer 
1980) and phenylhydrazine extraction (Archibald and Baddiley 1965). The 
Lafferty and Copenhagen strains contain both a and B N-
acetylglucosaminylribitol teichoic acid. The Wood 46 strain contains only 
B-N-acetylglucosaminylribitol teichoic acid which is present in 96-100% of 
human isolates of S.aureus. Thisyakorn et al (1984) found no difference in 
detection of teichoic acid antibody in ELISAs using teichoic acid prepared 
from Lafferty, Copenhagen or Wood 46 strains of S.aureus. 
Lysostaphin is a lytic factor which shows specific activity against 
staphlococci. The lysis is caused mainly by action of the peptidase which 
attacks glycyl-glycine linkages in the cross bridges of the staphylococcal cell 
wall peptidoglycan. All staphylococci possess this bridge which is exclusive 
to these types of bacteria (Gutierrez et al 1981). Lysostaphin susceptibility 
is a property directly related to the composition of the cell wall 
peptidoglycan and it seems to lyse staphylococci with low guanine and 
cytosine content. 
It is possible to get a non-specific reaction to protein A (present in most 
coagulase positive staphylococci) with the Fe fragment of IgG. Protein A 
can be eliminated by treating the antigen preparation with trypsin. 
The method for extraction and purification of teichoic acid from the Lafferty 
strain of S. aureus is described in detail in Appendix D and included trypsin 
treatment. 
The purified teichoic acid product obtained in this laboratory elicited a 
single line of identity in gel diffusion with commercial teichoic acid 
antibody (Meridian Diagnostics). 
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5.2.2.1 
5.2.2.2 
Comparison of reichoic acid antigens 
The only commercially available source of the teichoic acid was part of the 
'Endo-Staph' Ouchterlony kit (Meridian Diagnostics) used for 
semiquantitative measurement of antibodies to teichoic acid. Details of this 
antigen and its preparation are not available. It is supplied at low 
concentration (30 µg/ml protein), is relatively expensive and of limited 
availability. Several batches of teichoic acid were prepared in the laboratory 
for use in these assays and each batch was verified against the commercial 
preparation of Staphylococcal ribitol teichoic acid antibody (Meridian 
Diagnostics, Catalogue No 290202). 
Using both radioimmunodiffusion (RID) and ELISA the prepared teichoic 
acid antigen was compared to the commercial teichoic acid using normal 
pooled human immunoglobulin and the commercial anti-staphylococcal 
ribitol teichoic acid (Meridian Diagnostics, Catalogue No 290302). 
Comparison of commercial and in-house reichoic acid antigen by RID 
The method for immunodiffusion was adapted from the package insert of the 
Endostaph immunodiffusion assay (Appendix E). Briefly 1 % agarose in 
PBS (pH 7.4) containing 3.8% polyethylene glycol, 0.7% sodium chloride 
and 0.02 % sodium azide, was coated onto gelbond (10 cm x7.5 cm) (10 
ml/piece) and left to set. When set, 3 rows of wells (3 mm in diameter with 
an interval centre to centre distance of 5 mm) were cut. 5 µl of the purified 
teichoic acid antigen were added to the wells of the centre row and 5 µl of 
various dilutions of anti-teichoic acid antibody or serum were added to the 
wells of the top and bottom rows. The gel was incubated for 48 hours at 
4°C in a moist chamber. It was then soaked in 0.9% saline for 15 minutes, 
distilled water for 15 minutes, dried, fixed with 2 % acetic acid for 10 
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minutes and stained with amido black stain (0.5% in methanol/glacial acetic 
acid 9: 1). It was destained with methanol/glacial acetic acid 9: 1. 
The undiluted commercial teichoic acid antigen did not give a definite 
precipitation line with either pooled normal immunoglobulin or the 
commercial anti-teichoic acid antibody whereas the in-house teichoic acid 
preparation did. This was observed with several batches of commercial 
teichoic acid. Only minor precipitation lines were observed between 
undiluted commercial teichoic acid antibody and a 1 :4 dilution of pooled 
normal immunoglobulin (Figure 5.1). 
1 2 3 4 5 6 7 8 9 10 
b 
11 12 13 14 15 16 17 18 19 20 
Figure 5.1: Precipitin lines in agar gel showing a line of identity between the in-house 
teichoic acid preparation (wells a) and both normal human immunoglobulin (wells 1-
10) and commercial teichoic acid antibody (wells 11-20). Faint precipitation lines were 
seen with the commercial teichoic acid antigen (wells b) and normal human 
immunoglobulin but not with the commercial teichoic acid preparation. Wells of the 
top row contain serial dilutions from undiluted to 1:32 of normal human 
immunoglobulin. The middle row contains the teichoic acid antigen: a = in-house 
preparation; b = commercial preparation. Wells of the bottom row contain 
commercial teichoic acid antibody in serial dilutions from undiluted to 1:32 
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5.2.2.3 
5.2.2.4 
A 1: 8 dilution of the in-house teichoic acid showed optimal precipitation 
lines with undiluted antibody and a 1 :32 dilution of pooled normal 
immunoglobulin. 
Comparison of commercial and in-house S. aureus teichoic acid antigen by 
ELISA 
The ELISA method is described in detail in this chapter under section 5.3.2. 
A 1 :25 and 1 :500 dilution of commercial teichoic acid gave similar shaped 
curves to 1 :2 500-1 :25 000 dilutions of the in-house teichoic acid antigen for 
IgG, IgGl and IgG2 teichoic acid ELISAs (Figure 5.2). The standard 
curves obtained with the commercial antigen were not as steep and shifted to 
the left compared to the in-house teichoic acid antigen (Figure 5.2). 
Conclusion and discussion 
The commercial teichoic acid antigen did not give a definite precipitation 
line with commercial teichoic acid antibody whereas the in-house teichoic 
acid antigen did. In the teichoic acid ELISA the commercial and in-house 
teichoic acid antigen gave parallel standard curves at different 
concentrations. This demonstrated that the in-house product was similar to 
the commercial teichoic acid but was far more concentrated. 
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Figure 5.2: IgG, IgGl and IgG2 S.aureus teichoic acid ELISA standard curves assayed 
using laboratory prepared teichoic acid in a range of dilutions from 1:2 500 - 1:50 000: 
1:2 500 (•) 1:5 000 ( + ), 1:10 000 (*), 1:15 000 (0), 1:25 000 (x) and 1:50 000 ( +) and 
compared to the commercial teichoic acid antigen (CT A) at 1:25 (.1) and 1:500 (o) 
Antigen Coating 
IgG, IgGJ and IgG2 teichoic acid ELISAs 
Preliminary checkerboard titrations were done to determine optimum coating 
dilutions of teichoic acid. The microtitre plates were coated with 100 µl of 
teichoic acid dilutions ranging from 1: 1 000 to 1 :500 000 diluted in 
carbonate buffer pH 9. 6. Plates were incubated overnight in a moist 
chamber at 4 °C. A coating dilution of 1: 15 000 was selected for the IgG 
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5.2.4 
5.2.4.1 
5.2.4.2 
assay, 1 :5 000 for the IgG 1 assay and 1: 1 000 for the IgG2 assay (Figure 
5.2). All plates were coated just prior to use. 
Pooled human immunoglobulin was used (by back titration against newly 
prepared batches of antigen) to standardize the antigen coating concentration 
for construction of standard curves in these assays. 
Blocking Agents 
IgG, IgGJ and IgG2 teichoic acid ELISAs 
Casein 1 % (Centrolab, Saarchem, Catalogue No 1528140), BSA 2% 
(Albumin Fraction V, Boehringer Mannheim, Catalogue No 735086) and 
2 % denatured goat serum (for the IgG ELISA) were assessed as blockers in 
these assays. 1 % casein gave low background readings for all the blanks 
and was selected as the blocker and serum diluent in all three assays (Table 
5.1). 
Conclusion and discussion 
There are only a few reports of teichoic acid ELISA methods and in the 
most quoted method of Granstrom et al (1983) a blocking step is not 
mentioned. Where a blocking step is included BSA (0.5-2.0%) was used 
(Thisyakorn et al 1984; Ryden et al 1990). In this system 1 % casein gave 
the best results. 
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5.2.5 
5.2.5.1 
TABLE 5.1: EFFECT OF BLOCKING AGENTS ON BACKGROUND 
BLANK VALUES OF lgG, lgG 1, lgG2 TEICHOIC ACID SPECIFIC 
ASSAYS 
OPTICAL DENSITY (OD) OF 
BACKGROUND BLANKS 
(% of maximwn signal) 
Assay Blocker OD Maximum Minus Minus Minus 
Signal Antigen Serum Moab 
IgG TA 2% BSA 1.904 1.354 0.039 0.050 
(71.1) (2.1) (2.6) 
1 % Casein 2.145 0.139 0.007 0.047 
(6.5) (0.3) (2.2) 
Denatured 1.517 1.083 0.028 0.170 
Goat serum 2 % (71.4) (1.9) (1.1) 
IgGl TA 2% BSA 2.173 1.135 0.023 0.009 
(52.2) (1.1) (0.4) 
1 % Casein 2.240 0.147 0.012 0.006 
(6.6) (0.5) (0.3) 
IgG2 TA 2% BSA 2.198 0.135 0.122 0.104 
(6.1) (5.6) (4.7) 
1 % Casein 2.226 0.089 0.059 0.062 
(3.9) (2.6) (2.7) 
Serum Standards and Controls 
IgG, IgGJ and IgG2 teichoic acid ELISAs 
Normal pooled human immunoglobulin (NBTS), pooled AB serum and 
commercial anti-staphylococcal ribitol teichoic acid (Meridian Diagnostics, 
Catalogue No 290302) were compared as antibody standards and showed 
parallel curves (Figure 5.3). 
Normal pooled human immunoglobulin shifted the curve to the right 
compared to the AB serum and commercial teichoic acid antibody 
preparation (Figure 5.3). The normal pooled human immunoglobulin was 
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selected as the calibrator for the standard curve as it could be used in greater 
dilutions which resulted in lower uncoated (minus antigen) well blank 
readings. It was also commercially available at low cost whereas the 
commercial anti-teichoic acid antibody preparation was difficult to obtain, 
was more expensive and the stock of pooled AB serum was limited. 
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Figure 5.3: Comparison of IgG, IgGl and IgG2 S.aureus teichoic acid ELISA standard 
curves of normal pooled immunoglobulin (•), with the commercial anti-teichoic acid 
antibody serum ( +) and pooled AB serum (*) demonstrating parallelism 
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The commercial anti-staphylococcal ribitol teichoic acid and pooled AB 
serum were used as positive controls in the assay. Pooled batches of the 
standard and positive control were aliquotted and stored at -70°C until use. 
Various dilutions of the control and samples were compared to assess 
reproducibility of results. Calculated antibody concentrations were similar 
for dilutions read off the linear section of the curve. In the IgG teichoic 
acid assay the AB serum positive control was diluted 1: 100 and the 
commercial anti-teichoic acid antibody was diluted 1: 100 and 1 :500. 
In the IgG 1 teichoic acid ELISA the AB serum was diluted to 1: 75, the 
commercial anti-teichoic acid antibody was diluted to 1 :75 and 1: 100. 
In the IgG2 teichoic acid ELISA the AB serum was diluted to 1 :50 and 
commercial anti-teichoic acid antibody was diluted to 1 :750 and 1: 1 000. 
5.2.6 Incubation Periods 
No significant differences were found in the standard curve or sample data 
when the serum was incubated for either 1 hour at 37°C or overnight at 
40c. 
5.2. 7 Monoclonal Antibody - Selection 
5.2.7.1 
Details of the various IgG subclass specific monoclonal antibodies evaluated 
for these assays can be found in Appendix A. 
IgG reichoic acid ELISA 
In the total IgG teichoic acid ELISA the background blanks were acceptably 
low using the unbiotinylated antibody HP6064 (Table 5.2). The 
concentration of antibody was tested in dilutions ranging from 1 :250-
1: 10 000 and the optimal dilution of 1 :4 000 was selected. The biotinylated 
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antibody HP6017, gave low minus antigen, minus monoclonal and minus 
serum blanks (5.0%, 0.6% and 0.9% respectively of the maximum standard 
signal). However, this antibody had to be used at a dilution of 1:500 or less 
whereas the unbiotinylated antibody HP6064 could be used in dilutions of 
1 :4 000 and was thus far more economical. The curve was shifted to the 
right with HP6064, the most concentrated standard dilution being 1 :500 as 
opposed to 1 :20 with the biotinylated antibody HP6017 (Figure 5.4). 
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Figure 5.4: IgG, IgGl and IgG2 S.aureus teichoic acid ELISA standard curves 
assayed with various Moabs: IgG = HP6064 (•); No Moab ( +) (without monoclonal 
antibody and using an anti-human IgG conjugate); biotinylated HP6017 (HP6017B) 
(*). lgGl = biotinylated HP6069 (HP6069B) (•), HP6069 (+), HP6012 (*), HP6070 
(•). lgG2 = HP6008 (•), HP6008:HP6014 (2:1) ( + ), HP6009 (*), biotinylated HP6002 
(HP6002B) (•) 
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TABLE 5.2: BACKGROUND BLANKS IN THE lgG S.AUREUS 
TEICHOIC ACID ASSAY 
Moab OD Maximum OPTICAL DENSITY (OD) OF 
Optical BACKGROUND BLANKS 
Signal (% of maximwn signal) 
Minus Minus Minus 
Antigen Serum Moab 
HP6064 1.784 0.089 0.019 0.028 
(5.0) (1.1) (1.6) 
HP6017 1.588 0.080 0.010 0.014 
Biotinylated (5.0) (0.6) (0.9) 
No Moab 1.534 0.099 0.018 0.010 
(6.5) (1.3) (0.7) 
These assays were also assessed by using a polyclonal anti-human 
conjugated detecting antibody and omitting the intermediate monoclonal 
antibody. The shapes of the standard curves using these two formats are 
seen in Figure 5.4. The curve with the HP6064 monoclonal antibody was 
steeper than that with the polyclonal antibody although the value of the 
unknown samples read off both curves was similar. The assay format using 
the monoclonal antibody HP6064 was selected for use in these assays as it 
had a steeper slope which allowed a wider range of sample dilutions to be 
read off it. It was also more convenient as it was the format used in the 
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5.2.7.2 
IgG 1 teichoic acid and IgG2 teichoic acid assays and allowed 
synchronization of incubation steps. 
IgGl teichoic acid ELISA 
Although the shape of the standard curves were similar when using 
biotinylated HP6069 or unbiotinylated HP6069 monoclonal antibodies 
(Figure 5.4), the latter had higher background blanks (Table 5.3). The 
biotinylated HP6069 antibody was selected in preference to the antibody 
HP6012 as it gave a steeper standard curve (Figure 5.4). Minus antigen 
blanks were very high using the antibody HP6070 (Table 5.3) and the 
standard curve was very flat once these background blanks had been 
subtracted (Figure 5.3). The antibody HP6007 was initially tried but it gave 
a very poor signal and was not studied further. 
TABLE 5.3: EFFECT OF VARIOUS ANTI-IgGl MONOCLONAL 
ANTIBODIES ON BACKGROUND BLANKS IN THE lgGl 
TEICHOIC ACID ELISA 
OPTICAL DENSITY (OD) OF 
BACKGROUND BLANKS 
(% of maximum signal) 
Monoclonal OD Maximum Signal Minus Minus Minus 
Antibody 1: 1 000 Antigen Serum Moab 
HP6069 1.953 0.105 0.014 0.035 
Biotin y lated (5.4) (0.7) (1.8) 
HP6069 1.441 0.188 0.143 0.042 
Unbiotinylated (13.1) (9.9) (2.9) 
HP6012 2.328 0.436 0.346 0.173 
(18. 7) (14.8) (7.4) 
HP6070 1.369 0.736 0.056 0.165 
(53.8) (4.1) (12.1) 
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5.2.7.3 
Checkerboard titrations of the biotinylated HP6069 were done to find the 
optimal working dilution of this antibody. It was tested in a range from 
1 :500 to 1 :2 000 dilution and a dilution of 1: 1 000 was selected. 
IgG2 teichoic acid ELISA 
In the IgG2 teichoic acid ELISA there was no real difference in the shape of 
the standard curves produced using either HP6008, 'a5.4.1 
HP6009 or a combination of HP6008:HP6014 (2: 1) (Figure 5.4). In the assays the 
5.2. 7.4 
background blanks using these antibodies were similar and were less than 
7% of the maximum signal. The HP6008 antibody was selected for use in 
these assays as it could be used · at a greater dilution than the HP6009 
antibody and was thus more economical. HP6008 was tested in dilutions 
ranging from 1 :250 to 1 :2 000 and an optimal working dilution of 1: 1 000 
was selected. 
The biotinylated antibody HP6002 had to be used at a low dilution ( 1 :250) 
and produced a flat standard curve (Figure 5.4). 
Conclusion and discussion 
There are a few reports of the IgG subclass distribution of antibodies against 
S. aureus teichoic acid but the monoclonal antibodies used to detect the 
subclass specific teichoic acid antibodies are not detailed (Hammarstrom et 
al 1984, Hammarstrom and Smith 1986). In a report of the subclass 
distribution of antibodies against the whole staphylococcal organism 
(Monteil et al 1990) the mouse anti-human monoclonal antibodies used 
were: IgGl (HP6012), IgG2 (HP6014), IgG3 (HP6050) and IgG4 (HP6011 
and HP6013) all at 1: I 000 dilution. 
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5.2.8 
5.2.8.1 
Although the IgGl antibody HP6012 could have been used in the assays 
described in this thesis, HP6069 was selected due to its lower background 
values. 
Anti-IgG2 HP6014 is known to preferentially bind lambda over kappa 
bearing IgG2 protein (Hamilton 1987; Madassery et al 1988; Aucouturier et 
al 1992a) and is therefore not recommended for use on its own in subclass 
ELISAs. In these assays there was no advantage to using this antibody in 
combination with HP6008 over HP6008 alone. 
Evaluation of the Enzyme Detector System 
IgG teichoic acid ELISA 
The following conjugated antibodies were evaluated: 
non-affinity purified adsorbed HRPO sheep anti-mouse IgG (gamma 
chain) (Binding Site, Catalogue No PP272). 
non-affinity purified adsorbed HRPO sheep anti-mouse IgG, A, M 
(Binding Site, Catalogue No PP270). 
I 
affinity purified F(ab )2 goat anti-human gamma chain specific 
HRPO (Cappel, Catalogue No 3601-0121). 
The Binding Site sheep anti-mouse IgG, A, M HRPO conjugate was selected 
as it gave the lowest background blanks (Table 5 .4). It was diluted 1 :2 500 
in 1 % casein. 
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5.2.8.2 
TABLE 5.4: EFFECT OF CONJUGATES ON BACKGROUND 
BLANKS IN THE IgG TEICHOIC ACID ELISA 
OPTICAL DENSITY (OD) OF 
BACKGROUND BLANKS 
(% of maximum signal) 
Conjugate OD Minus Minus Minus Minus 
HRPO Maximum Antigen Moab Serum Moab 
Signal Minus 
Antigen 
Binding Site 1.503 0.316 0.461 0.510 0.466 
gamma chain (21.0) (30.7) (33.9) (31.0) 
specific 1: 750 
Binding Site 1.505 0.053 0.018 0.016 0.021 
IgG,A,M 1:2 500 (3.5) (1.2) (1.1) (1.4) 
I 
Cappel F(ab )2 1.895 0.477 0.049 0.238 0.057 
gamma chain (25.2) (2.6) (12.6) (3.0) 
specific 
1:1 000 
IgG I teichoic acid ELISA 
The detection antibody was streptavidin conjugated HRPO. The streptavidin 
peroxidase conjugates from Zymed (Catalogue No 43-4323) and Calbiochem 
(Catalogue No 189733) were evaluated. There was no difference in the 
shape of the standard curve obtained using either of these conjugates. As it 
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5.2.8.3 
5.2.8.4 
5.3 
was more readily available, streptavidin peroxidase (Zymed) at 1: 1 500 
dilution in 1 %casein was selected for these assays. 
IgG2 teichoic acid ELISA 
The conjugated antibodies detailed in 5.2.8.1 were also evaluated for use in 
this ELISA. The Binding Site sheep anti-mouse IgG, A, M HRPO 
conjugate was selected for use in these assays. It was diluted 1: 1 000 in 1 % 
casein. 
Conclusion and discussion 
Checkerboard titrations of each new batch of conjugate were done to find 
the optimum working dilution of the conjugate. Previous studies (Herzog et 
al 1984) have added protein A to the conjugate to reduce background levels 
when anti-human IgG conjugates were used. This was not found to be 
necessary in the present ELISAs. 
METHODS 
Optimum reaction conditions and reagents were determined in preliminary 
experiments detailed in Section 5.2. All reagents and samples were added to 
the wells in 100 µ1 volumes except for the 2N H2S04 of which 50 µl 
volumes were used. After each step in the procedure plates were hand 
washed five times with PBST unless otherwise stated. 
5.3.1 IgG teichoic acid ELISA 
Flat bottomed Nunc Maxisorb uncertificated microtitre plates (Weil, 
Catalogue No 4-4206) were coated with staphylococcal ribitol teichoic acid 
diluted 1: 15 000 in carbonate buffer pH 9.6. Plates were incubated for 2 
hours at room temperature. Non-specific protein binding sites were blocked 
with 250 µ1 1 % casein (Unilab) for 30 minutes at 37°C. Plates were 
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washed once with PBS and serial dilutions of sera diluted in 1 % casein were 
added to quadruplicate wells. Pooled normal human immunoglobulin in 9 
dilutions ranging from 1 :500 - 1 :200 000 (1 :500, 1: 1 000, 1 :2 000, 
1:5 000, 1:10 000, 1:20 000, 1:50 000, 1:100 000, 1:200 000) was used as 
the standards. Positive controls (commercial anti-staphylococcal ribitol 
teichoic acid) were added in two dilutions of 1: 1 500 and 1 :2 000. The sera 
from the patients was diluted 1:100, 1:200 and 1:400. The samples were 
diluted so as to be read on the linear section of the curve. Samples with 
absorbance readings which did not fall on the linear section of the curve 
were repeated at appropriate dilutions. The samples were incubated 
overnight at 4 °C. 
Buffer as well as a control serum with no detectable antibody were included 
in each assay as negative controls. 
The mouse anti-human monoclonal antibody HP6064, diluted 1 :4 000 in 1 % 
casein was added to the wells and incubated at room temperature for 1 hour. 
The plates were washed with PBST and then sheep anti-mouse IgG, A, M 
horseradish peroxidase conjugated antibody (Binding Site) diluted 1 :2 500 in 
1 % casein was added to the wells and incubated for 1 hour at room 
temperature. The plates were again washed with PBST. OPD substrate 
buffer was added and incubated for 15 minutes at room temperature in the 
dark. The reaction was stopped with 50 µl of 2N H2S04. The optical 
density was read at 492 nm in an SLT ELISA reader. 
5.3.2 lgG 1 teichoic acid ELISA 
This was similar to the method mentioned above for the IgG teichoic acid 
ELISA except for the following dilution and antibody differences: 
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The coating dilution of teichoic acid was 1 :5 000 
The standard curve dilutions of the normal pooled human 
immunoglobulin ranged from 1:25 to 1:20 000 (1:25, 1:100, 1:250, 
1:500, 1:1 000, 1:2 000, 1:5 000, 10 000, 1:20 000) 
Positive control serum (commercial anti-staphyloccal ribitol teichoic 
acid) was added in dilutions of 1: 100 and 1: 150 
Patient sera were added in dilutions 1: 100, 1 :400 and 1 :750 
The biotinylated mouse anti-human IgG subclass specific antibody to 
IgG 1 (HP6069) was diluted in 1 % casein to 1: 750 
Streptavidin peroxidase HRPO conjugate was diluted 1: 1 500 in 1 % 
casein 
5.3.3 lgG2 teichoic acid ELISA 
This was similar to the method mentioned above for the IgG 1 teichoic acid 
ELISA except for the following dilution and antibody differences: 
The coating dilution of the ribitol teichoic acid was 1: 10 000 
The standard curve dilutions of the pooled normal human 
immunoglobulin ranged from 1: 100 to 1 :50 000 (1: 100, 1 :250, 
1 :500, 1: 1 000, 1 :2 000, 1 :5 000, 1: 10 000, 1 :20 000, 1 :50 000). 
Positive control sera was added in dilutions of 1 :500 and 1 :750 
Patient sera were initially screened at a 1/5 dilution and then re-
assayed at appropriate dilutions if necessary 
The mouse anti-human IgG2 subclass specific antibody HP6008 was 
diluted to 1: 1 000 in 1 % casein 
Sheep anti-mouse IgG,A,M specific horseradish peroxidase conjugate 
(Binding Site)was diluted 1: 1 000 in 1 % casein. 
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5.3.4 Design of Plate 
Every assay plate included 9 dilutions of the standard normal human 
immunoglobulin for the calibration curves, background reaction wells 
(minus serum), uncoated (minus antigen) wells, minus monoclonal antibody 
wells (where applicable) and dilutions of the control staphylococcal ribitol 
teichoic acid antibody for monitoring reproducibility. All reactions were 
performed in triplicate. For the routine analysis of unknown samples the 
design of the plate is shown in Chapter 1, Figure 1.1. 
For all the assays the background values obtained from wells with antigen 
and monoclonal antibody but no serum (serum blanks) were very similar to 
those with antigen and serum (monoclonal antibody blanks) and those with 
antigen but no serum or monoclonal antibody (background blanks). Initially 
these blanks were carried out in triplicate but as they were consistently low 
they were only included as single blanks in routine runs to allow more 
unknown samples to be included in each run. 
5.3.S Calculation of Results 
A value of 100 units/ml for IgG, IgGl and IgG2 anti-teichoic acid antibody 
was arbitrarily assigned to the standard to allow the specific anti-teichoic 
acid antibodies to be quantitated. Levels of IgG, IgG 1 and IgG2 antibodies 
were calculated relative to these references. 
As previously described (Chapter 1.12) standard dose curves were 
constructed from average absorbance values and concentrations that had 
been entered into a curve fitting four parameter logistic programme. The 
concentration of each analyte in each sample was obtained by interpolating 
the average absorbance values from the standard curve and multiplying the 
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result by the dilution factor. Only values from the linear sections of the 
curves were considered valid. 
5.4 ASSAY STANDARDIZATION 
5.4.1 Standard Curves 
Standard curves for the IgG, IgG 1 and IgG2 teichoic acid ELIS As using the 
pooled normal human immunoglobulin, pooled AB serum and commercial 
teichoic acid antibody preparation were parallel (Figure 5.5). Thus the 
pooled normal human immunoglobulin preparation was used to construct 
standard curves for the teichoic acid ELISAs. Nine triplicate dilutions of 
the standard were used to construct curves for these ELISAs. 
For all 3 assays titration curves were constructed from patient samples in 
order to demonstrate parallelism to the standard curve at various dilutions. 
In the IgG and IgG 1 S. aureus teichoic acid ELISA test serum samples 
showed parallelism to the standard curves (Figure 5 .4). In the IgG2 teichoic 
acid ELISA samples with high IgG2 teichoic acid antibody concentrations 
demonstrated parallelism to the standard curve, but this disappeared as the 
antibody concentration decreased. 
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Figure 5.5: Curves of individual serwn samples, A (*), B (D), C ( + ), D (•) and E 
( +) for IgG, IgG 1 and lgG2 S. aureus teichoic acid and compared to the standard curve 
(•) demonstrating linearity and parallelism 
Precision and Sensitivity 
Two dilutions of the commercial teichoic acid preparation and of the pooled 
AB serum were inserted in every run. Running means were calculated from 
these controls inserted in each run and experiments were repeated if the 
values fell outside the 2 SD range. Assay precision was assessed using 
intra- and inter-assay and interdilutional coefficients of variation (Table 
5.5). 
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TABLE 5.5: EVALUATION OF S.AUREUS ELISA PRECISION 
Intra-assay CV% 
Inter-assay CV% 
Inter-dilutional CV% 
IgG 
7.1 
10.6 
13.2 
IgGl 
8.2 
11.1 
14.9 
IgG2 
6.0 
14.6 
11.8 
185 
The intra-assay variation was obtained by assaying the same sample 14 times 
in one run. This was done on 3 occasions and the mean CV was used. The 
inter-assay variation was assessed with 2 samples assayed in triplicate at 4 
dilutions in 18 different runs. The inter-dilutional variation was obtained by 
assaying 5 dilutions of the same sample on a plate. This was done on 18 
different samples over 6 weeks and the mean CV was used. 
The lower limit of quantitation for each assay was 0.001 units for IgG 
teichoic acid antibody, 0.005 units for IgG 1 teichoic acid and IgG2 teichoic 
acid antibodies. These lower detection limits in each assay were at least 2-3 
times the background absorbance of the highest blank. The OD of these 
lower limits correlated with the OD of the 1: 100 000 standard dilution of the 
IgG teichoic acid, the 1: 10 000 dilution of the IgG 1 teichoic acid and the 
1 :5 000 dilution of the IgG2 teichoic acid. For practical purposes samples 
were called negative if the OD was less than the OD of the above mentioned 
standard dilutions in that run. 
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5.4.3 Specificity 
The specificities of the IgG, IgG 1 and IgG2 teichoic acid ELISA assays 
were assessed by a competitive inhibition ELISA using either teichoic acid, 
or the non-specific antigens Hib PRP polysaccharide or pneumococcal 
polysaccharide (Pneumovax-Merck, Sharpe and Dohme). 
These ELISAs were carried out as described in Section 5.3.1, 5.3.2 and 
5.3.3 except that the competititve antigens were preincubated with an equal 
volume of standard serum for 2 hours at room temperature before the 
addition of the mixture to teichoic acid coated wells. Dilutions of the serum 
reading on the linear section of the sigmoid curves for each assay were 
selected. In the IgG teichoic acid ELISA the dilution was 1 :500, in the 
IgG 1 teichoic acid ELISA 1: 750 and in the IgG2 teichoic acid ELISA 
1: 1 000. The competitive antigens were mixed with the serum in 
concentrations ranging from 300 to 0.01 µg/ml of teichoic acid, 20 to 0.01 
µg/ml of pneumococcal polysaccharide and 20 to 0.01 µg/ml of Hib PRP 
pol ysaccharide. 
Binding of the teichoic acid antibody to wells coated with teichoic acid could 
be inhibited by incubation with teichoic acid antigen but not with non-
specific carbohydrate antigens - Hib PRP and pneumococcal polysaccharide 
(Table 5.6) 
These results show that the assays are specific for the measurement of 
teichoic acid antibodies. 
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5.4.4 
5.4.4.1 
TABLE 5.6: COMPETITIVE INHIBITION ELISAs FOR 
SPECIFICITY IN TEICHOIC ACID ASSAYS 
% INHIBITION 
TA µg/ml IgG IgGl IgG2 
200 85.3 85.3 
100 77.7 
20 89.8 60.4 99.8 
10 84.3 50.3 91.3 
5 82.2 43.8 92.7 
1 79.6 18.3 80.4 
0.75 66.9 13.9 72.3 
0.5 59.7 0.5 70.1 
0.25 55.8 0 68 
0.10 43.1 1 51.4 
0.05 34.5 5 36.8 
0.01 13.7 0 24.3 
* Hib PRP or pneumococcal polysacchairde (Pneumovax) (0.01-20 µg/ml) caused no 
inhibition in these assays 
Antibody Affinity 
DEA-ELISA/or IgGJ and IgG2 teichoic acid 
These assays were based on the method of Devey et al (1988) using DEA as 
a chaotropic agent and are similar to the DEA-ELISAs for TT and Rib PRP 
antibodies detailed in Chapter 3.3.6, 3.5 and Chapter 4.4.5. 
The incorporation of 5-50mM DEA in the serum diluent resulted in an 
increasing shift to the left of the dose response curve for both IgG 1 and 
IgG2 teichoic acid antibodies (Figure 5.6). The shift of the dose response 
curve was greater in the IgG2 teichoic acid assays than in the IgG 1 teichoic 
acid assays. 
SECTION A: Chapter 5: Teichoic Acid IgG Subclasses 188 
lgGI I~ 
2 OD /TI 
- IJTM 1.5 - CirM 1.5 +SnM +~ 
+ IOr/1 .. lllit1 
.. 1:m1 1 .. 15nt1 1 
.... 20rl1 .... Xm'1 
+7.:!rtl + 2l'Tt1 
.... 3!m1 Q5 .... 35nt1 Q5 
+ 5ClrM ... ~ 
0 0 
1 1.5 2 25 3 3.5 4 4.5 1.5 2 25 3 3.5 ,4. 45 5 
log sEmn dlulions log scrL.m dlutioos 
Figure 5.6: Effect of increasing concentrations of DEA on the standard curves of IgG 1 
and IgG2 teichoic acid antibodies. DEA concentration: 0 mM ( • ), 5 mM ( + ), 10 mM 
(*), 15 mM (•), 20 mM (x), 25 mM ( + ), 35 mM ( •) and 50 mM (o) DEA. The shift 
was measured at 50% of the maximum OD with no DEA which is represented by the 
solid line drawn at 0.90 and 0. 70 for the IgG 1 and IgG2 teichoic acid ELISAs 
respectively. 
The absorbance readings in the absence of DEA represented total binding of 
specific antibody. The shift in the log of the serum dilution from the initial 
OD reading to 50% of the initial OD reading was calculated with various 
molar concentrations of DEA. 
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Calculations of this shift at 50% of the maximum ODs showed that in this 
serum (normal human immunoglobulin), the shift for IgG2 teichoic acid 
antibody tended to be greater than that for IgG 1 teichoic acid antibody at 
higher DEA concentrations (Table 5. 7). This suggests that the IgG 1 
teichoic acid antibody response is of higher affinity than the IgG2 response. 
TABLE 5.7: EFFECT OF INCREASING CONCENTRATIONS OF 
DEA ON THE LEFT SHIFT OF THE DOSE-RESPONSE CURVE OF 
IgGl AND IgG2 TEICHOIC ACID ANTIBODIES IN NORMAL 
HUMAN IMMUNOGLOBULIN 
DEA Log10 dilution 
Concentra- at 50% max OD 
tion (mM) 
OD=0.6 OD=0.9 
IgGl lgG2 
0 3.099 3.462 
5 2.911 3.528 
10 2.876 3.325 
15 2.848 3.368 
20 2.859 3.265 
25 2.677 3.011 
35 2.616 2.761 
50 2.330 2.254 
5.5 SUMMARY 
Log 10 shift at 
50% max OD 
OD=0.6 0D=0.9 
lgGl IgG2 
- -
0.188 0.066 
0.233 0.137 
0.251 0.094 
0.240 0.197 
0.422 0.451 
0.483 0.701 
0.769 1.208 
% Shift 
lgG 1-lgG2x100 
lgGl 
lgGl 
-
7.52 
6.07 
8.10 
7.74 
13.62 
15.59 
24.81 
lgG2 
-
-
3.9 
2.7 
6 
3 
9 
3 
5 
9 
5.6 
13.0 
20.2 
34.8 
This chapter describes the development of IgG, IgGl and IgG2 subclass 
specific ELISAs to S. aureus teichoic acid antibodies. An in-house teichoic 
acid antigen preparation was used which had been compared to a 
commercially available 'standard' antigen. 
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The detection of teichoic acid antibody by ELISA has been reported to be 
more sensitive than the gel diffusion method (Thisyakom et al 1984). The 
only other reports of subclass specific antibodies to teichoic acid are from 
Hammarstrom et al 1984. The major disadvantage of the S.aureus teichoic 
acid assays, is that there is no standardized single antigen and different 
laboratories prepare and use their own antigen preparations. Sensitivity and 
specificity have varied widely making it difficult to compare results obtained 
by different groups. The assays described are simple, sensitive and 
reproducible. However, due to the non-parallelism between test sera with 
low concentrations of IgG2 teichoic acid specific antibodies and the 
standard, low levels of IgG2 teichoic acid antibodies cannot be accurately 
quantitated. Linearity between test samples and the standard is assumed 
when unknown concentrations of the sample are calculated off the standard 
curve. The assays were used to study the isotypic IgG, IgGl and IgG2 
teichoic acid specific antibody responses in children with S.aureus 
osteomyelitis/septic arthritis. 
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CHAPTER 6 
G2m(n) and Glm(O IMMUNOASSA YS 
In 1976 at a WHO meeting (WHO 1976) it was agreed to accept both alphameric and 
numeric nomenclature for immunoglobulin allotypes (Appendix F). In this study the 
alphameric nomenclature is used. Initially it was thought that immunoglobulin allotypes 
were of no clinical relevance except for the study of population genetics. Recently 
however, there have been associations described between allotype markers and 
susceptibility to Hib disease and response to Hib vaccination (Ambrosino et al 1985; 
Sarvas et al 1990). Although the haemagglutination inhibition test is the most widely used 
method for immunoglobulin allotyping it is semi-quantitative and cumbersome. ELISAs 
permit quick and simple, quantitative determination of allotypes. This chapter reviews the 
methods used to measure allotypes and the reasons for establishing these assays. The 
experiments done to establish optimal reagents and conditions for these ELISAs, the 
methods finally used for the assays and the results of experiments relating to the precision 
and standardization of the assays are described. 
6.1 INTRODUCTION 
6.2 DETERMINATION OF OPTIMAL ASSAY CONDITIONS 
6.3 MEIBODS 
6.4 ASSAY STANDARDIZATION 
6.5 SUMMARY 
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6.1 INTRODUCTION 
Allotypic antigens of human immunoglobulins were first described in 1956 
(Grubb 1956; Grubb and Laurell 1956). The test system used then, based 
on haemagglutination-inhibition is still widely used. This method is based 
on inhibition of agglutination of antigen coated red blood cells. The 
antibodies specifically directed against the antigen are complexed by the 
antigen if it is present in the sample tested, inhibiting the agglutination of 
the target-coated RBC. Although this method is qualitative, semi-
quantitative estimates of the concentration of the antigenic determinants can 
be obtained by assaying serial dilutions of test samples. 
Allotyping by classical immunodiffusion methods is used, widely in mice 
and rabbits but has rarely been possible due to the paucity of reagents 
available for humans studies (Kunkel 1966). However, with the availability 
of monocloncal antibodies to some of the allotypic markers this is now 
possible. Recent reports from Rautonen et al (1989) and Sarvas et al (1989) 
describe a double diffusion assay for genotyping G2m(n) with a monoclonal 
antibody and its differentiation into homozygous positive, homozygous 
negative and heterozygote patterns. 
Although radioimmunoassay (RIA) is one of the most convenient, sensitive 
and quantitative methods for measuring allotypes of mouse, rabbit and 
chicken immunoglobulins, there are only few reports of human typing by 
RIA (Reisner 1976, Salier et al 1979). This is largely a consequence of the 
difficulties experienced in retaining antibody activity after radiolabelling the 
anti-allotype antisera. 
Good typing reagents (antisera) for Gm allotyping are difficult to produce 
and not readily available. The reagents originally used for Gm typing were 
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obtained from sera of patients with rheumatoid arthritis. The generation of 
antibodies in non-rheumatoid donors occurs as a result of immunisation in 
recipients of multiple transfusions, multiparous women alloimmunized 
against paternal determinants and immunization of the fetus and newborn by 
genetically incompatible maternal IgG. Without further stimulation 
antibodies formed to incompatible maternal factors disappear between 5-10 
years of age. However, 1-2% of the adult population have antibodies to 
allotypic determinants (Schanfield and van Loghem 1986). 
The antisera obtained fortuitously from the above mentioned sources often 
required considerable processing to yield monospecific reagents needed for 
Gm typing. Antisera to particular Gm specifications are often limited in 
supply and may be impossible to replace once exhausted. Certain Gm 
allotypes have been lost when supplies of an antisera have become depleted 
e.g. Gm(r) and Gm(p). The development of typing antisera in animals has 
been partially successful (Kunkel 1966). 
The classic haemagglutination inhibition technique is still the most widely 
used method for routine immunoglobulin allotyping. Both human and 
polyclonal animal antisera are useful as typing reagents in haemagglutination 
inhibition (HAI) assays. However, this method presents several problems: 
(1) the shelf-life of coated red cells is relatively short and thus must be 
replaced at frequent intervals; (2) anti-Gm sera are scarce and of low titre; 
(3) the occasional occurence in serum samples of antibodies to IgG and/or 
red cell antigens invalidates the test unless they are adsorbed by a time 
consuming procedure; (4) the test cannot be used for the quantitative 
analysis of Gm allotypes. With the recent development and availability of 
monoclonal antibodies to several of the Gm allotypes serological methods 
have become more widely used. The monoclonal antibodies have several 
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advantages over the polyclonal anti-allotypic antisera in that they are 
monospecific, unlimited in supply, relatively cheap to produce and give 
reproducible results. In ELISA or RIA, these antibodies can be used at high 
dilutions with very small amounts of test sera. 
Recently, monoclonal antibodies to G2m(n) and Glm(t) allotypes have 
become commercially available. This chapter describes the development of 
a new method to measure G2m(n) and G lm(t) allotypes by ELISA using 
these monoclonal antibodies in a direct coating ELISA assay. 
The G2m(n) allotype is frequently found in whites but is rarely found in 
African Blacks (Shackelford et al 1985b; de Lange 1991). Although studies 
on Black Americans have shown the occasional presence of the G2m(n) 
allotype (Shackelford et al 1985b) this probably reflected the influence of 
racial admixture. Glm(t) is said never to have been found in Blacks (de 
Lange 1991). 
The purpose of establishing these assays was to determine: 
The frequency of G2m(n) and G 1 m(t) positive alleles in our local 
population 
Whether the G2m(n) allotype influences levels of total IgG2 and 
IgG2 polysaccharide specific antibody 
Whether the G 1 m(t) allotype influences levels of total IgG 1 and 
IgG 1 polysaccharide specific antibody 
Whether children with Hib meningitis, Hib osteomyelitis/septic 
arthritis and S.aureus osteomyelitis/septic arthritis have the same 
frequency of the G2m(n)+ve or Glm(t)+ve allele as the control 
group. 
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6.2 DETERMINATION OF OPTIMAL REAGENTS AND CONDITIONS 
This section describes various experimental conditions and reagents assessed 
in establishing the methods for the G2m(n) and Glm(f) ELISAs. The 
positive (Rl 110, Rll 14, Rl 117) and negative (Rll 13, Rll 18) G2m(n) and 
Glm(f) reference sera used in these assays were obtained from the central 
laboratory of the Netherlands Red Cross Blood Transfusion Service (CLB). 
6.2.1 Plates 
Experience from establishing IgG subclass and subclass specific tetanus 
toxoid ELISAs had shown that Nunc 96 well flat bottom microtitre plates 
were suitable for all ELISA systems tested, readily available, cheap and easy 
to load without splashing, therefore giving good reproducibility. Since the 
background blanks were in acceptable ranges using these plates, other 
sources and types of plates were not assessed. 
6.2.2 Coating - G2m(n) ELISA 
6.2.2.1 
Assays for determination of the G2m(n) allotype using a direct (coating with 
sera) and monoclonal capture (coating with G2m(n) antibody) ELISAs were 
compared. The monoclonal antibody used in these assays was mouse anti-
human IgG2 [G2m(n)] Clone SH-21 (Sigma, Catalogue No I-7010). 
Direct ELISA 
Preliminary checkerboard titrations were done to determine optimum coating 
sera dilutions, G2m(n) monoclonal antibody dilutions and conjugate 
dilutions. Pooled AB serum was used for coating the ELISA plates in 
dilutions ranging from 1 :250 to 1 :500 000. Various dilutions of the 
monoclonal antibody were evaluated ranging in dilutions from 1 :500 to 
1: 100 000 (Figure 6.1). Nine dilutions of AB sera ranging between 1:2 000 
and 1 :50 000 were selected for construction of the standard curve. A drop 
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off in signal was only noticed at dilutions greater than 1 :20 000. The 
optimum concentration of the G2m(n) monoclonal antibody in the direct 
ELISA was 1: 10 000 (Figure 6.1). 
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Figure 6.1: Comparison of standard curves obtained using G2m(n) direct ELISA or 
G2m(n) capture ELISA. The monoclonal antibody G2m(n) was tested at various 
dilutions: 1:500 (•); 1:1 500 ( + ); 1:2 000 (o); 1:5 000 (*); 1:10 000 (D); 1:20 000 (x); 
1:50 000 (+),and 1:100 000 (•) 
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6.2.2.2 
6.2.2.3 
Monoclonal capture ELISA 
The microtitre plates were coated with 100 µl of a purified monoclonal anti-
G2m(n) antibody in dilutions ranging from 1 :500 to 1 :20 000 in glycine/Tris 
buffered saline for 30 minutes at room temperature followed by incubation 
with 200 µl of 2 % BSA for 30 minutes at room temperature. A coating 
concentration of 1 :500 was selected (Figure 6.1). 
Samples of positive (Rl 110) and negative (Rl 113) control sera were diluted 
in 0.2% BSA/TBS/0.005% Tween 20 (1:10 blocker solution) and 100 µl of 
the dilutions 1: 100 - 1 :500 000 were added to the wells, and incubated for 
30 minutes at room temperature. 
The conjugates assessed were goat anti-human gamma chain specific IgG 
conjugated to horseradish peroxidase ( Cappel, Catalogue No 3001-0121 and 
Zymed, Catalogue No 628420) both diluted to 1: 1 000 in 1: 10 blocker 
solution. 
The substrate used was OPD and the reaction was stopped with 50 µl 2N 
H2S04. After each incubation the wells were washed 4 times with TBST. 
Conclusion and discussion 
The standard curve obtained using the direct (serum coating) ELISA was 
steeper than that of the capture ELISA (monoclonal antibody coating) and 
was shifted to the right (Figure 6.1). The negative control (Rll 13) was 
negligible in both assays (Table 6.1). 
The capture ELISA also had significantly higher blanks than the direct 
ELISA (Table 6.1). For these reasons the direct ELISA was selected. 
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TABLE 6.1: EFFECT ON BLANKS IN THE G2m(n) AND Glm(O 
ELISAs USING DIRECT OR CAPTURE ASSAYS 
ELISA Maximum Optimal Optical Density (OD) Negative 
Density of Signal of Background Blanks Control R1113 
(% of maximum signal) % of + ve control 
Dilution OD Minus Minus 
serum Moab 
Direct 1:2 000 1.495 0.041 0.098 0% 
G2m(n) (2. 74) (6.6) 
1:10000 
Capture 1:100 2.141 1.420 0.251 0% 
G2m(n) (66.32) (11. 7) 
1:2 000 
Direct 1:500 2.144 0.093 0.172 0% 
Glm(t) (4.34) (8.02) 
1: 1 500 
Capture 1:100 2.104 0.796 0.426 0% 
Glm(t) (37.8) (20.25) 
1:5 000 
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6.2.3 Coating - Glm(O ELISA 
6.2.3.1 
6.2.3.2 
A similar comparison of direct (coating with sera) and capture (coating with 
Glm(t) antibody) ELISAs was undertaken. The monoclonal antibody used 
in these assays was mouse anti-human IgGl (Fab specific) [Glm(f)], Clone 
SG-16 (Sigma, Catalogue No 1-5385). 
Direct ELISA 
Preliminary checkerboard titrations were performed to determine optimal 
dilutions of coating sera, G 1 m(f) monoclonal antibody and conjugate. The 
optimum dilution of the G lm(t) monoclonal antibody in the direct ELISA 
was 1: 1 500 (Figure 6.2). 
Monoclonal capture ELISA 
This method was similar to the G2m(n) capture ELISA except for the 
following dilution and antibody differences: 
The plates were coated with 100 µ1 of a purified monoclonal anti-
G 1 m(f) antibody solution ranging in dilution of 1: 100 to 1: 100 000 
(10-0.001 µg/ml) diluted in 1: 10 blocker solution. 
The conjugate used was a goat anti-human gamma chain specific IgG 
conjugated to horseradish peroxidase diluted to 1: 1 000 in 1/10 
blocker solution (Cappel, Catalogue No 3001-0121). 
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Figure 6.2: Comparison of standard curves obtained using Glm(f) direct ELISA or 
Glm(f) capture ELISA. The monoclonal antibody Glm(f) was tested at various 
dilutions: 1:500 (•); 1:1 500 ( + ); 1:2 000 (o); 1:5 000 (*); 1:10 000 (D); 1:20 OOO(x); 
1:50 000 (+) and 1:100 000 (•) 
Preliminary checkerboards had shown that the optimum Glm(t) monoclonal 
antibody concentration in the direct ELISA system was I: I 500 and for the 
capture ELISA system 1:5 000 (Figure 6.2). Using the Glm(t) monoclonal 
antibody in the capture assay at dilutions 1: 100 - 1 :2 000 the minus serum 
blanks ranged from 95.8% to 72.7% respectively. At a 1:5 000 dilution the 
minus serum blank was 37.8%. 
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6.2.3.3 
In both the direct and capture Glm(t) ELISA assays there was a clear 
discrimination of the positive control Rl 110 and the negative control Rl 113 
(Table 6.1). However in the direct system the blanks (minus monoclonal 
blanks and minus serum blanks) were much lower than in the capture ELISA 
(Table 6.1). 
Thus the direct ELISA method was also selected for the Glm(t) ELISA. 
Conclusion and discussion 
There are a few published reports of ELISAs to measure the G2m(n) 
allotype. Ota et al (1991) reported an inhibition ELISA using a G2m(n) 
myeloma protein (gift from Dr de Lange) as the coating antigen and adding 
samples that had been preincubated with a rabbit anti-Gm antiserum (made 
in their laboratory). These reagents are not readily available. 
A capture ELISA system has an advantage over the direct immobilization 
ELISA in being more sensitive. It has a disadvantage in being more 
complex and expensive as plates need to be coated with purified anti-
allotypes or anti-IgG subclass monoclonal antibodies as capture antibodies. 
There are several reports showing that a given monoclonal antibody may 
show assay restriction (Bird et al 1984; Jefferis et al 1985; de Lange et al 
1989; Nelson et al 1990) which appeared to be dependent on the means of 
antigen presentation. Thus antibodies must be assessed in the system they 
are to be used in. 
The CLB Netherlands recommend the capture ELISA for the determination 
of Gm allotypes Glm(z), Glm(a), Glm(t), G3m(g) using antibodies raised 
in their laboratory. However, an anti-Glm(t) monoclonal antibody (5F10) 
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6.2.4 
6.2.4.1 
6.2.4.1.1 
can be used in both direct or capture ELISAs (de Lange et al 1989). There 
are no published reports using this method for the G2m(n) ELISA. 
Tamaki et al (1990) also described direct and indirect ELISAs to measure 
anti-Glm(t) antibodies using a monoclonal antibody they had produced. 
They commented that low dilutions ( 1: 10 dilutions) of the serum sample 
should not be used because unrelated serum proteins compete with IgG in 
the sample for binding sites on the solid phase. High dilutions of sample 
gave reliable results and eliminated the need for removal of the competing 
proteins with DEAE-cellulose. In the direct ELISA described here, coating 
concentrations of samples were 1: 10 000 and dilutions of the standard curve 
ranged from 1 :500 to 1 :50 000. 
Antibody 
G2m(n) ELISA 
Both a monoclonal and polyclonal rabbit antibody to human G2m(n) were 
assessed for usefulness in this system. 
Polyclonal rabbit anti-G2m (n) antibody 
The rabbit anti-human G2m(n) polyclonal-antibody was obtained from the 
Central Laboratory of the Netherlands Red Cross Blood Transfusion Service 
(CLB) (CLB Product No R1072). This polyclonal antibody was tested at 
various dilutions from 1 :250 - 1: 16 000. Two detection conjugate 
antibodies were used: 
Goat anti-rabbit IgG, A, M conjugated to horseradish peroxidase. 
Cappel (Catalogue No 32120231) 
Goat anti-rabbit IgG affinity purified antibody conjugated to horse 
radish peroxidase. Kirkegaard and Perry (Catalogue No 14-15-16). 
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In this system the minus serum blanks were very low ( ~ 4 % of signal) but 
the minus polyclonal antibody blanks gave very high background signals 
using either of the above mentioned conjugate antibodies (Table 6.2). This 
system could not discriminate between the positive (Rl 110) and negative 
(Rl 113) controls whose standard curves created were virtually 
superimposable (Figure 6.3). 
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Figure 6.3: Comparison of dose response curves with the G2m(n) positive reference 
serum RlllO and the G2m(n) negative reference serum R1113 in the direct G2m(n) 
ELISA using polyclonal antiserum. Curves are drawn without ( + B) and with (-B) the 
background blanks subtracted 
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6.2.4.1.2 
TABLE 6.2: EFFECT ON THE BLANKS OF USING POLYCLONAL 
OR MONOCLONAL ANTI-G2m(n) ANTIBODIES IN THE ELISA 
OPTICAL DENSITY (OD) OF BACKGROUND 
ANTIBODY BLANKS 
(% of maximum signal) 
Minus Serum Minus Antibody 
Polyclonal anti-G2m(n) 4.1 % 77.0% 
Monoclonal anti-G2m(n) 2.7% 6.6% 
Monoclonal anti-G2m(n) antibody 
Checkerboard titrations of mouse anti-human IgG2 (G2m(n)) monoclonal 
antibody Clone SH-21 ranging in dilutions from 1:500 to 1:100 000 were 
done to find the optimum monoclonal antibody dilution to use. There was 
little difference in the shape of the curve using monoclonal antibody 
dilutions 1 :500 to 1 :20 000. There was a significant drop-off in signal and 
the curve became flatter using dilutions greater than 1 :50 000 (Figure 6.1). 
The monoclonal antibody dilution of 1: 10 000 was selected. 
With the monoclonal anti-G2m(n) antibody the minus serum blanks were 
low (::; 3 % of maximum signal) as were the minus monoclonal antibody 
blanks (6.6%) (Table 6.2). 
There was clear discrimination between the positive (Rl 110) and the 
negative (R 1113) control sera, the latter having no detectable signal in the 
assay. The monoclonal antibody to G2m(n) was clearly preferable to the 
polyclonal antibody. 
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6.2.4.2 
6.2.4.5 
Glm(f) ELISA 
The monoclonal anti-Glm(t) antibody Clone SG-16 was assessed for use in 
this system. Checkerboard titrations of monoclonal antibody in dilutions 
ranging from 1 :500 to 1: 100 000 were done to find the optimum monoclonal 
antibody dilution to use. There was little difference using a dilution of 
1 :500 or 1: 1 500 but the curve changed shape and became flatter using 
dilutions of 1: 1 500 or greater (Figure 6.2) and a dilution 1: 1 500 was 
selected. This resulted in minus serum and minus monoclonal blanks that 
were low (4.3 % and 8.0% of the maximum signal respectively) (Table 6.1) 
and there was also a clear discrimination between the positive (R 1110) and 
negative (Rl 113) controls. 
Conclusion and discussion 
The rabbit polyclonal anti-human G2m(n) antibody tested in the direct 
ELISA showed poor allotype detection whereas the monoclonal antibody 
SH-21 showed specificity. 
Several monoclonal antibodies have been raised in various laboratories to 
Glm(t) (Bird et al 1984; de Lange et al 1989; Tamaki et al 1990; Ota et al 
1991) and to G2m(n) (Ota et al 1991) which have been reported to be 
suitable for use in ELISA. To date there are three commercially available 
monoclonal antibodies to G lm(t); Clone SG-16 (Sigma, Biomakor) and 
Clone 5FI0 (CBL, Netherlands) and Clone TM14 (HP6027) (Zymed). 
There have been no reports of the comparison of these three antibodies in 
ELISA assays. 5FI0 has been shown to be useful in both a direct and 
capture ELISA system (de Lange et al 1989) and TM14 showed anti-
allotypic activity in direct and inhibition ELISAs but not in the capture 
ELISA (Nelson et al 1990). 
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6.2.5 
6.2.5.1 
Conjugates 
G2m(n) ELISA 
The various anti-mouse IgG antibodies coupled to horseradish peroxidase 
were evaluated: 
Non-affinity purified horseradish peroxidase goat anti-mouse IgG 
(gamma chain). (Cappel, Catalogue No 3301-0121) 
Horseradish peroxidase conjugated goat anti-mouse IgG (H and L) 
(Oxoid Catalogue No A81032). 
Non-affinity purified adsorbed horseradish peroxidase sheep anti-
mouse IgG, A, M (Binding Site, Catalogue No PP270). 
Non-affinity purified, adsorbed horseradish peroxidase sheep anti-
mouse IgG (gamma chain) (Binding Site, Catalogue No PP272). 
The Binding Site sheep anti-mouse IgG, A, M horseradish peroxidase 
conjugate was selected as it gave the lowest blank readings in both the minus 
serum and minus monoclonal blanks {Table 6.3). It was diluted 1: 1 000 in 
1: 10 blocker solution. 
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6.2.5.2 
TABLE 6.3: EFFECT OF CONJUGATED ANTIBODIES ON 
BLANKS IN THE G2m(n) ELISA 
Conjugate Dilution 
Oxoid GaM* H + L chain 1 :500 
Cappel GaM* 'Y chain 1: 1 500 
Binding site SaM** GAM 
1:1 000 
Binding site SaM** 'Y chain 
1:2 000 
* 
** 
GaM = goat anti mouse 
SaM = sheep anti mouse 
Glm(f) ELISA 
Maximum 
OD of 
Standard 
0.714 
1.268 
1.326 
1.029 
Optical Density (OD) 
of Background Blanks 
(% of maximum signal) 
Minus Minus 
Serum Moab 
0.026 0.153 
(3.6) (21.4) 
0.052 0.186 
(4.1) (14.6) 
0.033 0.074 
(2.5) (5.6) 
0.077 0.151 
(7.5) (14. 7) 
The same anti-mouse horseradish peroxidase antibodies were evaluated in 
the G 1 m(t) ELISA. There was little difference in the blanks between the 
Cappel goat anti-mouse conjugate and the Binding Site sheep anti-mouse 
IgG, A, M conjugate (Table 6.4). The blanks of both were significantly 
lower than the blanks of the Binding Site gamma chain specific conjugate. 
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The Binding Site IgG, A, M conjugate was selected for these ELISAs as it 
was also the conjugate best suited to the G2m(n) ELISA. 
TABLE 6.4: EFFECT OF CONJUGATED ANTIBODIES ON 
BLANKS IN THE Glm(O ELISA 
Optical Density (OD) 
of Background Blanks 
(% of maximwn signal) 
Maximwn Minus Minus 
Conjugate Dilution OD of Serwn Moab 
Standard 
Cappel GaM 'Y chain 1 :2 500 1.697 0.018 0.130 
(0.8) (7.7) 
Binding site SaM IgG, A, M 1.852 0.025 0.094 
1:1000 (1.3) (5.2) 
Binding site SaM 'Y chain 1 :500 1.472 0.405 0.361 
(27.5) (24.5) 
6.3 METHOD 
6.3.1 G2m(n) ELISA 
All reagents and samples were added to the wells in 100 µl volumes and all 
incubation periods were for 30 minutes at room temperature unless 
otherwise stated. After each step in the procedure plates were hand washed 
with TBST (20 mM TBS). 
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96 well Nunc maxisorb uncertificated flat bottomed plates (Weil, Catalogue 
No 4-4204) were coated with serum diluted in glycine/Tris buffer pH 7.0 -
7.5. A standard curve was constructed from nine dilutions of an in-house 
standard of pooled AB sera. The dilutions used for G2m(n) assay were 
1:2000, 1:4000, 1:6000, 1:8000, 1:10000, 1:15000, 1:20000, 
1:30000 and 1:50000. Two dilutions (1:15000 and 1:20000) of the 
positive (Rl 110) and negative (Rl 113) reference sera were included in each 
plate. Positive and negative reference controls were obtained from the CLB 
(Netherlands). Reference sera Rl 110 was G2m(n)+ve and Glm(f)+ve 
whereas sera Rll 13 was G2m(n)-ve and G lm(f)-ve. Patient sera were 
diluted 1: 15 000 for the G2m(n) assays. All sera were diluted in 
glycine/Tris buffer and were assayed in triplicate. The plates were washed 
once and then blocked with 2 % BSA in TBST. Plates were washed twice 
before the addition of the mouse anti-human IgG2 (G2m(n)) monoclonal 
antibody Clone SH-21. Monoclonal antibody SH-21 was diluted 1:10 000 
in 1: 10 blocker solution and then added to the wells. After a 30 minute 
incubation the plates were washed four times with TBST. The Binding Site 
IgG, A, M conjugate diluted 1: 1 000 in 1: 10 blocker solution was then 
added to the wells. After incubation and 5 washes the enzyme substrate 
OPD was added. The reaction was stopped after 15 minutes with the 
addition of 2N H2S04 and the plate was read on the ELISA reader, at 492 
nm. 
6.3.2 G lm(O ELISA 
This method was similar to the method mentioned above except for the 
following dilution and antibody differences. 
The standard curve dilutions of the 'in-house' standard were 1 :500, 
1:1 000, 1:2 500, 1:5 000, 1:7 500, 1:10 000, 1:15 000, 1:25 000 
and 1 :50 000. 
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Dilutions of positive (Rl 110) and negative (Rll 13) controls were 
1: 10 000 and 1: 15 000 and test sera 1: 10 000 
The monoclonal mouse anti-human IgGl (Fab specific) [Glm(t)] 
Clone SG-16 was diluted to 1: 1 500 in 1: 10 blocker solution. 
6.3.3 Design of the plate 
Every assay plate included 9 dilutions of the standard AB serum for the 
calibration curves, background reaction wells (minus monoclonal antibody), 
uncoated (minus monoclonal antigen wells) and dilutions of the positive and 
negative reference sera for monitoring reproducibility. All reactions were 
performed in triplicate. The design of the plate is similar for the G 1 m(t) 
and G2m(n) ELISAs and is illustrated in Chapter 1 (Figure 1.1). The 
blanks in column 10 in the Gm allotype ELISAs are: 
Row A, BC: Minus coating antigen (serum), plus monoclonal 
antibody 
RowD Minus monoclonal antibody, minus serum 
6.3.4 Calculation of results 
The blanks were subtracted from the mean of the triplicates of the standard 
sample dilutions. Standard curves relating absorbance to the concentration 
of IgGl Glm(t) and IgG2 G2m(n) subclass specific antibody were 
constructed. These standard curves were used to calculate the concentration 
of allotype specific immunoglobulin present in the sample. The pooled AB 
serum had been calibrated against the WHO standard 67/97 with assigned 
values for IgG 1 and IgG2 subclasses (Chapter 2.2. 7). Standard dose curves 
were constructed from average absorbance values and concentrations that 
had been entered into a curve fitting four parameter logistic programme 
based on the mathematical model described in Chapter 1.12. The 
concentration of analyte in each sample was obtained by interpolating the 
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6.4 
6.4.1 
6.4.1.1 
average absorbance values for the standard curve and multiplying the result 
by the dilution factor. Only values from the linear portions of the curves 
were considered valid. This allowed quantitative evaluation of the G lm(t) 
and G2m(n) allotype in each sample. The total IgG 1 and IgG2 level of 
each sample measured by the ELISAs described in Chapter 2.3, was 
compared to the G 1 m(t) IgG 1 and G2m(n) IgG2 measured in the ELISAs 
described here. In this way homo- and hetero-zygosity of the allotypes was 
determined (Chapter 9.3.2). If the subclass value of the sample measured in 
the allotype specific assay was 75 % or greater of the total subclass value, 
the sample was considered homozygous positive for the allotype. Samples 
with negative values in the allotype specific assays were homozygous 
negative. Samples of allotypic subclass with a value less than 75 % of the 
total subclass value were considered heterozygous for the allotype. 
ASSAY STANDARDISATION 
Standard Curves 
G2m (n) and G 1 m (f) 
Standard curves for the G2m(n) and G lm(t) ELISAs using the 'in-house' 
pooled AB serum standard and the positive reference control Rl 110 were 
parallel (Figure 6.4). Nine triplicate dilutions of pooled human AB serum 
were therefore used to construct the routine standard curves for both 
ELISAs. 
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6.4.2 
6.4.2.1 
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Figure 6.4: Comparison of G2m(n) and Glm(O standard curves of AB serum (•) with 
the reference standard RlllO ( +) 
PRECISION 
G2m(n) 
Two dilutions of the positive (Rl 110) and negative (Rl 113) reference serum 
were inserted in every assay. Running means were calculated from the 
positive reference control inserted in each run and experiments were 
repeated if the values fell outside the 2 SD range. Assay precision was 
assessed using inter- and intra-assay coefficient of variation (CV). The 
inter-assay CV was 13.57% calculated from values obtained in 40 runs over 
20 consecutive weeks. The intra-assay CV was 6.9% obtained by assaying 
the same sample 12 times in one run on 3 occasions and using the mean CV. 
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6.4.2.2 Glm(f) 
Running means were calculated from controls inserted in each run as 
described for G2m(n) ELISA and experiments were repeated if the values 
fell outside the 2 SD range. 
The inter- and intra-assay CV's were calculated as described above for the 
G2m(n) ELISA. The inter-assay CV was 11.6% and the intra-assay CV was 
3.1 %. 
6.4.3 Specificity 
6.4.3.1 
The specificity of the assays were assessed by competitive inhibition ELISAs 
by double diffusion in gels (G2m(n) only) and by haemagluttination 
inhibition. 
G2m(n) Competitive inhibition ELISA 
This ELISA was carried out as described in 6.3.1 except that various 
dilutions of G2m(n) +ve sera (1: 10-1 :200 000) were mixed with the anti-
G2m(n) monoclonal antibody and preincubated for 30 minutes at room 
temperature before addition to the coated ELISA plates. Preincubation of 
the monoclonal antibody with dilutions of G2m(n) +ve sera of up to 1 :2 000 
caused 100% inhibition in the G2m(n) ELISA. A 50% inhibition of the 
assay was caused with dilutions of positive sera in the range of 1 :2 000 to 
1:5 000 (Table 6.5). 
Negative control sera at dilutions of greater than 1 :30 cauused no significant 
inhibition (Table 6.5). Results were identical with several different 
G2m(n)+ve sera tested (data not shown). 
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6.4.3.2 Glm(f) Competitive inhibition ELISA 
This ELISA was carried out as described in 6.3.2 except that dilutions of 
Glm(t)+ve sera (1/10-1:200 000) were mixed with the anti-Glm(t) 
monoclonal antibody and pre-incubated for 30 minutes before addition to the 
coated plates. Dilutions up to 1: 1 000 caused 100% inhibition. The 
negative control sera did not cause significant inhibition at dilutions greater 
than 1 :20 (Table 6.5). Results were similar with several different 
Glm(t)+ve sera tested (results not shown). 
TABLE 6.5: G2m(n) AND Glm(O COMPETITIVE INHIBITION 
ELISAs 
% INHIBITION BY ALLOTYPIC POSITIVE SERA 
Dilution of 
Serum G2m(n)+ve G2m(n)-ve Glm(O+ve Glm(O-ve 
Serum Serum Serum Serum 
1/10 100 53 100 44 
1:20 100 37 100 37 
1:30 100 7 100 14 
1:40 100 0 100 1 
1:50 100 0 100 2 
1:100 100 0 100 4 
1:200 100 0 100 0 
1:500 100 0 100 0 
1:1 000 100 0 100 0 
1:2 000 88 81 
1:5 000 39 42 
1: 10 000 20 32 
1:20 000 18 27 
1:40 000 11 16 
1:100 000 19 15 
1:200 000 20 10 
SECTION A: Chapter 6: G2m(n) and Glm(f) lmmunoassays 215 
6.4.3.3 Double diffusion assay for genotyping of G2m(n) 
Gels for the double diffusion test contained 1 % agarose, 3.8% polyethylene 
glycol 6 000, 0.9% sodium chloride and 0.02% sodium azide in 0.05 M 
phosphate buffer pH 7.4. Agarose was coated onto gelbond (10 cm x 7.5 
cm) (10 ml/piece) and allowed to set. Three rows of wells (3 mm in 
diameter) were punched in the agarose. Each serum sample was 
simultaneously tested against anti-G2m(n) (SH-21 Sigma) and anti-IgG2 
(HP6014). 2 µl of anti-G2m(n) (SH-21) or 4 µl anti-IgG2 (HP6014) 
monoclonal antibody were added to alternate wells of the centre row (Figure 
6.5). 4 µl of test serum was added to the wells of the top row and 6 µl of 
test serum to the wells of the bottom row. The gel bond was incubated 
overnight at 4 °C in a moist chamber to prevent drying out. It was then 
soaked in 0.9% saline for 15 minutes, distilled water for 15 minutes, 
pressed between No 1 chromotography paper for 30 minutes and then left to 
dry overnight at 37°C. The gelbond was fixed with 2 % acetic acid for 10 
minutes and then stained for 15 minutes in amido black stain (0.5 % in 
methanol/glacial acetic acid 9: 1). It was destained with methanol/glacial 
acetic acid 9: 1. 
Specimens including positive and negative G2m(n) samples were measured 
with this technique and there was complete concordance with results 
obtained using the ELISA method. 
The three precipitation patterns I, X and T of G2m(n) homozygous negative, 
heterozygous and homozygous positive individuals described by Rautonen et 
al (1989) were duplicated in this study using identical antibodies and similar 
conditions. These precipitation patterns can be seen in Figure 6.5, when the 
test samples used were the positive (Rl 110, Rl 114 and Rl 117) and negative 
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(R1113, Rl118) G2m(n) reference sera and 1:1 mixtures of the positive and 
negative reference sera. 
n/n "/" -/- n/- n/n n/- nj- nJ- n/- n/-
Figure 6.5: Precipitation patterns detected with the three well double diffusion assay. 
Wells in the top contained 4 µI of sample and wells in the bottom row 6 µI of the same 
sample. Wells in the middle row alternately contained 2 µI anti-G2m(n) = (n) or anti-
IgG2 = (2). The interpretation of the resultant precipitation bands was: x = 
heterozygote n/-, T = homozygous positive n/n and I= homozygous negative-/-
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There was 95 % agreement in reading the patterns of the double diffusion 
gels between two independent observers. There was 96 % agreement 
between the G2m(n) ELISA and the Ouchterlony on the presence or absence 
of the allotype in known reference specimens. The only sample in 
disagreement was the negative reference standard (Rl 118) which was 
negative in the ELISA but had a small but definite precipitation line in the 
Ouchterlony. The other negative reference standard (Rl113) was negative 
in both assays. There was a 90% correlation between these two methods in 
determining the homo- or heterozygous state of positive reference 
specimens. With unknown samples there was a 75 % correlation between 
these two methods. 
Rautonen et al (1989) noted that monoclonal antibody SH-21 bound to IgG2 
molecules (Fe fragments) but binding was much weaker to G2m(n)-ve than 
G2m(n)+ve Fe regions. In gel G2m(n)+ve sera precipitated with SH-21 
and thus they used this monoclonal antibody as a typing reagent. 
G2m(n)+ve sera developed stronger precipitation bands with SH-21 than 
with anti-IgG2 HP6014. In the double diffusion assay testing each serum 
simultaneously against SH-21 and HP6014, three types of precipitation 
patterns developed. Samples of homozygous negative (-/-) individuals 
produced pattern I, heterozygous ( + /-) sera generated pattern X and 
homozygous positive (+I+) sera developed pattern T. The explanation for 
these patterns was that if the anti-G2m(n) precipitate emerged first, IgG2 
molecules of a + / + homozygote would be prevented from crossing the line 
and pattern T would develop. The G2m(n)-ve molecules of a heterozygote 
could partially cross the anti-G2m(n)+ve precipitate and pattern X would 
arise. Homozygous negative sera would give the pattern I as a precipitation 
line would only develop with anti-IgG2 and not with the SH-21 (anti-
G2m(n)) +ve antibody. 
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6.4.3.4 
6.5 
Rautonen, Sarvas and colleagues (Department of Bacteriology and 
Immunology, University of Helsinki, Finland) are the only group to have 
published data relating to the determination of heterozygous G2m(n) positive 
samples using the double diffusion method. In reproducing their method it 
was found that the precipitation lines were much clearer using 4 or 6 µl of 
sample rather than 2 or 4 µ1 originally described. 
There is no reference standard for G2m(n) heterozygous positive 
measurement. There was 75-90% correlation between the homo- or 
heterozygous positive samples measured in the G2m(n) ELISA and the 
double diffusion Ouchterlony. It was not possible, but would have been of 
interest, to have correlated samples typed by G2m(n) ELISA and 
Ouchterlony in this laboratory to those typed by the double diffusion method 
in Dr Rautonen' s laboratory. 
Haemagglutination inhibition 
G2m(n) and Glm(f) allotyping was undertaken by Dr G de Lange at CLB, 
Netherlands on 10 samples. Results obtained by this method were the same 
as those obtained with their ELISA method. 
SUMMARY 
The G2m(n) determinations for many of the studies worldwide have been 
assayed by haemagglutination inhibition (Ambrosino et al 1985; Petersen et 
al 1987; Sjoholm et al 1987). 
Direct, capture and inhibition ELISA assays have all been described for 
various Gm allotypes using polyclonal and monoclonal reagents (Bird et al 
1984; de Lange et al 1989; Tamaki et al 1990; Ota et al 1991; Oxelius and 
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Carlsson 1993). Despite the commercial availability for several years of 
anti-G2m(n) (SH-21) and anti-Glm(t) (SG-16) monoclonal antibodies there 
are no reports of ELISA systems utilizing them. The monoclonal antibody 
SH-21 has been reported to be specific for G2m(n) in both 
haemagglutination inhibition assays and precipitation after double diffusion 
in agar (Jefferis et al 1985; Rautonen et al 1989). The monoclonal antibody 
SG-16 has been reported to be specific for the Glm(t) allotype in ELISA 
(Jefferis et al 1985). In the monoclonal capture G2m(n) assay the 
background values of non-specific binding were greater than in the direct 
ELISA (Table 6.1). Since both the G2m(n) and G lm(t) were sensitive and 
specific using the direct ELISA system this was selected for convenience. 
Groups from Finland and Sweden (Rautonen et al 1989; Sarvas et al 1989, 
1990; Oxelius 1990a; Takala et al 1991) have published extensively on 
G2m(n) allotyping using the commercial monoclonal antibody SH-21 m a 
double diffusion system. 
This study is the first detailed report using commercial, readily available 
monoclonal antibodies G2m(n) (SH-21) and Glm(t) (SG-16) in ELISA. 
The direct ELISAs described are simple and practical in that they require 
only 2-3 hours of bench work and no specific coating antigens. The assays 
are specific, reproducible and quantitative and are sensitive enough for 
routine allotyping, being capable of detecting G2m(n) and G lm(t) allotypes 
in the nanogram range. In both assays there was a clear discrimination 
between the positive and negative controls. G2m(n) and Glm(t) typing by 
direct ELISA with these antibodies can reliably separate sera into positive 
and negative allotypes. This is confirmed by the results of samples kindly 
typed by Dr de Lange's Laboratory (CLB, Netherlands). It is more difficult 
to evaluate the reliability of the 'genotyping' as although the precipitation 
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patterns of the double diffusion method of Rautonen (1989) could be 
duplicated, there was not 100% agreement between samples tested in both 
methods. The final evaluation of the method must await the availability of 
other methodology. 
These assays will be used to study the 'gene dosage effect' in healthy 
children and in assessing the clinical significance of Gm allotypes in 
disease. 
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Km(3) IMMUNOASSAY 
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The typing of light chain kappa allotypes is commonly done by the classical agglutination 
inhibition test. However ELISA is now a practical alternative method as anti-Km(3) 
antibody raised in rabbits is commercially available. This ELISA system would not be 
suitable for the measurement of Km(l) antibodies as only polyclonal human anti-Km(l) 
antibody is available. The chapter is divided into a number of sections discussing previous 
methods for Km(3) measurement and reasons for establishing the ELISA. The method and 
development of a direct ELISA to measure Km(3) allotypes is detailed. Finally results of 
experiments relating to the precision of the assay and applications of the assay are 
described. 
7.1. INTRODUCTION 
7.2. DETERMINATION OF OPTIMAL ASSAY CONDITIONS 
7.3 METHODS 
7.4 ASSAY STANDARDIZATION 
7.5 SUMMARY 
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7.1 INTRODUCTION 
The typing of kappa markers is commonly done by the classical inhibition of 
agglutination technique where the test serum inhibits the agglutination of 
antigen coated erythrocytes by anti-allotypic sera. The control sera, anti-
allotypic sera and the method (Appendix G) are obtainable from the Central 
Laboratory of the Netherlands Blood Transfusion Service (CLB). Problems 
encountered with this method were the difficulty in obtaining a regular 
source of blood group OR2R2 erythrocytes, non-specific binding of 
uncoated erythrocytes with some of the control sera, and difficulty with 
scoring the results. 
Young et al (1989) reported a modification of this method using 2 µl of 
reagent volumes (not 25 µl volumes) which enabled considerable savings of 
the valuable reagents. This method was attempted (Appendix H) but again 
problems were encountered with supply of OR2R2 erythrocytes and non-
specific binding of uncoated erythrocytes. The plates were read 
microscopically and the agglutination results could be graded easily. 
Moxley and Gibbs (1992) have recently reported a novel polymerase chain 
reaction-based genotyping for Km allotypic markers. This involves 
amplification of the constant segment of the kappa chain by polymerase 
chain reaction (PCR) followed by restriction enzyme digestion. Restriction 
sites in this constant region PCR product correlate with allotypic differences 
among Km(l), Km(l ,2) and Km(3) alleles. 
The commercial availability of an anti-Km(3) antibody raised in rabbits 
made the ELISA a possible alternative. The ideal ELISA requires 
monoclonal antibodies which are currently not available for Km(l) or 
Km(3). 
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The purpose of establishing this ELISA was to determine: 
The frequency of Km(3) positive allotypes in our local population 
Whether children with Hib meningitis, Hib osteomyelitis/septic 
arthritis and S.aureus oesteomyelitis/septic arthritis have the same 
frequency of the Km(3) allele as the control group. 
Whether the presence of the Km(3) allele has any influence on IgG 
subclass or subclass specific antibody responses. 
7.2 DETERMINATION OF OPTIMAL REAGENTS AND CONDITIONS 
7.2.1 Coating 
Preliminary checkerboard titrations were done to determine the optimum 
coating concentration of the sera. Serial dilutions from 1: 1 000 to 1 :32 000, 
of the positive control serum giving the lowest signal (Rl 110), the negative 
control with the highest signal (R1118) and a 1:1 mixture of R11IO:Rlll8 
were used. A plateau effect was noted: there was no difference in signal 
with sera dilutions of 1: 1 000 or 1 :2 000 but the signal started to drop off 
with dilutions of 1 :5 000 and was significantly reduced at dilutions between 
1: 10 000 to 1:32 000 (Figure 7.1). A coating dilution of 1:8 000 was 
selected, which was on the linear portion of the curve. 
SECTION A: Chapter 7: Km(3) Immunoassay 224 
10) 
1:8000 
0.8 
R111QR1118 0.6 
-
1:0 
-+- Q1 
1:1 04 + 
02 
0-+----..-----,.--~--~---, 
25 3 35 4 45 5 
I og serum di I uti ons 
Figure 7.1: Km(3) ELISA titration curves with the positive standard RlllO (•), the 
negative standard Rl118 ( +) and a 1:1 mixture of RlllO and R1118 (*) using coating 
dilutions of sera ranging from 1:1 000 to 1:32 000. A coating dilution of 1:8 000 was 
selected 
7.2.2 Antibody 
Checkerboard titrations were done to determine optimum dilution of the 
rabbit anti-human Km(3) antibody (CLB, Product No Rl081). It was tested 
in doubling dilutions from 1: 125 to 1 :32 000. At dilutions of 1: 125 and 
1 :250 there was a clear distinction between the positive and negative 
controls and the ratio of positive (Rl 110): negative (Rl 118) sera was greater 
SECTION A: Chapter 7: Km(3) lmmunoassav 225 
than 2: 1. At dilutions of greater than 1: 1 000 the ratio remained constant at 
1.4: 1. A dilution of 1 :250 was selected for the assays. 
7 .2.3 Conjugates 
The detection antibody used was anti-rabbit IgG antibody coupled to 
horseradish peroxidase. 
evaluated: 
The following conjugated antibodies were 
Horseradish peroxidase goat anti-rabbit IgG (H and L) Kirkegaard 
and Perry Laboratories Inc, Catalogue No 14-15-16 
Horseradish peroxidase goat anti-rabbit G,A and M (H and L), 
Cappel, Catalogue No 3212-0231 
Affinity purified horseradish peroxidase goat anti-rabbit IgG (H and 
L), Zymed, Catalogue No 62-6120. 
The Zymed affinity purified goat anti-rabbit (H and L) horseradish 
peroxidase conjugate was selected as it gave the lowest uncoated well 
blanks {Table 7.1). The minus serum blanks were similar for all 3 
conjugates evaluated. 
TABLE 7.1: EFFECTS OF VARIOUS CONJUGATE ANTIBODIES ON 
BACKGROUND BLANKS IN THE Km(3) ELISA 
HORSERADISH~ OPTICAL DENSITY OF OPTICAL DENSITY (OD) 
PEROXIDASE POSITIVE CONTROL OF BACKGROUND 
CONJUGATES RlllO (1:1 000) BLANKS 
(% ofRlllO) 
Minus Minus 
Serum Antibody 
KP 1:2 000 1.426 0.139 0.442 
(9.8%) (31.0%) 
Zymed 1: 1 000 1.097 0.110 0.080 
(10.0%) (7.4%) 
Cappel 1 : 1 000 1.305 0.183 0.990 
(14.0%) (75.9%) 
* = See text for details (7.2.3) 
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7.3 METHOD 
7.3.1 Km(3) direct ELISA 
All reagents and samples were added to the wells in 100 µl volumes and all 
incubation periods were for 30 minutes at room temperature unless 
otherwise stated. After each step in the procedure plates were hand washed 
with Tris buffered saline (TBS) (20 mM) containing 0.01 % Tween 20 
(TBST). Nunc flat bottomed microtitre plates (non certificated) (Nunc 4-
42404), were coated with serum diluted to 1:8 000 in glycine/Tris buffer pH 
7.0-7.5. An initial serum dilution of 1:100 was made and this was then 
further diluted 1: 80. One positive control (R 1110), one negative control 
(R1118) and mixtures of 1:4, 1:19 and 1:99 of RlllO and R1118 reference 
sera were included in each plate. All samples were run in triplicate. The 
plates were washed once and then blocked with 2% BSA, 0.05% Tween 20 
and 1 % goat sera diluted in TBS. Plates were washed twice before the 
addition of the polyclonal rabbit anti-Km(3) antibody (Catalogue No Rl081, 
CLB) diluted 1 :250 in 1/10 blocker solution to the wells. After washing the 
plates four times, Zymed affinity purified horseradish peroxidase conjugated 
goat anti-rabbit IgG antibody diluted 1: 1 000 in 1/10 blocker with 1 % goat 
serum was added. After incubation and 6 washes the enzyme substrate OPD 
was added. The reaction was stopped after 15 minutes by the addition of 
100 µl of 2N H2S04 and the optical density was read at 492 nm and 620 nm 
on the Anthos Labtec ELISA reader. 
7.3.2 Design of plate 
The plate format used in the Km(3) ELISA is different to that used in all 
other ELISAs in this study and is shown in Figure 7.2. Each plate includes 
one Km(3) positive standard (Rl 110), one Km(3) negative standard 
(R1118), three control mixtures made ofa 1:4 (20%); 1:19 (5%) and 1:99 
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(1%) ratios of Rlll0:RI118, minus serum (uncoated wells) and minus 
polyclonal antibody well blanks. All reactions were performed in triplicate. 
The 'minus serum' blanks and the 'minus antibody' blanks were ~ 10% of 
the positive standard. The 'minus serum' and individual 'minus antibody' 
blanks were subtracted from the mean of the triplicates of their respective 
serum readings. 
1 2 3 4 5 6 7 8 9 10 11 12 I 
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B Bl SA1 PLE!h 
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Bl = minus serum blanks 
Figure 7.2: ELISA template 
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7 .3.3 Interpretation of results 
The OD ratio of the average of the positive control to the average of the 
negative control was calculated and varied from 2.0: 1.0 to 2.5: 1.0. The 
Km(3) positive standard Rl 113 gave a higher signal than the Rl 110 positive 
standard. 
The on-board software of the Anthos Labtec ELISA Reader was used to 
make a qualitative evaluation of the OD using programmed cut-offs to 
generate positive, negative or indeterminate results. Initially all unknown 
samples that gave an average OD that was greater than that of Rll 10 were 
interpreted as being positive for the Km(3) marker and samples were 
considered negative only if the average OD of the sample was below the 
highest single reading of the negative control Rl 118. 
A titration of R 1110/R 1118 mixture was performed in an attempt to type 
samples whose ODs fell inbetween the positive and negative control values. 
The results of a titration of mixtures from 1 % to 100% positive is shown in 
Figure 7.3. 
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Figure 7.3: Km(3) ELISA titration curves of the positive standard RlllO (•), the 
negative standard Rl 118 ( +) and mixtures of the positive:negative controls ranging 
from 50% to 1 %: 1:1 (*); 2:3 (D); 1:4 (x); 1:9 ( <> ); 1:19 (~) and 1:99 (o) 
The mean OD, SD, 2SD range and inter-assay CV were calculated from 10 
runs done over four weeks on the 1 % , 5 % and 20 % control mixtures, 10 
child control samples whose ODs fell between the positive and negative 
control values and 10 negative samples. From this data three clearcut 
groups could be distinguished (Figure 7.4). Samples with ODs below that 
of the 5 % control mixture were considered negative for the marker; 
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samples with ODs greater than that of the 20% control mixture were 
considered positive for the marker and those samples with ODs falling in 
between the 5 % and 20 % control mixture were classified as non-typable. 
Thus additional controls of a 5% and 20% mixture of Rll 10:Rll 18 were 
included in each run. All samples falling into the negative or non-typable 
groups were repeated and if they remained in these groups they were 
classified as such. Of 411 healthy controls assayed for the Km(3) allotype 
only 3.4% were non-typable and 3.2% Km(3) negative using the above 
criteria. 
Q5,.. .................................................................................. -................................ . 
Q5,.. ............................................................................ --............................. . 
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lllltrd Sffa 
Figure 7.4: Mean + /- 2 standard deviations (SD) of optical density of the positive 
control RlllO, the negative control Rl118 and 1 %, 5% and 20% mixtures of the 
positive and negative controls 
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7.4 ASSAY STANDARDISATION 
7.4.1 Precision 
The inter-assay coefficient of variation was 5. 95 % . This was calculated 
from the ratio of the positive to negative control over 23 consecutive runs. 
If the ratio of the positive to negative control (Rl 110:Rl 118) was not in the 
range of 2.1-2.5:1 the run was repeated. 
The results of ten specimens (2 negative, 8 positive) measured in the Km(3) 
ELISA correlated with the results obtained from the haemagglutination 
inhibition method done in Dr G de Lange's Laboratory, CLB Netherlands. 
7 .4.2 Specificity 
7.4.2.1 
The specificity of the assay was further assessed by an inhibition ELISA 
comparing the Km(3) positive reference serum Rl 113 against the Km(3) 
negative reference serum Rl 117 and Km(3) +ve light chain protein isolated 
from Bence-Jones Protein from the urine of a patient with multiple myeloma 
whose serum tested positive for Km(3) with the rabbit anti-human Km(3) 
antibody. 
Purification of light chains 
The light chains were separated by Fast Performance Liquid 
Chromatography (FPLC) using a Superose 6 (Pharmacia 17-0489-01) 
column. Alternating fractions #20-42 of the first peak emerging from the 
column were analysed by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) using a 10% discontinuous gel according to the 
method of Laemmli (1970). Samples were diluted 1/2 in 0.0625M Tris-
HCL (pH 6.8), 5% 2-mercaptoethanol, 2.5% SDS, 20% glycerol and 
0.001 % bromophenol blue. The proteins were then denatured by boiling 
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for 5 minutes. Separation of the samples (2-8 µg of protein per slot), was 
performed at constant voltage for 4 hours. The gel was stained with 
Coomassie Blue R250 and decolourised with glacial acetic acid/ethanol and 
dried using a Hoeffer Gel Dryer (Hoeffer SE S40). Low molecular weight 
markers (Pharmacia, Catalogue No 17-0446-61) were included and the 
molecular weight of the bands calculated. A band of 27 KD molecular 
weight corresponding to that of immunoglobulin light chains was evident 
from fractions #30 to #42 (Figure 7.5). Purified light chains in fraction #42 
were used in the inhibition ELISA. 
94 
67 
43 
30 
20 
1 2 3 4 5 6 7 8 9 
Figure 7.5: SOS-PAGE 10% discontinuous gel electrophoresis of Km(3) light chain 
proteins isolated from Bence Jones protein. Lane 1: low molecular markers; Lanes 2-
9: (#28,30,32,34,36,38,40 and 42) (2-8 µg protein/slot) 
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7.4.2.2 Competitive inhibition ELISA 
Binding of the Km(3) antibody to wells coated with both the positive control 
Rll 13 or purified light chains at a coating concentration of (1.25 µg/ml) 
could be inhibited by absorption with the isolated light chain protein (Figure 
7.6) or (Table 7.2). This coating concentration of light chains was selected 
as it gave a signal equivalent to the mean of the positive controls. The 
negative control R 1117 was unaffected in the inhibition ELISA. The 
competitive inhibition ELISA was carried out as described in 7.3.1 except 
that the Km(3)+ve light chains in concentrations ranging from 5 µg/ml -
0.08 µg/ml were mixed with rabbit Km(3) antibody (1:250) and added 
immediately to the plate. 
100 % inhibtion 
80 
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Figure 7.6: Competitive inhibition of Km(3) antibody with Km(3) positive light chains 
(•) and Km(3) positive sera Rl113 ( +) 
SECTION A: Chapter 7: Km(3) lmmunoassav 234 
TABLE 7.2: COMPETITIVE INHIBITION OF Km(3) ANTIBODY 
% INHIBITION OF UNABSORBED READING 
Purified Light 
Chains R1113 Purified Light Chains 
Positive 
Control 
5 µg/ml 45 78 
2.5 µg/ml 39 68 
1.25 µg/ml 29 51 
0.64 µg/ml 24 39 
0.32 µg/ml 16 25 
0.16 µg/ml 12 23 
0.08 µg/ml 11 18 
7.5 SUMMARY 
Most population studies have included only Km(l) allotyping due to the 
scarcity of sera with anti-Km(2) and anti-Km(3) activity (Steinberg 1969). 
The most commonly used method of Km(3) typing is the haemagglutination 
inhibition method although Lima and Newall (1990) reported an ELISA to 
identify Km(3) from dried blood stains. This assay has been successfully 
used to determine the presence or absence of the Km(3) allotype in human 
sera. The principle of the ELISA described by Lima and Newall (1990) is 
similar to the method described in this chapter with the test samples and 
controls coated on to the plates and revealed with a polyclonal antibody. 
The concentration of antigen coated onto the plate can not be compared 
since the sample was extracted from blood stained material and a 1 :300 
dilution made. The incubation time for coating was also short - 30 minutes. 
In both assays the ratio of the positive to negative controls was 2: 1. 2 % 
BSA with 0.05% Tween was used in this assay whereas 1 % BSA with 
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0.005% Tween was used Lima's assay. Blocking could be achieved at 37°C 
for 45 minutes instead of 4 °C overnight. Lima and Newall (1990) used the 
same antibody as in this assay but at a dilution of 1: 100. The assay 
described here could be performed in two and a half hours compared to 2 
days for the reported assay. 
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CHAPTER 8 
LITERATURE REVIEW 
The following review is divided into three sections. The first will cover the diseases Hib 
meningitis, Hib osteomyelitis/septic arthritis and Staphylococcus aureus 
osteomyelitis/septic arthritis (OM/SA). The epidemiology of the disease, the organisms 
and the immune response to these bacteria will be discussed. The second section reviews 
IgG subclasses, IgG subclass deficiency and regulation. Lastly, genetic susceptibility with 
particular reference to Gm and Km allotypes, C4B complotypes and mannose binding 
protein will be discussed. 
8.1 
8.1.1 
8.1.1.1 
ORGANISMS/DISEASE 
Haemophilus injluenzae type b (Hib) meningitis 
Epidemiology/incidence 
• Hib meningitis 
Rib, Streptococcus pneumonia and Neisseria meningitidis are the 
major aetiological pathogens in septic meningitis. There has been 
little change in the incidence of infection with each of these 
organisms over the past few decades and although mortality rates 
have declined, significant morbidity still occurs. 
Hib meningitis is a significant cause of morbidity and mortality in 
developed and developing countries (Ward and Cochi 1988). The 
reported incidence of Rib meningitis in children less than 5 years of 
age varies from 20-30 cases/100 000/year in England, the 
Scandinavian countries and the United States (Makela et al 1992) to 
150 - 450/100 000/year among native American, Alaskan or 
Australian populations. A recent study from South Africa (Hussey et 
al 1994) indicates that the overall incidence is similar to the USA and 
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Europe. However, the incidence is higher in Blacks and is similar to 
that from Gambia (300 cases/ 100 000/year in children less than 1 
year) (Table 8.1). The disease is more common in a poor socio-
economic setting. 
TABLE 8.1: INCIDENCE RATE PER 100 000 POPULATION 
FOR CHILDREN WITH Hib MENINGITIS IN DEVELOPED 
AND DEVELOPING AREAS OF THE WORLD 
LOCATION ANNUAL INCIDENCE/ REFERENCE 
100 000 POPULATION 
< 1 year < 5 years 
South Africa Hussey et al 1994 
Overall 112 34 
Black 210 50 
Coloured 113 27 
White 103 25 
Sweden 31 Bijlmer 1991 
UK - Oxford 25 Booy et al 1993 
USA 120-130 19-67 Bijlmer 1991 
Alaskan Eskimos 871 782 Ward et al 1986 
Najovo Indians 81 152 Bijlmer 1991 
Gambia 297 60 Bijlmer et al 1990 
Australia 450 Bijlmer et al 1990 
Aborigines 
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• Age and Sex 
Age is the most important risk factor for invasive Hib disease. The 
peak incidence of disease caused by Hib occurs between the age of 6 
months and 12 months in both the developed (Madore et al 1990) and 
developing world (Hussey et al 1994). In the developed world 50% 
of Hib infections occur in children under 1 year of age whereas in 
developing countries more than 80% of cases occur in this age 
group. 
Early occurrence of Hib disease occurs in the same populations that 
have a high incidence of the disease. Hib meningitis and septic 
arthritis are the most serious manifestations. Epiglottitis is a serious 
complication of Hib disease that usually occurs after 2 years of age. 
Epiglottitis in older children is rare in areas where almost all Hib 
disease is seen in children ::; 2 years of age. 
The sex distribution of invasive Hib disease shows a male 
predominance (Cochi et al 1985; Takala et al 1989; Gervaix and 
Suter 1991). 
• Race 
The incidence of Hib disease is higher among Blacks than Whites in 
the USA and South Africa (Ward and Cochi 1988; Hussey et al 
1994). The incidence of Hib meningitis in Coloured children in 
Cape Town is similar to that of White children in Cape Town and 
White children in the USA and Europe prior to immunization 
(Hussey et al 1994). Other ethnic groups at increased risk include 
Hispanics, Apache and Navajo Indians and Alaskan Eskimos 
(Hetherington and Lepow 1987; Ward and Cochi 1988). 
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• Socioeconomic 
Risk factors for primary invasive Hib disease include factors that 
increase exposure to Hib (day care attendance, presence of siblings, 
over crowded households and poverty) and factors that increase an 
individual's susceptibility to Hib infections (short duration of breast 
feeding, parental smoking and frequent infections in general) (Takala 
and Clements 1992). 
• Nutrition 
Nutritional status has not been associated with an increase risk of 
invasive disease. Rosen and Davis (1980) found no association 
between meningitis and malnutrition and this was confirmed by 
Mulla et al (1984) who found that malnourished children are not any 
more prone to develop pyogenic meningitis from H.influenzae, 
pneumococcus or meningococcus than well nourished children. 
Organism 
H. injluenzae is a gram negative pleomorphic coccobacillus which was first 
isolated by Pfeiffer in 1892. Man is the only natural host. In the 1930's 
Margaret Pittman defined two major groups of H. influenzae: encapsulated 
(typable) and unencapsulated (non-typable). Encapsulated isolates are 
surrounded by polysaccharide capsules which are distinguished serologically 
and are classified into six types, designated a to f depending on the basic 
sugar found in the capsule. Type b (Hib) is the most important pathogen 
and is responsible for more than 95 % of invasive childhood haemophilus 
infections (Table 8.2). 
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8.1.1.3 
TABLE 8.2: SPECTRUM OF H.INFLUENZAE DISEASE 
Invasive disease: (predominantly type b (95%)) 
Meningitis 
Epiglottitis 
Pericarditis 
Cellulitis 
Bacteraemia 
Empyema 
Septic arthritis 
Osteomyelitis 
Pneumonia 
Non-Invasive disease: (predominantly due to nontypable or non-type b 
strains) 
Bronchitis 
Sinusitis 
Otitis media 
Urinary tract infection 
The number of cases of other forms of invasive Hib disease (such as 
pneumonia, epiglottitis, cellulitis, arthritis, pericarditis) appears to be 
similar to the number of cases of Hib meningitis (Hill 1983). 
Immunity 
Natural immunity to Hib is multifactorial and involves the functioning and 
integration of many components of the immune system including: i) 
mucosal immune factors ii) humoral antibodies iii) complement mediated 
activation of inflammatory responses and opsonization iv) phagocytosis and 
killing by macrophages and polymorphonuclear cells and v) T-cell mediated 
immune functions. The mechanisms which determine the natural acquisition 
of anti-PRP antibodies is not completely understood. Most individuals 
acquire protective immunity in the first few years of life without ever having 
developed Hib disease. This naturally acquired immunity develops as a 
result of pharyngeal colonization with Hib as well as asymptomatic 
colonization of the gut with normal enteric flora that are antigenically cross 
reactive with Hib (e.g. E.coli KlOO) (Schneerson and Robbins 1975). 
H. injluenzae has at least 3 kinds of immunogenic surface components i.e. a 
polysaccharide capsule (PRP), outer membrane proteins (OMP) and 
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lipopolysaccharide (LPS). Although humans exposed to Hib may respond 
with serum antibody production to all three kinds of surface components, 
antibody to PRP appears to be most important in protection from Hib 
infection (Musher et al 1986). Antibody to Hib PRP is opsonic and 
bactericidal in the presence of complement and protective in humans and 
animals (Schreiber et al 1986). This polysaccharide capsule is composed of 
a linear polymer of ribose ribitol and phosphate [(-3) B-D-ribose (1-1) 
ribitol (5-phosphate -)] abbreviated PRP. 
The protective role of antibody to LPS or OMP is incompletely understood 
(Granoff and Rockwell 1978; Marks et al 1982; Kimura et al 1985). 
The importance of antibodies in providing protection against invasive Hib 
disease is suggested by the inverse relation between the age specific risk of 
Hib infection and the levels of naturally acquired Hib antibodies observed 
during the early years of life (Hall et al 1987). Very few children between 
the ages of 3 months and 18 months acquire Hib PRP antibody (Kayhty et al 
1981; Ward et al 1981; Claesson et al 1988). Newborns usually acquire 
transplacental bactericidal IgG antibodies but these antibodies wane in the 
early months of life and their loss is coincident with the marked increase in 
the risk of Hib disease. Production of PRP antibody is influenced by a 
variety of factors including age of the individual, and the type and duration 
of antigen exposure. The serum concentration of PRP antibody necessary 
for protection is not precisely known but is estimated to be 0.15-1.0 µg/ml 
(Kayhty et al 1983b). 
Natural acquisition of anticapsular antibodies starts after 2 years of age when 
the child's immune system becomes mature enough to respond to Hib 
polysaccharide and corresponds to a rapidly decreasing incidence of Hib 
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disease. Alaskan children who present with the disease at younger ages 
develop higher levels of antibody at earlier ages, a finding that suggests 
earlier and greater exposure to antigen stimulation (Ward et al 1981). The 
age dependent pattern of infection could thus be explained by the pattern of 
acquisition of specific anti-Hib antibodies. It is hypothesized that genetic 
factors contributing to impaired or delayed synthesis of anti-Hib antibodies 
could increase susceptibility to the disease and that the higher incidence in 
some populations might be due to a high prevalence of particular antibody 
genotypes. 
8.1.2 Hib osteomyelitis/septic arthritis (OM/SA) 
8.1.2.1 
There is experimental evidence suggesting that osteomyelitis and septic 
arthritis are manifestations of the same disease process in infants and 
children (Alderson et al 1986). Acute haematogenous OM/SA is a 
consequence of a bacteraemia or septicaemia which leads to gross 
destruction of the metaphysis, growth plate and epiphysis (Alderson et al 
1986). Although the pathogenesis of the two illnesses is similar, the site of 
initial infection and local anatomical and cellular defence mechanisms may 
affect the clinical presentation. In this study acute bone and joint infections 
have been considered as a spectrum of the same disease. 
Epidemiology Ii ncidence 
Septic arthritis accounts for 5-8 % of all Hib systemic disease in children 
(Dajani et al 1979) and is the most common cause of septic arthritis in 
infants under 2 years of age (Nelson 1972; Lebel and Nelson 1988). In 
reviews of childhood osteomyelitis the incidence of Hib infections varied 
from O to 6. 7% with a mean of 1.9% (Lebel and Nelson 1988). The 
majority of patients were less than 30 months of age which is similar to the 
distribution of Hib meningitis infection, but contrasts to the age distribution 
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8.1.3 
8.1.3.1 
of S.aureus OM/SA where 50% of children are older than 2 years (Fink and 
Nelson 1986). Males are more commonly affected (2.3: 1) (Dich et al 1975; 
Rotbart and Glode 1985; Hoffman et al 1990). Acute osteomyelitis of 
children frequently affects the femur and tibia (Nade 1983a) and acute septic 
arthritis usually involves the hip and knee joints (Nade 1983b ). 
Immune response 
The immune response to Hib OM/SA arthritis is presumably similar to that 
seen in Hib meningitis but this had not been extensively studied. 
S.aureus osteomyelitis/septic arthritis (OM/SA) 
Epidemiology/incidence 
Acute haematogenous OM/SA 1s predominantly a disease of children. 
S.aureus is the major aetiological agent accounting for about 70% of cases. 
In the Western Cape the incidence of acute osteomyelitis (all S.aureus) and 
septic arthritis (predominantly S. aureus and H. influenzae) is five times 
higher than that reported from developed communities (Hoffman et al 
1990). The reason for this high incidence in the Western Cape is not 
known. 
Little is known of specific risk factors predisposing to oesteomyelitis. A 
review assessing the importance of possible risk factors (age, sex, genetic, 
socioeconomic, distant foci of infection, minor trauma) based on pathogenic 
mechanisms of osteomyelitis detected no such factors (Wald 1985). In some 
diseases such as sickle cell anaemia, the haemoglobinopathies and chronic 
granulomatous disease a predisposition to osteomyelitis is recognised. 
Males are more often affected 2-3: 1 (Dich et al 1975; Hoffman et al 1990). 
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8.1.3.3 
Organism 
S. aureus 1s a gram positive coccus occurring m pairs, short chains and 
clusters. S. aureus is one of the earliest recognized and most studied human 
pathogens. This organism is a common cause of invasive infections in both 
normal and abnormal hosts, and causes a number of toxin mediated diseases. 
Staphylococcal infections in children range from mild furuncles to severe 
disseminated septicaemia and the toxic shock syndrome (Cohen 1986). 
S.aureus commonly colonizes the skin and mucous membranes and can 
cause a variety of severe infections such as septicaemia, pneumonia, 
endocarditis, osteomyelitis and arthritis (Sheagren 1984). 
Immunity 
The major components of the cell wall of S.aureus are peptidoglycan (50%), 
ribitol teichoic acid (TA) (40%) and protein A (5%). Peptidoglycan consists 
of alternating links of N-acetyl glucosamine and N-acetylmuramic acid. 
Attached to the carboxyl group of each N-acetylmuramic acid is a 
tetrapeptide cross-linked by a pentaglycine bridge to a neighbouring unit. 
S. aureus teichoic acid has either ex or I3 linked N-acetyl-glucosamine 
residues in contrast to teichoic acid of other gram positive organisms which 
is usually composed of glycerol residues. Protein A binds non-specifically 
to IgG heavy chains. 
The interactions of staphylococci and host defences are not completely 
understood. The occurence of antibodies to S.aureus cell wall determinants 
including peptidoglycan, teichoic acid and capsule (Verburgh et al 1981; 
Granstrom et al 1983; Wilkinson 1983) are widespread in humans. 
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Antibodies against many staphylococcal antigens occur in sera from healthy 
subjects as well as from patients with infections other than those caused by 
S.aureus (Ryden et al 1990). This can be explained by the fact that some 
antigens are commonly shared in gram positive bacteria. 
Serology to several antigens such as: extracellular toxins (e.g. alpha-toxin, 
beta-toxin, gamma-toxin and leucocidin) extracellular enzymes (e.g. 
nuclease, coagulase, staphylokinase and lipase); as well as cell surface 
components (such as teichoic acid, lipoteichoic acid and peptidoglycan) have 
been proposed for the diagnosis of staphylococcal infections (Ryden et al 
1990). S.aureus has a unique teichoic acid (a polymer of ribitol) as part of 
its cell wall. Teichoic acid antigens are in themselves poor immunogens, 
but when bound to peptidoglycan incite specific antibody formation. 
Antibody production to teichoic acid has been used as an aid to the diagnosis 
of staphylococcal infections. In adults with staphylococcal infection, sera 
containing teichoic acid antibodies (Granstrom et al 1983; Wheat et al 1984; 
Hammarstrom et al 1985) suggest that these antibodies are important in the 
defence against microorganisms. 
Teichoic acid antibody may rise significantly during staphylococcal 
bacteraemia. Following invasive S.aureus infection, antibody to teichoic 
acid can be detected within 11-12 days. Titres begin to decline within 2-4 
weeks after appropriate treatment and antibody is undetectable 2-5 months 
post infection (Tuazon and Sheagren 1976). 
Uncomplicated bacteraemia or non-bacteraemic S.aureus infections either do 
not stimulate an antibody response or produce a low titre. 
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Antibodies against teichoic acid have been demonstrated in patients with 
various staphylococcal infections especially endocarditis and osteomyelitis 
(Crowder and White 1972; Tuazon and Sheagren 1976; Mackowiak and 
Smith 1978; Wheat et al 1978; Tenebaum and Archer 1980; Gramstrom et 
al 1983; Julander et al 1983; White et al 1983; Wheat et al 1985; Jacob et al 
1987). 
Tests which have been used to measure teichoic acid antibody include 
counterimmunoelectrophoresis (CIE), ELISA, solid phase RIA and agar gel 
diffusion (Tuazon and Sheagren 1976; Wheat et al 1978; Mackowiak and 
Smith 1978; Granstrom et al 1983). The latter test has been the most widely 
used as it is commercially available and easy to use. Thisyakorn et al 
(1984) compared the sensitivity of gel diffusion and ELISA for the detection 
of teichoic acid antibodies in the serum of children with staphylococcal 
infections and found the latter to be superior. 
Sera from healthy children and adults contain teichoic acid antibodies 
(Granstrom et al 1983; Wheat et al 1986). Thus for optimal results the 
antibody levels of patients should be compared to age matched controls. 
Granstrom et al (1983) found that using age-correlated normal values their 
ELISA was a sensitive and specific diagnostic method for various 
staphyloccal infections. 
lgG SUBCLASSES (ISOTYPES) 
IgG isotype restriction and functional differences between the IgG subclasses 
have important implications in host defences and disease. Deficiencies can 
be manifested either as a deficiency of the IgG isotype or as an inability to 
make antibodies of a particular subclass to antigens despite normal 
concentrations of that isotype. 
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The inability to produce antibodies of the appropriate IgG subclass or to 
produce enough to protect against infection may lead to increased 
susceptibility to infection. 
Although the exact role of the IgG subclasses is still unknown it is of 
interest that a predominance of one or other of the IgG subclasses is 
specifically stimulated in the IgG responses to defined antigens. Anti-
carbohydrate antibodies are relatively restricted to the IgG2 subclass while 
antibodies to protein antigens are mainly of the IgG 1 subclass. 
8.2.1 Introduction 
Human IgG subclasses were first mentioned in 1960 by Dray (1960). Using 
antisera against normal human IgG that were prepared in rheseus monkeys, 
and adsorbed with selected IgG myeloma proteins he was able to 
discriminate between three antigenically different components of IgG. A 
few years later Terry and Fahey (1964) and Grey and Kunkel (1964) showed 
that there were four subclasses of IgG. These four subclasses were officially 
recognised in a World Health Organization publication (1966) and termed 
IgG 1, IgG2, IgG3 and IgG4. 
The basic immunoglobulin molecule is a four chain structure composed of 
two identical heavy chains and two identical light chains. Each chain is 
made up of a genetically distinct variable region and a constant region. 
Antibodies are categorised into their various isotypes depending upon which 
heavy chain constant region gene is utilized. In humans these isotypes are 
IgM, IgD, IgAl, IgA2, IgE and four IgG subclasses IgGl, IgG2, IgG3 and 
IgG4. Each represents the product of a specific gene that encodes for the 
constant region of human immunoglobulin heavy chains. The four IgG 
subclasss are antigenically distinct and have different physiochemical 
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properties. Subclasses of human IgG differ in their biologic activities. 
IgG 1, IgG2 and IgG3 fix complement whereas IgG4 does not. Although 
IgG2 is less able to activate the classical and alternative complement 
pathway, it is capable of doing so when the antibody and antigen ratio is 
high (Valim and Lachmann 1991). Three types of Fe gamma receptors (Fe 
'Y R) with different tissue distribution and physiological roles have been 
described on the basis of immunochemical and physiochemical differences: 
Fe 'Y Rl (CD 64), Fe 'Y Rl 1 (CD 32) and Fe 'Y Rl 11 (CD 16). Fe 'Y Rl la 
occurs in two allelic forms defined as low responders which interact with 
IgG2 and high responders which do not (Warmerdam et al 1991; Jefferis et 
al 1994) (Figure 8.3). This may prove to be of clinical significance for 
protection against encapsulated bacterial sepsis as IgG2 is the predominant 
subclass produced in response to bacterial polysaccharide antigens. The 
relative functional activities of each of the different IgG subclasses is not 
fully established. 
TABLE 8.3: PROPERTIES OF IgG SUBCLASSES 
ISOTYPE IgGl IgG2 lgG3 IgG4 
Proportion of total IgG 60-70% 15-25% 5-10% 3-6% 
Complement binding +++ + +++ 0 
Placental transfer ++ + ++ ++ 
t 1/2 (days) 21-23 20-23 7-8 21-23 
Specific antibody responses 
Tetanus toxoid +++ + + ++ 
Polysaccharides ++ +++ + (+) 
Blocking activity in 0 0 0 + 
allergy 
Binding to Staph + + 0 + 
protein A 
Fe receptor binding 
Fe 'Y Rl +++ 0 +++ ++ 
Fc'YRlla 
Low responder + + + 0 
High responder + 0 + 0 
Fc'YRlll + 0 + 0 
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8.2.1.1 Factors affecting nonnal development and expression of IgG subclasses 
• Antigen restriction 
In view of the biological differences among the IgG subclasses, it is 
not surprising that the IgG subclasses may be selectively produced. 
Although antigenic stimulation may potentially give rise to antibody 
of any IgG subclass it is usually restricted to one or two subclasses 
depending on the type of antigen. IgG 1 and IgG3 generally respond 
to the protein antigens of bacteria, viruses, vaccines and foods. IgG2 
antibodies are predominantly stimulated by carbohydrate antigens and 
are important in protection against polysaccharide encapsulated 
organisms such as Streptococcus pneumoniae, H. influenzae and 
Neisseria meningitidis. 
• Maturational delay 
Each IgG subclass has an individual pattern of development with 
IgG 1 and IgG3 attaining adult levels at an early age whereas adult 
levels of IgG2 and IgG4 are not reached until adolescence. It is 
speculated that the delayed ability to produce an immune response to 
carbohydrate antigens is linked to this late maturation of IgG2. In 
children IgG2 deficiency is predominant whereas in adults IgG3 
deficiency is more common (Hanson et al 1988). 
• Race 
Several studies have reported racial differences of IgG subclass 
values. Shackelford et al (1985b) found Blacks had higher IgG, 
IgG 1 and IgG2 concentrations than Whites. In contrast, Ambrosino 
et al (1991) found the IgG 1, IgG2 and IgG4 subclass concentrations 
of Black children were lower than those of White children. 
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• Sex 
IgG subclass deficiencies are reported to be more common amongst 
boys than girls but are more frequent in woman than men (Hanson et 
al 1988). This shift occurs around puberty suggesting that additional 
factors e.g. hormones, may affect IgG subclass levels. 
• Linkage 
The genes encoding IgG2, IgG4, IgA, IgE and IgD are closely 
linked. It follows that structural or regulatory defects on a genomic 
transcriptional or translational level may affect one or more of these 
closely related immunoglobulins. It is interesting that the physical 
relationship of the IgG subclasses on the genomic level is compatible 
with the combined IgG subclass deficiencies most frequently found in 
patients. In humans, the 5' - 3' CH region gene order is Cµ, C0, 
Cy 3, c,, 1, Ca 1, c,,2, c,,4, CE, Ca2· IgG2 deficiency is often 
associated with low IgG4 levels and selective IgA deficiency and 
may reflect this close linkage of the heavy chain genes (Oxelius et al 
1981). 
• Genetic factors 
Gm allotypes are genetic markers resulting from inherited amino acid 
differences in the IgG subclasses. The frequency of these 
immunoglobulin alleles varies between population groups, and Gm 
allotypes may influence the serum IgG subclass levels (Oxelius 
1990b) thereby affecting normal ranges for IgG subclasses in 
different population groups. 
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8.2.1.2.1 
IgG subclass deficiency has been reported in two patients with 
defective expression of MHC class II antigens (Bremard-Oury et al 
1986). 
• Environmental factors 
Environmental factors are also likely to influence the IgG subclass 
values. Repeated exposure to antigens is likely to stimulate the 
production of antibodies of a particular subclass more than would 
otherwise be expected. Egyptian patients with schistosomiasis have 
high concentrations of IgG4 (lskander et al 1981). 
IgG subclass deficiency 
The field has been extensively reviewed - Heiner 1987; Ochs and 
Wedgwood 1987; Schur 1987; Morgan and Levinsky 1988; Hanson et al 
1988; Jefferis and Kumararatne 1990; Morell 1990; Scott et al 1990; Smith 
1992. 
Deficiencies of individual subclasses of IgG were first described over 20 
years ago. IgG subclass deficiencies are increasingly being recognized as 
significant entities within the spectrum of antibody-deficiency syndromes. 
The exact prevalence and clinical significance of IgG subclass deficiencies 
is not accurately known but they do appear to be relatively common (Schur 
1987; Jefferis and Kumararatne 1990). Persons with immunoglobulin 
subclass deficiency range from healthy individuals to those with severe 
recurrent infections. 
Disease associations 
Many associations between IgG subclass deficiencies and disease conditions 
have been suggested (Table 8.4). 
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TABLE 8.4: ASSOCIATION OF ABNORMAL SERUM IgG 
SUBCLASS LEVELS AND DISEASE 
Infections 
Recurrent infections with 
capsulated bacteria 
Otitis media in children 
AIDS 
Allergic disease 
Bronchial asthma 
Atopic eczema dermatitis 
Allergy 
Autoimmune diseases 
Neurologic disorders 
Ataxia telangiectasia 
Frederich's ataxia 
Miscellaneous immunodeficiencies 
C3 deficiency 
IgA deficiency 
Adenosine deaminase deficiency 
Change in IgG subclass 
+ IgG2/IgG4 
+ IgG2, + IgG2 specific 
antibodies to pneumococcus 
Variable subclass deficiencies 
+ IgG2/IgG3/IgG4; t IgG4 
t IgG4 
t IgG4 
+ IgG2 
+ IgG2/IgG4 
+ IgG3 
+ IgG2 
+ IgG2/IgG4 
+ IgG2 
Patients with an IgG subclass deficiency commonly show an increased 
frequency of infections especially in the respiratory tract, including sinusitis, 
otitis media and bronchopneumonia, but also osteomyelitis, meningitis, 
septicaemia and various skin infections (Hanson et al 1988). 
The importance of IgG subclass immunity to bacteria with polysaccharide 
capsular antigen is suggested as patients with decreased concentrations of 
IgG subclasses in the blood, especially IgG2 and/or IgG4 are more likely to 
SECTION B: Chapter 8: Literature Review 253 
8.2.1.2.2 
have recurrent infections than healthy persons with normal levels (Schur et 
al 1970; Oxelius 1984; Stanley et al 1984; Freijd et al 1984; Shackelford et 
al 1986, 1990; Hanson et al 1988; Moss et al 1992). 
Lack of IgG2 has been shown to be related to low concentrations of 
antibodies against polysaccharides (Siber et al 1980; Insel and Anderson 
1986b) and this might explain the relationship between IgG2 deficiency and 
infection with polysaccharide encapsulated bacteria. However, a number of 
observations show that decreased concentrations of IgG2 are not strictly 
related to recurrent infections (Hammarstrom and Smith 1983; Out et al 
1986; Hammarstrom et al 1987; Nahm et al 1990). 
Beard et al (1990a) found that impaired antibody production may be a 
predisposing factor m osteomyelitis/septic arthritis in children. 
Osteomyelitis has been reported in association with IgG2 subclass deficiency 
(Gottsegen 1987) and in an IgG4 deficient patient (Heiner et al 1988). 
Carbohydrate specific antibody responses 
It is known that the four IgG subclasses may have different affinities for an 
antigen (Persson et al 1988; Devey et al 1989). 
Ideally it is desirable to measure antibodies against a range of bacterial 
antigens in order to obtain an insight into the immune competence of 
patients. This also permits a distinction to be made between specific 
antibody defects found in subjects with normal IgG subclass concentrations 
(Ambrosino et al 1987, 1988; Herrod et al 1989) and IgG subclass 
deficiencies of a more general type (Hammarstrom et al 1987). 
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The interaction of carbohydrate antigens with the immune system has a 
number of unusual characteristics. Responses to protein antigens are 
polyclonal, probably reflecting the many unique epitopes of these molecules. 
Polysaccharide antigens in contrast are large molecules with repeating 
determinants and relatively few epitopes. Antibodies to polysaccharides 
have been found to be oligoclonal rather than polyclonal. The influence of 
T-lymphocytes is limited and multiple exposure to antigen does not 
necessarily lead to a secondary immune response. The age intervals of 
natural immunity to carbohydrate antigens differs from most protein antigens 
(Briles et al 1987). IgG anti-polysaccharide antibodies are mainly of the 
IgG2 subclass. This subclass matures later than the other subclasses, 
resulting in a physiologic immunodeficiency up to 18-24 months of age or 
beyond. 
Antibody against the polysaccharide capsule of Hib has been shown to play a 
major role in protection against invasive Hib disease. This protection 
correlates with the presence of serotype-specific antibodies against bacterial 
capsular PRP (Schreiber et al 1986). 
Whether induced by infection or by immunization with PRP or PRP 
conjugate vaccines, the antibody response to PRP is clonally restricted (Insel 
et al 1985). Most people express a predominant idiotype (Hib idiotype -1 
[Hib Id-I]) in the antigen-binding site of PRP-specific antibody (Lucas 1988; 
Lucas and Granoff 1990) reflecting the response of the VII A2Z light chains 
to PRP. 
Several early studies have indicated that human polysaccharide antibodies 
(lgG) are predominantly IgG2 (Yount et al 1968; Barret and Ayoub 1986). 
The restriction of anti-carbohydrate antibodies to IgG2 is not absolute. 
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Recent reports indicate that after natural infections the IgG antibody 
response to some polysaccharide antigens is composed of IgG 1 and IgG2 
antibodies (Lane and MacLennan 1986; Claesson et al 1988). Most adults 
vaccinated with Hib or meningococcal group A polysaccharide develop 
substantial amounts of IgG 1 as well as IgG2 antibody (Rautonen et al 1986; 
Makela et al 1987; Shakelford et al 1987; Granoff et al 1988a) whereas 
pneumococcal IgG antibodies (types 2, 14 and 18c) are predominantly IgG2 
(Sarvas et al 1989). 
Immunization with Hib PRP covalently bound to a protein carrier shifted the 
polysaccharide specific IgG subclass from predominantly IgG2 to a mixture 
of IgG 1 and IgG2. This suggests that a switch from one activating pathway 
to another may have occurred. 
Children show predominantly IgG 1 responses to Hib polysaccharide 
(Granoff et al 1988b; Kayhty et al 1988) whereas adults produce both IgGl 
and IgG2 responses (Makela et al 1987; Shackelford et al 1987; Granoff et 
al 1988a; Seppala et al 1988). 
T-cell Influences 
One of the most fundamental concepts regarding an antibody response is that 
the amount of antibody produced is regulated by T-lymphocytes. Although 
it is clear that T-helper and T-suppressor cells control the antibody response 
to some bacterial polysaccharides, (meningococcal type A, type III 
Streptococcus pneumonia) it is not known whether this regulation is common 
to other clinically relevant bacterial polysaccharide antigens. The 
mechanisms by which T-suppressor and T-helper cells are activated and their 
exact mode of functioning remains unclear. 
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T-helper cells and/or their secreted cytokines regulate (i) the magnitude of 
the immune response; (ii) the isotype switch in immunoglobulin classes 
(IgM to IgG); (iii) the affinity maturation of antibody and (iv) the memory 
capacity (Abbas et al 1991). 
T-dependentand independent responses 
Based on T-cell involvement in antibody synthesis, antigens can be classified 
as thymus dependent (Td) or thymus independent (Ti) immunogens. Ti 
antigens are capable of activitating B-cells without T-cell help to produce 
mainly IgM antibody with few memory B-cells. Td antigens elicit stronger, 
earlier antibody responses, produce IgG antibody and induce memory cells 
(Stein 1992) (Table 8.5) 
Antibodies to protein antigens tend to be T-cell dependent and are usually 
IgG 1 and/or IgG3. Antibodies to carbohydrate antigens and polysaccharides 
including bacterial capsules tend to be T-cell independent and are usually 
IgG2 (Yount et al 1968; Freijd et al 1984; Barrett 1985). There is evidence 
that although T-cells are not required for the initiation of the antibody 
response they can influence the magnitude of the anti-polysaccharide 
response (Baker et al 1981). 
Capsular polysaccharide antigens cannot be processed by antigen presenting 
cells and alpha beta T-cell receptor bearing T-cells cannot recognise 
carbohydrate epitopes. There is some evidence that gamma/delta T-cell 
receptor bearing T-cells may respond to carbohydrate antigens. 
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TABLE 8.5: PROPERTIES OFT-CELL DEPENDENT AND T-CELL 
INDEPENDENT ANTIGENS 
T-DEPENDENT T-DEPENDENT 
TYPE 1 TYPE II 
Example Proteins Lipo- Poly-
Saccharide Saccharide 
T-cell required Yes No No 
for ab production 
Ontogeny of Present at birth Early 3-18 months 
response 
Response in No Yes Yes 
athymic mice 
Isotype switching Yes No No 
Secondary (memory) Yes No No 
response 
Antibody response Heterogeneous Restricted Restricted 
Affinity maturation Yes No No 
Polyclonal B cell No Yes No 
activation 
In humans the predominant subclass in response to T-dependent antigens is 
IgG I although IgG2 is also produced in adequate amounts. In contrast, 
responses to T-independent antigens show significant but varying degrees of 
restriction to IgG2 (Stein 1992). When a T-independent antipolysaccharide 
response is converted into a T-dependent response the IgG2 isotype 
restriction seen with the polysaccharide antigens is lost. 
Purified capsular polysaccharides are classified as type II T-cell-independent 
antigens, and the immature immune system of young infants appears 
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when they are conjugated to carrier proteins, capsular polysaccharides 
become more T-cell dependent and are more immunogenic in young infants. 
The involvement of helper T-lymphocytes is associated with a greater initial 
antibody response as well as with a true anamestic response with repeat 
immunization. 
The exact reason for the absence of an immune response to Ti antigens such 
as polysaccharides is not clear and various hypotheses have been proposed to 
explain it (Bixler and Pillai 1989). 
Lymphokine influences 
The differences in magnitude of antibody response may result from inherent 
differences in the ability of specific carrier proteins to induce T-cell 
proliferation and lymphokine release. 
Lymphokines regulate B-cell terminal differentiation and immunoglobulin 
production (Muraguchi et al 1988). In addition in humans and murine 
studies lymphokines appear to regulate IgG subclass selection (Snapper and 
Paul 1987; Lundgren et al 1989; Gascan et al 1991). Polysaccharide 
specific B-cells have also been shown to respond to interleukin-6 (IL-6) 
(Ambrosino et al 1990;). 
T-cells activated by protein antigen such as tetanus toxoid might 
preferentially secrete gamma-interferon and thus induce antigen specific B-
cells to produce IgG 1 antibody whereas T-cells activated by polysaccharide 
antigen secrete IL-4 and IL-5 and possibly IL-6 to provide help for the 
differentiation of antigen specific B-cells into IgG2 producing plasma cells. 
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Ambrosino et al (1990) underlined the need for IL-6 in the in-vitro antibody 
response to polysaccharides. In addition it has been shown that gamma 
interferon and IL-6 can augment in-vitro antibody responses to both protein 
and polysaccharide antigens provided B-cells are primed in-vivo with T-cell 
dependent conjugate vaccine (Peeters et al 1992). 
SUSCEPTIBILITY 
Young age is the most important risk factor for Hib disease although genetic 
and environmental factors can affect responses to individual antigens. 
Socioeconomic risk factors for invasive Hib disease have been reviewed 
recently by Takala and Clements (1992). These risk factors can be broadly 
divided into two groups: i) factors that increase exposure to Hib (e.g. day 
care outside the home, overcrowding, presence of young siblings); and ii) 
factors that increase the child's susceptibility to Hib (parental smoking, short 
duration of or no breast feeding). 
There is no explanation why only a small proportion of children develop 
invasive disease prior to the ability to synthesize protective levels of anti-Hib 
PRP or anti-teichoic acid antibody. However, the following evidence 
suggests that antibody responses to carbohydrate antigens and susceptibility 
to these bacterial infections may be under genetic control: 
• 
• 
• 
Children who have recovered from Hib meningitis have lower 
antibodies to the polysaccharide capsule than siblings (Whisnant et al 
1976) and do not respond to immunisation as well as controls 
(Norden et al 1975). 
Certain ethnic populations such as Alaskan Eskimos have very high 
incidences of infection with Hib (Ward et al 1981). 
Hib disease expression also differs in various races e.g. epiglottitis is 
common in Whites and rare in Blacks and Eskimos. 
SECTION B: Chapter 8: Literature Revieiv 260 
• Siblings of patients with meningitis have lower antibody responses to 
Hib-pertussis complex vaccine than control children (Granoff et al 
1983). 
• Children who develop bacterial meningitis or acute haematogenous 
osteomyelitis/septic arthritis are normally well nourished. Separate 
studies at Baragwanath Hospital and in Natal have shown that the 
incidence of malnourished children with bacterial meningitis is no 
greater than that of the general population (Rosen and Davis 1980; 
Mulla et al 1984). Most other infectious diseases are more common 
in undernourished children. 
It appears that nutritional factors, unlike in other common infections, have 
only a minor role to play while genetic factors affecting antibody formation 
to carbohydrate antigens could be important in determining susceptibility to 
Hib meningitis, Hib OM/SA, and S.aureus OM/SA. 
8.3.1 Allotypes 
The risk of disease in relation to the frequency of different allotypes is of 
interest as allotypes are hereditary antigenic determinants present on 
immunoglobulin molecules and are polymorphic. All allotypes are inherited 
in a Mendelian fashion and are co-dominant. Human allotypes are genetic 
markers expressed as antigens on the constant regions of heavy or light 
chains of immunoglobulions. 
Since 1956, 24 human immunoglobulin (lg) allotypes have been described. 
Four of these allotypes are localized on IgG 1 molecules (G 1 m), 1 on IgG2 
(G2m), 13 on IgG3 (G3m), 2 on IgA2 (A2m), I on IgE (Em) and 3 on the 
Kappa-light chains (Km). Alphameric nomenclature for the allotyopes has 
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been used in this study. The corresponding numeric nomenclature is found 
in Appendix F. 
Population studies have shown that some Gm haplotypes are characteristic 
for a particular race (de Lange 1991). 
lg allotypes have been studied in relation to the humoral immune response. 
Gm allotypes have been shown to influence IgG subclass levels (Morell et al 
1972; Steinberg et al 1973; Oxelius 1990a, 1993; Sarvas et al 1991). 
Studies have demonstrated the interaction between the Gm and Km genes in 
antibody responses particularly to Epstein-Barr virus infection and to 
immunization with type III group B streptococcal antigen (Whittingham and 
Propert 1986). Schanfield et al (1979) showed an association between Gm 
(1,3,5, 11, 13) and the response to tetanus toxoid in Melanesians. Recent 
studies indicate that genes associated with certain Gm and/or Km 
immunoglobulin allotypes may be associated with altered responsiveness to 
vaccines containing bacterial polysaccharides (Pandey et al 1979, 1981; 
Granoff et al 1984, 1988a; Ambrosino et al 1985; 1988a). 
The determination of allotypic markers is useful m the investigation of 
immune responses and disease susceptibility. 
Km light chain allotype 
The first allotype of immunoglobulin light chains was described by Robartz 
et al (1961) and termed InV (lnhibiteuir vim10ntois, named after the donor 
of the original antiserum), now designated Km (Kappa marker). The Km 
allotypes are inherited independently from the Gm allotypes. Human k light 
chains are encoded for by a single gene on chromosome 2 and are thus 
unlinked to the HLA loci. Three allotypes Km(l ,2) and Km(3) controlled 
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by the Km(l), Km(l ,2) and Km(3) alleles have been described. These 
allotypes are found in the constant portion of k light chains in all 
immunoglobulin classes. Usually Km(l) and Km(3) behave as antithetical 
alleles. 
Most allotypes have originated from gene mutation of only one of a few 
nucleotides resulting in a difference of 1 or 2 amino acids. Studies of the 
aminoacid sequences of k chains have shown that substitutions of amino 
acids at position 153 and position 191 result in homozygous and 
heterozygous phenotypes (Table 8.6). 
TABLE 8.6: RELATION BETWEEN THE Km ALLOTYPES AND 
THE AMINO ACID SEQUENCE OF THE CONSTANT REGION OF 
THE KAPPA LIGHT CHAIN 
ALLOTYPE ALLELE AMINO ACID RESIDUE 
POSITION 153 POSITION 191 
Km(l,2) Km(l,2) ala leu 
Km(l) Km(l) val leu 
Km(3) Km(3) ala val 
In almost all Caucasian subjects the Km(2) factor is found when the Km(l) 
factor is present since these factors are transmitted together by the Km(l ,2) 
allele. Subjects with the phenotype Km(-1,2,3) or Km(-1,2,-3) have not 
been reported (Lima and Newall 1990). Km(l) seems to be least frequent in 
Caucasians (10-18 % ) and most frequent in South American Indians (94 % ) 
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and varies from 80% to 50% for Mongoloids and Negroids (Lefranc and 
Lefranc 1990). The Km(3) allotype occurs frequently and is found in 
approximately 95 % of Caucasians. 
The accessibility of the Km(l) allotype to the anti-Km antibody depends on 
the isotype of the associated heavy chain and on the antibody quaternery 
structure. The gamma chain subclass influences the accessibility: the 'Y 1 
and 'Y 3 chains strengthen it, whereas the 'Y 4 and the 'Y 2 chains suppress it 
by epitope masking (Terry et al 1965; Steinberg and Rostenberg 1969). 
Allotypes have been associated with increased and decreased antibody 
responses to a variety of antigens. Various studies have shown substantial 
racial differences in associations between immunoglobulin allotypes and 
antibody responsiveness to the polysaccharide antigens of encapsulated 
bacteria. For example highly significant associations have been 
demonstrated between the Km(l) allotype and greater post-immunization 
antibody levels to H. in_fiuenzae and meningococcal C polysaccharides in 
white children but not in black children (Pandey et al 1979; 1981). Granoff 
et al (1984) found that the presence of the Km(l) allotype in both Black and 
White children was associated with a higher antibody response to Hib PRP 
than in children who lacked this allotype. The relative risk of meningitis 
was also lower among black children with the Km(l) allotype than in those 
who lacked this allotype although this effect was not observed in White 
children. 
G 1 m allorypes 
The four allotypes that may be present on the 'Y 1 chain of IgG 1 molecules 
are Glm(z), Glm(a), Glm(x), and Glm(t) (Appendix F). Glm(t) was 
initially reported by Steinberg and Wilson (1963) but was independently 
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discovered and characterized by Gold et al ( 1965). G 1 m(t) is located on the 
Fd fragment of the IgG 1 chain. Only a few allotypes are mutually 
exclusive, and therefore cannot be present on the same chain and 
Glm(t)/Glm(z) is one of them. It is known that the Glm(z) and Glm(t) 
allotypes correlate with lysine and arginine respectively at position 214 of 
the 'Y 1 chain. 
There have been very few studies looking at the interactive effect of G lm(t), 
antibody responses and disease susceptibility (Whittingham and Propert 
1986). Considering the increasing recognition of the importance of IgG 1 
responses to carbohydrate antigens in children the influence of the G 1 m(t) 
allotype in Hib meningitis, Hib OM/SA and S.aureus OM/SA was 
examined. 
G2m allotypes 
G2m(n) (G2m[23] in American literature) is the only allotype known on 
IgG2 molecules. It is found in 60-70% of Caucasians (Ambrosino et al 
1985). It occurs as two alleles G2m(n) +ve or G2m(n) -ve (Kunkel et al 
1966). The G2m(n) allele occurs at a frequency of 0.4 to 0.6 in Europe and 
0.1 to 0.8 in Asia. It has been shown that this allele is present in Australian 
Aborigines at a frequency of 0. 7 and that it is extremely rare in Blacks 
(Shackelford et al 1985b; de Lange 1991). 
The exact location of the G2m(n) allotype on the CH2 domain of the -y2 
chain is not yet known (Lefranc and Lefranc 1990). 
It is well known that Gm allotypes influence IgG subclass levels (Sarvas et 
al 1991). Healthy adults expressing the G2m(n) marker have been reported 
to have higher concentrations of IgG2 in serum than those who were 
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negative (Morell et al 1972b; Steinberg et al 1973; van der Giessen et al 
1973; Ambrosino et al 1985; Rautonen et al 1989; Oxelius 1993). There 
were no differences with respect to G2m(n) on IgG 1 concentrations (Morell 
et al 1972b). 
There is considerable controversy about the effect of the G2m(n) allotype on 
the specific antibody response to polysaccharide antigens (Table 8. 76). 
Ambrosino et al (1985) found that G2m(n) positive individuals had better 
IgG responses to several polysaccharide vaccines than G2m(n) negative 
individuals. However, other studies have failed to confirm these findings 
(Granoff et al 1984, 1986a, 1988a). Although Granoff et al (1988a) found 
no significant differences in the magnitude of total IgG or IgGl antibody 
responses between n-positive and n-negative individuals the n-positive 
individuals had higher IgG2 anticapsular antibody than n-negative 
individuals. More recently it was shown that the IgG2 specific response to 
several polysaccharide antigens was higher in n-positive than n-negative 
individuals (Morell et al 1989; Sarvas et al 1989, 1990). Interestingly 
Sarvas et al (1990) only found the effect of G2m(n) on the antibody 
response when the immunogen was the Hib PRP polysaccharide and not the 
Hib PRP conjugated to diphtheria toxoid. All these studies have been done 
in Caucasians. 
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TABLE: 8.7: EFFECT OF POSITIVE OR NEGATIVE G2m(n) ON 
ANTIBODY RESPONSE TO POLYSACCHARIDE VACCINES 
REFERENCE AGE POLY-
SACCHARIDE 
SPECIFIC ab G2m(n)+:G2m(n)-
Ambrosino 
et al 1985 
Granoff 
et al 1984 
Granoff 
et al 1986a 
Granoff 
et al 1988b 
Sarvas 
et al 1989 
Sarvas 
et al 1990 
Adults Hib PRP IgG 
Children Hib PRP - IgG 
pertussis 
Children Hib PRP - IgG 
pertussis 
Adults Hib PRP vaccine IgG, IgG 1 
IgG2 
Adults Pneumococcal 
Children 3, 14, 18 
Adults/ Hib PRP 
children Hib conjugate 
Adults Hib PRP/ 
PRP conjugate 
IgG2 
IgGI 
IgG2 
IgG2 
IgGI 
Increase 
No difference 
No difference 
No difference 
Increase 
Increase 
No difference 
Increase 
No difference 
No difference 
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Ambrosino et al ( 1985) have indicated an increased risk of Hib infections 
other than epiglottitis in G2m(n) negative individuals. However, other 
studies with larger numbers of patients have failed to confirm these findings 
(Granoff et al 1984; Granoff et al 1989; Takala et al 1991). The presence 
of G2m(n) may also be associated with a lower relative risk of vaccine 
failure (Granoff et al 1986b). 
Zygosity of G2m(n) 
It has been suggested that one of the paired G2m(n) alleles may be more 
productive than the other (Morell et al 1972b). In view of the functional 
differences between alleles it is useful to divide IgG2 into positive and 
negative forms and also to determine intermediate heterozygotes. 
Heterozygous status cannot be easily determined as there are no antibodies 
available to the negative alleles of the markers. Rautonen et al (1989) have 
developed a triple well precipitation method to determine G2m(n) homo-
and heterozygosity. Using this method Sarvas et al (1989) and Granoff and 
Holmes (1992) found adults homozygous positive for G2m(n) had higher 
IgG2 antibody responses to pneumococcal types 14 and 18c polysaccharides 
or Hib PRP than did those who were G2m(n) negative. Heterozygotes had 
intermediate levels. 
8.3.2 C4 
Other important defence mechanisms against invasive Hib disease are the 
complement system and phagocytosis. The complement system enhances 
clearance of H. injluenwe from the bloodstream through its action as an 
opsonin in both non-immune and immune hosts. Complement deficiency is 
very rare and could not explain the incidence of Hib disease seen. 
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IgG 1 anti-capsular antibody seems to be more efficient than IgG2 anti-
capsular antibody at promoting complement-dependent opsonization of Hib 
and at initiating complement dependent bactericidal activity (Amir et al 
1990). IgG 1 subclass specific antibodies to Hib PRP are able to kill 
significantly more Hib than are comparable amounts of IgG2 Hib PRP 
antibodies in the presence of excess complement. In addition IgG 1 requires 
lower concentrations of complement than IgG2 to generate comparable 
amounts of bacteriolytic activity. 
The fourth component of complement (C4) is necessary for host defense 
against infection since one of its cleavage products (C4b) forms part of the 
enzyme (C4b, 2a) responsible for activating C3 and C5-C9 via the classical 
pathway. C4 is encoded by two closely linked loci within the major 
histocompatability complex. The gene products C4A and C4B share major 
structural characteristics but differ with respect to electrophoretic mobility, 
haemolytic activity and binding specificities. C4B preferentially binds to 
hydroxy groups and has four times the functional haemolytic activity than 
C4A on a mol-per-mol basis (lsenmen and Young 1984). C4A 
preferentially binds to amino groups and is more efficient at inhibiting 
immune precipitation. 
Most individuals express four gene products although various combinations 
of deletions and duplications exist. The null alleles (QO = quantity zero, 
* * C4A QO, C4B QO) are defined by the hetero-or homozygous lack of C4A 
or C4B in the serum. Partial deficiencies of C4 are relatively common. It 
has been estimated that only 50-65 % of people have four functional C4 
genes, 30-38 % have three, and that 5-10% have only two functional C4 
genes. However, complete C4 deficiency is uncommon as C4A * QO and 
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* C4B QO genes rarely present on the same chromosome (Hauptmann et al 
1988). 
The prevalence in the general population of homozygous C4A deficiency is 
1 % and homozygous C4B deficiency is 3% (Awdeh and Alper 1980). The 
prevalence of homozygous C4B deficiency has been shown by some to be 
independent of ethnicity whereas others have shown population group 
differences in the frequency of the complement genes (Rowe et al 1989; 
Bishof et al 1990; Imanishi et al 1991). 
No consistant immunological abnormalities have been detected in healthy 
individuals with C4A *Qo or C4B*Qo alleles. Recently a relatively 
common deficiency of one isotype of C4 (C4B) has been shown to be 
associated with invasive Hib disease (Bishof et al 1990) suggesting that 
defects in complement-mediated host defence may be more common in 
systemic Hib infections than previously thought. 
Two independent studies have found an increase in C4B deficiency in 
children with systemic infections with encapsulated bacteria (Rowe et al 
1989; Bishof et al 1990). However more recent studies have not confirmed 
these findings (Cates et al 1992). 
Susceptibility to disease may be influenced by other genes within the MHC. 
C4A/21-0H deletion has been reported to be increased in patients with IgA 
deficiency/common variable immunodeficiency (French and Dawkins 1990). 
The reason that a C4B deficiency may predispose an individual to bacterial 
meningitis is unknown. Possibilities include: 
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• As C4B preferentially binds to hydroxyl groups and since bacterial 
cell walls and capsules are rich in carbohydrates it is possible that 
C4B is more efficient in binding to bacterial surfaces, in assembling 
the C3-cleaving enzyme (C4b, 2a) and thus generating opsonically 
active C3b. 
• C4B is encoded by genes located within the MHC class III complex 
in humans and may be in linkage disequilibrium with other genes in 
the MHC which are themselves in some way responsible for an 
abnormal immune response. 
8.4. MANNOSE BINDING PROTEIN (MBP) 
MBP is an acute phase protein synthesized m the liver (Esekowitz et al 
1988; Thiel et al 1992). It is a C-type lectin with a binding specificity 
towards carbohydrate structures containing mannose or N-acetyl 
glucosamine. It is able to activate complement by the classical pathway 
upon binding to a mannose-rich surface (Ikeda et al 1987). These 
carbohydrates are found on a number of bacteria and yeasts and can activate 
the complement system without the involvement of specific antibodies. 
Failure to opsonize baker's yeast is a defect found in 5-7% of the general 
population of healthy Caucasians. The presence of the defect has been 
linked to low levels of MBP (Super et al 1989). The frequency of MBP 
deficiency is similar in both Caucasians and Chinese but is unknown in 
Black and Coloured populations. The deficiency has been reported to be 
significantly more common in infants with recurrent respiratory tract 
infection, otitis media and chronic diarrhoea (Turner et al 1991). 
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MBP activation of the classical pathway of complement may be significant 
when other partial defects of the immune system exist leaving individuals 
compromised and susceptible to disease. 
MBP may be especially important in early life. It has been speculated that 
infants between 6 and 24 months of age are most at risk when antibody 
independent mechanisms of complement activation such as MBP may play a 
critical role in protection against infections. 
CONCLUSION 
This review of the literature indicates that IgG subclass levels, specific IgG 
subclass antibody production, allotype regulation of IgG subclasses, C4B 
deficiency and MBP deficiency may be factors associated with an increased 
susceptibility to invasive H. injluenzae and Staphlococcus aureus infections. 
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CHAPTER 9 
HEAL THY CHILDREN AND ADULTS - RESULTS AND DISCUSSION 
This chapter describes: 
9.1 CONTROL STUDY POPULATION - this describes the population used to 
establish the normal ranges for the IgG subclass levels. 
9.2 IgG AND IgG SUBCLASSES - this describes the frequency distribution, 
the transformation and statistical analysis of the IgG subclasses which 
resulted in the establishment of age, race and sex related percentile charts of 
normal ranges of IgG and IgG subclasses. 
9.3 ALLOTYPES - describes the frequency of Glm(f), G2m(n) and Km(3) 
allotypes in the control groups. The effect these allotypes have on the IgG 
and IgG subclass levels is assessed. 
9.4 C4 PROTEIN TYPING - describes the measurement and determination of 
the frequency of C4B*QO in the Black and Coloured population of the 
Western Cape. 
9.5 MANNOSE BINDING PROTEIN (MBP) - describes the measurement of 
and determination of MBP levels in Black adults of the Western Cape. 
9.6 SUMMARY OF MAIN FINDINGS 
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9.1. STUDY POPULATION AND COLLECTION OF SAMPLES 
Permission for collection of samples was obtained from the Ethics and 
Research Committee, University of Cape Town, from the Divisional 
Council which run the well baby clinics and from the children's parents. 
In this chapter children and adults of different ethnic backgrounds are 
referred to as Black, Coloured (mixed population inheritance) and White. 
Although population classification and apartheid have been abolished these 
racial groups have been retained because of important heritable and social 
differences that continue to exist. 
Blood was collected under sterile conditions. Test serum was stored at 
-70°C in small aliquots to avoid repeated freezing and thawing of the 
samples. 
9.1.1 &timation of possibility of HIV infection in controls 
The majority of specimens for this study were collected prior to 1990. At 
that time the incidence of human immunodeficiency virus (HIV) in the 
Western Cape was estimated to be very low (0.76%) (Epidemiological 
Comments 1993). Random samples of control specimens were sent for 
anonymous HIV testing. None of the 200 control specimens tested were 
positive. It was therefore concluded that the presence of HIV infection in 
the populations studied was most unlikely. 
9.1.2 Children 
Blood specimens were collected from 730 healthy children attending 
schools, community health clinics or from preoperative patients admitted for 
elective surgery. Four hundred and sixty seven of the samples were from 
Coloured children, 253 from Black children and 10 from White children. 
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The race and sex distributions of the controls are shown in Table 9 .1. The 
racial distribution is representative of the ethnic groups attending this 
hospital. Because of the small number of both white patients and controls 
these have not been included in further analysis. One hundred specimens 
from Black children came from rural school children in the Transkei. All 
other specimens were collected from children resident in the Western Cape. 
Children with a history of previous hospitalization for an infective illness, or 
with an acute infectious illness, or who gave a history of frequent infections 
or immunodeficiency were excluded. 
TABLE 9.1: RACE AND SEX DISTRIBUTIONS OF THE 
CONTROLS 
CHILDREN 
Race Female Male Total 
Black 119 134 253 
(47.0%) (53.0%) (34.7%) 
Coloured 154 313 467 
(33.0%) (67.0%) (64.0%) 
TOTAL 273 447 720 
ADULTS 
Race Female Male Total 
Black 50 25 75 
(66.7%) (33.3%) (44.1 %) 
Coloured 19 29 48 
(39.6%) (60.4%) (28.2%) 
White 25 22 47 
(53.2%) (46.8%) (27.6%) 
TOTAL 94 76 170 
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9.1.3 Adults 
Samples from 170 healthy adults were obtained from the Western Province 
Blood Transfusion Service (Table 9.1). All blood donors were screened for 
HIV infection. 
9.2 lgG AND lgG SUBCLASSES 
IgG was measured by nephelometry using a Behring Nephelometer analyser 
(Software version 2.2.EXT). IgG subclasses were measured by ELISAs as 
described in Chapter 2. 
9.2.1 Distribution 
The IgG and IgG subclass distributions in 720 randomly selected healthy 
control children were studied. Frequency histograms of IgG and IgG 1 in 
Black children and Coloured male children were Normally distributed. 
Figure 9.1 shows the distribution histograms of the IgG2, IgG3 and IgG4 
levels of the Black children. The IgG 1 results of Coloured female children 
and the IgG2, IgG3 and IgG4 data of all groups of children showed non-
Normal negatively skewed frequencies (Table 9.2). The data were thus log 
transformed. 
Log10 transformation of the data 'normalized' the frequency distribution 
except in the case of the IgG of the Coloured male children, the IgG2 of the 
Black children and the IgG4 of children of both races (Table 9.2). As the 
IgG, IgGl, IgG2, IgG3 and IgG4 data were neither constantly Normally nor 
log10 Normally distributed, the Box Cox transformation regression model 
was evaluated. 
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TABLE 9.2: TEST OF GOODNESS OF FIT OF OBSERVED 
FREQUENCY DISTRIBUTIONS OF CONTROL DATA WITH 
NORMAL DISTRIBUTIONS 
IgG B 
IgG CM 
IgG CF 
IgGl B 
IgGl CM 
IgGl CF 
IgG2 B 
IgG2 C 
IgG3 B 
IgG3 CM 
IgG3 CF 
IgG4 B 
IgG4 CM 
IgG4 CF 
Untransformed 
Normal 
Normal 
Normal 
Normal 
Normal 
non-Normal 
non-Normal 
non-Normal 
non-Normal 
non-Normal 
non-Normal 
non-Normal 
non-Normal 
non-Normal 
B = Black children 
CF = Coloured female children 
Log10 
Transformed 
Normal 
non-Normal 
Normal 
Normal 
Normal 
Normal 
non-Normal 
Normal 
Normal 
Normal 
Normal 
non-Normal 
non-Normal 
non-Normal 
Box Cox 
Transformed 
Normal 
Normal 
Normal 
Normal 
Normal 
Normal 
Normal 
Normal 
Normal 
Normal 
Normal 
non-Normal 
non-Normal 
non-Normal 
CM = Coloured male children 
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Figure 9.1: Distribution histogram of the untransformed, the log10 transformed and 
Box Cox transformed data of the IgG2, IgG3 and IgG4 subclass levels of the Black 
children. The expected Normal distribution is shown by the broken line(-) 
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The Box Cox transformation regression model was used for IgG, IgG 1, 
IgG2, IgG3 and IgG4 (Box and Cox 1964). Age and sex and their 
interaction were included in the model in finding the appropriate Box-Cox 
transform (i.e. the A parameter). The resulting transformed data were then 
checked for Normal distribution. The models fitted are in Table 9.3. 
TABLE 9.3: FITTED MODELS OF BOX COX TRANSFORMATION 
IgG B (IgG)0.34 = 2.24075 + 0.007927 age - 0.000028681 age2 
IgG CM (lgG)0·47 = 2.8988 + 0.007212 age 
IgG CF (lgG)0.60 = 3.7241 + 0.024909 age - 0.000070779 age2 
IgGl B (lgG)0.24 = 1.7945 + 0.001406 age 
IgGl CM (lgG1)0·14 = 1.3657 + 0.000421 age 
IgG 1 CF (IgG 1 )0·23 = 1.6784 + 0.001405 age 
IgG2 B (IgG2)o.o7 = 0.9565 + 0.000483 age 
IgG2 C (lgG2)0.21 = 0.89903 + 0.001274 age 
IgG3 B (lgG3)o.o4 = 0.9694 + 0.000209 age 
IgG3 CM (lgG3r0·01 = 1.008901 + 0.000008041 age - 0.000000501 age2 
IgG3 CF (lgG3)o.os = 0.9311 + 0.000408 age 
IgG4 B (lgG4)o.os = 0.8176 + 0.002836 age - 0.000014193 age2 
IgG4 CM (lgG4)0·26 = 0.4257 + 0.005653 age - 0.000024659 age2 
IgG4 CF (lgG4)0·22 = 0.4927 + 0.003837 age - 0.000013110 age2 
B = Black children CM = Coloured male children 
CF = Coloured female children 
The Box Cox transformations of the IgG, IgGl, IgG2 and IgG3 were 
symmetrical and not statistically different from the Normal distribution 
(Table 9.2). IgG4 Box Cox transformation was symmetrical although this 
distribution differed from the Normal distribution (Figure 9.1). 
The statistical significance of the discrepancy between the observed 
frequency distributions of the untransformed, log transformed and Box Cox 
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9.2.1.2 
transformed data with the Normal distributions was evaluated with the Chi-
square goodness of fit test. The log10 and Box Cox transformation 
significantly Normalised the data distribution in most groups (Table 9.2). 
The frequency histograms of the log10 transformed data showed Normal 
distribution in all groups except for IgG of Coloured male children, IgG2 of 
Black children and IgG4 levels of both groups. Box Cox transformation of 
IgG2 values of the Coloured male children produced a Normal distribution 
although log transformation of the same data did not (Table 9.2). 
Although the frequency distribution of Box Cox transformated IgG4 differed 
significantly (p = :$; 0.05) from the Normal distribution, this 
transformation gave the data a symmetrical distribution not seen in the 
untransformed or log10 transformed data (Figure 9.1). For this reason in 
the statistical analyses of IgG4, Box Cox transformed data has been treated 
as having a Normal distribution. 
Discussion 
The frequency distributions of the four human subclasses have not been 
extensively investigated although the distribution of data is of importance 
when choosing a method of analysis. These data show that generally the 
IgG and IgG 1 untransformed values of Black and Coloured children, were 
Normally distributed and that the Box Cox transformed data of the IgG, 
IgG 1, IgG2 and IgG3 values, but not the IgG4 values were Normally 
distributed in Black children and Coloured children (Table 9.3). With the 
exception of IgG values of Coloured males, IgG2 values of Coloured 
children and IgG4 of both races the log10 transformed data was Normally 
distributed. In some cases inclusions resulting from visual assessment of the 
histograms were different from those based on statistical tests of goodness of 
fit. This highlights the importance of using a statistical test of goodness of 
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fit although most of the previous reports of frequency distribution of 
subclasses have relied on visual inspection of the frequency histograms 
(Shakib et al 1975; French and Harrison 1984; Bird et al 1985). The IgG4 
data did not have a Normal distribution and neither log 1 o nor Box Cox 
transformation was able to Normalize the data. 
As concentrations of the four subclasses are neither consistently Normal or 
log Normal distributed (Djurup et al 1988) calculations of normal ranges 
should not be based on the assumption of such frequency distributions. 
In normal adults there is general agreement about the frequency distribution 
of each subclass (Shakib et al 1975, French and Harrison 1984). IgGl is 
Normally distributed about the mean whereas the frequency distributions of 
the other subclasses particularly IgG4 are skewed. In children IgG 1 has 
been found to be Normally distributed whereas IgG2 and IgG3 were 
approximately log Normally distributed and no transformation normalized 
the IgG4 data (Bird et al 1985). 
A recent study by Djurup et al (1988) compared IgG subclass concentrations 
in sera from 200 normal adults measured in 2 different laboratories using the 
same technique (radial immunodiffusion) and reagents. In one laboratory 
the distributions of IgG 1 and IgG2 were normal whereas those of IgG3 and 
IgG4 were skewed, whereas in the other laboratory all four subclasses were 
significantly different from a Normal distribution. The observed frequency 
distribution of a subclass may be influenced by the technical performance of 
the assay. Thus each laboratory evaluating IgG subclasses should determine 
the frequency distribution of the subclasses before undertaking statistical 
analysis and determination of normal ranges, and should not interpret results 
from a reference range that has been established in another laboratory. 
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9.2.2 Age 
A regression analysis of the IgG and IgG subclasses against age 
demonstrated a correlation with age (Figure 9.2). The respective r and p 
values were: IgG r = 0.61 (p= ~0.0001), IgGl r = 0.38 (p= ~0.0001), 
IgG2 r = 0.45 (p= ~0.0001), IgG3 r = 0.42 (p= ~0.0001) and IgG4 r = 
0.41 (p= ~ 0.0001). 
Age had to be taken into account in Box Cox transformation of IgG and the 
four IgG subclasses (Table 9.3). The concentration of IgG and IgG 
subclasses increase with age and the ages at which the IgG and IgG subclass 
concentrations of the children in this study reached adult and peak levels are 
variable and are listed in Table 9.4 
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Figure 9.2: Regression analysis of IgG and IgG subclass levels against age in healthy 
children in the Western Cape. 
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TABLE 9.4: lgG and lgG SUBCLASS LEVELS - 50TH PERCENTILE 
AGE AT WHICH LEVEL REACHED 
PEAK LEVEL ADULT LEVEL 
IgG B 
IgG CM 
IgG CF 
IgGl B 
IgGl CM 
IgGl CF 
IgG2 B 
IgG2 C 
IgG3 B 
IgG3 CM 
IgG3 CF 
IgG4 B 
IgG4 CM 
IgG4 CF 
B = Black children 
CF = Coloured female children 
12 y 
12 y 
12 y 
12 y 
> 12 y 
> 12 y 
> 12 y 
> 12 y 
> 12 y 
> 12 y 
> 12 y 
8y 
> 12 y 
> 12 y 
6y 
7y 
6y 
1 y 
4y 
0.5 y 
> 12 y 
> 12 y 
10 y 
10 y 
9y 
6.5 y 
> 12 y 
8y 
CM = Coloured male children 
The attainment of mean adult levels was not synonymous with the peak 
level. The peak level, with the exception of IgG2, was greater than the 
mean adult level and generally had not been reached by 12 years of age. 
The IgG, IgG 1 and IgG3 of the Blacks reached adult levels at an earlier age 
than the Coloured patients. 
IgG declines over the first 6 months of life; thereafter a slow increase in 
serum IgG levels is observed with 70% of adult levels being reached by the 
end of the second year of life; adult levels are reached between 7-13 years 
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of age (Buckley et al 1968; Schur et al 1979; Jolliff et al 1982; Shackelford 
et al 1985b). 
In published studies of normal ranges there is no consensus about the exact 
age at which the IgG subclasses reach adult levels. IgG subclasses attain 
adult serum concentrations at variable ages with IgG 1 and IgG3 reaching 
adult levels at an earlier age than IgG2 and IgG4 (Lee et al 1986). IgG2 has 
been reported to be the most delayed and probably does not do so until after 
12 years of age (Aucouturier et al 1988). The findings in this study are in 
agreement with these reports. IgG2 was the most delayed and had not 
reached adult levels by 12 years of age. Children of 2 years had only 27% 
of adult levels of IgG2 whereas those of 12 years had 58% (Figure 9.3). 
140 
120 
100----------
80 
60 
40 
20 
0 
lgGI lgG2 lgG3 lgG4 
• 2 .,ea-s ~ 12 .,ea-s 
Figure 9.3: Concentrations of IgG, IgGl, IgG2, IgG3 and IgG4 levels of children 2 
and 12 years of age expressed as a % of the adult mean. 
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9.2.3 Proportion of lgG subclasses of the total lgG 
Although the total serum IgG levels may vary considerably between healthy 
adults, the proportions of the 4 subclasses are maintained within a relatively 
narrow range (Table 9.5). Adult controls tested in this study exhibited 
similar proportions (Table 9.5). In children of 2 and 12 years of age IgGl 
levels were proportionately higher, IgG2 and IgG4 proportionately lower 
and IgG3 proportions were similar to adult concentrations (Table 9.5). 
These results show that the proportion of each subclass present in adults 
does not exist in children due to variable ontogeny of subclasses. There are 
no previously published reports on the proportion of the IgG subclasses in 
young children. 
TABLE 9.5: lgG SUBCLASSES AS A% OF MEASURED TOTAL IgG 
ACCORDING TO AGE AND RACE 
Children Adults ADULTS 
2 yrs 12 yrs (Jefferis & 
Kumararatne 1990) 
IgGl B 94.4% 89.2% 71.6% 
CM 90.8% 70.7% 74.2% 60 - 65% 
CF 92.8% 83.1 % 64.1% 
IgG2 B 4.9% 7.4% 14.8% 
CM 6.6% 5.5% 17.4% 20 - 25% 
CF 6.2% 5.2% 16.4% 
IgG3 B 4.1 % 5.1 % 5.3% 
CM 3.9% 5.8% 5.4% 5 - 10% 
CF 4.2% 4.7% 4.9% 
IgG4 B 0.6% 1.2% 2.2% 
CM 0.9% 1.7% 2.9% 3-6% 
CF 0.5% 1.6% 1.6% 
B = Black CM = Coloured male CF = Coloured female 
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9.2.4 Percentile Ranges 
Predictive percentiles were obtained from the Box Cox scale of IgG or IgG 
subclass and transformed back to the original scale. 
Smooth age-specific reference ranges for IgG and IgG subclasses have been 
produced. The data points and the percentile ranges (2.5%, 5%, 25%, 
50%, 75%, 95% and 97.5%) for IgG and IgG subclasses are shown in 
Figures 9.4a, 9.4b and 9.4c (enlarged figures of these percentile charts can 
be found in Appendix I). The percentile values for racially matched adults 
are also shown. 
As the IgG subclass levels of the Black and Coloured children were 
significantly different and as a sex difference was noticed in the Coloured 
children for the IgG, IgGl, IgG3 and IgG4 values, normal ranges have been 
independently determined for the Black children, Coloured male and 
Coloured female children. Tables of age, race and sex related normal 
ranges for IgG subclasses can be found in Appendix J. 
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Figure 9.4a: IgGl, IgG2, IgG3, IgG4 and IgG concentration percentiles for Black 
children. Percentile lines are 2.5%, 5%, 25%, 50%, 75%, 95% and 97.5%. The 
equivalent adult centile points are shown ( 0) 
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9.2.4.1 Discussion 
Normal values are needed to identify individuals with IgG subclass 
deficiencies. The choice of statistical method can greatly influence the 
calculated normal range. A comparison of normal reference ranges from 
various studies is complicated because different statistical analyses have been 
applied and the frequency distributions have not always been taken into 
consideration. Details of published IgG subclasses normal ranges and the 
methods used to obtain them are shown in Table 9.6. The most common 
practice of establishing reference ranges for IgG subclasses has been to use 
the mean of the data plus or minus two standard deviations. This method 
assumes the data to have a Normal distribution. Most studies have shown 
that the IgG subclasses (with the possible exception of IgGl) are not 
Normally distributed (Table 9.6). If the data is either Normal or log-
Normal distributed, normal range estimates obtained by non-parametric 
methods requires more samples to obtain the same precision of estimation as 
those obtained using parametric methods. When data are not Normally 
distributed as assumed, non-parametric estimates are more accurate (Reed et 
al 1971). Reference ranges derived by parametric methods are more 
affected by outliers than when non-parametric methods are used. IgG 
subclasses in children are age dependent and it is difficult to analyse data 
with non-parametric statistical methods and to acount for the effect of age. 
Reed et al (1971) and Hapke and Patil (1981) recommend that non-
parametric percentile estimates of the normal range are superior to 
parametric estimates when applied to biological data. The percentile method 
avoids the need to assess the frequency distribution of data. The use of non-
parametric reference intervals does not necessitate the use of non-parametric 
statistical tests. Unless the distribution of data being compared is markedly 
skewed parametric tests are 'robust' enough to analyse data that do not have 
a perfectly Normal distribution (Hapke and Patil 1981). 
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Variations in normal ranges found m studies using different methods, 
different antisera, different reference standards and different cut-off criteria 
indicate the need for the standardization of IgG subclass measurement 
methods and statistical analyses if meaningful comparison of results obtained 
in different laboratories is to be possible. Very few methods have 
demonstrated the correctness of their statistical methods. 
The determination of reference ranges for serum immunoglobulins has often 
been hampered by the ethical and practical difficulties of obtaining blood 
from healthy children. Many previous studies have used sera from hospital 
in-patients (Oxelius 1979; Aucouturier et al 1987). In other studies too few 
subjects of different ages have been tested leading to unreliable reference 
ranges (Oxelius 1979; Singh 1988; Plebani et al 1989). 
In this study normal references ranges were established from randomly 
selected healthy children rather than attempting to obtain matched controls 
for the following reasons: 
The patient groups with Hib infections were much younger than the 
group with S.aureus infections which would have necessitated two 
separate control groups. 
As it is ethically and practically difficult to obtain blood from healthy 
children, it is easier to take blood from randomly selected controls 
rather than to select controls to match patients. 
Selection of a matched group of controls from the randomly selected 
group is likely to show some bias. 
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It is preferable to calculate age-related percentiles that vary smoothly with 
age rather than considering subclass concentrations at each age 
independently of those at other ages. The different age groups used in 
reference ranges vary between studies and are usually determined by the 
number of specimens obtained in each group rather than by any biologically 
significant factor. Using mean ± 2 SD to estimate normal values for IgG 
and IgG subclasses, 2.5% of normal donors will be considered deficient in 
one or other subclass. 
In this study the Box Cox (Box and Cox 1964) transformation was used to 
construct age, race and sex related IgG and IgG subclass percentiles. Dr 
Derek Chalton, Division of Biostatistics, Medical Research Council, 
calcuated the approximate Box Cox transform (i.e. the )... parameter) 
including the effects of age, race and sex for each subclass. Once the A 
parameter had been calculated this could be used in the Box Cox of 
Statgraphics 6 programme to draw age related percentile charts and for 
analysis of various groups compared to the controls. 
As it was known that the IgG and IgG subclass values change with age and 
that Box Cox transformation 'Normalized' the data, the analysis of 
covariance (ANCOV A) with age as a covariant was used to determine the 
effect of race, sex or allotype on the IgG subclass levels using the Box Cox 
transformed data. 
Although the distribution of the IgG4 data could not be 'Normalized' using 
either log10 or Box Cox transformation in this study the latter 
transformation gave a symmetrical frequency distribution. Percentile ranges 
have been used to establish reference ranges and parametric statistical 
methods have been used to analyse data. 
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IgG and IgG subclasses were found to be much higher than those reported 
from infants in developed countries (Bird et al 1985; Shackelford et al 
1985b; Singh 1988; Beard et al 1990b). The differences are large enough to 
influence the interpretation of laboratory results if the correct age, race and 
sex matched reference ranges are not used. 
Although great care was taken to achieve valid and plausible reference 
ranges, the end result is largely dependent on the representativeness of the 
children in the study. One hundred of the Black school children lived in a 
rural area of the Transkei and the environmental effect on the 
immunoglobulins of these children could be different to those of Black 
children from poor urban areas of Cape Town. 
It will be important to collect further specimens from Black school children 
in Cape Town to ascertain if their levels differ from the Black children in 
the rural areas of the Transkei. 
9.2.5 R.ace 
There were statistically significant differences in the IgG, IgG 1, IgG2 and 
IgG3 subclasses of the Black and Coloured racial groups (Figures 9.4a, 9.4b 
and 9.4c). The Blacks had higher levels than the Coloureds (IgG p = < 
0.0001; IgGl p = < 0.0001; IgG2 p = 0.0136; IgG3 p = < .0001). 
There was no significant difference in the IgG4 levels of the Black and 
Coloured groups. 
In South Africa higher levels of IgG have been reported in Blacks than in 
Whites in both adults and children (Milner and Calitz 1971; Shulman et al 
1975; Shulman and Gilich 1976) and newborns (Van Rijswyk et al 1985). 
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The IgG values of the Cape Coloured population have also been found to be 
significantly higher than the Whites (Fraser et al 1981). 
There is only one study directly comparing Black and Cape Coloured 
immunoglobulin levels (which was done on cord blood). The Black and 
Coloured IgG levels were significantly higher than the Whites but there was 
not a significant difference in the IgG values of the Black and Coloured 
subjects (Van Rijswyk et al 1985). 
In North-America Buckley et al (1968) reported signicantly higher 
concentrations of IgG in Black subjects betweeen 6 and 14 years of age 
compared to those in Whites of comparable age. No significant differences 
in IgG concentrations were found in Black and White children less than 6 
years of age, however, no correction was made for age. Correcting for age 
Shackelford et al (1985b) found higher concentrations of IgG in Black 
children. They also reported that although Black adults had higher IgG 1 and 
IgG2 concentrations than White adults, the IgG 1 and IgG2 levels in Black 
and White children were not significantly different. In contrast, in a more 
recent study with larger numbers of children, the IgG 1, IgG2 and IgG4 
subclass concentrations of Black childen were lower than White children 
(Ambrosino et al 1991). 
In this study the Black children had significantly higher IgG, IgG 1, IgG2 
and IgG3 levels than the Coloured children. It would have been interesting 
to have compared these levels to those of White children but unfortunately 
insufficient controls were collected for statistical analysis. There are no 
previous reports of IgG subclass values in South African children of any 
racial group. 
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9.2.6 Sex 
In Black children and adults the IgG and IgG subclass levels were not 
significantly different in males and females. In Coloured children the IgG, 
IgG 1, IgG3 and IgG4 levels were significantly higher in males than in 
females but no sex difference was noted for IgG2. This sex effect was not 
seen in the IgG and IgG subclass levels of Coloured adults. 
No significant sex differences for IgG values have been reported in Black 
subjects (Roode 1980) but Cape Coloured males had significantly higher 
values than females (Fraser et al 1981). Sufficient information concerning 
the effect of sex on serum IgG and IgG subclass concentrations has only 
been reported in a small number of studies. Several studies have shown that 
IgG4 concentrations are higher in males than females (van der Giessen et al 
1975, Merrett et al 1983, Aucouturier et al 1984; French and Harrison 
1984; Plebani et al 1989; Beard et al 1990b) although this has not been 
found in all studies. In contrast studies reporting sex differences for IgG 1 
(Shackelford et al 1985b), IgG2 (van der Giessen et al 1975; Beard et al 
1990b) and IgG3 (French and Harrison 1984) have found females to have 
higher concentrations than males. However, these sex differences for the 
IgG subclass values are not constant findings. Shakib et al (1975) and 
Plebani et al ( 1989) found no differences in IgG 1, IgG2 or IgG3 levels in 
adults or children. Beard et al (1990b) did not find a sex difference 
between males and females for IgG 1 values. Differences in the relative 
proportions of males and females in different studies could be a factor 
accounting for discrepancies between studies. This may also explain the 
differences between races noted in this study as the male:female ratio was 
2: 1 in the Coloured children where a sex difference was noted and 1: 1 in the 
Blacks where no sex difference was found. 
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9.3. ALLOTYPES 
9.3.1 Statistical Analysis 
The frequency of the allotypes amongst the patients was compared to normal 
controls. The potential risk associated with an allotype was estimated with 
the odds ratio (OR) with 95% confidence intervals (CI). 
Due to the known association of IgG subclass levels with age, analysis of 
variance (ANCOV A) (using Box Cox tranformed data) with age as a 
covariant was used in evaluating the effect that an allotype may have on IgG 
subclass or subclass specific antibody concentration. The Kruskal Wallis 
test (using untransformed data) gave statistically similar significance values 
to the analysis of variance (ANCOV A) and in no case were discordant 
conclusions reached by the two methods. 
9.3.2 Determination of zygosity of Glm(O and G2m(n) allotypes 
To determine Glm(t) zygosity, the amount of IgGl as measured by the 
G 1 m(t) ELISA was expressed as a percentage of the amount of IgG 1 
determined by the IgGl subclass ELISA. The Glm(t) negative samples had 
undetetable levels in the assay. All the G lm(t) positive samples had a value 
of ~ 28 % of the IgG 1 value. A frequency histogram of these ratios was 
plotted for the controls (Figure 9.5). From this plot there appeared to be 
two populations. A cut-off of 75 % was taken to distinguish G 1 m(t) positive 
homo- and heterozygosity i.e. those with a level below 75% were defined as 
being heterozygous positive for the marker and those with a percentage 
value greater than 75 % were considered homozygous positive. Similar 
measurements and calculations were undertaken using the G2m(n) and the 
IgG2 ELISA to determine the zygosity of G2m(n). 
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Figure 9.5: Frequency histograms of the Glm(O positive IgGl and G2m(n) positive 
lgG2 expressed as a percentage of IgGl and IgG2. The cut-off of 75% used to 
distinguish between positive homo- and heterozygosity is indicated with an arrow 
The G2m(n) negative samples had undetectable levels in the assay. All the 
G2m(n) positive samples had a value of at least 29 % . A frequency 
histogram of these ratios was plotted (Figure 9.5). The division between 
positive homo- and heterozygosity was not as obvious as for the Glm(t). 
However, a cut-off point of 75% was selected and all values of greater than 
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75 % were considered homogygous positive and below which they were 
considered heterozygous. 
9.3.3 Prevalence of Glm(fj, G2m(n) and Km(3) allotypes in controls 
The prevalence of these allotypic markers is shown in Table 9. 7. The 
G 1 m(f) allotype is uncommon in Black children but occurred in 52 % of 
Coloured children. Amongst the Glm(f) positive Coloured children 54% 
were homozygous and 46 % heterozygous using the criteria described above. 
Two of the three Glm(f) positive Black children were homozygous and the 
other heterozygous for the marker. The presence of Glm(f) allotype in 
these two population groups is statistically different (OR = 49.47 (15.82 < 
OR <247.02); p = 0.0001). 
TABLE 9.7: FREQUENCY OF TIIE Glm(fj, G2m(n) AND Km(3) 
ALWTYPES IN BLACK AND COWURED CHILDREN 
Glm(O+/+ Glm(f)+/- Glm(O-/-
Black 2 1 135 
n = 138 (1.5 % ) (0.7%) (97.8%) 
Coloured 76 65 130 
n = 271 (28.0%) (24.0%) (48%) 
G2m(n)+/+ G2m(n)+/- G2m(n)-/-
Black 0 4 134 
n = 138 (0%) (2.9%) (97.1 %) 
Coloured 53 40 178 
n = 271 (19.6%) (14.8%) (65.7%) 
Km(3) +ve Km(3) -ve NT* 
Black 124 7 7 
n = 138 (88.9%) (5.1 % ) (5.1 %) 
Coloured 260 6 5 
n = 271 (95.9%) (2.2%) (1.8%) 
* = Not typable 
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9.3.3.1 
The G2m(n) marker, like the Glm(f) allotype, is uncommon in Black 
children (2.9%) whereas the G2m(n) allotype was found in approximately a 
third of the Coloured children. This difference was statistically significant 
(OR = 18.55 (6.72 < OR < 70.82) p = 0.0001). The four G2m(n) 
positive Black children were all heterozygous for this marker, and 57% of 
Coloured children were homozygous and 43 % were heterozygous. 
The Km(3) allotype is common in both the Coloured children (95.9%) and 
Black children (88.6%) (Table 9. 7). 
Sex had no effect on the frequency of either the Glm(f), G2m(n) or Km(3) 
allotypes. 
Discussion 
The frequency of the Glm(f), G2(m)n and Km(3) allotypes in South African 
Black and Coloured populations is not known. The Glm(f) and G2m(n) 
allotypes are typical Caucasian alleles, the frequency of which varies in 
Europe from 0.6 to 0.8 and 0.4 to 0.6 respectively. The frequency of the 
Km(3) allotype is about 0.9 in Caucasoids and varies from 0.5 to 0.8 for 
Negroids (Lefranc and Lefranc 1990). 
The Glm(f) and G2m(n) frequencies differ between the Black and Coloured 
children. The frequencies of the Glm(f), G2m(n) and Km(3) allotypes were 
respectively 52.4%, 35.6% and 93.97% in Coloured children and 2.2%, 
2.9% and 93.4% in Black children in the Western Cape. Glm(f) and 
G2m(n) have been reported to be completely absent in Black populations (de 
Lange 1991). However, Granoff et al (1984) found the G2m(n) allotype 
infrequently (13 % ) in North American Blacks. When present in Black 
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9.3.4 
9.3.4.1 
populations this allotype may reflect racial admixture. In this study the 
G2m(n) was present in 2.9% of Black children and the fact that these were 
all heterozygous supports this hypothesis. In studies of immunoglobulin 
allotypes appropriate local race matched control groups are therefore 
important in assessing whether a specific allotype is significantly over- or 
under-represented in the study groups. 
Influence of allotype on lgG and lgG subclass concentrations 
Influence ofGlm(f) on IgG, IgGJ, IgG2, IgG3, IgG4 
In male Coloured children the G 1 m(t) positive allotype was associated with 
lower IgG and IgG 1 levels and higher IgG2 and IgG3 levels when compared 
to children with absence of this allotype. In female Coloured children the 
Glm(t) allotype was only statistically associated with higher IgG2 levels 
although the other trends seen in male children were detectable (Table 9. 8). 
This effect of the Glm(t) allotypes on the IgG, IgGl and IgG3 subclass 
levels in Coloured male children was unaffected by the presence or absence 
of the G2m(n) allotype. 
There were insufficient G 1 m(t) positive Black children (3/ 138) on which to 
do meaningful statistical analysis. 
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TABLE 9.8: RELATIONSHIP BETWEEN THE Glm(O AND G2m(n) 
ALWTYPE AND IgG SUBCLASS LEVELS IN COLOURED 
CHILDREN 
Geometric Mean Antibody Concentration (g/1) 
Coloured male Glm(O Coloured female G lm(O 
n = 107 n = 90 n = 34 n = 40 
+ + 
IgG 12.57* 13.61 13.47 13.56 
IgGl 10.12* 11.03 11.70 11.15 
IgG2 1.10** 0.83 1.00* 0.73 
IgG3 0.53* 0.46 0.60 0.48 
IgG4 0.23 0.22 0.13 0.19 
Coloured male G2m(n) Coloured female G2m(n) 
n = 74 n = 123 n = 19 n = 55 
+ + 
IgG 12.65 13.28 13.14 13.65 
IgGl 10.40 10.83 11.19 11.48 
IgG2 1.25** 0.83 1.21** 0.73 
IgG3 0.50 0.48 0.57 0.52 
IgG4 0.23 0.22 0.13 0.18 
* p = < 0.05 •• p = < 0.01 
The effects of homo- and heterozygosity of Glm(t) on Coloured male and 
female children's IgG subclass levels are shown in Table 9. 9. In most cases 
where differences were noted between G 1 m(t) homozygote positives and 
negatives (lgG, IgGl, IgG2, IgG3), intermediate levels were seen in 
heterozygotes. 
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9.3.4.2 
TABLE 9.9: RELATIONSHIP OF HOMO- AND HETEROZYGOUS 
G lm(O ALLOTYPES AND IgG SUBCLASS LEVELS IN COLOURED 
CHILDREN 
Glm(O +I+ +I- -/-
Males n = 61 (31.0%) n = 46 (23.3%) n = 90 (45.7%) 
g/1 g/1 g/1 
IgG 12.17 12.93 13.61 
IgGl 9.51 * 10.94 11.03 
IgG2 1.16 1.02 0.83 
IgG3 0.52 0.54 0.46 
IgG4 0.25 0.19 0.22 
Glm(O +I+ +I- -/-
Females n = 15 (20.3%) n = 19 (25.7%) n = 40 (54.0%) 
g/1 g/1 g/1 
IgG 13.24 13.19 13.56 
IgGl 10.49 12.60 11.15 
IgG2 0.88 1.06 0.73 
IgG3 0.55 0.63 0.48 
IgG4 0.12 0.13 0.19 
* p = < 0.05 denotes a significant difference of the subclass levels between 
homozygous and heterozygous Glm(f) allotype individuals 
Influence of G2m(n) on IgG, IgGJ, lgG2, JgG3 and IgG4 
The effect of G2m(n) allotypes on subclass levels is shown in Table 9.8. 
Both male and female Coloured children had significantly higher IgG2 levels 
associated with the G2m(n) positive allotype. 
Heterozygotes for G2m(n) had higher mean levels than either G2m(n) 
homozygous positive or negative children (Table 9.10). 
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9.3.4.3 
As in the Glm(f) analysis, there were too few G2m(n) positive Blacks 
(4/134) for accurate statistical analysis on the effect of the marker on the 
IgG subclass levels. 
TABLE 9.10: RELATIONSHIP OF HOMO- AND HETEROZYGOUS 
G2m(n) ALWTYPES AND lgG SUBCLASS LEVELS IN COWURED 
CHILDREN 
G2m(n) +!+ +!- -!-
Males n = 42 (21.3%) n = 32 (16.2%) n = 123 (62.4%) 
g/1 g/1 g/1 
IgG 12.45 12.82 13.28 
IgGl 9.86 10.26 10.83 
IgG2 1.05 1.56* 0.83 
IgG3 0.53 0.50 0.48 
IgG4 0.21 0.25 0.22 
G2m(n) +I+ +!-
-!-
Females n = 11 (14.9%) n = 8(10.8%) n = 55 (74.3%) 
g/1 g/1 g/1 
IgG 13.45 13.47 13.65 
IgGl 11.90 11.72 11.48 
IgG2 1.22 1.47* 0.73 
IgG3 0.62 0.53 0.52 
IgG4 0.13 0.14 0.18 
* p = < O.OS denotes a significant difference of the subclass levels between 
heterozygous and homozygous positive and negative G2m(n) individuals 
The combined effect of Glm(/) and G2m(n) on lgG subclass levels 
The combined presence of the Glm(f) and G2m(n) allotypes resulted in a 
statistically significant increase in IgG2 levels (Tables 9.11). This is 
probably largely due to the influence of the G2m(n) allotype on IgG2 levels 
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as the IgG2 level was significantly higher in G2m(n) positive Coloured male 
and female children (Table 9.8). The presence or absence of the Glm(t) 
marker did not influence the IgG2 levels of the G2m(n) positive male 
controls (p= 0.42) {Table 9.11). 
TABLE 9.11: THE COMBINED EFFECT OF Glm(f) AND G2m(n) 
ON lgG SUBCLASS LEVELS IN COWURED MALE CHILDREN 
IgG 
IgGl 
IgG2 
IgG3 
IgG4 
IgGlm(f)+ve COWURED MALE CONTROLS 
lgG2m(n) + ve 
n = 69 
g/l 
12.53 
10.04 
1.25 
0.55 
0.23 
IgG2m(n)-ve 
n = 38 
g/l 
12.42 
10.20 
0.86 
0.50 
0.22 
p 
0.853 
0.784 
0.0001 
0.340 
0.913 
These IgG2 levels were unaffected by the accompanying Glm(t) +ve or -ve 
haplotype {Table 9.11). The G2m(n) negative control children had a low 
mean concentration of IgG2 whether they were G 1 m(t) positive or negative. 
Heterozygotes ( n/-) and positive homozygotes had high IgG2 levels 
regardless of the accompanying haplotype. 
The G2m(n) allotypic marker did not affect the IgG, IgGl, IgG3 or IgG4 
subclass levels of Coloured control children. 
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9.3.4.4 
9.3.4.5 
Influence of Km(3) on IgG, IgGJ, IgG2, IgG3, IgG4 
The IgG and IgG subclass levels were unaffected by the accompanying 
Km(3) allotype. Although there were very few Km(3) negative samples the 
subclass levels of these specimens all fell within the mean + /- 2 SD range 
of the Km(3) positive controls. 
Summary 
Allotype-associated differences have been reported for IgG 1, IgG2 and IgG3 
(van der Giessen et al 1975; Grubb et al 1986; Sarvas et al 1991; Oxelius 
1993). The molecular mechanism which explains why allotypes affect IgG 
subclass concentrations is unknown. 
Analysis of the effect of the Glm(f) and G2m(n) allotypic markers on the 
IgG, IgGl, IgG2, IgG3 and IgG4 subclass levels was not possible in Black 
children due to the small numbers which were positive for these markers. 
In Coloured children the Glm(f) allotype was associated with decreased IgG 
and IgGl levels and increased IgG2 and IgG3 levels. The Glm(f) positive 
heterozygotes were mostly associated with intermediate levels. Although the 
male and female Coloured children were different when analysing the effect 
of the Glm(f) allotype, these differences were only noted in the degree of 
significance and not in the trends. The fact that a greater statistical 
significance was found in male children may be due to the greater numbers 
in this group. It may be valid to draw similar conclusions on the effects of 
allotypes on IgG subclass levels in both male and female Coloured children. 
Litwin and Balaban (1972) found Glm(f) individuals to have higher 
concentrations of IgG 1 than those lacking the marker. G 1 m( f) negative 
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Finnish individuals have significantly higher IgGl levels than Glm(f) 
positive individuals (Sarvas et al 1991). 
IgG2 levels were higher in the Coloured children who have the G2m(n) 
allotype when compared to those negative for the marker. Average 
concentrations of IgG2 were 50.6% and 74.9% higher respectively in 
G2m(n) positive children than in G2m(n) negative Coloured male and 
female children. There was no effect of this marker on the other IgG 
subclass concentrations. A high concentration of IgG2 has been found to be 
associated with the G2m(n) allotype in several studies (Morell et al 1972b; 
van der Giessen et al 1975; Sarvas et al 1990; Sarvas et al 1991). Steinberg 
et al 1973 did not find a correlation between the G2m(n) allotype and IgG2 
levels. 
The male and female Coloured children who were G2m(n) positive 
heterozygotes, had IgG2 concentrations 88 % and 101 % higher respectively, 
than homozygous negative individuals. The homozygous positive male and 
female Coloured children had IgG2 levels 26% and 67% higher respectively 
than the homozygous negative individuals. 
There is no obvious explanation why the G2m(n) heterozygotes had higher 
IgG2 levels than G2m(n) homogygotes. Steinberg et al (1973) previously 
reported that IgG2 concentrations of G2m(n) heterozygotes were higher than 
G2m(n) positive homogyzotes. Other studies have found the heterozygotes 
to have intermediate levels between positive and negative homozygotes 
(Sarvas et al 1991). 
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The positive effect of Glm(t) on IgG2 was only seen in G2m(n) positive 
children. This increase in IgG2 is mainly due to the effect of the G2m(n) 
allotype. 
Because of the infrequency of both the Glm(t) and G2m(n) allotype in 
Blacks it was not possible to analyse the effects of these allotypes on IgG 
subclass levels. However, it is worth noting that Black children had higher 
levels of IgGl and IgG2 even though the majority were Glm(t) and G2m(n) 
negative whereas in Coloured children this resulted in lower IgG 1 and IgG2 
levels. 
The Km(3) negative allotype was infrequent in both the Black and Coloured 
children and had no effect on the IgG subclass levels. 
9.4 C4 PROTEIN TYPING 
9.4.1 Measurement of C4A and C4B 
Assays for the determination of C4A and C4B were performed by Dr P 
Creemers, Department of Tissue Immunology, Medical School, University 
of Cape Town using the following methods. 
Sera were pretreated overnight at room temperature with carboxypeptidase B 
and neuraminidase. Electrophoresis was performed in 0.45% (w/v) agarose 
gel at 500 V for 3 hours using a discontinuous Tris-glycine-barbital buffer 
system. The C4 migration patterns were detected by immunofixation with a 
sheep anti-human C4 serum and stained with 0.1 % Coomassie blue. C4A 
and C4B proteins were distinguished by haemolytic overlay gel (Mauff et al 
1983; Sim and Cross 1986; Zhang et al 1988). Alleles were assigned by 
visual comparison with known alleles, as well as by calculation of the 
relative migration. These assignment methods were performed 
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independently by two different technologists. In the case of disagreement 
the samples were re-run. 
9.4.2 Samples 
The control groups for the C4 typing were 260 Black adults, 100 Coloured 
adults and 69 White adults. These normal control sera were supplied by the 
Department of Tissue Immunology from their sera bank. 
9.4.3 C4 isotype frequencies 
Black adults had a statistically significant increased frequency of C4B 
deficiency (C4B*QO) (p = < 0.001) and a decreased frequency of C4A 
deficiency (C4A *QO) (p = < 0.001) as compared to White adults (Table 
9.12). The difference in these antigen frequencies between Black and 
Coloured adults and between Coloured and White adults was not statistically 
significant. 
TABLE 9.12: C4A *Qo AND C4B*Qo ANTIGEN FREQUENCY 
** ANTIGEN FREQUENCY 
C4A*Qo C4B*Qo 
Controls 
** 
White ( n = 69) 0.241 0.060 
Coloureds (n = 100) 0.093 0.130 
Blacks (n = 260) 0.069 0.250 
Distribution for the null alleles conformed to the Hardy Weinberg equilibrium 
for homozygosity 
Population group differences in the frequency of the complement genes have 
been shown (Imanishi et al 1991) but no significant differences in the 
frequency of homozygous C4B deficiency have been found between adults 
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and children or between healthy Black and Caucasian Americans (Rowe et al 
1989; Bishof et al 1990). However, in these reports the groups were small 
and may not have been suitable for accurate statistical analysis. Greater 
admixture of Caucasian genes in the American Blacks, as compared to South 
African Blacks may also explain these differences. 
9.5 MANNOSE BINDING PROTEIN (MBP) 
9.5.1 MBP Assays 
Measurement of human MBP levels was performed by Professor M W 
Turner, The Molecular Immunology Unit, Institute of Child Health, 
University of London. The method used was a sandwich ELISA 
(Lipscombe et al 1992). Briefly, a mouse monoclonal antibody to human 
MBP (MAB 37) diluted to 1 µg/ml in carbonate-bicarbonate buffer was 
coated onto Dynatech microtitre plates overnight at 4 °C. After washing 
with PBS/T serum samples were incubated in the coated plates for 100 
minutes at 37°C. After washing, horseradish peroxidase conjugated 
streptavidin was added and incubated for 60 minutes at 37°C before the 
addition of the substrate OPD. 
9.5.2 Control samples 
The normal controls for the MBP measurement were 55 healthy Black adults 
supplied from the Western Province Blood Transfusion Service, Cape Town. 
9 .5 .3 MBP levels 
The median levels and 95 % confidence intervals of serum MBP in the South 
African Blacks were 2386 (1256-3706) ng/ml with a range (mean ± 2 SD) 
of ~ 10-5779 ng/ml. 
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In this study MBP deficiency was defined as a MBP concentration ~ 10 
ng/ml. Using this definition 3.6% (2/55) of the Black adult controls had a 
MBP deficiency. The frequency of MBP deficiency in healthy Caucasian 
and Chinese populations has been estimated to be between 5 % and 10% 
(Turner 1991). 
Racial differences of MBP have been reported (Lipscombe et al 1992). 
They found the Chinese had significantly higher levels than the Caucasians 
and Gambians. The levels of the Black South African adult controls were 
not significantly different to those of the Caucasians and Gambians (Figure 
9.6). 
0----=---"'.·-:--------:-..... •--:-----...._1 _____ .__1 _ __. 
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Figure 9.6: The median levels, 95% confidence intervals (95% CI) and 5% confidence 
intervals (5% CI) of serum mannose binding protein levels in Gambian, Caucasian, 
Chinese (Lipscombe et al 1992) and South African Black adults 
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9.6 SUMMARY OF MAIN FINDINGS 
• IgG and IgG subclass age related percentile ranges were established 
for children in the Western Cape from 4 months to 12 years of age. 
• Due to statistically significant racial differences separate normal 
ranges were established for Black and Coloured children. 
• A sex difference was found in Coloured children for IgG, IgG 1, 
IgG3 and IgG4 but not IgG2. Thus separate charts were created for 
Coloured male and Coloured female children. 
• The serum IgG subclasses do not increase in parallel 
• The proportions of the IgG subclasses in children differ from those 
of adults 
• The Glm(t) allotype was present in 52% of the Coloured children 
but in only 2.2 % of the Black children. The G2m(n) marker 
occurred in 34.4% of the Coloured children and in 2.9% of the 
Black children. The Km(3) allotypes was very common in both 
Coloured and Black children. 
• As the Glm(t) and G2m(n) allotypes are uncommon in Black 
children it was not possible to assess the effect of these markers on 
the IgG subclasses in these children. 
• The Glm(t) marker had a negative influence on IgG and IgGl levels 
and a positive effect on IgG2 and IgG3 levels of Coloured children. 
• G2m(n) negative Coloured children had lower IgG2 levels than 
G2m(n) positive children. 
• 
• 
• 
Km(3) allotype did not affect the IgG subclass levels . 
The Black and Coloured adult controls had a higher frequency of 
C4B*Qo deficiency than the White adult controls. 
Mannose Binding protein deficiency was found in 3. 6 % of Black 
South Africans which is similar to that reported for Caucasians, 
Chinese and Gambians. 
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CHAPTER 10 
PATIENTS - RESULTS AND DISCUSSION 
This chapter reports the results obtained in children with Haemophilus influenzae 
meningitis or osteomyelitis/septic arthritis and children with S.aureus osteomyelitis/septic 
arthritis. 
10.1 PATIENTS - a description of the patient groups including details of 
infection and the race, sex, age and nutritional status of the patients. 
10.2 IgG and IgG SUBCLASSES - an analysis of immunoglobulin levels in the 
patient groups compared to the normal age matched controls and analysis of 
changes during the course of the disease. 
10.3 ANTI-Hib PRP ANTIBODIES - Results of specific antibody assays for 
anti-Hib PRP during the course of infection 
10.4 ANTI-S.AUREUS TEICHOIC ACID ANTIBODY - Results of specific 
teichoic acid antibody assays in sera from patients with S.aureus 
osteomyelitis/septic arthritis 
10.5 ANTI-TETANUS TOXOID ANTIBODIES - used as an assessment in 
patients of the capacity of their immune system to respond to antigenic 
stimulation with tetanus toxoid immunization 
10.6 Glm(f), G2m(n) AND Km(3) ALLOTYPES - the frequency of these 
allotypes in the patient groups and comparison to those obtained in normal 
control groups 
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10. 7 C4 PROTEIN TYPING - a description of the frequency of C4A *QO and 
C4B*QO in the Hib meningitis patients and comparison with the frequency 
of these haplotypes in normal control subjects 
10.8 MANNOSE BINDING PROTEIN - a descriptiion of levels of MBP in the 
patient groups and comparison with local and reported levels of MBP in 
normal groups 
10.9 SUMMARY 
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10.1 PATIENTS 
10.1.1 
Children admitted to the Red Cross War Memorial Children's Hospital 
between February 1988 and December 1991 with bacteriologically proven 
H. infiuenzae type b (Hib) meningitis, Hib osteomyelitis/ septic arthritis 
(OM/SA) and S.aureus OM/SA were enrolled into the study. Permission 
for collection of samples was obtained from the Ethics and Research 
Committee, University of Cape Town and from the children's parents. 
Blood was collected under sterile conditions. Test serum was stored at 
-70°C in small aliquots in order to avoid repeated freezing and thawing of 
the samples. 
None of the 100 randomly selected samples from these patients were HIV 
positive. 
Meningitis 
Sera from 89 children with bacteriologically proven Hib meningitis were 
collected. All patients had either a positive cerebrospinal fluid (CSF) or 
blood culture for H. infiuenzae. H. infiuenzae capsular type b was confirmed 
by slide agglutination (Murex, Dartford, England, Catalogue No ZM21). 
In addition all the patients had a CSF compatible with bacterial meningitis 
including: pleocytosis with predominance of polymorphs, and reduced CSF 
glucose ( < 60% of serum glucose) and/or a raised CSF protein ( ~ 0.5 g/1). 
Blood specimens were taken on admission, 7-10 days later (2nd specimen) 
and 6 weeks later at a follow-up appointment (3rd specimen). 
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10.1.2 
10.1.3. 
Osteomyelitis/septic Arthritis (OM/SA) 
Race 
207 children admitted to the Red Cross War Memorial Children's 
Hospital during the period 1987-1991 with clinically diagnosed 
OM/SA were studied. In all patients S.aureus or Hib were isolated 
from pus aspirates or blood culture. 
The diagnosis of acute osteomyelitis was made when pus was found 
during surgical drainage, or if not operated, on when subsequent 
bony changes developed on X-ray. 
Only patients with primary acute bone and joint infections were 
included in this study. Patients with subacute osteomyelitis and with 
bone and joint infection secondary to compound fractures or 
penetrating joint injuries were excluded. 
Patients were immunized with 0.5 ml adsorbed tetanus toxoid 
vaccine on admission. Blood specimens were taken on admission 
prior to the tetanus toxoid immunization and again 3-4 weeks later at 
a follow-up visit. 
The ethnic distribution of the patients is shown in Table 10.1. There were 
two white children with Hib meningitis and 2 with S. aureus OM/SA. 
Because of the small number of white patients and controls these have not 
been included in further analysis. 
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TABLE 10.1: ETHNIC AND SEX DISTRIBUTION OF PATIENTS 
Black 
Coloured 
TOTAL 
Black 
Coloured 
TOTAL 
Black 
Coloured 
TOTAL 
Female 
18 
28 
46 
Female 
8 
5 
13 
Female 
17 
51 
68 
Hib Meningitis 
Male 
14 
27 
41 
Hib OM/SA 
Male 
8 
12 
20 
S. aureus OM/SA 
Male 
29 
75 
104 
Total 
32 
55 
87 
Total 
16 
17 
33 
Total 
46 
126 
172 
SECTION B: Chapter JO: Patients - Results and Discussion 319 
10.1.4 
In the Rib meningitis patients and S.aureus OM/SA patients the majority of 
patients were Coloured children. This ethnic distribution is comparable to 
hospital in-patient admission ratios and to the control group. However, in 
the Rib OM/SA patients there was an equal distribution of Black and 
Coloured patients (Table 10.1). 
Sex 
The sex distribution of the patients is shown in Table 10.1. In the patients 
with OM/SA the overall sex ratio of 1.53: 1 of male to female patients is in 
keeping with the male preponderance in most previous studies (Dich et al 
1975; Waldvogel and Vasey 1980; Hoffman et al 1990). In contrast there 
was an equal distribution of male to female patients in the Rib meningitis 
group. 
10.1.5. Age 
The patients with Rib meningitis and Rib OM/SA were of similar ages and 
in both groups the patients were significantly younger than those with 
S.aureus OM/SA (Table 10.2). There was no significant difference between 
the ages of the Coloured and Black patients in any of the groups. 
TABLE 10.2: AGE DISTRIBUTION IN MONTHS OF PATIENTS 
Hib meningitis 
Rib OM/SA 
S. aureus OM/SA 
Mean 
12.2 
12.6 
82.5 
Median 
8.4 
11.2 
85.8 
25 centile 
6.1 
8.7 
53.5 
75 centile 
11.9 
16.6 
118.8 
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10.1.6 Nutritional status 
A child was considered undernourished if the weight for age percentiles was 
lower than the third percentile. 
There was no significant difference in the weight for age percentiles between 
the Hib OM/SA and S.aureus OM/SA patient groups (Table 10.3). There 
were statistically significantly fewer Hib meningitis children with weight for 
age percentiles below the third percentile when compared to Hib OM/SA 
group (p = 0.03) or the S.aureus OM/SA group (p = $; 0.01). Previous 
studies (Rosen and Davis 1980; Mulla et al 1984) have shown no association 
between meningitis and malnutrition and this is confirmed in this study. 
Although the S. aureus OM/SA group of children are older than the Hib 
OM/SA group the above findings did not alter whether the comparison was 
made to the S.aureus group as a whole or just to those children less than 48 
months. 
TABLE 10.3: WEIGHT FOR AGE PERCENTILE OF PATIENTS 
Hib meningitis 
Hib OM/SA 
S. aureus OM/SA 
~ 3rd Percentile 
15.2% 
27.2% 
20.9% 
~ 3rd Percentile 
84.8% 
72.7% 
79.1 % 
It was not possible to determine the weight for age percentiles in the control 
group of children but a study from Khayelitsha (a black housing area of 
Cape Town) found 10-20% of preschool ( < 6 years) children fell below the 
third percentile for weight for age (Hugo-Hamman et al 1987). An earlier 
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study (Jacobs et al 1988) found similar percentages of Coloured preschool 
children ::; 3rd percentile weight for age. 
Malnutrition has been linked to many abnormalities which may leave the 
patient more vulnerable to bacterial infection (Gross and Newberne 1980). 
This does not seem to be a major contributing factor in the predisposition of 
patients to Hib meningitis, Hib OM/SA and S.aureus OM/SA in this study. 
10.2 lgG AND IgG SUBCLASSES 
10.2.1 
The IgG and IgG subclasses of Hib meningitis, Hib OM/SA and S.aureus 
OM/SA patients (taken on admission) were compared to the age, sex and 
race matched normal range of healthy children comparing frequencies based 
on quartile categories. The four categories compared were ~ 75th 
percentile; 50-75th percentile; 25-50th percentile and ::; 25th percentile. 
The Chi-square test was used to determine whether there were equal 
numbers of patients in each category. 
As IgG subclass levels are age related, statistical analysis was done using 
ANCOVA with age as a covariant, to counteract this, so the comparisons 
were age related. 
Patients vs controls 
Results in patients are displayed graphically using multiple notched Box-and-
Whisker plots. These plots display the median value and the range and 
distribution of data (Figure 10.1). The central box represents the range of 
data values from the 25th to the 75th percentile. The 'whiskers' extend out 
to the minimum and maximum values that are within 1.5 times the 
interquantile range. The other values (beyond 1.5 times the box length 
(interquantile range)) are plotted as separate points. The central line is the 
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10.2.1.1 
median (50th percentile). The notch of each box corresponds to the width 
of the confidence interval for the median. The confidence level on the 
notches allows comparisons to be made at the 95 % level by examining 
whether the two notches overlap. The width of the box is proportional to 
the square root of the number of observations in the data set. 
40 
30 
20 
10 
Figure 10.1: Example of a notched Box-and-Whisker plot 
Hib meningitis 
The IgG 1, IgG2 and IgG4 levels of the Black children with Hib meningitis 
were significantly decreased compared to control values (Figure 10.2a). 
Both male and female Coloured children showed significantly decreased 
IgG4 levels (Figures 10.2b and 10.2c). 
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Figure 10.2a: Comparison of the distribution of IgG and IgG subclass values in Black 
children: child controls (BCC); children with Hib meningitis (HibM); children with Hib 
osteomyelitis/septic arthritis (BHibO) and children with S. aureus osteomyelitis/septic 
arthritis (BSAO). A * denotes a statistically significant difference (p ~ 0.05) between the patient groups and controls. 
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Figure 10.2b: Comparison of the distribution of IgG and IgG subclass values in Coloured male children: controls (CCC); children with Hib meningitis (CHibl\f); 
children with Hib osteomyelitis/septic arthritis (CHibO) and children with S.aureus 
osteomyelitis/septic arthritis (CSAO). A * denotes a statistically significant difference ( p s 0.05) between the patient groups and controls. 
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Figure 10.2c: Comparison of the distribution of IgG and IgG subclass values in 
Coloured female children: child controls (CCC); children with Hib meningitis 
(CHibM); children with Hib osteomyelitis/septic arthritis (CHibO) and children with 
S.aureus osteomyelitis/septic arthritis (CSAO). A * denotes a statistically significant 
difference ( p s 0.05) between the patient groups and controls. 
SECTION B: Chapter JO: Patients - Results and Discussion 326 
10.2.1.2 
10.2.1.3 
10.2.1.4 
Hib OM/SA 
No significant differences in the IgG and IgG subclasses of the Hib OM/SA 
patients in either racial group were found when compared to the controls 
(Figures 10.2a, 10.2b and 10.2c). 
S.aureus OM/SA 
The IgG, IgG 1 and IgG3 of Black patients with S. aureus OM/SA were 
significantly increased. The IgG and all the IgG subclasses were 
significantly increased in male and female Coloured children. 
Discussion 
The relationship between selective IgG subclass deficiencies and 
susceptibility to infection is controversial and has been reviewed recently by 
Smith (1992). The first report of a selective IgG deficiency and 
susceptibility to recurrent pyogenic infection was from Schur et al (1970). 
Subnormal levels of one or more of the IgG subclasses have been shown to 
be associated with an increased susceptibility to bacterial infections 
especially of the respiratory tract (Schur et al 1970; Oxelius 1974; Stanley et 
al 1984) and otitis media (Friejd et al 1985). 
Decreased IgG subclass concentrations have been reported in children with 
osteomyelitis and septic arthritis (Gottsegen 1987; Beard et al 1990). The 
incidence of subclass aberrations in patients with Hib meningitis, Hib 
OM/SA and S.aureus OM/SA has not been well documented. 
In this study Black children with Hib meningitis had statistically lower levels 
of IgG 1, IgG2 and IgG4 whereas Coloured children had only lower IgG4 
levels. The IgG and IgG subclasses of the Hib OM/SA group were no 
different to the controls. In contrast the S. aureus OM/SA patients generally 
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had increased IgG and IgG subclass levels which may be interpreted as an 
appropriate response to a bacterial infection. 
The age difference in patients with infections due to S. aureus or Hib (Table 
10.2) may be one explanation as to why the S.aureus OM/SA patients but 
not the Hib OM/SA group of patients responded to the infection with an 
increase of IgG and IgG subclass levels. As the majority of people have 
detectable teichoic acid antibody levels (from previous exposure to cross-
reacting antigens) a superimposed S.aureus OM/SA infection could give rise 
to a secondary antibody response in older patients. 
No evidence was found for a deficiency of IgG or IgG subclass levels in 
acute Hib OM/SA or S.aureus OM/SA. 
This finding is in disagreement of those of Eid et al (1980) who found that 
the majority of patients with primary S. aureus osteomyelitis had a 
depression of their IgG, IgM and IgA immune response to an acute 
infection. 
The results in this study point to a possible association between susceptibility 
to Hib meningitis and low IgG 1, IgG2 and IgG4 subclasses in Black patients 
and low IgG4 levels in Coloured patients. Although not statistically 
significant both the Coloured male and female children with Hib meningitis 
also showed a trend of low IgG 1 and IgG2 levels. 
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10.2.2 
10.2.2.1 
10.2.2.2 
IgG and IgG subclass levels during disease 
Serum IgG and IgG subclass levels 
The IgG or IgG subclass levels did not increase during the course of the 
disease in patients with Hib meningitis or Hib OM/SA. A significant 
increase of IgG, IgG 1 and IgG2 levels occurred during the course of the 
disease in patients with S.aureus OM/SA. There was no increase in IgG3 
levels. The IgG4 levels of the of S. aureus OM/SA patients tended to 
increase during the course of the disease but this difference was only 
statistically significant in the Coloured female patients (Table 10.4). 
TABLE 10.4: COMPARISONS OF IgG AND IgG SUBCLASS 
VALUES IN INITIAL AND FOLWW-UP SPECIMENS DURING THE 
COURSE OF THE DISEASE IN S.AUREUS OM/SA PATIENTS 
Black Patients Coloured Male 
Patients 
1 2 1 2 
IgG 20.23 26.32* 16.21 22.56* 
IgGl 17.96 23.81 * 13.87 18.90* 
IgG2 1.15 1.88* 1.03 2.1s* 
IgG3 0.88 1.03 0.74 0.82 
IgG4 0.36 0.50 0.33 0.49 
• p = < 0.05 
1 = Initial specimen taken at the time of diagnosis of disease 
2 = Specimen taken at time of follow-up (3-4 weeks later) 
Discussion 
Coloured 
Female Patients 
1 2 
17.14 22.11* 
14.37 18.98* 
1.03 2.15* 
0.73 0.77 
0.27 0.40* 
Earlier studies have shown an impaired IgG antibody response in young 
children with Hib meningitis (Norden et al 1972; O'Reilly et al 1975). 
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Kouvalainen et al (1977) found that although IgG levels increased over 2 
weeks during bacterial meningitis due to other organisms no rise in IgG 
levels were seen in children with Hib meningitis. This is in agreement with 
the findings in these studies. Children with S. aureus OM/SA showed an 
increase of IgG, IgG 1 and IgG2 antibodies during the course of disease 
although children with Hib OM/SA did not. This suggests that impairment 
of IgG and IgG subclass responses may be involved in the pathogenesis of 
Hib meningitis and Hib OM/SA but not S. aureus OM/SA. It may also, 
however, be a reflection of the different mean age of the groups and the 
capacity for older children to increase their IgG levels in response to 
infection. 
10.3 ANTI-Hib PRP ANTIBODIES 
10.3.1 
An impaired antibody response has been described in children with IgG 
subclass deficiencies (Umetsu et al 1985; Insel and Anderson 1986). 
Selective antibody deficiency to polysaccharide antigens can also be present 
in patients with normal IgG subclass concentrations (Ambrosino et al 1988). 
Analysis of PRP antibodies 
The assays used to measure the IgG, IgGl and IgG2 subclass specific anti-
Hib PRP antibodies have been detailed in Section A, Chapter 4.3. The 
assays are specific and sensitive with lower limits of detection of 0.011 
µg/ml for IgG, 0.012 µg/ml for IgG 1 and 0.006 µg/ml for IgG2. 
The minimum concentration of PRP antibody necessary for protection is not 
precisely known. Robbins et al (1973) estimated the protective serum level 
of anti-Hib antibody to be 0.06-0.1 µg/ml, whilst Kayhty et al (1983) 
estimated it to be 0.15 µg/ml in non-vaccinated serum. A level of 1 µg/ml 
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10.3.1.1 
of anti-Hib PRP antibody was associated with protection after immunization 
with a polysaccharide vaccine (Kayhty et al 1983b; Anderson 1984). 
These levels cannot be equated with the values obtained in this study as all 
the methods measured total PRP antibody with a RABA assay. In this study 
IgG, IgG 1 and IgG2 subclass specific antibodies were measured using an 
ELISA. 
The antibody concentrations in the majority of Hib meningitis and Hib 
OM/SA patients were less than 0.15 µglml. To aid in the analysis cut-off 
values were selected based on the lower limits of detection of the assays and 
on estimated protective values from the literature as discussed above. The 
data were analysed in 4 groups: undetectable; less than 0.06 µg/ml; between 
0.06 and 0.15 µg/ml; and greater than 0.15 µg/ml (Table 10.5). The lower 
limit of detection for IgG was 0.012 µg/ml, for IgGl was 0.012 µg/ml and 
for IgG2 was 0.006 µglml. 
There was only sufficient serum to measure Hib PRP antibodies from 69 of 
the 87 patients with Hib meningitis. Of these only 58 had a second sample 
(on average 10 days later) and 27 a third sample (on average 40 days later). 
There was only sufficient serum on 31 of the 33 patients with Hib OM/SA 
for Hib PRP antibody measurement and only 19 patients had a second 
specimen. 
IgG Hib PRP antibody levels 
The Hib meningitis and Hib OM/SA patients had very low levels of Hib 
PRP antibody levels (Table 10.5) 
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TABLE 10.5: CONCENTRATIONS OF IgG, IgGl AND IgG2 Hib 
PRP ANTIBODIES IN CHILDREN WITH Hib MENINGITIS AND Hib 
OM/SA ON ADMISSION 
IgG PRP IgGl PRP lgG2 PRP 
Hib Meningitis 
Undetectable 11.6% 33.3% 96.7% 
< 0.06 µg/ml 55.1 % 52.2% 1.6% 
0.06-0.15 µg/ml 27.5% 11.6% 1.6% 
> 0.15 µg/ml 5.8% 2.9% 0% 
Hib OM/SA 
Undetectable 12.9% 19.4% 83.9% 
< 0.06 µg/ml 61.3% 74.2% 16.1 % 
0.06-0.15 µg/ml 22.6% 10.5% 0% 
> 0.15 µg/ml 3.2% 0% 0% 
27.5% of the Hib meningitis and 25.8% of the Hib OM/SA patients had an 
IgG Hib PRP antibody level greater than the minimum level considered to 
be protective (0.06 µg/ml) and only 5.8% and 3.2% respectively had a level 
greater than the more generally accepted protective level (0.15 µg/ml). 
14.5% of the Hib meningitis patients and 10.5% of the Hib OM/SA had a 
IgGl Hib PRP level ;;=: 0.06 µg/ml and only 2.9% of the Hib meningitis 
and none of the Hib OM/SA patients had levels ;;=: 0.15 µglml. Only 3.2 % 
of Hib meningitis and 16.1 % of Hib OM/SA patients had detectable IgG2 
Hib PRP antibodies present. 
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10.3.1.2 Hib PRP antibody levels during disease 
The IgG or IgG 1 specific Hib PRP antibody levels did not increase 
significantly during the course of the disease in Black or Coloured patients 
with Hib meningitis or with Hib OM/SA. However, 5% and 10% of 
follow-up specimens of the Hib meningitis and Hib OM/SA patients 
respectively had an IgG PRP level ~ 1.0 µg/ml whereas none of these 
patients had baseline levels ~ 1.0 µg/ml (data not shown). 
The IgG2 Hib PRP data was not analysed as the majority of the patients had 
undetectable antibody levels. 
10.3.1.3 Race 
10.3.1.4 
The Chi-square test was used to analyse any differences of Hib PRP 
antibody levels between Black and Coloured patients. Race had no effect on 
the IgG, IgG 1 or IgG2 Hib PRP antibody levels in either disease group. 
Discussion 
Using the assays developed in this study, which are sensitive and specific, 
the majority of infants had low ( ~ 0.15 µg/ml) baseline levels of Hib PRP 
antibodies. These levels are too low for statistical comparison with regard 
to the age of patients, to serum IgG and IgG subclass levels and to the 
influence of the allotypic markers Glm(f), G2m(n) and Km(3). 
There was a lack of specific Hib PRP antibody response in the children with 
Hib meningitis or Hib OM/SA during the course of the disease. This 
finding is in contrast to Rijkers et al (1988) who found that children below 2 
years of age do develop anti-PRP antibodies during the course of Hib 
meningitis. 
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Levels of Hib PRP antibodies were measured in five healthy children (12-15 
months old) pre- and two weeks post-Hib Titer vaccination. All of these 
children had detectable ( ~ 0.012 µg/ml) pre-immunization IgG and IgGl 
Hib PRP levels but none had protective levels ( ~ 0.06 µg/ml). 
Four responded to immunization with post immunization antibody levels 
increasing to protective levels ( ~ 0.15 µg/ml) although none had levels ~ 
1.0 µglml (Table 10.6). The baseline levels of IgG and IgGl antibodies to 
Hib PRP in the patients with Hib meningitis and Hib OM/SA were similar 
to those measured pre-immunization in these 5 healthy control children and 
to published data from similarly age matched children (Greenberg et al 
1987) and were generally less than 0.06 µg/ml. The majority of patients 
had low levels (not protective) of IgG and IgG 1 Hib PRP antibodies and 
only 5 % had detectable IgG2 Hib PRP antibody. In the immunized control 
children none of them had detectable IgG2 Hib PRP antibody before or after 
immunization (Table 10.6). 
TABLE 10.6: Hib PRP ANTIBODY LEVELS (µg/ml) IN 5 HEALTHY 
CHILDREN Th™UNIZED WITH Hib TITER VACCINE 
IgG IgGl IgG2 
Pre Post Pre Post Pre Post 
1 0.031 0.315 0.024 0.303 0.0 0.0 
2 0.057 0.140 0.036 0.210 0.0 0.0 
3 0.057 0.035 0.056 0.037 0.0 0.0 
4 0.032 0.715 0.027 0.638 0.0 0.0 
5 0.018 0.416 0.017 0.434 0.0 0.0 
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A strong correlation between IgG2 specific Hib PRP antibody and total PRP 
antibody in young children with invasive Hib disease has been shown 
(Ramadas et al 1986). Few of the patients in this study had IgG2 specific 
Hib PRP antibody. There are increasing reports that in young children most 
PRP antibody is of the IgG 1 subclass and a gradual shift to IgG2 is seen as 
the immune system matures (Hammarstrom and Smith 1986b). Although 
this assay is sensitive, specific and accurate and allows IgG, IgG 1 and IgG2 
specific Hib PRP antibodies to be quantitated it is not possible to determine 
the proportion of each subclass making up the total PRP antibody. Using 
these assays it has been demonstrated that young children with invasive Hib 
meningitis or OM/SA do not have or develop protective anti-Hib PRP 
antibodies which confirms previous findings (Ramadas et al 1986). 
10.4 ANTI-S.AUREUS TEICHOIC ACID ANTIBODIES 
The ELISA assays used to measure the IgG, IgG 1 and IgG2 antibodies have 
been detailed in Section A, Chapter 5.3. These assays are specific and 
sensitive with lower limits of detection of 0.001 units for IgG, and 0.005 
units for IgG 1 teichoic acid and IgG2 teichoic acid antibodies. 
The IgG, IgG 1 and IgG2 teichoic acid specific antibodies were measured in 
patients at the time of diagnosis of S. aureus OM/SA and again 3-4 weeks 
later. 
Levels of teichoic acid antibodies were also measured in 4 children with 
pneumococcal OM/SA, 11 children with Hib OM/SA and 16 children with 
group A 6-haemolytic streptococcal OM/SA. The mean age of these 
children was 47.4 months with a range of 2-145 months. 
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10.4.1 Anti-teichoic acid antibody levels 
S. aureus OM/SA patients all have IgG antibody to S. aureus ribitol teichoic 
acid. The majority of the antibody is IgG 1 and very few of the patients 
have significant levels of IgG2 (Figure 10.3). 
lcj; 
I~ 
70,,...i __________ _ 
8J .... .. .............................................................. .. 
lgG2 
100,,...i __________ __, 
!l) ..... .. ........................................................... . 
,10 
20 
a 
Figure 10.3: Serum lgG, lgGl and IgG2 teichoic acid (TA) antibody concentrations 
(units/ml) in children with S.aureus OM/SA (SA OM/SA) and in children with 
OM/SA due to organisms other than S.aureus (other OM/SA) 
Overall, there were no significant differences in the teichoic acid antibody 
levels measured in the specimens taken at the time of diagnosis and the 
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10.4.2 
specimen taken at follow-up a few weeks later. Because the antibody 
measurements were performed on sera obtained at various intervals after 
illness the effect of the length of time after illness on antibody level was also 
analysed. There was no significant correlation with time after illness and 
the IgG, IgG 1 and IgG2 teichoic acid specific antibody concentrations. 
These results were compared to the levels of teichoic acid antibody levels in 
patients with acute OM/SA due to organisms other than S. aureus i.e. 
S.pneumoniae (4 patients), Hib (11 patients) and group A fl-haemolytic 
streptococcus (16 patients). Arbitrary cut-off values for IgG, IgGl and 
IgG2 teichoic acid antibody levels were selected as shown in Figure 10.3. 
None of the 31 patients with OM/SA caused by organisms other than 
S.aureus had IgG teichoic acid levels greater than 2 units/ml whereas 71.2% 
of S.aureus OM/SA patients had levels above this. 
Similarly for IgGl, only 25.7% of patients with OM/SA other than S.aureus 
had levels greater than 2 units/ml whereas 90.1 % of the S.aureus OM/SA 
patients had levels in this range. 
16. 25 % of the S. aureus OM/SA patients had IgG2 teichoic acid levels 
greater than 0.5 units/ml and none of the other patients with OM/SA had 
levels above this. 
Race and age 
There was no difference m the teichoic acid antibody levels between the 
Black and Coloured patients. Nor was there any correlation between the 
IgG, IgGl and IgG2 teichoic acid antibody levels and age (r = 0.2; r = 
0.24 and r = 0.03 respectively). 
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10.4.3 Discussion 
Rising or elevated serum levels of antibodies to staphylococcal cell wall 
teichoic acid correlates with the development of serious infections due to 
S.aureus (Crowder and White 1972; Nagel et al 1975; Tuazon and Sheagren 
1976; Wheat et al 1978). 
Levels of teichoic acid antibodies vary substantially in normal control 
populations and in patients with various types of staphylococcal infections 
(Granstrom et al 1983; Wise and Tosolini 1992). 
The ELISA has been used to determine antibodies to teichoic acid 
(MacKowiak and Smith 1978; Verburgh et al 1981; Granstrom et al 1983; 
Hammarstrom et al 1984). Granstrom et al (1983) found increased IgG 
titres in 87% of patients with endocarditis, 79% with complicated 
septicaemia and 50% with uncomplicated septicamia in serum samples 
drawn between 7-30 days of disease onset. 
In the S.aureus OM/SA patients only 12.5% had IgG and 7.5% had IgGl 
teichoic acid antibody levels less than 1 unit/ml. In patients with OM/SA 
due to organisms other than S.aureus 87.1 % had IgG and 61.3% had IgGl 
teichoic acid antibody levels less than 1 unit/ml. In contrast 97.5% of 
S.aureus OM/SA patients and 100% of patients with OM/SA due to 
organisms other than S. aureus had IgG2 teichoic acid antibody levels less 
than 1 unit/ml. 
Of the patients with S.aureus OM/SA 43.8% and 72.8% respectively had 
IgG and IgG 1 teichoic acid antibody levels greater than 5 units/ml. Of the 
patients with OM/SA due to organisms other than S.aureus 0% and 16.0% 
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respectively had IgG and IgG 1 teichoic acid antibody levels greater than 5 
units/ml (Figure 10.3). 
These data show that in most children IgG 1 antibodies form the majority of 
the IgG teichoic acid antibodies and that very few children produce 
quantitative IgG2 teichoic acid antibody levels. In contrast previous studies 
have shown that anti-teichoic acid antibodies and antibodies against whole 
staphylococcus were primarily of the IgG2 subclass (Hammarstrom et al 
1984; Monteil et al 1990). 
No rise of anti-teichoic acid antibodies was observed in children during the 
course of S.aureus OM/SA. This latter finding makes the value of 
measuring IgG teichoic acid antibodies in acute S. aureus infection doubtful. 
10.5 ANTI-TETANUS TOXOID ANTIBODIES 
The response to booster tetanus toxoid immunization as measured by levels 
of anti-tetanus toxoid antibodies in serum was used as an indicator of 
immunological competence. Anti-tetanus antibody levels were determined 
in pre- and post-tetanus toxoid immunization samples in the children with 
Hib OM/SA and S.aureus OM/SA. In most of the Hib meningitis patients 
tetanus toxoid immunization was not given as they had recently had a 
routine diphtheria, pertussis, and tetanus immunization in the previous two 
months (documented on the clinic card). The tetanus toxoid antibody levels 
measured on the admission specimen were regarded in these patients as the 
post immunization specimens. 
The assays used to measure the IgG, IgG 1 and IgG4 tetanus toxoid 
antibodies are detailed in Section A, Chapter 3.3. The lower limit of 
detection for IgG was 0.003 U/ml and for IgG I and IgG4 0.005 U/ml. 
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10.5.2 
An antitoxin level of 0.01 IU/ml is widely employed as an indicator of 
immunity (Sedgwick et al 1983, Virella et al 1985; Porter et al 1992), 
although others feel that levels of 2 0.1 IU/ml are safer (Simonsen et al 
1987). A level 2 2 IU/ml is considered suitable for production of human 
anti-tetanus immunoglobulin (Barr et al 1975). 
The units of the IgG tetanus toxoid assays are calibrated against a 
commercially available reference standard. The units for the IgG 1 and IgG4 
tetanus toxoid ELISAs are arbitrary. To aid in the analysis, cut-off values 
of tetanus toxoid antibody levels were selected based on protective values 
quoted in the literature. They were used only to aid in analysis and not to 
comment on whether the levels are protective or not. 
Tetanus toxoid antibody levels 
All the patient groups had post IgG tetanus toxoid or IgG 1 tetanus toxoid 
antibody levels 2 0.01 U/ml which is considered a protective level. Most 
of the Hib meningitis patients had post-IgG4 tetanus toxoid levels < 0.1 
U/ml whereas 23.8% of Hib OM/SA and 64.2% of S.aureus OM/SA 
patients had levels 2 0.1 U/ml (Table 10. 7). 
The percentage of patients in each group with pre- and post-IgG and IgG 1 
tetanus toxoid levels of greater than 0.01 U/ml were not significantly 
different. In contrast the Hib meningitis patients produced less IgG4 tetanus 
toxoid than the S.aureus OM/SA or Hib OM/SA patients. 
The IgG 1 tetanus toxoid levels correlated strongly with the IgG tetanus 
toxoid levels (r = 0.93) whereas there was little correlation between the 
SECTION B: Chapter JO: Patients - Results and Discussion 340 
10.5.3 
IgG4 tetanus toxoid and IgG tetanus toxoid levels (r = 0.1). There was no 
correlation between the IgG, IgG 1 and IgG4 tetanus toxoid levels and age. 
TABLE 10.7: IgG, IgGl and IgG4 TETANUS TOXOID ANTIBODY 
LEVELS PRE- AND POST-TETANUS TOXOID IMMUNIZATION IN 
HEALTHY INFANTS AND PATIENTS WITH Hib MENINGITIS, Hib 
AND S.AUREUS OSTEOMYELITIS/SEPTIC ARTHRITIS 
U/ml Hib Men Hib OM/SA 
IgG Pre ~ 0.1 90.5% 
~2.0 23.8% 
~10.0 4.8% 
IgG Post ~0.1 100% 100% 
~2.0 36.7% 85.7% 
~10.0 3.3% 52.4% 
IgGl Pre ~0.1 95.3% 
~2.0 19.1 % 
~10.0 4.8% 
IgGl Post ~0.1 100% 100% 
~2.0 35.7% 85.7% 
~10.0 0% 42.9% 
IgG4 Pre ~0.1 0% 
~2.0 0% 
~10.0 0% 
IgG4 Post ~0.1 3.6% 23.8% 
~2.0 0% 4.8% 
~10.0 0% 0% 
Hib Men = H. influenzae type b meningitis 
Hib OM/SA = H. influenzae osteomyelitis/septic arthritis 
S.aureus OM/SA = S.aureus osteomyelitis/septic arthritis 
Discussion 
S.aureus 
OM/SA 
92.6% 
31.5% 
6.5% 
98.2% 
89.8% 
69.9% 
94.3% 
32.1 % 
6.6% 
98.1 % 
92.5% 
58.5% 
39.6% 
8.5% 
0.9% 
64.2% 
44.3% 
20.8% 
The interpretation of results of randomly collected individual samples is 
difficult since there are no established normal limits for different age 
groups. This is complicated by factors such as the age of the patient and the 
number and timing of previous tetanus toxoid immunizations. The use of 
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paired samples pre- and post-immunization avoids establishing normal 
values of anti-tetanus toxoid antibody levels. However, previous studies 
have shown great variability of individual responses to tetanus toxoid 
immunization in healthy controls (French and Harrison 1985; Virella et al 
1985). 
The limit of detection of IgG tetanus toxoid antibody (0.0022 U/ml) is more 
than adequate for detecting levels greater than 0.01 U/ml which was taken 
as the lower protective limit in this analysis. 
The mam objective of establishing these assays was to determine the 
immunocompetency of the patients when confronted with a protein antigen. 
The patients all showed an appropriate antibody response to tetanus toxoid 
antigen and can be regarded as immunocompetent with respect to tetanus 
toxoid. All but one patient had post-immunization IgG tetanus toxoid 
antibody levels ~ 0.1 U/ml and that patient had a level between 0.01 and 
0.1 U/ml. Earlier authors have also observed a predominance of IgG 1 
tetanus toxoid antibodies (French and Harrison 1985; Rubin et al 1986; 
Moss et al 1987). The distribution of IgGl and IgG4 tetanus toxoid 
antibodies is interesting. The post-immunization IgG4 tetanus toxoid 
antibody levels of the Hib meningitis patients were much lower than the Hib 
OM/SA and S.aureus OM/SA patients. The following factors may have 
influenced this: 
The time interval between the tetanus toxoid immunization and the 
'post' specimen was greatest for the Hib meningitis patients 
The majority of Hib meningitis patients were immunized prior to 
getting the disease whereas the other patient groups were immunized 
at the time of diagnosis of the disease. 
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10.6 
10.6.1 
10.6.1.1 
A healthy group of young Black children tested as part of another study 
showed similar results to the patient groups. IgG, IgGl and IgG4 tetanus 
toxoid antibody levels of greater than 0.1 U/ml pre- and post-tetanus toxoid 
immunization were: pre-IgG tetanus toxoid = 90.7%; post-IgG tetanus 
toxoid = 97. 3 % ; pre-IgG 1 tetanus toxoid = 93. 3 % ; post-IgG 1 tetanus 
toxoid = 98.7%; pre-IgG4 tetanus toxoid = 0%; post-IgG4 tetanus toxoid 
= 5.3%. The low IgG4 tetanus toxoid levels in this healthy group of 
children may have been due to their young age (range 6-9 months; mean 6.9 
months). 
Glm(O, G2m(n) AND Km(3) ALLOTYPES 
Frequency of Glm(O, G2m(n) and Km(3) in patients 
Data were analysed by Chi-square and the odds ratios and 95% confidence 
intervals were calculated. The significance levels of the Fisher two-tailed 
test were used due to the small numbers in some groups. 
Hib meningitis 
Glm(f) was present in 53.2% of Coloured Hib meningitis patients which 
was not significantly different to the frequency of the marker in the control 
population (Chi-square value = 0.01; p = 0.92; OR = 1.03 (0.53 < OR 
< 2.01)) (Table 10.8). However, the frequency of the G2m(n) marker 
(8.5 % ) was significantly lower in the Coloured Hib meningitis patients than 
in the controls (35.6%) (Chi-square value = 13.65; p = 0.0002; OR = 
0.17 (0.04 < OR < 0.48)) (Table 10.9). 
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TABLE 10.8: FREQUENCY OF Glm(O IN CONTROLS AND 
PATIENTS 
Glm(t)+ Glm(t)- p value * 
Coloured 
Controls 144 131 
(52.4%) (47.6%) 
Hib meningitis 25 22 0.92 
(53.2%) (46.8%) 
Hib OM/SA 6 11 0.18 
(35.3%) (64.7%) 
S. aureus OM/SA 61 65 0.51 
(48.4%) (51.7%) 
Black 
Controls 3 135 
(2.2%) (97.8%) 
Hib meningitis 0 30 
(0%) (100%) 
Hib OM/SA 0 15 
(0%) (100%) 
S. aureus OM/SA 3 43 
(6.5%) (93.5%) 
• Statistical analysis of patients groups compared to controls 
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TABLE 10.9: FREQUENCY OF G2m(n) IN CONTROLS AND 
PATIENTS 
G2m(n)+ G2m(n)- p value 
Coloured 
Controls 98 177 
(35.6%) (64.4%) 
Hib meningitis 4 43 0.0002 
(8.5%) (91.5%) 
Hib OM/SA 0 17 0.002 
(0%) (100%) 
S. aureus OM/SA 41 85 0.50 
(32.5%) (67.5%) 
Black 
Controls 4 134 
(2.9%) (97.1 %) 
Hib meningitis 0 30 
(0%) (100%) 
Hib OM/SA 0 15 
(0%) (100%) 
S. aureus OM/SA 1 45 
(2.2%) (97.8%) 
* Statistical analysis of patient groups compared to controls 
No Black patients were either Glm(t) or G2m(n) positive but the frequency 
of these markers is so low in the control group (Glm(t) = 2.2% and 
G2m(n) = 2.9%) that this was not statistically significant (Tables 10.8 and 
10.9). 
The frequency of the Km(3) positive allotype in both the Black and 
Coloured Hib meningitis patients was significantly decreased compared to 
the control population. Chi-square value = 4.82; p = 0.02; OR = 0.21 
(0.05 < OR < 0.96) for the Black patients and Chi-square value 4.37; p = 
0.03; OR = 0.21 (0.05 < OR < 1.06) for the Coloured patients (Table 
10.10). 
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TABLE 10.10: FREQUENCY OF Km(3) IN CONTROLS AND 
PATIENTS 
Km(3)+ve Km(3)-ve NT* p value ** 
Coloureds 
Controls 260 6 5 
(95.9%) (2.2 % ) (1.9%) 
Hib 36 4 3 0.03 
meningitis (83. 7%) (9.3%) (7.0%) 
Hib OM/SA 16 1 0 0.35 
(94.1 %) (5.9%) (0%) 
S.aureus 117 5 4 0.49 
OM/SA (92.9%) (4.0%) (3.1 % ) 
Blacks 
Controls 124 7 9 
(88.6%) (5.0%) (6.4%) 
Hib 19 5 2 
meningitis (73.1 % ) (19.2%) (7.7%) 0.02 
Hib OM/SA 15 1 0 1.0 
(93.7%) (6.3%) (0%) 
S.aureus 44 1 1 0.68 
OM/SA (95.6%) (2.2%) (2.2%) 
* NT = not typable 
** Statistical analysis of patient groups compared to controls 
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10.6.1.2 
10.6.1.3 
10.6.1.4 
Hib OM/SA 
Glm(f) was present in 35.3% of Coloured patients and 52.4% of the 
controls (Chi-square value= 1.77, p = 0.18, OR= 0.50 (0.15 <OR< 
1.55)) which was not a significant difference Table (10.8). 
Coloured patients had a significantly lower frequency of the G2m(n) 
allotype (0%) than the controls (35.6%) (Chi-square value = 9.26, p = 
.002, OR = 0.002 (0.00 < OR < 0.44)) (Table 10.9). 
Although no Black patients were either Glm(f) or G2m(n) positive, the 
frequency of these markers is so low in the control group that this was not 
statistically significant (Tables 10.8 and 10.9). 
The frequency of the Km(3) allotype in the Black or Coloured Hib OM/SA 
patients was not significantly different to racially matched controls (Table 
10.10). 
S.aureus OM/SA 
There were no statistically significant differences in the frequency of the 
G 1 m(f), G2m(n) or Km(3) allotypes in either the Black or coloured patients 
when compared to racially matched controls (Table 10.8, 10.9 and 10.10). 
Discussion 
The frequency of the Glm(f) allotype marker was not different between the 
patient and control groups. The frequency of the G2m(n) marker in the Hib 
meningitis and Hib OM/SA patient groups was significantly decreased. The 
Km(3) positive allotype was significantly decreased in Black and Coloured 
children with Hib meningitis. The findings, in Coloured children, are 
summarized in Figure 10.4. Both G2m(n) and Glm(f) positive allotypes are 
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rare in Black children thereby precluding analysis of these allotype 
frequencies in this ethnic group. 
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Figure 10.4: Frequency of the Glm(O, G2m(n) and Km(3) allotypes in healthy 
Coloured children and Coloured children with: Hib meningitis, Hib OM/SA or 
S. aureus OM/SA. A statistically significant difference (p ~ 0.05) between the patients 
compared to the controls is denoted by (*) 
Of the 73 patients with Hib meningitis approximately 18 would have been 
expected to have been G2m(n) positive considering the frequency of the 
allotype in the Black and Coloured patients. There were only 4 Coloured 
and no Black patients positive for the G2m(n) allotype. 
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Of the 32 patients with Hib OM/SA, 7 patients would have been expected to 
be G2m(n) positive. No patients were positive for the G2m(n) allotype. 
No significant difference in the frequency of the G2m(n) allotype was found 
in the S. aureus OM/SA patients when compared to the control subjects. 
The results show a highly significant association between Hib meningitis 
and OM/SA and a decreased frequency of the G2m(n) marker and provides 
evidence that absence of the G2m(n) allotype is associated with an increased 
susceptibility to invasive Hib infection in Coloured children. The lack of 
association between G2m(n) and S. aureus OM/SA adds further weight to 
this observation. 
Significant associations have been demonstrated between the Km(l) allotype 
and the post immunization antibody levels to Haemophilus i,ifl.uenzae and 
meningococcus C polysaccharides in White children but not in Black 
children and adults (Pandey et al 1979, Pandey et al 1981). Granoff et al 
(1984) showed that both Black and White Km(l) positive children had a 
higher antibody response to H. i,ifl.uenzae type b vaccine than children 
lacking the allotype, although only Black children with the Km(l) allotype 
showed a decreased risk of meningitis (Granoff et al 1984). There are no 
reports in the literature on the frequency of the Km(3) allotype in 
haemophilus infections. The finding that the Km(3) negative allotype is 
more frequent in patients with Hib meningitis is therefore a new 
observation. 
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10.6.2 
10.6.2.1 
10.6.2.2 
Effect of Glm(O, G2m(n) and Km(3) allotypes on lgG and lgG 
subclasses in patients 
This analysis was only done on the Coloured male patients for the following 
reasons: 
i. The G lm(f) and G2m(n) allotypes are uncommon in South African 
Blacks. There were no Glm(f) or G2m(n) positive Black patients in 
the Hib meningitis or Hib OM/SA groups and only three Glm(f) and 
one G2m(n) positive patients in the S.aureus OM/SA group. 
11. There were only five Coloured female patients with Hib OM/SA 
which is too few for meaningful statistical analysis. Since the IgG, 
IgG 1 and IgG3 and IgG4 levels of the Coloured male and female 
healthy controls had been shown to be statistically different the 
Coloured male and female patients had to be analysed separately. 
Glm(f) 
No effect of the G 1 m(f) allotype on the IgG or IgG subclass levels of 
patients with Hib meningitis, Hib OM/SA and S.aureus OM/SA patients 
was found. This may be due to smaller numbers when compared to the 
control study. 
G2m(n) 
The G2m(n) allotype had a positive influence on the IgG2 levels of the 
S.aureus OM/SA patients. A similar positive effect of the G2m(n) allotype 
on IgG2 had been noted in control subjects (Section B: Chapter 9.3.6.2). 
The influence of this allotype on IgG2 in Hib meningitis and Hib OM/SA 
patients could not be assessed as there were only 4 G2m(n) positive Hib 
patients and no G2m(n) positive Hib OM/SA patients (Table 10.10). 
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10.6.2.3 Km(3) 
10.6.2.4 
10.7 
10.7.1 
10.7.2 
There was no effect of the Km(3) allotype on IgG subclass concentrations in 
any of the three patient groups. 
Discussion 
In Coloured male patients the G 1 m(t) had no effect on IgG subclass levels. 
In the control group the Glm(t) had a negative influence on IgG and IgGl 
levels and a positive influence on IgG2 levels. 
The G2m(n) had a positive influence on the IgG2 levels of S. aureus OM/SA 
patients. 
C4 PROTEIN TYPING 
Samples 
C4 typing was done in 39 (44.8%) of the children with Hib meningitis. 
Twenty seven of these children were Coloured and 12 were Black. 
Frequency of C4A *Qo and C4B*Qo in Hib meningitis patients 
The prevalence of C4A *Qo or C4B*Qo antigens in the children with 
meningitis did not differ from that in the Black and Coloured control 
subjects (Table 10.11). Distribution of homozygosity for these alleles in the 
study group conformed with the Hardy-Weinberg equilibrium. 
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10.7.3 
TABLE: 10.11: FREQUENCY OF C4A *Qo AND C4B*Qo IN Hib 
MENINGITIS PATIENTS 
PATIENTS * ** CA4 QO (p =) (p =) ** 
Coloured n = 27 0.09 (0.7) 0.01 (0.8) 
Black n = 12 0.07 (0.2) 0.25 (0.1) 
All n = 39 0.07 (0.3) 0.21 (0.2) 
** p = By Fisher's exact test with Yates correction 
Discussion 
Rowe et al (1989) have reported an increase in C4B deficiency in 46 patients 
with meningitis. Bishof et al (1990) found that in White patients but not in 
Black patients a complete C4B deficiency (e.g. C4B*Qo homozygosity) is a 
risk factor for invasive disease with encapsulated organisms. Cates et al 
(1992) found no increase in C4B deficiency with bacteraemia or meningitis 
caused by encapsulated bacteria. 
The present analysis was done on the Hib meningitis group as a whole as 
well as on an ethnic basis because of the relatively small numbers of Black 
(n = 12) and Coloured (n = 27) patients would have decreased the accuracy 
of the frequency analysis. Frequency of homozygosity of C4A * QO and 
CAB*Qo was not increased in either the Black or Coloured children (results 
not shown). It is therefore concluded from this study that there is 
insufficient evidence that C4B deficiency is associated with disease caused 
by Hib encapsulated bacteria. 
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10.8 
10.8.1 
10.8.2 
MANNOSE BINDING PROTEIN (MBP) 
Patient samples 
MBP was measured at the onset of illness in 76 (87.4 % ) of the children with 
Hib meningitis and in all of the children with Hib OM/SA. 
MBP levels 
The median levels and 95 % confidence levels of the Black and Coloured 
children with Hib meningitis or Hib OM/SA are shown in Table 10.12. and 
compared to the Black adult controls. 
TABLE 10.12: SERUM MBP LEVELS OF PATIENT AND CONTROL 
GROUPS 
RACE NO MEDIAN RANGE 
MBP (ng/ml) Mean± 2SD 
Patients 
Hib meningitis B 27 2068 ~ 10-8548 
C 49 2386 ~ 10-8379 
Hib OM/SA B 16 678 ~ 10-8166 
C 17 2703 ~ 10-9561 
Controls 
South African B 55 838 ~ 10-5779 
Black adults 
B = Black C = Coloured 
The values of the patient groups were compared to the adult controls as age 
does not appear to influence MBP levels (Lipscombe et al 1992). 
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10.8.3 
The 95 % confidence intervals of the median values of the patient groups had 
a much wider range than the South African Black adult controls or the 
reported range of adult controls (Lipscombe et al 1992). 
The median values of the Black and Coloured patients were not significantly 
different from the controls although the median values of the Coloured 
patients tended to be higher than the Black patients and controls (Table 
10.12). The latter findings may be due to a racial difference as MBP 
measurements were only done on Black and not Coloured adult controls. 
Frequency of MBP deficiency in patients 
There was no signficant difference in the frequency of MBP deficiency ( ~ 
10 ng/ml) in either the Hib meningitis or Hib OM/SA patients when 
compared to the controls (Figure 10.5). 
MBP levels were higher in the infected patient groups and this may be due 
to the fact that MBP is an acute phase protein. It would have been better to 
measure MBP levels after the patients had recovered and the acute phase 
response had settled. It is possible that if this were done additional cases of 
MBP deficiency as defined in the literature may have been uncovered. 
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Figure 10.5: Serwn MPB concentrations (ng/ml) in Black adult controls and in Black 
and Coloured patients with Hib meningitis and Hib OM/SA. B = Black patients and 
C = Coloured patients 
10.9 SUMMARY OF MAIN FINDINGS 
• Children with Hib infections are younger than those with S. aureus 
infections. 
• There is a male predominance in patients with Hib and S. aureus 
OM/SA. This was not seen in Hib meningitis patients. 
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• Hib meningitis children are no more malnourished than control 
children. 
• Black children with Hib meningitis had lower levels of IgG 1, IgG2 
and IgG4 than the control children. 
• Coloured children with Hib meningitis only had lower IgG4 levels. 
• The IgG and IgG subclass levels of the Hib OM/SA patients were no 
different to the controls. 
• Children with S.aureus OM/SA had increased levels of IgG, IgGl 
and IgG3. 
• The IgG or IgG subclass levels did not increase during the illness in 
patients with Hib meningitis or Hib OM/SA whereas the IgG, IgGl 
and IgG2 levels of S.aureus OM/SA patients did. 
• Children with Hib meningitis or Hib OM/SA had low levels of Hib 
PRP antibodies and did not respond to Hib infection with a rise of 
Hib PRP specific antibodies. 
• The tetanus toxoid antibody response of the patients was similar to 
that of child controls. 
• IgG 1 was the predominant anti-tetanus toxoid antibody. 
• In Coloured patients with invasive haemophilus infections there was 
a decreased frequency of the G2m(n) allotype. 
• In both the Coloured and Black Hib meningitis patients there was a 
decreased frequency of the Km(3) allotype. 
• The frequency of Glm(t), G2m(n) and Km(3) allotypes of the 
S.aureus OM/SA patients were not significantly different to the 
controls. 
• 
• 
The C4A *QO and C4B*QO antigens in the Hib meningitis patients 
did not differ from the controls. 
MBP deficiency was not increased in the Hib meningitis or Hib 
OM/SA patients. 
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SUMMARY 
The main objective of the experiments described in Section A of this thesis was to establish 
reliable and sensitive assays for the measurement of (i) IgG subclasses; (ii) IgG, IgGl and 
IgG4 subclass specific antibodies to tetanus toxoid; (iii) IgG, IgG 1 and IgG2 subclass 
specific antibodies to H.injluenzae type b polyribosylribitol phosphate (Hib PRP); (iv) IgG, 
IgGl and IgG2 subclass specific antibodies to S.aureus teichoic acid; and (v) Glm(t), 
G2m(n) and Km(3) allotypes. In Section B these assays were used to test the hypothesis 
that a lack of, or an impairment in IgG subclass or subclass specific antibody responses to 
carbohydrate antigens is a risk factor in the pathogenesis of H. injluenzae type b (Hib) 
meningitis and Hib and S.aureus osteomyelitis/septic arthritis (OM/SA) in children. 
Invasive infections due to these organisms may be more likely to occur in children with 
decreased concentrations of IgG subclasses and/or IgG subclass specific antibodies. In 
addition the antibody responses of these patients may be influenced by host factors such as 
immunoglobulin allotypes, C4B alleles and mannose binding protein levels. 
A solid phase capture non-competitive ELISA system using commercially available 
monoclonal antibodies was developed to quantitate IgG subclass levels. Each plate 
routinely included an in-house control as well as a dilution of the World Health 
Organization's primary reference serum for IgG, IgA and IgM (WHO 67/97). Results 
obtained with these assays were also evaluated in an international quality assurance scheme 
for the measurement of IgG subclasses. The sum of the four IgG subclasses measured by 
ELISA correlated well (r = 0. 89) with the total IgG measured by nephelometry. These 
ELISAs were shown to be quantitative, sensitive and reproducible and are highly suitable 
for measurements in small children because ten microlitres of serum was sufficient to 
measure all four subclass levels. 
The development of sensitive, specific IgG subclass ELISAs enabled measurement of IgG 
subclass concentrations in normal children from 3 months to 12 years of age. An analysis 
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of IgG subclass levels must take into account their non-Normal distribution, wide Normal 
ranges, and ethnic and sex differences. Age related percentile charts from healthy children 
in the Western Cape were established using the Box Cox transformation to construct 
smooth age-related percentile charts. IgG and IgG 1 subclass levels were found to be 
higher than those reported from normal children in developed countries. In addition, the 
proportion of IgG 1 of the total IgG in 2 year and 12 year old children was higher (90-95 % ) 
than in matched adults (65-75%). These age and race related differences in IgG subclass 
levels make it imperative to establish local normal values. 
Black children with Hib meningitis had lower levels of IgG 1, IgG2 and IgG4 than control 
children whereas in Coloured children only the IgG4 level was decreased. The IgG and 
IgG subclass levels of the Hib OM/SA patients were no different from the controls whereas 
children with S. aureus OM/SA had increased levels of IgG, IgG 1 and IgG3. 
Because of adsorption induced denaturation of coated antigen it is important to show that 
specificity has been maintained. This specificity was demonstrated in all the subclass 
specific ELISAs developed in this study by using soluble antigen to inhibit antibody 
binding to the immobilized antigen. 
IgG, IgG 1 and IgG4 tetanus toxoid specific antibodies were measured by ELISAs. The 
values of the IgG tetanus toxoid antibodies were calibrated against a commercially 
available reference standard. Although the assigned IgG 1 and IgG4 tetanus toxoid values 
are arbitrary, they allow for comparison of values between pre- and post-tetanus toxoid 
immunization and also between different groups of children. All patient groups responded 
to the tetanus toxoid antigen suggesting normal immunocompetence to protein antigens. 
ELISA is widely used to determine antibodies to protein antigens but there have been 
difficulties in its application to measure antibodies to polysaccharide antigens. In this 
study a method to measure IgG, IgG 1 and IgG2 Hib PRP antibodies is described. These 
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assays have proved to be simple, specific, sensitive and reproducible. Serum anti-Hib PRP 
antibodies were measured to evaluate the antibody response to Hib PRP after invasive Hib 
infections. 
Hib PRP antibodies were found to be low in young children with Hib meningitis and Hib 
OM/SA and did not increase significantly in the 2-3 weeks following the disease. In young 
children the Hib PRP antibodies were predominantly IgG 1 and were not restricted to the 
IgG2 isotype as suggested from earlier studies. It would be informative to assess whether 
children with previous Hib disease responded to immunization with Hib vaccine to the 
same extent as children who had not had Hib disease especially with respect to the isotype 
and magnitude of the IgG subclass specific response. This may provide information on 
whether Hib disease arises as a result of a predisposed inability to mount a specific 
antibody response. 
Antibodies to teichoic acid were determined by ELISA in patients with S. aureus OM/SA 
and in patients with OM/SA due to other organisms (who served as controls). The levels 
of IgG and IgG 1 teichoic acid antibodies were significantly higher in patients with S. aureus 
OM/SA but no rise of specific teichoic acid antibody level was seen during S. aureus 
infections. Because variation of teichoic acid antibody levels has been reported in healthy 
children (Granstrom et al 1983) it would provide further information if normal 
concentrations in various age groups were determined. This may add weight to the 
argument that defective antibody production during invasive staphylococcal disease does 
not appear to be a major causative factor. 
Immunological assays reflect the affinity as well as the concentration of the antibody. A 
predominantly low affinity antibody response may be considered an expression of 
immunodeficiency and may be an important factor in susceptibility to infection. Various 
IgG subclasses may show different affinities for an antigen (Persson et al 1988; Devey et al 
1989). Diethylamine ELISAs which are practical and easy to perform were used to assess 
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antibody affinity. In the tetanus toxoid ELISAs the IgG 1 antibody was not only the 
predominant class of antibody but it also had a higher affinity than the IgG4 anti-tetanus 
toxoid antibody. The IgG 1 and IgG2 Hib PRP antibodies had a similar affinity. Although 
all patients had low levels of Hib PRP antibody, most had detectable levels of IgG 1 Hib 
PRP antibody but few had detectable IgG2 PRP antibody levels. In the S. aureus teichoic 
acid ELISAs the IgG 1 antibody had a higher affinity than the IgG2 antibody. While most 
patients had IgG 1 teichoic acid antibody, very few had measurable levels of IgG2 teichoic 
acid antibody. No evidence was found for an association between the production of low 
affinity antibodies and Hib meningitis, Hib OM/SA and S. aureus OM/SA. 
IgG subclass measurements are assuming an increasing importance in paediatrics. The 
significance of incorporating the measurement of antibody responses to protein as well as 
to polysaccharide antigens in the assessment of humoral immunodeficiency is also 
recognised. The assays developed in this study are suitable for the evaluation of patients 
referred for investigation of immunodeficiency. 
There is evidence that allotypic markers influence IgG subclass levels and have an effect on 
disease susceptibility. ELISA methods for the quantitation of G 1 m(t) and G2m(n) 
allotypes in serum were established and are simple, quick, specific, reproducible and 
sensitive. The Glm(t) allotype was present in 52% of Coloured children but in only 2.2% 
of Black children. The G2m(n) allotype occurred in 34.4 % of Coloured children and 
2.9% of Black children. This difference in allotype frequency in Black and Coloured 
populations of the Western Cape has not been previously reported. The Glm(t) allotype in 
the patients with Hib meningitis, Hib OM/SA or S.aureus OM/SA did not differ 
significantly from the controls. There was a significantly decreased frequency of the 
G2m(n) positive allotype in Coloured patients with Hib meningitis and Hib OM/SA which 
was not present in patients with S.aureus OM/SA. This finding has not been previously 
reported. In Coloured children the G 1 m(t) positive allotype was associated with lower IgG 
and IgG 1 levels and higher IgG2 and IgG3 levels whereas G2m(n) positive allotype was 
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associated with higher IgG2 levels. In Black subjects meaningful statistical analysis was 
not possible due to the low frequency of these markers. 
A qualitative ELISA was established for the Km(3) allotype using a commercially available 
polyclonal antibody. It clearly discriminated between Km(3) negative and positive 
individuals except in about 2% of samples which were recorded as 'not typable'. The 
assay is simple, quick and reproducible. This allotype was very common in both the 
Coloured (94%) and Black (93.4%) populations. The allotype had no influence on IgG 
subclass levels, but in both the Coloured and Black children with Hib meningitis there was 
a significantly decreased frequency of the Km(3) allotype. 
There have been several recent reports of an association between C4B deficiency and 
bacterial meningitis (Rowe et al 1989; Bishof et al 1990). Mannose binding protein 
deficiency has also been associated with increased infections in children. The frequency of 
C4A *Q() and C4B*Q() antigen in the Hib meningitis patients did not differ from the 
controls. MBP deficiency was not found to be increased in Hib meningitis or Hib OM/SA 
patients. 
This study has clearly shown an association between a decrease in frequency of the G2m(n) 
allotype and Km(3) allotype and susceptibility to invasive infections caused by 
H. injluenzae. G2m(n) positive individuals had higher IgG2 levels than G2m(n) negative 
individuals. The biological and genetic regulation of IgG subclass antibody induction and 
the roles that allotypic markers play in this process needs further investigation. The role of 
cytokines in isotype switching would be of particular interest because of their capacity to 
regulate B-cell terminal differentiation and immunoglobulin production. 
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APPENDIX A 
ANTI-HUMAN IgG MONOCLONAL ANTIBODIES 
IUIS/WHO# MOUSE HUMAN IgG BIOTINY- CATALOGUE 
STUDY NO ISOTYPE SPECIFICITY LATED NO 
HP6064 IgGl IgG-Fc No o* M06014 
HP6017 IgG2a-k IgG-Fc Yes z**o5-420l 
HP6007 IgGl IgGl No z**o5-0201 
HP6012 IgGl IgGl No o* M15015 
HP6069 IgGl-k IgGl-Fc No z** 05-3301 
HP6069 IgG 1-k IgGl- Fe Yes z** 05-3340 
HP6070 IgGl IgGl-Fc No z** 05-3401 
IgGl IgGl-Fab No s*** I-5385 
HP6008 IgGl IgG2-Fc No o* Ml0015 
HP6009 IgGI IgG2-Fc No z**o5-030I 
HP6014 IgGl-k IgG2-Fd No o* M73013 
HP6002 IgGl IgG2-Fc Yes z** 05-3540 
IgGl IgG2 No s*** 1-1010 
HP6010 IgGl IgG3 hinge No o* M08010 
H06047 IgGl IgG3 hinge Yes z** 05-3640 
HP6013 IgGI IgG4-Fc No o* M16013 
HP6025 IgGl-k IgG4-Fc Yes z** 05-3840 
HP601 l IgGI IgG4-Fc No o* MI1013 
# Referred to in text hy IUIS number only 
* Oxoid ** Zymed *** Sigma 
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APPENDIX B 
PREPARATION OF H.INFLUENZAE TYPE b (Hib) PRP ANTIGEN 
Polyribose phosphate (PRP) is a linear polymer of ribose, ribitol and phosphate (fl -D-
ribose (1 Y) ribitol (5-phosphate)) found in the polysaccharide capsule of Haemophilus 
influenzae type b. PRP was prepared using a method adapted from Insel and Anderson 
(1986) as follows: 
Hemin (Sigma Catalogue No H2250)was added to 2 litres brain heart infusion 
medium (37 g/litre Difeo Laboratories) in a Erlanmeyer flask to a final 
concentration of 1 mg/litre before autoclaving. After autoclaving B-Nicotanamide 
Adenine Dinucleotide (Sigma, Catalogue No N-7004) was added to a final 
concentration of 1 mg/litre. Haemophilus influenzae (type b) previously cultured 
on a boiled blood agar plate in a CD2 incubator was used to innoculate the broth. 
The culture was left on a shaker in a 37°C incubator until the late stationary phase 
of growth had been reached ( ± 30 hours growth) 
The culture was centrifuged twice at 3 500 rpm (2 800 g) for 30 minutes. Unless 
otherwise stated, all centrifugation steps were performed at these settings. 
The supernatant was added to an equal volume of cold absolute ethanol and left 
overnight at 4 °C. 
This solution was centrifuged in 50 ml conical tubes and the gummy brown deposit 
dissolved in approximately 100 ml distiled water and left overnight at 4 °C. 
Hexadecyltri-methylammonium bromide (Cetavlon, Sigma, Catalogue No H-5882) 
was added to a final concentration of 0.01 M and left at 4 °C for 30 minutes before 
centrifugation. 
The precipitate was extracted with 1 M NaCl and recentrifuged. The residual 
precipitate was extracted with 0.25 M NaCl, agitated and centrifuged. 
The supernatant was retained and tested for the presence of carbohydrate (400 µl 
PRP, 200 µl 5 % phenol and 1 ml concentrated sulphuric acid were mixed together 
and carbohydrate presence was indicated by a strong orange colour). 
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An equal volume of 90% phenol was added and stirred at room temperature for 30 
minutes before centrifugation. 
The aqueous phase was retained and the phenol extraction was repeated until the 
interface was clear (usually 3-4 extractions). All phases were checked at this stage 
for carbohydrate presence. 
PRP was precipitated from the aqueous phase by adding NaCl to 0.1 M and the 
addition of an equal volume of cold absolute ethanol. 
PRP was dissolved in distilled water after centrifugation. 
The NaCl precipitation was repeated until the absorbance at 260 nm fell to a 
plateau, indicating removal of residual phenol. 
Final PRP was dissolved in 4 ml distilled water, dialysed against running tap water 
overnight, and freeze-dried. 
Composition of the PRP was assessed by HPLC on derivatives of trifluoro acetic acid 
(TFA) hydrolysates. This was done by Dr E Merrifield, Department of Medical 
Biochemistry, University of Cape Town using an aminex HPX-87H (Biorad, Cat No 
125.0140) which is on 8% crosslinked cation exchange resin optimized for the analysis of 
carbohydrates in solution. All laboratory preparations, the gift of PRP from Lederle and a 
standard of ribose were run on the HPLC. A single peak produced at 7.04 - 7.14 mins 
was produced by ribose. The peak at 4.2 to 4.4 minutes was produced by TFA. 
All preparations were pure with no contaminants. 
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APPENDIX C 
CONJUGATION OF POLY-L-LYSINE TO PRP 
To optimise coating of antigen to the plates, the PRP was linked to poly-L-lysine (PLL) 
(Sigma, Catalogue No P9404) using a method adapted from Gray (1979). 
The freeze-dried PRP was reconstituted in sterile distilled water to a 1 mg/ml 
solution. 
A small beaker on ice on a magnetic stirrer was set up in a fume cupboard. 750 µl 
of 1 mg/ml PRP solution was pipetted and a micro pH probe inserted in the 
solution. 
300 µl of a 25 mg/ml Cyanogen bromide (Merck, Catalogue No 820193) in 0.1 N 
NaOH was added and the pH monitored every 2 minutes for 10 minutes. The pH 
was controlled between 10.5 and 11.5 with the addition of 0.02 N NaOH. 
At 10 minutes 750 µl of a 0.5 mg/ml solution of PLL in 0.5 M NaHC03 (pH 8.5) 
containing 0.5 M NaCl was added. Although the pH started to decrease, a few 
drops of 0.5 M HCI were required to bring the pH down to the desired pH of 8.5. 
The solution was dialysed against several changes of phosphate buffered saline (pH 
7.2) at 4 °C overnight. 
The resulting volume was measured and the concentration of PRP in mg/ml was 
calculated and stored in aliquots at -70°C. 
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APPENDIX D 
PREPARATION OF S.AUREUS RIBITOL TEICHOIC ACID 
ANTIGEN 
The antigen was prepared from log phase cultures of fresh isolates of S. aureus Lafferty 
strain adopted from the method of White et al 1983. The Lafferty strain of S.aureus was 
obtained from Professor Koornhof (Department of Microbiology, SAIMR, Johannesburg). 
A broth culture of S.aureus Lafferty strain was grown up in a tryptic soya broth for 24-48 
hours at 37°C. The broth was centrifuged at 2 500 rpm for 30 minutes. The supernatant 
was decanted and the precipitate redissolved in sterile saline and centrifuged (3 000 rpm) 
for 35 minutes. The sterile saline washes were repeated three times. After the final wash 
the precipitate was resuspended in saline (5-10 mls). Lysostaphin was added at a 
concentration of 10 U/ml to the suspension. This was incubated at 37°C for 11/2 hours 
with constant vigorous shaking. Then trypsin (0.1 mg/10 ml of staph suspension) was 
added. Shaking/agitating at 37°C was continued for a further 30 minutes to inactivate any 
autolysin as well as any residual trypsin. The suspension was then boiled for 30 minutes. 
This was followed by sonicating the suspension for 15 minutes (24 µ). The suspension was 
then spun at 10 000-12 000 rpm for 15-30 minutes. The supernatant was then aliquoted 
and lypohilized. Reconstituted preparations were stored at -20°C. 
The partially purified preparations were characterized by immunodiffusion using Meridian 
Diagnostic Endo-Staph Kits (see Appendix E). 
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APPENDIX E 
ENDO-STAPH IMMUNODIFFUSION ASSAY 
The teichoic acid antibody assay materials and procedure are described in the package 
insert and are supplied by Meridian Diagnostics, Inc., Cincinnati, Ohio (Catalogue No 
H290100). The antigen is a partially purified teichoic acid prepared by phenylhydrazine 
extraction of the Lafferty strain of S. aureus. The test antigen used in the assay is 
standardized to contain 30 mg of teichoic acid per litre, as determined by radial 
immunodiffusion by reference to the purified ribitol teichoic acid. The positive control 
serum sample is prepared by immunizing rabbits with this partially purified ribitol teichoic 
acid. In immunodiffusion, the control serum sample forms a single precipitin line of 
identity with test antigen and the purified teichoic acid. A 40 µ1 portion of the purified 
antigen is placed in the central well, 40 µl of the rabbit anti ribitol teichoic acid (positive 
control) is placed in each of two of the surrounding wells and 40 µ1 of the twofold serial 
dilutions of sera is placed in each of the remaining wells. The plates are incubated at room 
temperature in 24 h in Parafilm-sealed petridishes. The teichoic acid titre is taken as the 
highest serum dilution forming a precipitin line of identity with the positive control serum 
sample. 
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APPENDIX F 
RECOMMENDED ALLOTYPE DESIGNATIONS 
(A) Immunoglobulin allotypes currently testable 
Recommended designations 
Location Alphameric Numeric 
IgGl Glm (a) Glm (1) 
(x) (2) 
(t) (3) 
(z) (17) 
IgG2 G2m (n) G2m (23) 
IgG3 G3m (bO) G3m (11) 
(bl) (5) 
(b3) (13) 
(b4) (14) 
(b5) (10) 
(c3) (6) 
(c5) (24) 
(g) (21) 
(s) (15) 
(t) (16) 
(u) (26) 
(v) (27) 
IgA2 A2m (1) A2m (1) 
A2m (2) A2m (2) 
K-chain Km (1) Km (1) 
(2) (2) 
(3) (3) 
(B) Specificities no longer testable due to a lack of reagents 
Gm (r) = 7 R 03 = 19 
(p) = 9 20 = 20 
R 02 = 18 y = 22 
Reference: 
WHO. Review of the notation for the allotypic and related markers of human 
Immunoglobulins. Eur J Immunol 1976; 6:599-601. 
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APPENDIX G 
DETERMINATION OF Km ALLOTYPES BY HAEMAGGLUTINATION 
INHIBITION METHOD 
(Ref: Dr G de Lange, CLB Laboratory, Netherlands) 
MATERIALS AND METHODS 
a. Materials 
1. Kappa marker sera: anti-Km(l), anti-D Km(l), anti-Km(3) and anti-D 
Km(3) obtained from the Central Laboratory of Netherlands (CLB) 
Amsterdam. 
11. Red blood cells - Group OR 1 R2 or Group OR2R2 were obtained from a 
donor at the Western Province Blood Transfusion Service, Cape Town. 
m. Preservation fluid -
IV. Reference sera 
b. Method 
Rl 117 = 
Rl 113 = 
Km(l) pos 
Km(3) pos 
Antigen coated erythrocytes were prepared from either EDTA blood group OR2R2 
(cDE/cDE) or blood group OR 1 R2 (CDe/cDE) washed four times in PBS pH 7.2. 
Cells were coated by incubating one volume of packed washed erythrocytes with 
four volumes of anti-Rh serum and 4 volumes of PBS at 37°C for 60 minutes. 
Every 15 minutes the cells were mixed by inverting the tubes. Cells were then 
washed four times in PBS and stored at 4 °C in preservation fluid or PBS. 
Coated erythrocytes can be stored at 4 °C in PBS, for one week. If the coated 
erythrocytes are stored in preservation fluid, they can be used 4-6 weeks. Every 2-
3 days a fresh 0.1 % suspension has to be made. 
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The working dilution of each allotype-specific antiserum was determined by the 
antiserum in doubling dilutions from undiluted to 1 :512 diluent. 
Equal volumes (25 µ1) of serum, in the appropriate dilution in PBS and antiserum in 
the optimal dilutions in PBS were mixed in V shaped microtitre plates followed by 
a 0.1 % suspension in PBS of antigen coated erythrocytes. After mixing again the 
plates were left overnight at 4 °C when they were read macroscopically after tilting 
the plate for 10 minutes at 60°C. 
Results were interpreted as: 
No agglutination = inhibition; allotype present 
Agglutination = no inhibition; allotype absent. 
Controls must include: 
1. Antiserum and antigen coated erythrocytes: antigen coated erythrocytes with 
the diluted antiserum must show sufficiently strong agglutination. 
2. Serum and antigen coated erythrocytes: the sample must not show 
agglutination after incubation with the coated erythrocyte only. This may 
occur when the sample contains antibodies against the erythrocytes or the 
antigen used for cell coating. 
3. Positive and negative controls: known allotyped samples have to be included 
in at least the same dilutions as the samples to be tested. 
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APPENDIX H 
A MINIATURISED METHOD FOR IMMUNOGLOBULIN ALLOTYPE 
SEROLOGY 
(Young NT, Street J and Darke C. J Immunol Methods 1989; 122:143-147) 
The antigen coated erythrocytes were prepared from a fresh group OR 1 R2 blood sample by 
the same method mentioned in Appendix G. 
The working dilution of each allotype-specific antiserum was determined by titrating the 
antiserum in doubling dilutions from undiluted to 1 :512 in diluent and dispensing a 2 µl 
aliquot of each dilution into the wells of a plastic 60 conical well Terasaki plate using a 
Hamilton syringe. 2 µl of antigen coated erythrocyte cell suspension was added to wells 
and the plates incubated at 22 °C for 30 mins. The plates were then centrifuged at 130 x g 
for 1 minute and placed at an angle of 60° until the cells settled (about 20 minutes). 
Results were read on an inverted phase microscope at 10 x magnification. The working 
dilution of each antiserum was defined as the last doubling dilution which gave a definitive 
positive reaction. 
Inhibition of agglutination was determined by testing one antigen positive and one antigen 
negative serum for each allotype in doubling dilutions from 1 :4 to 1 :512 in diluent. 2 µl 
aliquots of the working dilution of each antiserum were added to 2 µl of each dilution of 
reference serum in the wells of the Terasaki plate and incubated at 22 ° C for 20-30 
minutes. 2 µl of appropriately coated cell suspension were added to each well and the 
plates incubated, centrifuged and read as before. Inhibition of agglutination by the antigen 
positive serum and agglutination of cells in the presence of the antigen negative serum 
indicated that the typing system was suitable for use. 
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APPENDIX I 
NORMAL PERCENTILE CHARTS FOR IgG SUBCLASSES 
The following figures are the IgGl, IgG2, IgG3, IgG4 and IgG concentration percentile 
charts for Black, Coloured male and Coloured female children. The percentile lines shown 
are 2.5%, 5%, 25%, 50%, 75%, 95% and 97.5%. The equivalent adult percentile points 
are shown ( <> ). As there was no significant difference between the IgG2 values of the 
Coloured male and female children they are shown together on one chart. 
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APPENDIXJ 
NORMAL RANGES FOR lgG SUBCLASSES 
AGE GROUP PERCENTILES lgG : BLACK MALE AND FEMALE CONTROLS 
AGE 2.5% 5% 25% 50% 75% 95% 97.5% 
6 mths 6.632 7.121 9.547 11.219 13.303 16:977 19.205 
1 yr 7.098 7.610 10.138 11.877 14.038 17.839 20.139 
2 yrs 8.022 8.577 11.302 13.166 15.475 19.518 21.956 
3 yrs 8.919 9.513 12.422 14.403 16.849 21.116 23.681 
4 yrs 9.770 10.401 13.478 15.565 18.136 22.607 25.289 
5 yrs 10.557 11.221 14.449 16.632 19.315 23.968 26.753 
6 yrs 11.265 11.957 15.317 17.584 20.365 25.178 28.052 
7 yrs 11.878 12.594 16.067 18.405 21.268 26.216 29.167 
8 yrs 12.384 13.121 16.684 19.080 22.011 27.067 30.080 
9 yrs 12.774 13.526 17.158 19.597 22.579 27.719 30.778 
10 yrs 13.039 13.801 17.480 19.949 22.964 28.160 31.251 
11 yrs 13.174 13.941 17.644 20.127 23.160 28.384 31.491 
12 yrs 13.176 13.943 17.646 20.130 23.163 28.387 31.495 
Adults 10.900 12.000 15.500 17.250 19.400 23.300 23.700 
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AGE GROUP PERCENTILES lgGl : BLACK MALE AND FEMALE CONTROLS 
AGE 2.5% 5% 25% 50% 75% 95% 97.5% 
6 mths 6.422 6.997 9.521 11. 734 13.712 18.411 20.641 
1 yr 6.568 7.153 9.717 11.964 13.971 18.734 20.995 
2 yrs 6.867 7.472 10.199 12.434 14.500 19.395 21. 715 
3 yrs 7.176 7.801 10.534 12.919 15.044 20.073 22.453 
4 yrs 7.496 8.142 10.961 13.417 15.603 20.769 23.211 
5 yrs 7.826 8.494 11.402 13.931 16.178 21.483 23.988 
6 yrs 8.167 8.857 11.855 14.458 16.770 22.216 24.784 
7 yrs 8.520 9.231 12.323 15.001 17.377 22.967 25.601 
8 yrs 8.884 9.618 12.804 15.560 18.001 23.738 26.437 
9 yrs 9.259 10.017 13.299 16.134 18.642 24.528 27.294 
10 yrs 9.647 10.428 13.809 16.724 19.300 25.338 28.173 
11 yrs 10.047 10.852 14.333 17.330 19.976 26.168 29.072 
12 yrs 10.459 11.289 14.872 17.953 20.669 27.019 29.994 
Adults 5.730 7.420 9.460 12.350 14.960 18.680 20.730 
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AGE GROUP PERCENTILES lgG2 : BLACK MALE AND FEMALE CONTROLS 
AGE 2.5% 5% 25% 50% 75% 95% 97.5% 
6 mths 0.201 0.219 0.375 0.568 0.811 1.258 1.404 
1 yr 0.211 0.230 0.392 0.593 0.846 1.311 1.462 
2 yrs 0.231 0.252 0.428 0.646 0.919 1.421 1.584 
3 yrs 0.253 0.276 0.467 0.703 0.999 1.540 1.716 
4 yrs 0.278 0.302 0.510 0.765 1.085 1.669 1.858 
5 yrs 0.304 0.330 0.556 0.832 1.178 1.807 2.001 
6 yrs 0.332 0.361 0.606 0.905 1.278 1.957 2.175 
7 yrs 0.363 0.395 0.660 0.984 1.386 2.117 2.352 
8 yrs 0.397 0.431 0.718 1.068 1.503 2.289 2.543 
9 yrs 0.434 0.471 0.782 1.160 1.628 2.475 2.747 
10 yrs 0.473 0.514 0.850 1.259 1.764 2.675 2.967 
11 yrs 0.516 0.560 0.924 1.365 1.909 2.889 3.203 
12 yrs 0.563 0.610 1.004 1.480 2.066 3.119 3.456 
Adults 0.700 0.770 1.888 2.553 3.240 3.900 4.593 
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AGE GROUP PERCENTILES lgG3 : BLACK MALE AND FEMALE CONTROLS 
AGE 2.5% 5% 25% 50% 75% 95% 97.5% 
6 mths 0.159 0.184 0.317 0.492 0.671 1.141 1.415 
1 yr 0.164 0.191 0.328 0.508 0.693 1.177 1.459 
2 yrs 0.176 0.204 0.350 0.542 0.738 0.253 1.552 
3 yrs 0.188 0.218 0.374 0.578 0.787 1.333 1.650 
4 yrs 0.201 0.233 0.399 0.616 0.838 1.418 1.755 
5 yrs 0.215 0.249 0.426 0.657 0.893 1.508 1.866 
6 yrs 0.230 0.266 0.454 0.700 0.951 1.604 1.983 
7 yrs 0.246 0.284 0.484 0.746 1.012 1.706 2.108 
8 yrs 0.262 0.303 0.517 0.795 1.078 1.814 2.240 
9 yrs 0.280 0.324 0.551 0.847 1.147 1.928 2.380 
10 yrs 0.300 0.346 0.588 0.902 1.221 2.050 2.529 
11 yrs 0.320 0.369 0.626 0.961 1.299 2.178 2.686 
12 yrs 0.342 0.394 0.668 1.023 1.382 2.315 2.853 
Adults 0.314 0.380 0.610 0.915 1.239 1.640 1.804 
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AGE GROUP PERCENTILES lgG4 : BLACK MALE AND FEMALE CONTROLS 
AGE 2.5% 5% 25% 50% 75% 95% 97.5% 
6 mths 0.002 0.004 0.013 0.027 0.051 0.119 0.162 
1 yr 0.004 0.006 0.019 0.039 0.073 0.168 0.227 
2 yrs 0.009 0.012 0.037 0.075 0.136 0.307 0.411 
3 yrs 0.016 0.023 0.065 0.128 0.229 0.506 0.672 
4 yrs 0.026 0.037 0.101 0.198 0.350 0.758 1.001 
5 yrs 0.038 0.053 0.144 0.277 0.485 1.038 1.365 
6 yrs 0.050 0.069 0.185 0.354 0.615 1.306 1.712 
7 yrs 0.059 0.082 0.218 0.414 0.717 1.512 1.979 
8 yrs 0.064 0.089 0.234 0.444 0.768 1.616 2.112 
9 yrs 0.063 0.087 0.231 0.438 0.757 1.593 2.083 
10 yrs 0.057 0.078 0.208 0.396 0.686 1.450 1.899 
11 yrs 0.046 0.064 0.171 0.328 0.572 1.217 1.597 
12 yrs 0.034 0.047 0.129 0.249 0.437 0.940 1.237 
Adults 0.050 0.080 0.210 0.380 0.568 1.320 1.480 
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AGE GROUP PERCENTILES lgG : COLOURED MALE CONTROLS 
AGE 2.5% 5% 25% 50% 75% 95% 97.5% 
6 mths 5.328 5.984 8.224 9.713 11.754 15.323 16.8334 
1 yr 5.554 6.224 8.507 10.023 12.097 15.717 17.248 
2 yrs 6.020 6.719 9.090 10.658 12.797 16.520 18.091 
3 yrs 6.507 7.235 9.694 11.314 13.519 17.345 18.956 
4 yrs 7.014 7.771 10.318 11.990 14.262 18.191 19.843 
5 yrs 7.541 8.327 10.963 12.688 15.025 19.059 20.751 
6 yrs 8.089 8.903 11.628 13.406 15.810 19.948 21.680 
7 yrs 8.657 9.500 12.314 14.145 16.616 20.858 22.631 
8 yrs 9.245 10.118 13.022 14.906 17.443 21.790 23.604 
9 yrs 9.854 10. 756 13.750 15.687 18.292 22.744 24.598 
10 yrs 10.483 11.415 14.499 16.490 19.162 23.179 25.615 
11 yrs 11.133 12.094 15.269 17.314 20.053 24.716 26.653 
12 yrs 11.804 12.795 16.061 18.159 20.966 25.735 27.713 
Adults 10.700 11.000 12.100 14.350 17.000 21.000 21.700 
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AGE GROUP PERCENTILES lgG : COLOURED FEMALE CONTROLS 
AGE 2.5% 5% 25% 50% 75% 95% 97.5% 
6 mths 4.582 5.179 5.629 9.554 11.633 15.101 15.626 
1 yr 5.025 5.644 8.169 10.144 12.270 15.808 16.343 
2 yrs 5.907 6.565 9.231 11.299 13.513 17.180 17.733 
3 yrs 6.772 7.466 10.258 12.409 14.704 18.488 19.057 
4 yrs 7.606 8.332 11.239 13.465 15.833 19.722 20.306 
5 yrs 8.399 9.154 12.162 14.456 16.889 20.873 21.470 
6 yrs 9.141 9.921 13.019 15.374 17.864 21.933 22.542 
7 yrs 9.823 10.626 13.803 16.210 18. 751 22.895 23.515 
8 yrs 10.438 11.259 14.505 16.959 19.544 23.753 24.382 
9 yrs 10.978 11.816 15.121 17.614 20.237 24.501 25.138 
10 yrs 11.440 12.291 15.644 18.170 20.824 25.135 25.778 
11 yrs 11.817 12.679 16.072 18.623 21.303 25.651 26.299 
12 yrs 12.107 12.978 16.399 18.971 21.669 26.046 26.698 
Adults 9.810 9.810 12.300 15.200 16.600 19.200 19.200 
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AGE GROUP PERCENTILES lgG 1 : COLOURED MALE CONTROLS 
AGE 2.5% 5% 25% 50% 75% 95% 97.5% 
6 mths 4.812 5.411 7.641 9.544 11. 754 14.800 16. 739 
1 yr 4.882 5.489 7.746 9.670 11.905 14.984 16.944 
2 yrs 5.025 5.647 7.958 9.927 12.212 15.358 17.359 
3 yrs 5.172 5.809 8.175 10.190 12.526 15.740 17.784 
4 yrs 5.322 5.975 8.398 10.459 12.847 16.130 18.217 
5 yrs 5.476 6.145 8.625 10.733 13.175 16.529 18.660 
6 yrs 5.633 6.319 8.858 11.014 13.510 16.936 19.111 
7 yrs 5.795 6.497 9.096 11.302 13.852 17.351 19.572 
8 yrs 5.960 6.679 9.340 11.595 14.202 17.776 20.043 
9 yrs 6.130 6.866 9.589 11.895 14.559 18.209 20.523 
10 yrs 6.304 7.058 9.844 12.202 14.924 18.651 21.013 
11 yrs 6.481 7.254 10.105 12.516 15.297 19.103 21.513 
12 yrs 6.664 7.455 10.372 12.836 15.678 19.564 22.024 
Adults 5.710 6.060 7.290 10.640 12.200 13.980 16.970 
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AGE GROUP PERCENTILES IgG 1 : COLOURED FEMALE CONTROLS 
AGE 2.5% 5% 25% 50% 75% 95% 97.5% 
6 mths 4.527 5.241 7.558 9.830 12.453 16.077 18.238 
1 yr 4.645 5.374 7.733 10.044 12.711 16.391 18.584 
2 yrs 4.889 5.646 8.094 10.485 13.238 17.032 19.290 
3 yrs 5.143 5.930 8.467 10.940 13.782 17.692 20.016 
4 yrs 5.407 6.224 8.853 11.410 14.334 18.371 20.763 
5 yrs 5.681 6.529 9.253 11.896 14.922 19.071 21.531 
6 yrs 5.965 6.846 9.667 12.397 15.519 19.791 22.321 
7 yrs 6.261 7.174 10.094 12.914 16.133 20.531 23.133 
8 yrs 6.567 7.514 10.536 13.448 16.766 21.293 23.968 
9 yrs 6.885 7.867 10.993 13.999 17.419 22.076 24.826 
10 yrs 7.215 8.232 11.465 14.567 18.090 22.882 25.707 
11 yrs 7.557 8.610 11.952 15.152 18. 781 23.710 26.612 
12 yrs 7.911 9.002 12.456 15.756 19.493 24.560 27.541 
Adults 5.167 5.167 9.450 9.740 11.340 12.912 12.912 
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AGE GROUP PERCENTILES IgG2 COLOURED MALE AND FEMALE 
CONTROLS 
AGE 2.5% 5% 25% 50% 75% 95% 97.5% 
6 mths 0.158 0.200 0.425 0.627 0.930 1.587 1.808 
1 yr 0.167 0.210 0.444 0.652 0.965 1.640 1.867 
2 yrs 0.185 0.232 0.484 0.706 1.038 1.751 1.989 
3 yrs 0.205 0.256 0.526 0.763 1.115 1.867 2.118 
4 yrs 0.227 0.282 0.572 0.824 1.197 1.989 2.253 
5 yrs 0.251 0.310 0.620 0.888 1.283 2.118 2.395 
6 yrs 0.276 0.340 0.672 0.956 1.374 2.253 2.543 
7 yrs 0.303 0.372 0.726 1.029 1.470 2.394 2.699 
8 yrs 0.333 0.406 0.785 1.105 1.572 2.543 2.863 
9 yrs 0.365 0.444 0.847 1.186 1.678 2.699 3.034 
10 yrs 0.399 0.483 0.913 1.272 1.791 2.862 3.213 
11 yrs 0.435 0.526 0.982 1.363 1.909 3.033 3.400 
12 yrs 0.474 0.571 1.056 1.458 2.034 3.212 3.595 
Adults 0.730 0.810 1.368 2.488 2.980 3.993 4.000 
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AGE GROUP PERCENTILES lgG3 : COLOURED MALE CONTROLS 
AGE 2.5% 5% 25% 50% 75% 95% 97.5% 
6 mths 0.151 0.176 0.284 0.416 0.576 0.929 1.205 
1 yr 0.151 0.176 0.285 0.416 0.577 0.930 1.206 
2 yrs 0.153 0.178 0.288 0.421 0.584 0.941 1.220 
3 yrs 0.157 0.183 0.296 0.433 0.599 0.966 1.253 
4 yrs 0.163 0.190 0.308 0.450 0.624 1.006 1.305 
5 yrs 0.172 0.201 0.325 0.476 0.659 1.064 1.380 
6 yrs 0.185 0.215 0.348 0.510 0.707 1.141 1.480 
7 yrs 0.201 0.234 0.379 0.555 0.769 1.241 1.610 
8 yrs 0.221 0.258 0.418 0.612 0.848 1.370 1.778 
9 yrs 0.247 0.288 0.467 0.685 0.950 1.534 1.992 
10 yrs 0.281 0.327 0.530 0.777 1.079 1.744 2.265 
11 yrs 0.323 0.376 0.611 0.896 1.243 2.012 2.614 
12 yrs 0.377 0.439 0.714 1.047 1.454 2.355 3.061 
Adults 0.230 0.240 0.500 0.780 1.057 1.338 1.758 
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AGE GROUP PERCENTILES lgG3 : COWURED FEMALE CONTROLS 
AGE 2.5% 5% 25% 50% 75% 95% 97.5% 
6 mths 0.158 0.189 0.293 0.429 0.602 1.026 1.258 
1 yr 0.164 0.196 0.303 0.443 0.622 1.057 1.297 
2 yrs 0.176 0.210 0.324 0.473 0.662 1.124 1.377 
3 yrs 0.189 0.225 0.346 0.505 0.706 1.194 1.461 
4 yrs 0.202 0.241 0.370 0.538 0.751 1.268 1.550 
5 yrs 0.217 0.258 0.395 0.574 0.800 1.346 1.644 
6 yrs 0.233 0.277 0.422 0.612 0.851 1.429 1.744 
7 yrs 0.249 0.296 0.451 0.652 0.905 1.516 1.849 
8 yrs 0.267 0.317 0.481 0.694 0.963 1.609 1.959 
9 yrs 0.285 0.338 0.513 0.740 1.024 1.706 2.076 
10 yrs 0.305 0.362 0.547 0.787 1.088 1.809 2.199 
11 yrs 0.327 0.387 0.583 0.838 1.156 1.917 2.329 
12 yrs 0.349 0.413 0.622 0.891 1.228 2.032 2.466 
Adults 0.310 0.310 0.580 0.750 1.005 1.680 1.680 
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AGE GROUP PERCENTILES lgG4 : MALE COLOURED CONTROLS 
AGE 2.5% 5% 25% 50% 75% 95% 97.5% 
6 mths 0.001 0.002 0.017 0.053 0.111 0.231 0.301 
1 yr 0.003 0.004 0.024 0.068 0.137 0.274 0.353 
2 yrs 0.007 0.009 0.042 0.104 0.195 0.368 0.467 
3 yrs 0.013 0.017 0.063 0.145 0.259 0.469 0.586 
4 yrs 0.022 0.027 0.088 0.189 0.326 0.571 0.706 
5 yrs 0.031 0.038 0.113 0.233 0.390 0.668 0.819 
6 yrs 0.041 0.049 0.137 0.273 0.449 0.754 0.918 
7 yrs 0.049 0.059 0.157 0.306 0.496 0.824 0.999 
8 yrs 0.055 0.066 0.171 0.330 0.531 0.874 1.056 
9 yrs 0.059 0.070 0.179 0.343 0.549 0.900 1.086 
10 yrs 0.059 0.070 0.180 0.344 0.550 0.901 1.088 
11 yrs 0.056 0.066 0.173 0.332 0.533 0.877 1.061 
12 yrs 0.050 0.059 0.159 0.309 0.501 0.830 1.006 
Adults 0.012 0.143 0.311 0.419 0.51 1.050 1.270 
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AGE GROUP PERCENTILES lgG4 : COLOURED FEMALE CONTROLS 
AGE 2.5% 5% 25% 50% 75% 95% 97.5% 
6 mths 0.002 0.006 0.227 0.047 0.101 0.193 0.223 
1 yr 0.003 0.008 0.028 0.057 0.119 0.221 0.255 
2 yrs 0.006 0.013 0.041 0.079 0.158 0.284 0.324 
3 yrs 0.011 0.020 0.057 0.105 0.202 0.352 0.400 
4 yrs 0.016 0.028 0.075 0.134 0.248 0.423 0.478 
5 yrs 0.022 0.038 0.094 0.164 0.296 0.495 9.557 
6 yrs 0.029 0.048 0.114 0.194 0.343 0.565 0.634 
7 yrs 0.035 0.058 0.133 0.223 0.388 0.631 0.705 
8 yrs 0.042 0.067 0.151 0.249 0.428 0.689 0.769 
9 yrs 0.047 0.075 0.166 0.271 0.462 0.738 0.822 
10 yrs 0.052 0.081 0.178 0.288 0.487 0.775 0.862 
11 yrs 0.055 0.086 0.186 0.299 0.504 0.799 0.888 
12 yrs 0.056 0.087 0.189 0.304 0.511 0.809 0.899 
Adults 0.028 0.028 0.110 0.240 0.401 1.310 1.310 
APPENDIX K 
The following figures are the IgG 1, IgG2, IgG3 and IgG4 and IgG values of individual 
patients with Hib meningitis, Hib OM/SA and S. aureus OM/SA superimposed on age and 
sex matched percentile charts created from values from healthy children (Appendix I). 
The percentile lines shown are 2.5%, 5%, 25%, 50%, 75%, 95% and 97.5%. The 
individual patient values are shown (*). As the age distribution of the children with Hib 
meningitis, Hib OM/SA and S. aureus OM/SA are significantly different the data for the 
three patient groups is shown on separate graphs. 
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BUFFERS AND SOLUTIONS 
Buffers and Solutions 
1. Glycine/Tris Buff er 
Stock Solution 
Glycine (0.05M) (Merck) 
Dissolve in 900 ml distilled water 
Adjust to pH of 2.5 with IN HCl 
Make up to 1000 ml with distilled water 
Store at 4°C 
Working solution 
Add solid Tris (Boehringer Mannheim) to stock solution to pH of 7.2 
Make up freshly before use 
ii. Phosphate Buffered Saline (PBS) 
lOx PBS 
NaCl (137 mM) (Univar) 
KCl (2.68 mM) (NT Lab Supplies) 
Na2HP04 (8.1 mM) anhydrous (BDH Analar) 
KH2P04 (1.47 mM) (BDH Analar) 
Make up to 5000 ml with distilled water 
Dilute 1: 10 before use 
pH 7.3 
iii. PBST 
3.75 g 
400 g 
10 g 
57.5 g 
10 g 
Add 250 µl (0.005%)* Tween 20- (Sigma) (Catalogue No P1379) to 5 litres PBS 
Add 2500 µl (0.05%)** Tween 20 to 5 litres PBS 
* 0.005 % PBST used in subclass ELISAs 
** 0.05% PBST used in tetanus toxoid specific ELISAs 
Buffers and Solutions 
iv. 0.25% BSA in PBST 
BSA (Boehringer Mannheim) (Catalogue No 735086) 
Dissolve in 100 ml PBST 
v. Tris Buffered Saline (TBS) 
Tris* (10 mM) (Boehringer Mannheim) 
Tris** (20 mM) (Boehringer Mannheim) 
NaCl (154 mM)) (Univar) 
Dissolve in 900 ml distilled water 
Adjust to pH of 7.5 with lN HCl 
Make up to 1000 ml with distilled water 
* 
** 
vi. TBST 
10 mM Tris used in IgG subclass and tetanus toxoid ELIS As 
20 mM Tris used in Gm and Km allotype ELISAs 
Add* 100 µl (0.01 %) Tween 20 (Sigma) (Catalogue No P1379) 
0.25 g 
1.21 g 
2.42 g 
9g 
Add** 500 µl (0.05%) Tween 20 (Sigma) (Catalogue No P1379) to 1 litre TBS 
* 
** 
0.01 % TBST used in washing 
0.05% TBST used in blocking 
vii. 1 % Casein in 10 mM TBS 
Casein (1 % ) (Hammarsten) (Catalogue No 44020) 
Dissolve in 1000 ml 10 mM TBS 
Store at 4°C 
pH7.6 
10 g 
Buffers and Solutions 
1 % casein in PBS 
Casein (1 %) (Saarchem) (Catalogue No 152813) 
Dissolve in 1000 ml PBS pH 7. 6 
Store at 4 °C 
pH 7.6 
viii. 2% Bovine serum albumin (BSA) in 0.05% TBST (20 mM) 
Gm allotype blocker 
10 g 
BSA fraction V (2 % ) (Boehringer Mannheim) (Catalogue No 735086) 20 g 
Dissolve in 1000 ml 20 mM TBS 
Add 500 µl (0.05%) Tween20 
Store at 4°C 
1: 10 blocker solution 
Gm allotype diluent 
0.2% BSA/TBS/0.005% Tween20 
ix. Carbonate buff er 
Na2C03 (15 mM) anhydrous (BDH Analar) 
NaHC03 (35 mM) (BDH Analar) 
Thymol (0.67 mM) (BDH Analar) 
Dissolve in 1000 ml distilled water 
Note that the pH is 9.6 
x. 0.1 M Citrate Buffer 
Solution A 
Citric Acid (0.1 M) (BDH Analar) 
Dissolve in 1000 ml distilled water 
1.59 g 
2.93 g 
0.1 g 
21 g 
Buffers and Solutions 
Solution B 
Tri Sodium Citrate (0.1 M) (BDH Analar) 
Dissolve in 1000 ml distilled water 
Solution A 
Solution B 
Make up to 100 ml with distilled water 
Adjust to pH of 5.0 with 4 M NaOH 
Note that the pH is critical 
xi. o-Phenylenediamine dichloride (OPD) solution 
29.4 g 
20.5 ml 
29.5 ml 
Note that OPD (Sigma) (Catalogue No P1526) may be weighed in small aliquots 
and stored at -20°C in the dark 
Add 2.5 ml citrate buffer per mg of OPD 
Add 1 µl of 30% H2~ per ml of citrate buffer 
Make up freshly before use 
xii. 2N H2S04 
Formula: N required = Equivalent weight x 
Specific Gravity 
H2S04 (NT Lab Supplies) 
100 
% Impurities 
Add to 500 ml distilled water and make up to 1000 ml when cool 
xiii. 1 % Agarose/3.8% PEG 
Agarose A (1 % ) (Pharmacia) (Catalogue No 17-0422-01) 
0.05 M Phosphate buffer, pH 7.4 
Dissolve agarose in buffer, by heating and stirring, 
in boiling waterbath. 
Add: PEG 6000 (BDH) 
Dissolve as above, with swirling 
53.3 ml 
lgm 
± 80 ml 
3.8 gm 
Buffers and Solutions 
Add: NaCl 
Na Azide 
Make up to 100 ml with 0.05 M Phoshpate buffer 
Aliquot and store in 10 ml amounts 
For use: Dissolve in boiling waterbath 
Pour onto glass slide or Gelbond 
xiv. 0.9% NaCl 
NaCl 
xv. 
Distilled water 
Amido Black Stain 
Amido Black 
Methanol 
Glacial Acetic Acid 
Dissolve Amido Black in Methanol/ Acetic acid 
xvi. Destainer 
Methanol 
Glacial Acetic Acid 
xvii. 2 % acetic acid 
Glacial acetic acid 
Distilled water 
0.9 gm 
0.2gm 
9gm 
1 litre 
0.5 gms 
90 ml 
10ml 
900ml 
100ml 
2 ml 
98 ml 
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